id	sid	tid	token	lemma	pos
admet-2956	1	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	1	2	in	in	ADP
admet-2956	1	3	pd	pd	PROPN
admet-2956	1	4	-	-	PUNCT
admet-2956	1	5	l1	l1	PROPN
admet-2956	1	6	-	-	PUNCT
admet-2956	1	7	positive	positive	ADJ
admet-2956	1	8	advanced	advanced	ADJ
admet-2956	1	9	non	non	ADJ
admet-2956	1	10	-	-	ADJ
admet-2956	1	11	small	small	ADJ
admet-2956	1	12	cell	cell	NOUN
admet-2956	1	13	lung	lung	NOUN
admet-2956	1	14	carcinoma	carcinoma	NOUN
admet-2956	1	15	:	:	PUNCT
admet-2956	1	16	a	a	DET
admet-2956	1	17	meta	meta	ADJ
admet-2956	1	18	-	-	PUNCT
admet-2956	1	19	analysis	analysis	NOUN
admet-2956	1	20	of	of	ADP
admet-2956	1	21	survival	survival	NOUN
admet-2956	1	22	benefits	benefit	NOUN
admet-2956	1	23	and	and	CCONJ
admet-2956	1	24	immune	immune	NOUN
admet-2956	1	25	-	-	PUNCT
admet-2956	1	26	related	relate	VERB
admet-2956	1	27	toxicity	toxicity	NOUN
admet-2956	1	28	events	event	NOUN
admet-2956	1	29	patterns	pattern	NOUN
admet-2956	1	30	doi	doi	NOUN
admet-2956	1	31	:	:	PUNCT
admet-2956	1	32	http://dx.doi.org/10.5599/admet.2956	http://dx.doi.org/10.5599/admet.2956	X
admet-2956	1	33	1	1	NUM
admet-2956	1	34	admet	admet	X
admet-2956	1	35	&	&	CCONJ
admet-2956	1	36	dmpk	dmpk	PROPN
admet-2956	1	37	13(5	13(5	NUM
admet-2956	1	38	)	)	PUNCT
admet-2956	1	39	(	(	PUNCT
admet-2956	1	40	2025	2025	NUM
admet-2956	1	41	)	)	PUNCT
admet-2956	1	42	2956	2956	NUM
admet-2956	1	43	;	;	PUNCT
admet-2956	1	44	doi	doi	NOUN
admet-2956	1	45	:	:	PUNCT
admet-2956	1	46	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	1	47	open	open	ADJ
admet-2956	1	48	access	access	NOUN
admet-2956	1	49	:	:	PUNCT
admet-2956	1	50	issn	issn	PROPN
admet-2956	1	51	:	:	PUNCT
admet-2956	1	52	1848	1848	NUM
admet-2956	1	53	-	-	SYM
admet-2956	1	54	7718	7718	NUM
admet-2956	1	55	http://www.pub.iapchem.org/ojs/index.ph-p/admet/index	http://www.pub.iapchem.org/ojs/index.ph-p/admet/index	PROPN
admet-2956	1	56	original	original	ADJ
admet-2956	1	57	scientific	scientific	ADJ
admet-2956	1	58	paper	paper	NOUN
admet-2956	1	59	pembrolizumab	pembrolizumab	NOUN
admet-2956	1	60	in	in	ADP
admet-2956	1	61	pd	pd	PROPN
admet-2956	1	62	-	-	PUNCT
admet-2956	1	63	l1	l1	PROPN
admet-2956	1	64	-	-	PUNCT
admet-2956	1	65	positive	positive	ADJ
admet-2956	1	66	advanced	advanced	ADJ
admet-2956	1	67	non	non	ADJ
admet-2956	1	68	-	-	ADJ
admet-2956	1	69	small	small	ADJ
admet-2956	1	70	cell	cell	NOUN
admet-2956	1	71	lung	lung	NOUN
admet-2956	1	72	carcinoma	carcinoma	NOUN
admet-2956	1	73	:	:	PUNCT
admet-2956	1	74	a	a	DET
admet-2956	1	75	meta	meta	ADJ
admet-2956	1	76	-	-	PUNCT
admet-2956	1	77	analysis	analysis	NOUN
admet-2956	1	78	of	of	ADP
admet-2956	1	79	survival	survival	NOUN
admet-2956	1	80	benefits	benefit	NOUN
admet-2956	1	81	and	and	CCONJ
admet-2956	1	82	immunerelated	immunerelate	VERB
admet-2956	1	83	toxicity	toxicity	NOUN
admet-2956	1	84	events	event	NOUN
admet-2956	1	85	patterns	pattern	NOUN
admet-2956	1	86	alendra	alendra	VERB
admet-2956	1	87	chakramurty1	chakramurty1	NOUN
admet-2956	1	88	,	,	PUNCT
admet-2956	1	89	*	*	PUNCT
admet-2956	1	90	,	,	PUNCT
admet-2956	1	91	adetya	adetya	PROPN
admet-2956	1	92	rahma	rahma	PROPN
admet-2956	1	93	dinni2	dinni2	PROPN
admet-2956	1	94	,	,	PUNCT
admet-2956	1	95	ihda	ihda	PROPN
admet-2956	1	96	silvia3	silvia3	PROPN
admet-2956	1	97	,	,	PUNCT
admet-2956	1	98	aprilyan	aprilyan	PROPN
admet-2956	1	99	laras	laras	PROPN
admet-2956	1	100	cantika4	cantika4	PROPN
admet-2956	1	101	and	and	CCONJ
admet-2956	1	102	citrawati	citrawati	PROPN
admet-2956	1	103	dyah	dyah	PROPN
admet-2956	1	104	kencono	kencono	PROPN
admet-2956	1	105	wungu5	wungu5	PROPN
admet-2956	2	1	1department	1department	NUM
admet-2956	2	2	of	of	ADP
admet-2956	2	3	anatomical	anatomical	ADJ
admet-2956	2	4	pathology	pathology	NOUN
admet-2956	2	5	,	,	PUNCT
admet-2956	2	6	faculty	faculty	NOUN
admet-2956	2	7	of	of	ADP
admet-2956	2	8	medicine	medicine	NOUN
admet-2956	2	9	,	,	PUNCT
admet-2956	2	10	universitas	universita	NOUN
admet-2956	2	11	swadaya	swadaya	NOUN
admet-2956	2	12	gunung	gunung	PROPN
admet-2956	2	13	jati	jati	PROPN
admet-2956	2	14	,	,	PUNCT
admet-2956	2	15	cirebon	cirebon	NOUN
admet-2956	2	16	,	,	PUNCT
admet-2956	2	17	indonesia	indonesia	PROPN
admet-2956	2	18	2department	2department	NUM
admet-2956	2	19	of	of	ADP
admet-2956	2	20	pulmonology	pulmonology	NOUN
admet-2956	2	21	,	,	PUNCT
admet-2956	2	22	faculty	faculty	NOUN
admet-2956	2	23	of	of	ADP
admet-2956	2	24	medicine	medicine	NOUN
admet-2956	2	25	,	,	PUNCT
admet-2956	2	26	universitas	universita	NOUN
admet-2956	2	27	swadaya	swadaya	NOUN
admet-2956	2	28	gunung	gunung	PROPN
admet-2956	2	29	jati	jati	PROPN
admet-2956	2	30	,	,	PUNCT
admet-2956	2	31	cirebon	cirebon	NOUN
admet-2956	2	32	,	,	PUNCT
admet-2956	2	33	indonesia	indonesia	PROPN
admet-2956	2	34	3department	3department	NUM
admet-2956	2	35	of	of	ADP
admet-2956	2	36	internal	internal	ADJ
admet-2956	2	37	medicine	medicine	NOUN
admet-2956	2	38	,	,	PUNCT
admet-2956	2	39	gunung	gunung	PROPN
admet-2956	2	40	jati	jati	PROPN
admet-2956	2	41	general	general	ADJ
admet-2956	2	42	hospital	hospital	NOUN
admet-2956	2	43	,	,	PUNCT
admet-2956	2	44	cirebon	cirebon	NOUN
admet-2956	2	45	,	,	PUNCT
admet-2956	2	46	indonesia	indonesia	PROPN
admet-2956	2	47	4department	4department	NUM
admet-2956	2	48	of	of	ADP
admet-2956	2	49	medical	medical	ADJ
admet-2956	2	50	education	education	NOUN
admet-2956	2	51	and	and	CCONJ
admet-2956	2	52	bioethics	bioethic	NOUN
admet-2956	2	53	,	,	PUNCT
admet-2956	2	54	faculty	faculty	NOUN
admet-2956	2	55	of	of	ADP
admet-2956	2	56	medicine	medicine	NOUN
admet-2956	2	57	,	,	PUNCT
admet-2956	2	58	universitas	universita	NOUN
admet-2956	2	59	swadaya	swadaya	NOUN
admet-2956	2	60	gunung	gunung	PROPN
admet-2956	2	61	jati	jati	PROPN
admet-2956	2	62	,	,	PUNCT
admet-2956	2	63	cirebon	cirebon	NOUN
admet-2956	2	64	,	,	PUNCT
admet-2956	2	65	indonesia	indonesia	PROPN
admet-2956	2	66	5department	5department	NUM
admet-2956	2	67	of	of	ADP
admet-2956	2	68	physiology	physiology	NOUN
admet-2956	2	69	and	and	CCONJ
admet-2956	2	70	medical	medical	ADJ
admet-2956	2	71	biochemistry	biochemistry	NOUN
admet-2956	2	72	,	,	PUNCT
admet-2956	2	73	faculty	faculty	NOUN
admet-2956	2	74	of	of	ADP
admet-2956	2	75	medicine	medicine	NOUN
admet-2956	2	76	,	,	PUNCT
admet-2956	2	77	universitas	universita	NOUN
admet-2956	2	78	airlangga	airlangga	NOUN
admet-2956	2	79	,	,	PUNCT
admet-2956	2	80	surabaya	surabaya	PROPN
admet-2956	2	81	,	,	PUNCT
admet-2956	2	82	indonesia	indonesia	PROPN
admet-2956	2	83	*	*	PUNCT
admet-2956	2	84	corresponding	correspond	VERB
admet-2956	2	85	author	author	NOUN
admet-2956	2	86	:	:	PUNCT
admet-2956	3	1	e	e	NOUN
admet-2956	3	2	-	-	NOUN
admet-2956	3	3	mail	mail	NOUN
admet-2956	3	4	:	:	PUNCT
admet-2956	3	5	alendra.chakramurty@ugj.ac.id	alendra.chakramurty@ugj.ac.id	PROPN
admet-2956	3	6	;	;	PUNCT
admet-2956	3	7	haliru.aa@gmail.com	haliru.aa@gmail.com	PROPN
admet-2956	3	8	received	receive	VERB
admet-2956	3	9	:	:	PUNCT
admet-2956	3	10	july	july	PROPN
admet-2956	3	11	19	19	NUM
admet-2956	3	12	,	,	PUNCT
admet-2956	3	13	2025	2025	NUM
admet-2956	3	14	;	;	PUNCT
admet-2956	3	15	revised	revise	VERB
admet-2956	3	16	:	:	PUNCT
admet-2956	3	17	september	september	PROPN
admet-2956	3	18	26	26	NUM
admet-2956	3	19	,	,	PUNCT
admet-2956	3	20	2025	2025	NUM
admet-2956	3	21	;	;	PUNCT
admet-2956	3	22	published	publish	VERB
admet-2956	3	23	:	:	PUNCT
admet-2956	3	24	october	october	PROPN
admet-2956	3	25	14	14	NUM
admet-2956	3	26	,	,	PUNCT
admet-2956	3	27	2025	2025	NUM
admet-2956	3	28	abstract	abstract	ADJ
admet-2956	3	29	background	background	NOUN
admet-2956	3	30	and	and	CCONJ
admet-2956	3	31	objective	objective	NOUN
admet-2956	3	32	:	:	PUNCT
admet-2956	3	33	pembrolizumab	pembrolizumab	NOUN
admet-2956	3	34	has	have	AUX
admet-2956	3	35	shown	show	VERB
admet-2956	3	36	significant	significant	ADJ
admet-2956	3	37	therapeutic	therapeutic	ADJ
admet-2956	3	38	benefit	benefit	NOUN
admet-2956	3	39	in	in	ADP
admet-2956	3	40	advanced	advanced	ADJ
admet-2956	3	41	non	non	ADJ
admet-2956	3	42	-	-	ADJ
admet-2956	3	43	small	small	ADJ
admet-2956	3	44	cell	cell	NOUN
admet-2956	3	45	lung	lung	NOUN
admet-2956	3	46	cancer	cancer	NOUN
admet-2956	3	47	(	(	PUNCT
admet-2956	3	48	nsclc	nsclc	NOUN
admet-2956	3	49	)	)	PUNCT
admet-2956	3	50	,	,	PUNCT
admet-2956	3	51	but	but	CCONJ
admet-2956	3	52	it	it	PRON
admet-2956	3	53	remains	remain	VERB
admet-2956	3	54	uncertain	uncertain	ADJ
admet-2956	3	55	which	which	PRON
admet-2956	3	56	patients	patient	NOUN
admet-2956	3	57	will	will	AUX
admet-2956	3	58	benefit	benefit	VERB
admet-2956	3	59	the	the	DET
admet-2956	3	60	most	most	ADJ
admet-2956	3	61	,	,	PUNCT
admet-2956	3	62	and	and	CCONJ
admet-2956	3	63	recent	recent	ADJ
admet-2956	3	64	data	datum	NOUN
admet-2956	3	65	suggest	suggest	VERB
admet-2956	3	66	that	that	SCONJ
admet-2956	3	67	programmed	program	VERB
admet-2956	3	68	death	death	NOUN
admet-2956	3	69	-	-	PUNCT
admet-2956	3	70	ligand	ligand	NOUN
admet-2956	3	71	1	1	NUM
admet-2956	3	72	(	(	PUNCT
admet-2956	3	73	pd	pd	NOUN
admet-2956	3	74	-	-	PUNCT
admet-2956	3	75	l1	l1	NOUN
admet-2956	3	76	)	)	PUNCT
admet-2956	3	77	expression	expression	NOUN
admet-2956	3	78	as	as	ADP
admet-2956	3	79	a	a	DET
admet-2956	3	80	single	single	ADJ
admet-2956	3	81	predictive	predictive	ADJ
admet-2956	3	82	biomarker	biomarker	NOUN
admet-2956	3	83	is	be	AUX
admet-2956	3	84	insufficient	insufficient	ADJ
admet-2956	3	85	.	.	PUNCT
admet-2956	4	1	this	this	DET
admet-2956	4	2	systematic	systematic	ADJ
admet-2956	4	3	review	review	NOUN
admet-2956	4	4	and	and	CCONJ
admet-2956	4	5	meta	meta	ADJ
admet-2956	4	6	-	-	PUNCT
admet-2956	4	7	analysis	analysis	NOUN
admet-2956	4	8	looked	look	VERB
admet-2956	4	9	at	at	ADP
admet-2956	4	10	the	the	DET
admet-2956	4	11	safety	safety	NOUN
admet-2956	4	12	and	and	CCONJ
admet-2956	4	13	efficacy	efficacy	NOUN
admet-2956	4	14	of	of	ADP
admet-2956	4	15	pembrolizumab	pembrolizumab	NOUN
admet-2956	4	16	in	in	ADP
admet-2956	4	17	pd	pd	ADJ
admet-2956	4	18	-	-	ADJ
admet-2956	4	19	l1positive	l1positive	ADJ
admet-2956	4	20	advanced	advanced	ADJ
admet-2956	4	21	nsclc	nsclc	NOUN
admet-2956	4	22	patients	patient	NOUN
admet-2956	4	23	,	,	PUNCT
admet-2956	4	24	with	with	ADP
admet-2956	4	25	a	a	DET
admet-2956	4	26	particular	particular	ADJ
admet-2956	4	27	focus	focus	NOUN
admet-2956	4	28	on	on	ADP
admet-2956	4	29	disparities	disparity	NOUN
admet-2956	4	30	in	in	ADP
admet-2956	4	31	treatment	treatment	NOUN
admet-2956	4	32	response	response	NOUN
admet-2956	4	33	to	to	ADP
admet-2956	4	34	pd	pd	PROPN
admet-2956	4	35	-	-	PUNCT
admet-2956	4	36	l1	l1	PROPN
admet-2956	4	37	level	level	NOUN
admet-2956	4	38	of	of	ADP
admet-2956	4	39	expression	expression	NOUN
admet-2956	4	40	and	and	CCONJ
admet-2956	4	41	demographic	demographic	ADJ
admet-2956	4	42	characteristics	characteristic	NOUN
admet-2956	4	43	.	.	PUNCT
admet-2956	5	1	method	method	NOUN
admet-2956	5	2	:	:	PUNCT
admet-2956	5	3	according	accord	VERB
admet-2956	5	4	to	to	ADP
admet-2956	5	5	the	the	DET
admet-2956	5	6	prisma	prisma	PROPN
admet-2956	5	7	2020	2020	NUM
admet-2956	5	8	guidelines	guideline	NOUN
admet-2956	5	9	,	,	PUNCT
admet-2956	5	10	six	six	NUM
admet-2956	5	11	large	large	ADJ
admet-2956	5	12	databases	database	NOUN
admet-2956	5	13	were	be	AUX
admet-2956	5	14	searched	search	VERB
admet-2956	5	15	up	up	ADP
admet-2956	5	16	to	to	ADP
admet-2956	5	17	march	march	PROPN
admet-2956	5	18	2025	2025	NUM
admet-2956	5	19	for	for	ADP
admet-2956	5	20	randomized	randomized	ADJ
admet-2956	5	21	controlled	control	VERB
admet-2956	5	22	trials	trial	NOUN
admet-2956	5	23	comparing	compare	VERB
admet-2956	5	24	pembrolizumab	pembrolizumab	NOUN
admet-2956	5	25	with	with	ADP
admet-2956	5	26	chemotherapy	chemotherapy	NOUN
admet-2956	5	27	in	in	ADP
admet-2956	5	28	patients	patient	NOUN
admet-2956	5	29	with	with	ADP
admet-2956	5	30	such	such	ADJ
admet-2956	5	31	conditions	condition	NOUN
admet-2956	5	32	.	.	PUNCT
admet-2956	6	1	overall	overall	ADJ
admet-2956	6	2	survival	survival	NOUN
admet-2956	6	3	(	(	PUNCT
admet-2956	6	4	os	os	NOUN
admet-2956	6	5	)	)	PUNCT
admet-2956	6	6	and	and	CCONJ
admet-2956	6	7	progression	progression	NOUN
admet-2956	6	8	-	-	PUNCT
admet-2956	6	9	free	free	ADJ
admet-2956	6	10	survival	survival	NOUN
admet-2956	6	11	(	(	PUNCT
admet-2956	6	12	pfs	pfs	PROPN
admet-2956	6	13	)	)	PUNCT
admet-2956	6	14	were	be	AUX
admet-2956	6	15	chosen	choose	VERB
admet-2956	6	16	as	as	ADP
admet-2956	6	17	primary	primary	ADJ
admet-2956	6	18	outcomes	outcome	NOUN
admet-2956	6	19	,	,	PUNCT
admet-2956	6	20	and	and	CCONJ
admet-2956	6	21	overall	overall	ADJ
admet-2956	6	22	response	response	NOUN
admet-2956	6	23	rate	rate	NOUN
admet-2956	6	24	(	(	PUNCT
admet-2956	6	25	orr	orr	PROPN
admet-2956	6	26	)	)	PUNCT
admet-2956	6	27	and	and	CCONJ
admet-2956	6	28	safety	safety	NOUN
admet-2956	6	29	profiles	profile	NOUN
admet-2956	6	30	as	as	ADP
admet-2956	6	31	secondary	secondary	ADJ
admet-2956	6	32	endpoints	endpoint	NOUN
admet-2956	6	33	.	.	PUNCT
admet-2956	7	1	a	a	DET
admet-2956	7	2	meta	meta	ADJ
admet-2956	7	3	-	-	PUNCT
admet-2956	7	4	analysis	analysis	NOUN
admet-2956	7	5	was	be	AUX
admet-2956	7	6	conducted	conduct	VERB
admet-2956	7	7	using	use	VERB
admet-2956	7	8	a	a	DET
admet-2956	7	9	random	random	ADJ
admet-2956	7	10	-	-	PUNCT
admet-2956	7	11	effects	effect	NOUN
admet-2956	7	12	model	model	NOUN
admet-2956	7	13	,	,	PUNCT
admet-2956	7	14	and	and	CCONJ
admet-2956	7	15	the	the	DET
admet-2956	7	16	cochrane	cochrane	NOUN
admet-2956	7	17	risk	risk	NOUN
admet-2956	7	18	of	of	ADP
admet-2956	7	19	bias	bias	NOUN
admet-2956	7	20	(	(	PUNCT
admet-2956	7	21	rob2	rob2	NOUN
admet-2956	7	22	)	)	PUNCT
admet-2956	7	23	tool	tool	NOUN
admet-2956	7	24	was	be	AUX
admet-2956	7	25	employed	employ	VERB
admet-2956	7	26	to	to	PART
admet-2956	7	27	evaluate	evaluate	VERB
admet-2956	7	28	study	study	NOUN
admet-2956	7	29	quality	quality	NOUN
admet-2956	7	30	.	.	PUNCT
admet-2956	8	1	seven	seven	NUM
admet-2956	8	2	randomized	randomized	ADJ
admet-2956	8	3	controlled	control	VERB
admet-2956	8	4	trials	trial	NOUN
admet-2956	8	5	involving	involve	VERB
admet-2956	8	6	4,900	4,900	NUM
admet-2956	8	7	patients	patient	NOUN
admet-2956	8	8	were	be	AUX
admet-2956	8	9	included	include	VERB
admet-2956	8	10	in	in	ADP
admet-2956	8	11	the	the	DET
admet-2956	8	12	analysis	analysis	NOUN
admet-2956	8	13	.	.	PUNCT
admet-2956	9	1	key	key	ADJ
admet-2956	9	2	results	result	NOUN
admet-2956	9	3	:	:	PUNCT
admet-2956	9	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	9	5	had	have	VERB
admet-2956	9	6	a	a	DET
admet-2956	9	7	substantially	substantially	ADV
admet-2956	9	8	better	well	ADJ
admet-2956	9	9	performance	performance	NOUN
admet-2956	9	10	compared	compare	VERB
admet-2956	9	11	to	to	ADP
admet-2956	9	12	chemotherapy	chemotherapy	NOUN
admet-2956	9	13	for	for	ADP
admet-2956	9	14	all	all	DET
admet-2956	9	15	the	the	DET
admet-2956	9	16	measures	measure	NOUN
admet-2956	9	17	of	of	ADP
admet-2956	9	18	efficacy	efficacy	NOUN
admet-2956	9	19	:	:	PUNCT
admet-2956	9	20	os	os	PROPN
admet-2956	9	21	(	(	PUNCT
admet-2956	9	22	hazard	hazard	NOUN
admet-2956	9	23	ratio	ratio	NOUN
admet-2956	9	24	(	(	PUNCT
admet-2956	9	25	hr	hr	NOUN
admet-2956	9	26	)	)	PUNCT
admet-2956	9	27	0.65	0.65	NUM
admet-2956	9	28	,	,	PUNCT
admet-2956	9	29	95	95	NUM
admet-2956	9	30	%	%	NOUN
admet-2956	9	31	confidence	confidence	NOUN
admet-2956	9	32	interval	interval	NOUN
admet-2956	9	33	(	(	PUNCT
admet-2956	9	34	ci	ci	NOUN
admet-2956	9	35	):	):	PUNCT
admet-2956	9	36	0.57	0.57	NUM
admet-2956	9	37	to	to	ADP
admet-2956	9	38	0.73	0.73	NUM
admet-2956	9	39	,	,	PUNCT
admet-2956	9	40	p	p	X
admet-2956	9	41	<	<	X
admet-2956	9	42	0.00001	0.00001	NUM
admet-2956	9	43	)	)	PUNCT
admet-2956	9	44	,	,	PUNCT
admet-2956	9	45	pfs	pfs	PROPN
admet-2956	9	46	(	(	PUNCT
admet-2956	9	47	hr	hr	NOUN
admet-2956	9	48	0.55	0.55	NUM
admet-2956	9	49	,	,	PUNCT
admet-2956	9	50	95	95	NUM
admet-2956	9	51	%	%	NOUN
admet-2956	9	52	ci	ci	NOUN
admet-2956	9	53	:	:	PUNCT
admet-2956	9	54	0.42	0.42	NUM
admet-2956	9	55	to	to	ADP
admet-2956	9	56	0.72	0.72	NUM
admet-2956	9	57	,	,	PUNCT
admet-2956	9	58	p	p	X
admet-2956	9	59	<	<	X
admet-2956	9	60	0.0001	0.0001	NUM
admet-2956	9	61	)	)	PUNCT
admet-2956	9	62	and	and	CCONJ
admet-2956	9	63	orr	orr	PROPN
admet-2956	9	64	(	(	PUNCT
admet-2956	9	65	relative	relative	ADJ
admet-2956	9	66	risk	risk	NOUN
admet-2956	9	67	2.10	2.10	NUM
admet-2956	9	68	,	,	PUNCT
admet-2956	9	69	95	95	NUM
admet-2956	9	70	%	%	NOUN
admet-2956	9	71	ci	ci	NOUN
admet-2956	9	72	:	:	PUNCT
admet-2956	9	73	1.51	1.51	NUM
admet-2956	9	74	to	to	ADP
admet-2956	9	75	2.93	2.93	NUM
admet-2956	9	76	,	,	PUNCT
admet-2956	9	77	p	p	X
admet-2956	9	78	<	<	X
admet-2956	9	79	0.0001	0.0001	NUM
admet-2956	9	80	)	)	PUNCT
admet-2956	9	81	.	.	PUNCT
admet-2956	10	1	subgroup	subgroup	NOUN
admet-2956	10	2	analysis	analysis	NOUN
admet-2956	10	3	showed	show	VERB
admet-2956	10	4	greater	great	ADJ
admet-2956	10	5	survival	survival	NOUN
admet-2956	10	6	benefit	benefit	NOUN
admet-2956	10	7	in	in	ADP
admet-2956	10	8	patients	patient	NOUN
admet-2956	10	9	younger	young	ADJ
admet-2956	10	10	than	than	ADP
admet-2956	10	11	65	65	NUM
admet-2956	10	12	years	year	NOUN
admet-2956	10	13	(	(	PUNCT
admet-2956	10	14	os	os	NOUN
admet-2956	10	15	hr	hr	NOUN
admet-2956	10	16	0.55	0.55	NUM
admet-2956	10	17	)	)	PUNCT
admet-2956	10	18	compared	compare	VERB
admet-2956	10	19	to	to	ADP
admet-2956	10	20	patients	patient	NOUN
admet-2956	10	21	aged	age	VERB
admet-2956	10	22	65	65	NUM
admet-2956	10	23	and	and	CCONJ
admet-2956	10	24	older	old	ADJ
admet-2956	10	25	(	(	PUNCT
admet-2956	10	26	os	os	NOUN
admet-2956	10	27	hr	hr	NOUN
admet-2956	10	28	0.72	0.72	NUM
admet-2956	10	29	)	)	PUNCT
admet-2956	10	30	,	,	PUNCT
admet-2956	10	31	and	and	CCONJ
admet-2956	10	32	in	in	ADP
admet-2956	10	33	females	female	NOUN
admet-2956	10	34	(	(	PUNCT
admet-2956	10	35	os	os	ADP
admet-2956	10	36	hr	hr	NOUN
admet-2956	10	37	0.44	0.44	NUM
admet-2956	10	38	)	)	PUNCT
admet-2956	10	39	compared	compare	VERB
admet-2956	10	40	to	to	ADP
admet-2956	10	41	males	male	NOUN
admet-2956	10	42	(	(	PUNCT
admet-2956	10	43	os	os	NOUN
admet-2956	10	44	hr	hr	NOUN
admet-2956	10	45	0.67	0.67	NUM
admet-2956	10	46	)	)	PUNCT
admet-2956	10	47	.	.	PUNCT
admet-2956	11	1	of	of	ADP
admet-2956	11	2	most	most	ADV
admet-2956	11	3	significant	significant	ADJ
admet-2956	11	4	importance	importance	NOUN
admet-2956	11	5	,	,	PUNCT
admet-2956	11	6	those	those	PRON
admet-2956	11	7	with	with	ADP
admet-2956	11	8	pd	pd	PROPN
admet-2956	11	9	-	-	PUNCT
admet-2956	11	10	l1	l1	PROPN
admet-2956	11	11	expression	expression	NOUN
admet-2956	11	12	<	<	X
admet-2956	11	13	1	1	NUM
admet-2956	11	14	%	%	NOUN
admet-2956	11	15	also	also	ADV
admet-2956	11	16	saw	see	VERB
admet-2956	11	17	considerable	considerable	ADJ
admet-2956	11	18	benefit	benefit	NOUN
admet-2956	11	19	in	in	ADP
admet-2956	11	20	survival	survival	NOUN
admet-2956	11	21	(	(	PUNCT
admet-2956	11	22	os	os	INTJ
admet-2956	11	23	hr	hr	NOUN
admet-2956	11	24	0.60	0.60	NUM
admet-2956	11	25	)	)	PUNCT
admet-2956	11	26	,	,	PUNCT
admet-2956	11	27	casting	cast	VERB
admet-2956	11	28	doubts	doubt	NOUN
admet-2956	11	29	over	over	ADP
admet-2956	11	30	the	the	DET
admet-2956	11	31	existing	exist	VERB
admet-2956	11	32	biomarkerbased	biomarkerbase	VERB
admet-2956	11	33	selection	selection	NOUN
admet-2956	11	34	criteria	criterion	NOUN
admet-2956	11	35	.	.	PUNCT
admet-2956	12	1	conclusion	conclusion	NOUN
admet-2956	12	2	:	:	PUNCT
admet-2956	12	3	in	in	ADP
admet-2956	12	4	conclusion	conclusion	NOUN
admet-2956	12	5	,	,	PUNCT
admet-2956	12	6	pembrolizumab	pembrolizumab	NOUN
admet-2956	12	7	achieves	achieve	VERB
admet-2956	12	8	clinically	clinically	ADV
admet-2956	12	9	meaningful	meaningful	ADJ
admet-2956	12	10	survival	survival	NOUN
admet-2956	12	11	benefits	benefit	NOUN
admet-2956	12	12	and	and	CCONJ
admet-2956	12	13	an	an	DET
admet-2956	12	14	acceptable	acceptable	ADJ
admet-2956	12	15	toxicity	toxicity	NOUN
admet-2956	12	16	in	in	ADP
admet-2956	12	17	pd	pd	PROPN
admet-2956	12	18	-	-	PUNCT
admet-2956	12	19	l1	l1	PROPN
admet-2956	12	20	-	-	PUNCT
admet-2956	12	21	positive	positive	ADJ
admet-2956	12	22	advanced	advanced	ADJ
admet-2956	12	23	nsclc	nsclc	NOUN
admet-2956	12	24	.	.	PUNCT
admet-2956	13	1	the	the	DET
admet-2956	13	2	high	high	ADJ
admet-2956	13	3	efficacy	efficacy	NOUN
admet-2956	13	4	observed	observe	VERB
admet-2956	13	5	even	even	ADV
admet-2956	13	6	in	in	ADP
admet-2956	13	7	low	low	ADJ
admet-2956	13	8	pd	pd	PROPN
admet-2956	13	9	-	-	PUNCT
admet-2956	13	10	l1	l1	PROPN
admet-2956	13	11	expressers	expresser	NOUN
admet-2956	13	12	,	,	PUNCT
admet-2956	13	13	and	and	CCONJ
admet-2956	13	14	demographic	demographic	ADJ
admet-2956	13	15	differences	difference	NOUN
admet-2956	13	16	in	in	ADP
admet-2956	13	17	drug	drug	NOUN
admet-2956	13	18	response	response	NOUN
admet-2956	13	19	,	,	PUNCT
admet-2956	13	20	suggest	suggest	VERB
admet-2956	13	21	that	that	SCONJ
admet-2956	13	22	existing	exist	VERB
admet-2956	13	23	patient	patient	ADJ
admet-2956	13	24	selection	selection	NOUN
admet-2956	13	25	criteria	criterion	NOUN
admet-2956	13	26	could	could	AUX
admet-2956	13	27	potentially	potentially	ADV
admet-2956	13	28	be	be	AUX
admet-2956	13	29	extended	extend	VERB
admet-2956	13	30	.	.	PUNCT
admet-2956	14	1	these	these	DET
admet-2956	14	2	findings	finding	NOUN
admet-2956	14	3	justify	justify	VERB
admet-2956	14	4	the	the	DET
admet-2956	14	5	application	application	NOUN
admet-2956	14	6	of	of	ADP
admet-2956	14	7	a	a	DET
admet-2956	14	8	more	more	ADV
admet-2956	14	9	advanced	advanced	ADJ
admet-2956	14	10	approach	approach	NOUN
admet-2956	14	11	involving	involve	VERB
admet-2956	14	12	multiple	multiple	ADJ
admet-2956	14	13	biomarkers	biomarker	NOUN
admet-2956	14	14	for	for	ADP
admet-2956	14	15	more	more	ADV
admet-2956	14	16	precise	precise	ADJ
admet-2956	14	17	treatment	treatment	NOUN
admet-2956	14	18	allocation	allocation	NOUN
admet-2956	14	19	.	.	PUNCT
admet-2956	15	1	©	©	PROPN
admet-2956	15	2	2025	2025	NUM
admet-2956	15	3	by	by	ADP
admet-2956	15	4	the	the	DET
admet-2956	15	5	authors	author	NOUN
admet-2956	15	6	.	.	PUNCT
admet-2956	16	1	this	this	DET
admet-2956	16	2	article	article	NOUN
admet-2956	16	3	is	be	AUX
admet-2956	16	4	an	an	DET
admet-2956	16	5	open	open	ADJ
admet-2956	16	6	-	-	PUNCT
admet-2956	16	7	access	access	NOUN
admet-2956	16	8	article	article	NOUN
admet-2956	16	9	distributed	distribute	VERB
admet-2956	16	10	under	under	ADP
admet-2956	16	11	the	the	DET
admet-2956	16	12	terms	term	NOUN
admet-2956	16	13	and	and	CCONJ
admet-2956	16	14	conditions	condition	NOUN
admet-2956	16	15	of	of	ADP
admet-2956	16	16	the	the	DET
admet-2956	16	17	creative	creative	ADJ
admet-2956	16	18	commons	common	NOUN
admet-2956	16	19	attribution	attribution	NOUN
admet-2956	16	20	license	license	NOUN
admet-2956	16	21	(	(	PUNCT
admet-2956	16	22	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	PROPN
admet-2956	16	23	)	)	PUNCT
admet-2956	16	24	.	.	PUNCT
admet-2956	17	1	keywords	keyword	VERB
admet-2956	17	2	immunotherapy	immunotherapy	NOUN
admet-2956	17	3	;	;	PUNCT
admet-2956	17	4	systematic	systematic	ADJ
admet-2956	17	5	review	review	NOUN
admet-2956	17	6	;	;	PUNCT
admet-2956	17	7	biomarker	biomarker	NOUN
admet-2956	17	8	,	,	PUNCT
admet-2956	17	9	overall	overall	ADJ
admet-2956	17	10	survival	survival	NOUN
admet-2956	17	11	,	,	PUNCT
admet-2956	17	12	progression	progression	NOUN
admet-2956	17	13	-	-	PUNCT
admet-2956	17	14	free	free	ADJ
admet-2956	17	15	survival	survival	NOUN
admet-2956	17	16	,	,	PUNCT
admet-2956	17	17	drug	drug	NOUN
admet-2956	17	18	response	response	NOUN
admet-2956	17	19	http://dx.doi.org/10.5599/admet.2956	http://dx.doi.org/10.5599/admet.2956	PRON
admet-2956	17	20	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	17	21	http://www.pub.iapchem.org/ojs/index.ph-p/admet/index	http://www.pub.iapchem.org/ojs/index.ph-p/admet/index	PROPN
admet-2956	17	22	mailto:haliru.aa@gmail.com	mailto:haliru.aa@gmail.com	PROPN
admet-2956	17	23	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	PROPN
admet-2956	17	24	a.	a.	PROPN
admet-2956	17	25	chakramurty	chakramurty	PROPN
admet-2956	17	26	et	et	PROPN
admet-2956	17	27	al	al	PROPN
admet-2956	17	28	.	.	PROPN
admet-2956	17	29	admet	admet	PROPN
admet-2956	17	30	&	&	CCONJ
admet-2956	17	31	dmpk	dmpk	PROPN
admet-2956	17	32	13(5	13(5	NUM
admet-2956	17	33	)	)	PUNCT
admet-2956	17	34	(	(	PUNCT
admet-2956	17	35	2025	2025	NUM
admet-2956	17	36	)	)	PUNCT
admet-2956	17	37	2956	2956	NUM
admet-2956	17	38	2	2	NUM
admet-2956	17	39	introduction	introduction	NOUN
admet-2956	17	40	lung	lung	NOUN
admet-2956	17	41	cancer	cancer	NOUN
admet-2956	17	42	remains	remain	VERB
admet-2956	17	43	the	the	DET
admet-2956	17	44	leading	lead	VERB
admet-2956	17	45	cause	cause	NOUN
admet-2956	17	46	of	of	ADP
admet-2956	17	47	cancer	cancer	NOUN
admet-2956	17	48	-	-	PUNCT
admet-2956	17	49	related	relate	VERB
admet-2956	17	50	deaths	death	NOUN
admet-2956	17	51	worldwide	worldwide	ADV
admet-2956	17	52	,	,	PUNCT
admet-2956	17	53	with	with	ADP
admet-2956	17	54	non	non	ADJ
admet-2956	17	55	-	-	ADJ
admet-2956	17	56	small	small	ADJ
admet-2956	17	57	cell	cell	NOUN
admet-2956	17	58	lung	lung	NOUN
admet-2956	17	59	cancer	cancer	NOUN
admet-2956	17	60	(	(	PUNCT
admet-2956	17	61	nsclc	nsclc	NOUN
admet-2956	17	62	)	)	PUNCT
admet-2956	17	63	accounting	account	VERB
admet-2956	17	64	for	for	ADP
admet-2956	17	65	roughly	roughly	ADV
admet-2956	17	66	85	85	NUM
admet-2956	17	67	%	%	NOUN
admet-2956	17	68	of	of	ADP
admet-2956	17	69	all	all	DET
admet-2956	17	70	cases	case	NOUN
admet-2956	17	71	[	[	X
admet-2956	17	72	1,2	1,2	NUM
admet-2956	17	73	]	]	PUNCT
admet-2956	17	74	.	.	PUNCT
admet-2956	18	1	over	over	ADP
admet-2956	18	2	the	the	DET
admet-2956	18	3	past	past	ADJ
admet-2956	18	4	decade	decade	NOUN
admet-2956	18	5	,	,	PUNCT
admet-2956	18	6	treatment	treatment	NOUN
admet-2956	18	7	strategies	strategy	NOUN
admet-2956	18	8	for	for	ADP
admet-2956	18	9	advanced	advanced	ADJ
admet-2956	18	10	nsclc	nsclc	NOUN
admet-2956	18	11	have	have	AUX
admet-2956	18	12	shifted	shift	VERB
admet-2956	18	13	dramatically	dramatically	ADV
admet-2956	18	14	,	,	PUNCT
admet-2956	18	15	moving	move	VERB
admet-2956	18	16	from	from	ADP
admet-2956	18	17	conventional	conventional	ADJ
admet-2956	18	18	chemotherapy	chemotherapy	NOUN
admet-2956	18	19	toward	toward	ADP
admet-2956	18	20	personalized	personalized	ADJ
admet-2956	18	21	targeted	target	VERB
admet-2956	18	22	therapies	therapy	NOUN
admet-2956	18	23	and	and	CCONJ
admet-2956	18	24	immune	immune	ADJ
admet-2956	18	25	checkpoint	checkpoint	NOUN
admet-2956	18	26	inhibitors	inhibitor	NOUN
admet-2956	18	27	(	(	PUNCT
admet-2956	18	28	icis	icis	NOUN
admet-2956	18	29	)	)	PUNCT
admet-2956	19	1	[	[	X
admet-2956	19	2	3	3	NUM
admet-2956	19	3	-	-	SYM
admet-2956	19	4	5	5	NUM
admet-2956	19	5	]	]	PUNCT
admet-2956	19	6	.	.	PUNCT
admet-2956	20	1	these	these	DET
admet-2956	20	2	advances	advance	NOUN
admet-2956	20	3	have	have	AUX
admet-2956	20	4	translated	translate	VERB
admet-2956	20	5	into	into	ADP
admet-2956	20	6	meaningful	meaningful	ADJ
admet-2956	20	7	improvements	improvement	NOUN
admet-2956	20	8	in	in	ADP
admet-2956	20	9	clinical	clinical	ADJ
admet-2956	20	10	outcomes	outcome	NOUN
admet-2956	20	11	,	,	PUNCT
admet-2956	20	12	offering	offer	VERB
admet-2956	20	13	durable	durable	ADJ
admet-2956	20	14	treatment	treatment	NOUN
admet-2956	20	15	responses	response	NOUN
admet-2956	20	16	and	and	CCONJ
admet-2956	20	17	prolonged	prolonged	ADJ
admet-2956	20	18	survival	survival	NOUN
admet-2956	20	19	for	for	ADP
admet-2956	20	20	patient	patient	ADJ
admet-2956	20	21	groups	group	NOUN
admet-2956	20	22	that	that	PRON
admet-2956	20	23	previously	previously	ADV
admet-2956	20	24	had	have	VERB
admet-2956	20	25	very	very	ADV
admet-2956	20	26	limited	limited	ADJ
admet-2956	20	27	options	option	NOUN
admet-2956	20	28	[	[	X
admet-2956	20	29	6,7	6,7	NUM
admet-2956	20	30	]	]	PUNCT
admet-2956	20	31	.	.	PUNCT
admet-2956	21	1	among	among	ADP
admet-2956	21	2	immune	immune	ADJ
admet-2956	21	3	checkpoint	checkpoint	NOUN
admet-2956	21	4	pathways	pathway	NOUN
admet-2956	21	5	,	,	PUNCT
admet-2956	21	6	the	the	DET
admet-2956	21	7	programmed	program	VERB
admet-2956	21	8	cell	cell	NOUN
admet-2956	21	9	death	death	NOUN
admet-2956	21	10	protein-1	protein-1	PROPN
admet-2956	21	11	(	(	PUNCT
admet-2956	21	12	pd-1	pd-1	X
admet-2956	21	13	)	)	PUNCT
admet-2956	21	14	and	and	CCONJ
admet-2956	21	15	its	its	PRON
admet-2956	21	16	ligand	ligand	ADJ
admet-2956	21	17	pd	pd	PROPN
admet-2956	21	18	-	-	PROPN
admet-2956	21	19	l1	l1	PROPN
admet-2956	21	20	have	have	AUX
admet-2956	21	21	emerged	emerge	VERB
admet-2956	21	22	as	as	ADP
admet-2956	21	23	central	central	ADJ
admet-2956	21	24	therapeutic	therapeutic	ADJ
admet-2956	21	25	targets	target	NOUN
admet-2956	21	26	[	[	X
admet-2956	21	27	8,9	8,9	NUM
admet-2956	21	28	]	]	PUNCT
admet-2956	21	29	.	.	PUNCT
admet-2956	22	1	their	their	PRON
admet-2956	22	2	interaction	interaction	NOUN
admet-2956	22	3	functions	function	NOUN
admet-2956	22	4	as	as	ADP
admet-2956	22	5	a	a	DET
admet-2956	22	6	key	key	ADJ
admet-2956	22	7	immune	immune	ADJ
admet-2956	22	8	checkpoint	checkpoint	NOUN
admet-2956	22	9	,	,	PUNCT
admet-2956	22	10	preventing	prevent	VERB
admet-2956	22	11	excessive	excessive	ADJ
admet-2956	22	12	t	t	NOUN
admet-2956	22	13	-	-	PUNCT
admet-2956	22	14	cell	cell	NOUN
admet-2956	22	15	activation	activation	NOUN
admet-2956	22	16	and	and	CCONJ
admet-2956	22	17	maintaining	maintain	VERB
admet-2956	22	18	immune	immune	ADJ
admet-2956	22	19	balance	balance	NOUN
admet-2956	22	20	[	[	X
admet-2956	22	21	10	10	NUM
admet-2956	22	22	]	]	PUNCT
admet-2956	22	23	.	.	PUNCT
admet-2956	23	1	however	however	ADV
admet-2956	23	2	,	,	PUNCT
admet-2956	23	3	tumour	tumour	NOUN
admet-2956	23	4	cells	cell	NOUN
admet-2956	23	5	often	often	ADV
admet-2956	23	6	exploit	exploit	VERB
admet-2956	23	7	this	this	DET
admet-2956	23	8	mechanism	mechanism	NOUN
admet-2956	23	9	by	by	ADP
admet-2956	23	10	overexpressing	overexpresse	VERB
admet-2956	23	11	pd	pd	PROPN
admet-2956	23	12	-	-	PUNCT
admet-2956	23	13	l1	l1	PROPN
admet-2956	23	14	,	,	PUNCT
admet-2956	23	15	thereby	thereby	ADV
admet-2956	23	16	suppressing	suppress	VERB
admet-2956	23	17	t	t	NOUN
admet-2956	23	18	-	-	PUNCT
admet-2956	23	19	cell	cell	NOUN
admet-2956	23	20	-	-	PUNCT
admet-2956	23	21	mediated	mediate	VERB
admet-2956	23	22	anti	anti	ADJ
admet-2956	23	23	-	-	ADJ
admet-2956	23	24	tumour	tumour	ADJ
admet-2956	23	25	responses	response	NOUN
admet-2956	23	26	and	and	CCONJ
admet-2956	23	27	escaping	escape	VERB
admet-2956	23	28	immune	immune	ADJ
admet-2956	23	29	surveillance	surveillance	NOUN
admet-2956	24	1	[	[	X
admet-2956	24	2	11	11	NUM
admet-2956	24	3	-	-	SYM
admet-2956	24	4	13	13	NUM
admet-2956	24	5	]	]	PUNCT
admet-2956	24	6	.	.	PUNCT
admet-2956	25	1	blocking	block	VERB
admet-2956	25	2	this	this	DET
admet-2956	25	3	pathway	pathway	NOUN
admet-2956	25	4	with	with	ADP
admet-2956	25	5	monoclonal	monoclonal	NOUN
admet-2956	25	6	antibodies	antibody	NOUN
admet-2956	25	7	has	have	AUX
admet-2956	25	8	proven	prove	VERB
admet-2956	25	9	effective	effective	ADJ
admet-2956	25	10	in	in	ADP
admet-2956	25	11	restoring	restore	VERB
admet-2956	25	12	immune	immune	NOUN
admet-2956	25	13	-	-	PUNCT
admet-2956	25	14	driven	drive	VERB
admet-2956	25	15	tumour	tumour	NOUN
admet-2956	25	16	destruction	destruction	NOUN
admet-2956	25	17	across	across	ADP
admet-2956	25	18	multiple	multiple	ADJ
admet-2956	25	19	cancer	cancer	NOUN
admet-2956	25	20	types	type	NOUN
admet-2956	26	1	[	[	X
admet-2956	26	2	14,15	14,15	NUM
admet-2956	26	3	]	]	PUNCT
admet-2956	26	4	.	.	PUNCT
admet-2956	27	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	27	2	,	,	PUNCT
admet-2956	27	3	a	a	DET
admet-2956	27	4	humanized	humanize	VERB
admet-2956	27	5	igg4	igg4	NOUN
admet-2956	27	6	-	-	PUNCT
admet-2956	27	7	κ	κ	NOUN
admet-2956	27	8	monoclonal	monoclonal	NOUN
admet-2956	27	9	antibody	antibody	NOUN
admet-2956	27	10	that	that	PRON
admet-2956	27	11	targets	target	VERB
admet-2956	27	12	pd-1	pd-1	ADV
admet-2956	27	13	,	,	PUNCT
admet-2956	27	14	has	have	AUX
admet-2956	27	15	demonstrated	demonstrate	VERB
admet-2956	27	16	substantial	substantial	ADJ
admet-2956	27	17	clinical	clinical	ADJ
admet-2956	27	18	benefit	benefit	NOUN
admet-2956	27	19	in	in	ADP
admet-2956	27	20	advanced	advanced	ADJ
admet-2956	27	21	nsclc	nsclc	NOUN
admet-2956	27	22	[	[	X
admet-2956	27	23	16,17	16,17	NUM
admet-2956	27	24	]	]	PUNCT
admet-2956	27	25	.	.	PUNCT
admet-2956	28	1	results	result	NOUN
admet-2956	28	2	from	from	ADP
admet-2956	28	3	the	the	DET
admet-2956	28	4	pivotal	pivotal	ADJ
admet-2956	28	5	keynote	keynote	NOUN
admet-2956	28	6	trials	trial	NOUN
admet-2956	28	7	consistently	consistently	ADV
admet-2956	28	8	show	show	VERB
admet-2956	28	9	improved	improve	VERB
admet-2956	28	10	overall	overall	ADJ
admet-2956	28	11	survival	survival	NOUN
admet-2956	28	12	(	(	PUNCT
admet-2956	28	13	os	os	NOUN
admet-2956	28	14	)	)	PUNCT
admet-2956	28	15	and	and	CCONJ
admet-2956	28	16	progression	progression	NOUN
admet-2956	28	17	-	-	PUNCT
admet-2956	28	18	free	free	ADJ
admet-2956	28	19	survival	survival	NOUN
admet-2956	28	20	(	(	PUNCT
admet-2956	28	21	pfs	pfs	PROPN
admet-2956	28	22	)	)	PUNCT
admet-2956	28	23	compared	compare	VERB
admet-2956	28	24	with	with	ADP
admet-2956	28	25	standard	standard	ADJ
admet-2956	28	26	chemotherapy	chemotherapy	NOUN
admet-2956	28	27	,	,	PUNCT
admet-2956	28	28	leading	lead	VERB
admet-2956	28	29	to	to	ADP
admet-2956	28	30	its	its	PRON
admet-2956	28	31	approval	approval	NOUN
admet-2956	28	32	and	and	CCONJ
admet-2956	28	33	widespread	widespread	ADJ
admet-2956	28	34	use	use	NOUN
admet-2956	28	35	in	in	ADP
admet-2956	28	36	clinical	clinical	ADJ
admet-2956	28	37	practice	practice	NOUN
admet-2956	28	38	[	[	X
admet-2956	28	39	18	18	NUM
admet-2956	28	40	-	-	SYM
admet-2956	28	41	20	20	NUM
admet-2956	28	42	]	]	PUNCT
admet-2956	28	43	.	.	PUNCT
admet-2956	29	1	these	these	DET
admet-2956	29	2	findings	finding	NOUN
admet-2956	29	3	have	have	AUX
admet-2956	29	4	established	establish	VERB
admet-2956	29	5	pembrolizumab	pembrolizumab	NOUN
admet-2956	29	6	as	as	ADP
admet-2956	29	7	a	a	DET
admet-2956	29	8	cornerstone	cornerstone	NOUN
admet-2956	29	9	of	of	ADP
admet-2956	29	10	first	first	ADJ
admet-2956	29	11	-	-	PUNCT
admet-2956	29	12	line	line	NOUN
admet-2956	29	13	therapy	therapy	NOUN
admet-2956	29	14	for	for	ADP
admet-2956	29	15	advanced	advanced	ADJ
admet-2956	29	16	nsclc	nsclc	NOUN
admet-2956	29	17	,	,	PUNCT
admet-2956	29	18	fundamentally	fundamentally	ADV
admet-2956	29	19	reshaping	reshape	VERB
admet-2956	29	20	treatment	treatment	NOUN
admet-2956	29	21	guidelines	guideline	NOUN
admet-2956	29	22	and	and	CCONJ
admet-2956	29	23	prognostic	prognostic	ADJ
admet-2956	29	24	expectations	expectation	NOUN
admet-2956	29	25	[	[	X
admet-2956	29	26	21,22	21,22	X
admet-2956	29	27	]	]	X
admet-2956	29	28	.	.	PUNCT
admet-2956	30	1	despite	despite	SCONJ
admet-2956	30	2	these	these	DET
admet-2956	30	3	advances	advance	NOUN
admet-2956	30	4	,	,	PUNCT
admet-2956	30	5	important	important	ADJ
admet-2956	30	6	challenges	challenge	NOUN
admet-2956	30	7	remain	remain	VERB
admet-2956	30	8	in	in	ADP
admet-2956	30	9	refining	refining	NOUN
admet-2956	30	10	patient	patient	ADJ
admet-2956	30	11	selection	selection	NOUN
admet-2956	30	12	for	for	ADP
admet-2956	30	13	pembrolizumab	pembrolizumab	NOUN
admet-2956	30	14	.	.	PUNCT
admet-2956	31	1	currently	currently	ADV
admet-2956	31	2	,	,	PUNCT
admet-2956	31	3	pd	pd	PROPN
admet-2956	31	4	-	-	PUNCT
admet-2956	31	5	l1	l1	PROPN
admet-2956	31	6	expression	expression	NOUN
admet-2956	31	7	assessed	assess	VERB
admet-2956	31	8	by	by	ADP
admet-2956	31	9	immunohistochemistry	immunohistochemistry	NOUN
admet-2956	31	10	serves	serve	VERB
admet-2956	31	11	as	as	ADP
admet-2956	31	12	the	the	DET
admet-2956	31	13	primary	primary	ADJ
admet-2956	31	14	predictive	predictive	NOUN
admet-2956	31	15	biomarker	biomarker	NOUN
admet-2956	31	16	,	,	PUNCT
admet-2956	31	17	with	with	ADP
admet-2956	31	18	tumour	tumour	NOUN
admet-2956	31	19	proportion	proportion	NOUN
admet-2956	31	20	scores	score	NOUN
admet-2956	31	21	(	(	PUNCT
admet-2956	31	22	tps	tps	NOUN
admet-2956	31	23	)	)	PUNCT
admet-2956	31	24	≥50	≥50	NUM
admet-2956	31	25	%	%	NOUN
admet-2956	31	26	indicating	indicate	VERB
admet-2956	31	27	the	the	DET
admet-2956	31	28	highest	high	ADJ
admet-2956	31	29	likelihood	likelihood	NOUN
admet-2956	31	30	of	of	ADP
admet-2956	31	31	response	response	NOUN
admet-2956	31	32	to	to	ADP
admet-2956	31	33	monotherapy	monotherapy	NOUN
admet-2956	31	34	[	[	X
admet-2956	31	35	23,24	23,24	NOUN
admet-2956	31	36	]	]	PUNCT
admet-2956	31	37	.	.	PUNCT
admet-2956	32	1	yet	yet	ADV
admet-2956	32	2	,	,	PUNCT
admet-2956	32	3	increasing	increase	VERB
admet-2956	32	4	evidence	evidence	NOUN
admet-2956	32	5	suggests	suggest	VERB
admet-2956	32	6	that	that	SCONJ
admet-2956	32	7	pd	pd	PROPN
admet-2956	32	8	-	-	PROPN
admet-2956	32	9	l1	l1	PROPN
admet-2956	32	10	alone	alone	ADV
admet-2956	32	11	is	be	AUX
admet-2956	32	12	insufficient	insufficient	ADJ
admet-2956	32	13	for	for	ADP
admet-2956	32	14	guiding	guide	VERB
admet-2956	32	15	treatment	treatment	NOUN
admet-2956	32	16	.	.	PUNCT
admet-2956	33	1	some	some	DET
admet-2956	33	2	patients	patient	NOUN
admet-2956	33	3	with	with	ADP
admet-2956	33	4	little	little	ADJ
admet-2956	33	5	or	or	CCONJ
admet-2956	33	6	no	no	PRON
admet-2956	33	7	pd	pd	ADJ
admet-2956	33	8	-	-	PUNCT
admet-2956	33	9	l1	l1	PROPN
admet-2956	33	10	expression	expression	NOUN
admet-2956	33	11	achieve	achieve	VERB
admet-2956	33	12	meaningful	meaningful	ADJ
admet-2956	33	13	responses	response	NOUN
admet-2956	33	14	,	,	PUNCT
admet-2956	33	15	while	while	SCONJ
admet-2956	33	16	others	other	NOUN
admet-2956	33	17	with	with	ADP
admet-2956	33	18	high	high	ADJ
admet-2956	33	19	expression	expression	NOUN
admet-2956	33	20	levels	level	NOUN
admet-2956	33	21	derive	derive	VERB
admet-2956	33	22	limited	limited	ADJ
admet-2956	33	23	benefit	benefit	NOUN
admet-2956	33	24	[	[	X
admet-2956	33	25	25,26	25,26	NUM
admet-2956	33	26	]	]	X
admet-2956	33	27	.	.	PUNCT
admet-2956	34	1	this	this	DET
admet-2956	34	2	paradox	paradox	NOUN
admet-2956	34	3	underscores	underscore	VERB
admet-2956	34	4	the	the	DET
admet-2956	34	5	complexity	complexity	NOUN
admet-2956	34	6	of	of	ADP
admet-2956	34	7	tumour	tumour	ADJ
admet-2956	34	8	-	-	PUNCT
admet-2956	34	9	immune	immune	ADJ
admet-2956	34	10	interactions	interaction	NOUN
admet-2956	34	11	,	,	PUNCT
admet-2956	34	12	which	which	PRON
admet-2956	34	13	can	can	AUX
admet-2956	34	14	not	not	PART
admet-2956	34	15	be	be	AUX
admet-2956	34	16	fully	fully	ADV
admet-2956	34	17	explained	explain	VERB
admet-2956	34	18	by	by	ADP
admet-2956	34	19	a	a	DET
admet-2956	34	20	single	single	ADJ
admet-2956	34	21	biomarker	biomarker	NOUN
admet-2956	34	22	[	[	X
admet-2956	34	23	27,28	27,28	NUM
admet-2956	34	24	]	]	X
admet-2956	34	25	.	.	PUNCT
admet-2956	35	1	clinical	clinical	ADJ
admet-2956	35	2	data	datum	NOUN
admet-2956	35	3	also	also	ADV
admet-2956	35	4	reveal	reveal	VERB
admet-2956	35	5	wide	wide	ADJ
admet-2956	35	6	variability	variability	NOUN
admet-2956	35	7	in	in	ADP
admet-2956	35	8	treatment	treatment	NOUN
admet-2956	35	9	outcomes	outcome	NOUN
admet-2956	35	10	across	across	ADP
admet-2956	35	11	patient	patient	ADJ
admet-2956	35	12	subgroups	subgroup	NOUN
admet-2956	35	13	,	,	PUNCT
admet-2956	35	14	indicating	indicate	VERB
admet-2956	35	15	that	that	SCONJ
admet-2956	35	16	demographic	demographic	ADJ
admet-2956	35	17	and	and	CCONJ
admet-2956	35	18	molecular	molecular	ADJ
admet-2956	35	19	factors	factor	NOUN
admet-2956	35	20	beyond	beyond	ADP
admet-2956	35	21	pd	pd	PROPN
admet-2956	35	22	-	-	PUNCT
admet-2956	35	23	l1	l1	PROPN
admet-2956	35	24	play	play	VERB
admet-2956	35	25	a	a	DET
admet-2956	35	26	role	role	NOUN
admet-2956	35	27	[	[	X
admet-2956	35	28	29	29	NUM
admet-2956	35	29	-	-	SYM
admet-2956	35	30	31	31	NUM
admet-2956	35	31	]	]	PUNCT
admet-2956	35	32	.	.	PUNCT
admet-2956	36	1	for	for	ADP
admet-2956	36	2	instance	instance	NOUN
admet-2956	36	3	,	,	PUNCT
admet-2956	36	4	age	age	NOUN
admet-2956	36	5	and	and	CCONJ
admet-2956	36	6	sex	sex	NOUN
admet-2956	36	7	have	have	AUX
admet-2956	36	8	been	be	AUX
admet-2956	36	9	suggested	suggest	VERB
admet-2956	36	10	as	as	ADP
admet-2956	36	11	potential	potential	ADJ
admet-2956	36	12	modifiers	modifier	NOUN
admet-2956	36	13	of	of	ADP
admet-2956	36	14	immunotherapy	immunotherapy	NOUN
admet-2956	36	15	efficacy	efficacy	NOUN
admet-2956	36	16	,	,	PUNCT
admet-2956	36	17	but	but	CCONJ
admet-2956	36	18	these	these	DET
admet-2956	36	19	influences	influence	NOUN
admet-2956	36	20	remain	remain	VERB
admet-2956	36	21	underexplored	underexplored	ADJ
admet-2956	36	22	in	in	ADP
admet-2956	36	23	systematic	systematic	ADJ
admet-2956	36	24	analyses	analysis	NOUN
admet-2956	37	1	[	[	X
admet-2956	37	2	32	32	NUM
admet-2956	37	3	-	-	SYM
admet-2956	37	4	35	35	NUM
admet-2956	37	5	]	]	PUNCT
admet-2956	37	6	.	.	PUNCT
admet-2956	38	1	in	in	ADP
admet-2956	38	2	addition	addition	NOUN
admet-2956	38	3	,	,	PUNCT
admet-2956	38	4	long	long	ADJ
admet-2956	38	5	-	-	PUNCT
admet-2956	38	6	term	term	NOUN
admet-2956	38	7	follow	follow	NOUN
admet-2956	38	8	-	-	PUNCT
admet-2956	38	9	up	up	ADP
admet-2956	38	10	data	datum	NOUN
admet-2956	38	11	from	from	ADP
admet-2956	38	12	pivotal	pivotal	ADJ
admet-2956	38	13	trials	trial	NOUN
admet-2956	38	14	,	,	PUNCT
admet-2956	38	15	along	along	ADP
admet-2956	38	16	with	with	ADP
admet-2956	38	17	emerging	emerge	VERB
admet-2956	38	18	real	real	ADJ
admet-2956	38	19	-	-	PUNCT
admet-2956	38	20	world	world	NOUN
admet-2956	38	21	evidence	evidence	NOUN
admet-2956	38	22	,	,	PUNCT
admet-2956	38	23	are	be	AUX
admet-2956	38	24	providing	provide	VERB
admet-2956	38	25	new	new	ADJ
admet-2956	38	26	insights	insight	NOUN
admet-2956	38	27	into	into	ADP
admet-2956	38	28	pembrolizumab	pembrolizumab	NOUN
admet-2956	38	29	’s	’s	PART
admet-2956	38	30	clinical	clinical	ADJ
admet-2956	38	31	profile	profile	NOUN
admet-2956	38	32	that	that	PRON
admet-2956	38	33	call	call	VERB
admet-2956	38	34	for	for	ADP
admet-2956	38	35	updated	update	VERB
admet-2956	38	36	evaluation	evaluation	NOUN
admet-2956	38	37	[	[	X
admet-2956	38	38	36	36	NUM
admet-2956	38	39	-	-	SYM
admet-2956	38	40	38	38	NUM
admet-2956	38	41	]	]	PUNCT
admet-2956	38	42	.	.	PUNCT
admet-2956	39	1	although	although	SCONJ
admet-2956	39	2	several	several	ADJ
admet-2956	39	3	meta	meta	NOUN
admet-2956	39	4	-	-	PUNCT
admet-2956	39	5	analyses	analysis	NOUN
admet-2956	39	6	have	have	AUX
admet-2956	39	7	assessed	assess	VERB
admet-2956	39	8	pembrolizumab	pembrolizumab	NOUN
admet-2956	39	9	in	in	ADP
admet-2956	39	10	nsclc	nsclc	NOUN
admet-2956	39	11	,	,	PUNCT
admet-2956	39	12	most	most	ADV
admet-2956	39	13	included	include	VERB
admet-2956	39	14	unselected	unselected	ADJ
admet-2956	39	15	patient	patient	NOUN
admet-2956	39	16	populations	population	NOUN
admet-2956	39	17	or	or	CCONJ
admet-2956	39	18	did	do	AUX
admet-2956	39	19	not	not	PART
admet-2956	39	20	focus	focus	VERB
admet-2956	39	21	specifically	specifically	ADV
admet-2956	39	22	on	on	ADP
admet-2956	39	23	pd	pd	PROPN
admet-2956	39	24	-	-	PUNCT
admet-2956	39	25	l1	l1	ADJ
admet-2956	39	26	-	-	PUNCT
admet-2956	39	27	positive	positive	ADJ
admet-2956	39	28	disease	disease	NOUN
admet-2956	39	29	using	use	VERB
admet-2956	39	30	the	the	DET
admet-2956	39	31	most	most	ADV
admet-2956	39	32	contemporary	contemporary	ADJ
admet-2956	39	33	data	datum	NOUN
admet-2956	39	34	[	[	X
admet-2956	39	35	39,40	39,40	NUM
admet-2956	39	36	]	]	X
admet-2956	39	37	.	.	PUNCT
admet-2956	40	1	a	a	DET
admet-2956	40	2	critical	critical	ADJ
admet-2956	40	3	knowledge	knowledge	NOUN
admet-2956	40	4	gap	gap	NOUN
admet-2956	40	5	therefore	therefore	ADV
admet-2956	40	6	persists	persist	VERB
admet-2956	40	7	regarding	regard	VERB
admet-2956	40	8	the	the	DET
admet-2956	40	9	true	true	ADJ
admet-2956	40	10	therapeutic	therapeutic	ADJ
admet-2956	40	11	value	value	NOUN
admet-2956	40	12	of	of	ADP
admet-2956	40	13	pembrolizumab	pembrolizumab	NOUN
admet-2956	40	14	in	in	ADP
admet-2956	40	15	patients	patient	NOUN
admet-2956	40	16	with	with	ADP
admet-2956	40	17	pd	pd	PROPN
admet-2956	40	18	-	-	PUNCT
admet-2956	40	19	l1	l1	PROPN
admet-2956	40	20	-	-	PUNCT
admet-2956	40	21	positive	positive	ADJ
admet-2956	40	22	advanced	advanced	ADJ
admet-2956	40	23	nsclc	nsclc	NOUN
admet-2956	40	24	,	,	PUNCT
admet-2956	40	25	particularly	particularly	ADV
admet-2956	40	26	in	in	ADP
admet-2956	40	27	light	light	NOUN
admet-2956	40	28	of	of	ADP
admet-2956	40	29	evolving	evolve	VERB
admet-2956	40	30	biomarker	biomarker	NOUN
admet-2956	40	31	limitations	limitation	NOUN
admet-2956	40	32	and	and	CCONJ
admet-2956	40	33	patient	patient	NOUN
admet-2956	40	34	-	-	PUNCT
admet-2956	40	35	related	relate	VERB
admet-2956	40	36	factors	factor	NOUN
admet-2956	40	37	influencing	influence	VERB
admet-2956	40	38	treatment	treatment	NOUN
admet-2956	40	39	response	response	NOUN
admet-2956	40	40	[	[	X
admet-2956	40	41	41,42	41,42	NOUN
admet-2956	40	42	]	]	PUNCT
admet-2956	40	43	.	.	PUNCT
admet-2956	41	1	to	to	PART
admet-2956	41	2	address	address	VERB
admet-2956	41	3	this	this	DET
admet-2956	41	4	gap	gap	NOUN
admet-2956	41	5	,	,	PUNCT
admet-2956	41	6	we	we	PRON
admet-2956	41	7	conducted	conduct	VERB
admet-2956	41	8	a	a	DET
admet-2956	41	9	systematic	systematic	ADJ
admet-2956	41	10	review	review	NOUN
admet-2956	41	11	and	and	CCONJ
admet-2956	41	12	meta	meta	NOUN
admet-2956	41	13	-	-	PUNCT
admet-2956	41	14	analysis	analysis	NOUN
admet-2956	41	15	to	to	PART
admet-2956	41	16	evaluate	evaluate	VERB
admet-2956	41	17	the	the	DET
admet-2956	41	18	efficacy	efficacy	NOUN
admet-2956	41	19	and	and	CCONJ
admet-2956	41	20	safety	safety	NOUN
admet-2956	41	21	of	of	ADP
admet-2956	41	22	pembrolizumab	pembrolizumab	NOUN
admet-2956	41	23	in	in	ADP
admet-2956	41	24	pd	pd	PROPN
admet-2956	41	25	-	-	PUNCT
admet-2956	41	26	l1	l1	PROPN
admet-2956	41	27	-	-	PUNCT
admet-2956	41	28	positive	positive	ADJ
admet-2956	41	29	advanced	advanced	ADJ
admet-2956	41	30	nsclc	nsclc	NOUN
admet-2956	41	31	,	,	PUNCT
admet-2956	41	32	with	with	ADP
admet-2956	41	33	a	a	DET
admet-2956	41	34	particular	particular	ADJ
admet-2956	41	35	focus	focus	NOUN
admet-2956	41	36	on	on	ADP
admet-2956	41	37	clinical	clinical	ADJ
admet-2956	41	38	and	and	CCONJ
admet-2956	41	39	molecular	molecular	ADJ
admet-2956	41	40	predictors	predictor	NOUN
admet-2956	41	41	of	of	ADP
admet-2956	41	42	response	response	NOUN
admet-2956	41	43	.	.	PUNCT
admet-2956	42	1	our	our	PRON
admet-2956	42	2	primary	primary	ADJ
admet-2956	42	3	objective	objective	NOUN
admet-2956	42	4	was	be	AUX
admet-2956	42	5	to	to	PART
admet-2956	42	6	synthesize	synthesize	VERB
admet-2956	42	7	evidence	evidence	NOUN
admet-2956	42	8	from	from	ADP
admet-2956	42	9	randomized	randomized	ADJ
admet-2956	42	10	controlled	control	VERB
admet-2956	42	11	trials	trial	NOUN
admet-2956	42	12	to	to	PART
admet-2956	42	13	assess	assess	VERB
admet-2956	42	14	survival	survival	NOUN
admet-2956	42	15	outcomes	outcome	NOUN
admet-2956	42	16	across	across	ADP
admet-2956	42	17	different	different	ADJ
admet-2956	42	18	pd	pd	PROPN
admet-2956	42	19	-	-	PROPN
admet-2956	42	20	l1	l1	PROPN
admet-2956	42	21	expression	expression	NOUN
admet-2956	42	22	thresholds	threshold	NOUN
admet-2956	42	23	and	and	CCONJ
admet-2956	42	24	patient	patient	ADJ
admet-2956	42	25	subgroups	subgroup	NOUN
admet-2956	42	26	.	.	PUNCT
admet-2956	43	1	secondary	secondary	ADJ
admet-2956	43	2	objectives	objective	NOUN
admet-2956	43	3	included	include	VERB
admet-2956	43	4	a	a	DET
admet-2956	43	5	comprehensive	comprehensive	ADJ
admet-2956	43	6	evaluation	evaluation	NOUN
admet-2956	43	7	of	of	ADP
admet-2956	43	8	safety	safety	NOUN
admet-2956	43	9	and	and	CCONJ
admet-2956	43	10	an	an	DET
admet-2956	43	11	examination	examination	NOUN
admet-2956	43	12	of	of	ADP
admet-2956	43	13	demographic	demographic	ADJ
admet-2956	43	14	factors	factor	NOUN
admet-2956	43	15	related	relate	VERB
admet-2956	43	16	admet	admet	PROPN
admet-2956	43	17	&	&	CCONJ
admet-2956	43	18	dmpk	dmpk	PROPN
admet-2956	43	19	13(5	13(5	NUM
admet-2956	43	20	)	)	PUNCT
admet-2956	43	21	(	(	PUNCT
admet-2956	43	22	2025	2025	NUM
admet-2956	43	23	)	)	PUNCT
admet-2956	43	24	2956	2956	NUM
admet-2956	43	25	pembrolizumab	pembrolizumab	NOUN
admet-2956	43	26	in	in	ADP
admet-2956	43	27	pd	pd	PROPN
admet-2956	43	28	-	-	PUNCT
admet-2956	43	29	l1	l1	PROPN
admet-2956	43	30	-	-	PUNCT
admet-2956	43	31	positive	positive	ADJ
admet-2956	43	32	advanced	advanced	ADJ
admet-2956	43	33	non	non	ADJ
admet-2956	43	34	-	-	ADJ
admet-2956	43	35	small	small	ADJ
admet-2956	43	36	cell	cell	NOUN
admet-2956	43	37	lung	lung	NOUN
admet-2956	43	38	carcinoma	carcinoma	NOUN
admet-2956	43	39	doi	doi	NOUN
admet-2956	43	40	:	:	PUNCT
admet-2956	43	41	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	43	42	3	3	NUM
admet-2956	43	43	to	to	ADP
admet-2956	43	44	treatment	treatment	NOUN
admet-2956	43	45	outcomes	outcome	NOUN
admet-2956	43	46	.	.	PUNCT
admet-2956	44	1	our	our	PRON
admet-2956	44	2	analysis	analysis	NOUN
admet-2956	44	3	indicates	indicate	VERB
admet-2956	44	4	that	that	SCONJ
admet-2956	44	5	pembrolizumab	pembrolizumab	NOUN
admet-2956	44	6	significantly	significantly	ADV
admet-2956	44	7	improves	improve	VERB
admet-2956	44	8	survival	survival	NOUN
admet-2956	44	9	across	across	ADP
admet-2956	44	10	all	all	DET
admet-2956	44	11	pd	pd	PROPN
admet-2956	44	12	-	-	ADJ
admet-2956	44	13	l1	l1	PROPN
admet-2956	44	14	expression	expression	NOUN
admet-2956	44	15	levels	level	NOUN
admet-2956	44	16	,	,	PUNCT
admet-2956	44	17	with	with	ADP
admet-2956	44	18	unexpected	unexpected	ADJ
admet-2956	44	19	benefits	benefit	NOUN
admet-2956	44	20	in	in	ADP
admet-2956	44	21	traditionally	traditionally	ADV
admet-2956	44	22	“	"	PUNCT
admet-2956	44	23	biomarker	biomarker	NOUN
admet-2956	44	24	-	-	PUNCT
admet-2956	44	25	negative	negative	ADJ
admet-2956	44	26	”	"	PUNCT
admet-2956	44	27	patients	patient	NOUN
admet-2956	44	28	and	and	CCONJ
admet-2956	44	29	distinct	distinct	ADJ
admet-2956	44	30	response	response	NOUN
admet-2956	44	31	patterns	pattern	NOUN
admet-2956	44	32	linked	link	VERB
admet-2956	44	33	to	to	ADP
admet-2956	44	34	demographic	demographic	ADJ
admet-2956	44	35	characteristics	characteristic	NOUN
admet-2956	44	36	.	.	PUNCT
admet-2956	45	1	these	these	DET
admet-2956	45	2	findings	finding	NOUN
admet-2956	45	3	challenge	challenge	VERB
admet-2956	45	4	current	current	ADJ
admet-2956	45	5	patient	patient	NOUN
admet-2956	45	6	selection	selection	NOUN
admet-2956	45	7	paradigms	paradigm	VERB
admet-2956	45	8	and	and	CCONJ
admet-2956	45	9	highlight	highlight	VERB
admet-2956	45	10	the	the	DET
admet-2956	45	11	need	need	NOUN
admet-2956	45	12	for	for	ADP
admet-2956	45	13	multidimensional	multidimensional	ADJ
admet-2956	45	14	biomarker	biomarker	NOUN
admet-2956	45	15	strategies	strategy	NOUN
admet-2956	45	16	in	in	ADP
admet-2956	45	17	the	the	DET
admet-2956	45	18	era	era	NOUN
admet-2956	45	19	of	of	ADP
admet-2956	45	20	precision	precision	NOUN
admet-2956	45	21	immunotherapy	immunotherapy	NOUN
admet-2956	45	22	.	.	PUNCT
admet-2956	46	1	research	research	NOUN
admet-2956	46	2	design	design	VERB
admet-2956	46	3	a	a	DET
admet-2956	46	4	comprehensive	comprehensive	ADJ
admet-2956	46	5	literature	literature	NOUN
admet-2956	46	6	search	search	NOUN
admet-2956	46	7	was	be	AUX
admet-2956	46	8	conducted	conduct	VERB
admet-2956	46	9	across	across	ADP
admet-2956	46	10	multiple	multiple	ADJ
admet-2956	46	11	electronic	electronic	ADJ
admet-2956	46	12	databases	database	NOUN
admet-2956	46	13	,	,	PUNCT
admet-2956	46	14	including	include	VERB
admet-2956	46	15	pubmed	pubmed	PROPN
admet-2956	46	16	/	/	SYM
admet-2956	46	17	medline	medline	PROPN
admet-2956	46	18	,	,	PUNCT
admet-2956	46	19	scopus	scopus	PROPN
admet-2956	46	20	,	,	PUNCT
admet-2956	46	21	the	the	DET
admet-2956	46	22	cochrane	cochrane	NOUN
admet-2956	46	23	library	library	NOUN
admet-2956	46	24	,	,	PUNCT
admet-2956	46	25	web	web	NOUN
admet-2956	46	26	of	of	ADP
admet-2956	46	27	science	science	NOUN
admet-2956	46	28	,	,	PUNCT
admet-2956	46	29	sciencedirect	sciencedirect	PROPN
admet-2956	46	30	and	and	CCONJ
admet-2956	46	31	ebsco	ebsco	PROPN
admet-2956	46	32	,	,	PUNCT
admet-2956	46	33	covering	cover	VERB
admet-2956	46	34	publications	publication	NOUN
admet-2956	46	35	from	from	ADP
admet-2956	46	36	inception	inception	NOUN
admet-2956	46	37	through	through	ADP
admet-2956	46	38	march	march	PROPN
admet-2956	46	39	2025	2025	NUM
admet-2956	46	40	.	.	PUNCT
admet-2956	47	1	the	the	DET
admet-2956	47	2	search	search	NOUN
admet-2956	47	3	strategy	strategy	NOUN
admet-2956	47	4	combined	combine	VERB
admet-2956	47	5	medical	medical	ADJ
admet-2956	47	6	subject	subject	NOUN
admet-2956	47	7	headings	heading	NOUN
admet-2956	47	8	(	(	PUNCT
admet-2956	47	9	mesh	mesh	NOUN
admet-2956	47	10	)	)	PUNCT
admet-2956	47	11	with	with	ADP
admet-2956	47	12	free	free	ADJ
admet-2956	47	13	-	-	PUNCT
admet-2956	47	14	text	text	NOUN
admet-2956	47	15	keywords	keyword	NOUN
admet-2956	47	16	such	such	ADJ
admet-2956	47	17	as	as	ADP
admet-2956	47	18	“	"	PUNCT
admet-2956	47	19	non	non	ADJ
admet-2956	47	20	-	-	ADJ
admet-2956	47	21	small	small	ADJ
admet-2956	47	22	cell	cell	NOUN
admet-2956	47	23	lung	lung	NOUN
admet-2956	47	24	cancer	cancer	NOUN
admet-2956	47	25	”	"	PUNCT
admet-2956	47	26	,	,	PUNCT
admet-2956	47	27	“	"	PUNCT
admet-2956	47	28	pembrolizumab	pembrolizumab	NOUN
admet-2956	47	29	”	"	PUNCT
admet-2956	47	30	and	and	CCONJ
admet-2956	47	31	“	"	PUNCT
admet-2956	47	32	pd	pd	PROPN
admet-2956	47	33	-	-	PUNCT
admet-2956	47	34	l1	l1	PROPN
admet-2956	47	35	”	"	PUNCT
admet-2956	47	36	,	,	PUNCT
admet-2956	47	37	using	use	VERB
admet-2956	47	38	boolean	boolean	ADJ
admet-2956	47	39	operators	operator	NOUN
admet-2956	47	40	(	(	PUNCT
admet-2956	47	41	and	and	CCONJ
admet-2956	47	42	,	,	PUNCT
admet-2956	47	43	or	or	CCONJ
admet-2956	47	44	)	)	PUNCT
admet-2956	47	45	to	to	PART
admet-2956	47	46	ensure	ensure	VERB
admet-2956	47	47	sensitivity	sensitivity	NOUN
admet-2956	47	48	and	and	CCONJ
admet-2956	47	49	specificity	specificity	NOUN
admet-2956	47	50	.	.	PUNCT
admet-2956	48	1	to	to	PART
admet-2956	48	2	minimize	minimize	VERB
admet-2956	48	3	publication	publication	NOUN
admet-2956	48	4	bias	bias	NOUN
admet-2956	48	5	,	,	PUNCT
admet-2956	48	6	additional	additional	ADJ
admet-2956	48	7	gray	gray	ADJ
admet-2956	48	8	literature	literature	NOUN
admet-2956	48	9	sources	source	NOUN
admet-2956	48	10	were	be	AUX
admet-2956	48	11	explored	explore	VERB
admet-2956	48	12	,	,	PUNCT
admet-2956	48	13	including	include	VERB
admet-2956	48	14	institutional	institutional	ADJ
admet-2956	48	15	repositories	repository	NOUN
admet-2956	48	16	and	and	CCONJ
admet-2956	48	17	relevant	relevant	ADJ
admet-2956	48	18	scientific	scientific	ADJ
admet-2956	48	19	platforms	platform	NOUN
admet-2956	48	20	.	.	PUNCT
admet-2956	49	1	eligibility	eligibility	NOUN
admet-2956	49	2	criteria	criterion	NOUN
admet-2956	49	3	studies	study	NOUN
admet-2956	49	4	were	be	AUX
admet-2956	49	5	considered	consider	VERB
admet-2956	49	6	eligible	eligible	ADJ
admet-2956	49	7	if	if	SCONJ
admet-2956	49	8	they	they	PRON
admet-2956	49	9	met	meet	VERB
admet-2956	49	10	the	the	DET
admet-2956	49	11	following	follow	VERB
admet-2956	49	12	criteria	criterion	NOUN
admet-2956	49	13	:	:	PUNCT
admet-2956	49	14	1	1	X
admet-2956	49	15	)	)	PUNCT
admet-2956	49	16	population	population	NOUN
admet-2956	49	17	:	:	PUNCT
admet-2956	49	18	adults	adult	NOUN
admet-2956	49	19	with	with	ADP
admet-2956	49	20	pd	pd	PROPN
admet-2956	49	21	-	-	PUNCT
admet-2956	49	22	l1	l1	ADJ
admet-2956	49	23	-	-	PUNCT
admet-2956	49	24	positive	positive	ADJ
admet-2956	49	25	nsclc	nsclc	NOUN
admet-2956	49	26	with	with	ADP
admet-2956	49	27	histologic	histologic	ADJ
admet-2956	49	28	confirmation	confirmation	NOUN
admet-2956	49	29	;	;	PUNCT
admet-2956	49	30	2	2	X
admet-2956	49	31	)	)	PUNCT
admet-2956	49	32	intervention	intervention	NOUN
admet-2956	49	33	:	:	PUNCT
admet-2956	49	34	pembrolizumab	pembrolizumab	NOUN
admet-2956	49	35	monotherapy	monotherapy	NOUN
admet-2956	49	36	or	or	CCONJ
admet-2956	49	37	combination	combination	NOUN
admet-2956	49	38	therapy	therapy	NOUN
admet-2956	49	39	in	in	ADP
admet-2956	49	40	phase	phase	PROPN
admet-2956	49	41	ii	ii	PROPN
admet-2956	49	42	/	/	SYM
admet-2956	49	43	iii	iii	PROPN
admet-2956	49	44	randomized	randomize	VERB
admet-2956	49	45	controlled	control	VERB
admet-2956	49	46	trials	trial	NOUN
admet-2956	49	47	;	;	PUNCT
admet-2956	49	48	3	3	X
admet-2956	49	49	)	)	PUNCT
admet-2956	49	50	control	control	NOUN
admet-2956	49	51	:	:	PUNCT
admet-2956	49	52	chemotherapy	chemotherapy	NOUN
admet-2956	49	53	;	;	PUNCT
admet-2956	49	54	4	4	X
admet-2956	49	55	)	)	PUNCT
admet-2956	49	56	outcomes	outcome	NOUN
admet-2956	49	57	:	:	PUNCT
admet-2956	49	58	os	os	ADJ
admet-2956	49	59	,	,	PUNCT
admet-2956	49	60	pfs	pfs	PROPN
admet-2956	49	61	,	,	PUNCT
admet-2956	49	62	overall	overall	ADJ
admet-2956	49	63	response	response	NOUN
admet-2956	49	64	rate	rate	NOUN
admet-2956	49	65	(	(	PUNCT
admet-2956	49	66	orr	orr	PROPN
admet-2956	49	67	)	)	PUNCT
admet-2956	49	68	,	,	PUNCT
admet-2956	49	69	and	and	CCONJ
admet-2956	49	70	safety	safety	NOUN
admet-2956	49	71	outcomes	outcome	NOUN
admet-2956	49	72	;	;	PUNCT
admet-2956	49	73	5	5	X
admet-2956	49	74	)	)	PUNCT
admet-2956	49	75	language	language	NOUN
admet-2956	49	76	:	:	PUNCT
admet-2956	49	77	english	english	ADJ
admet-2956	49	78	-	-	PUNCT
admet-2956	49	79	language	language	NOUN
admet-2956	49	80	publications	publication	NOUN
admet-2956	49	81	.	.	PUNCT
admet-2956	50	1	study	study	NOUN
admet-2956	50	2	selection	selection	NOUN
admet-2956	50	3	was	be	AUX
admet-2956	50	4	independently	independently	ADV
admet-2956	50	5	performed	perform	VERB
admet-2956	50	6	by	by	ADP
admet-2956	50	7	two	two	NUM
admet-2956	50	8	reviewers	reviewer	NOUN
admet-2956	50	9	following	follow	VERB
admet-2956	50	10	a	a	DET
admet-2956	50	11	predefined	predefine	VERB
admet-2956	50	12	protocol	protocol	NOUN
admet-2956	50	13	.	.	PUNCT
admet-2956	51	1	disagreements	disagreement	NOUN
admet-2956	51	2	were	be	AUX
admet-2956	51	3	resolved	resolve	VERB
admet-2956	51	4	by	by	ADP
admet-2956	51	5	discussion	discussion	NOUN
admet-2956	51	6	and	and	CCONJ
admet-2956	51	7	,	,	PUNCT
admet-2956	51	8	when	when	SCONJ
admet-2956	51	9	necessary	necessary	ADJ
admet-2956	51	10	,	,	PUNCT
admet-2956	51	11	consultation	consultation	NOUN
admet-2956	51	12	with	with	ADP
admet-2956	51	13	a	a	DET
admet-2956	51	14	third	third	ADJ
admet-2956	51	15	reviewer	reviewer	NOUN
admet-2956	51	16	.	.	PUNCT
admet-2956	52	1	data	datum	NOUN
admet-2956	52	2	analysis	analysis	NOUN
admet-2956	52	3	data	datum	NOUN
admet-2956	52	4	were	be	AUX
admet-2956	52	5	extracted	extract	VERB
admet-2956	52	6	on	on	ADP
admet-2956	52	7	study	study	NOUN
admet-2956	52	8	design	design	NOUN
admet-2956	52	9	,	,	PUNCT
admet-2956	52	10	patient	patient	ADJ
admet-2956	52	11	demographics	demographic	NOUN
admet-2956	52	12	,	,	PUNCT
admet-2956	52	13	intervention	intervention	NOUN
admet-2956	52	14	details	detail	NOUN
admet-2956	52	15	,	,	PUNCT
admet-2956	52	16	and	and	CCONJ
admet-2956	52	17	clinical	clinical	ADJ
admet-2956	52	18	outcomes	outcome	NOUN
admet-2956	52	19	.	.	PUNCT
admet-2956	53	1	the	the	DET
admet-2956	53	2	methodological	methodological	ADJ
admet-2956	53	3	quality	quality	NOUN
admet-2956	53	4	of	of	ADP
admet-2956	53	5	included	include	VERB
admet-2956	53	6	studies	study	NOUN
admet-2956	53	7	was	be	AUX
admet-2956	53	8	assessed	assess	VERB
admet-2956	53	9	using	use	VERB
admet-2956	53	10	the	the	DET
admet-2956	53	11	revised	revise	VERB
admet-2956	53	12	cochrane	cochrane	NOUN
admet-2956	53	13	risk	risk	NOUN
admet-2956	53	14	of	of	ADP
admet-2956	53	15	bias	bias	NOUN
admet-2956	53	16	tool	tool	NOUN
admet-2956	53	17	(	(	PUNCT
admet-2956	53	18	rob	rob	PROPN
admet-2956	53	19	2	2	NUM
admet-2956	53	20	)	)	PUNCT
admet-2956	53	21	,	,	PUNCT
admet-2956	53	22	which	which	PRON
admet-2956	53	23	evaluates	evaluate	VERB
admet-2956	53	24	five	five	NUM
admet-2956	53	25	domains	domain	NOUN
admet-2956	53	26	of	of	ADP
admet-2956	53	27	potential	potential	ADJ
admet-2956	53	28	bias	bias	NOUN
admet-2956	53	29	.	.	PUNCT
admet-2956	54	1	statistical	statistical	ADJ
admet-2956	54	2	analyses	analysis	NOUN
admet-2956	54	3	were	be	AUX
admet-2956	54	4	performed	perform	VERB
admet-2956	54	5	using	use	VERB
admet-2956	54	6	review	review	NOUN
admet-2956	54	7	manager	manager	NOUN
admet-2956	54	8	(	(	PUNCT
admet-2956	54	9	revman	revman	NOUN
admet-2956	54	10	)	)	PUNCT
admet-2956	54	11	version	version	NOUN
admet-2956	54	12	5.4	5.4	NUM
admet-2956	54	13	.	.	PUNCT
admet-2956	55	1	hazard	hazard	NOUN
admet-2956	55	2	ratios	ratio	NOUN
admet-2956	55	3	(	(	PUNCT
admet-2956	55	4	hrs	hrs	NOUN
admet-2956	55	5	)	)	PUNCT
admet-2956	55	6	with	with	ADP
admet-2956	55	7	95	95	NUM
admet-2956	55	8	%	%	NOUN
admet-2956	55	9	confidence	confidence	NOUN
admet-2956	55	10	intervals	interval	NOUN
admet-2956	55	11	(	(	PUNCT
admet-2956	55	12	cis	cis	NOUN
admet-2956	55	13	)	)	PUNCT
admet-2956	55	14	were	be	AUX
admet-2956	55	15	used	use	VERB
admet-2956	55	16	for	for	ADP
admet-2956	55	17	timeto	timeto	NOUN
admet-2956	55	18	-	-	PUNCT
admet-2956	55	19	event	event	NOUN
admet-2956	55	20	outcomes	outcome	NOUN
admet-2956	55	21	,	,	PUNCT
admet-2956	55	22	overall	overall	ADJ
admet-2956	55	23	survival	survival	NOUN
admet-2956	55	24	(	(	PUNCT
admet-2956	55	25	os	os	NOUN
admet-2956	55	26	)	)	PUNCT
admet-2956	55	27	and	and	CCONJ
admet-2956	55	28	progression	progression	NOUN
admet-2956	55	29	-	-	PUNCT
admet-2956	55	30	free	free	ADJ
admet-2956	55	31	survival	survival	NOUN
admet-2956	55	32	(	(	PUNCT
admet-2956	55	33	pfs	pfs	PROPN
admet-2956	55	34	)	)	PUNCT
admet-2956	55	35	,	,	PUNCT
admet-2956	55	36	while	while	SCONJ
admet-2956	55	37	relative	relative	ADJ
admet-2956	55	38	risks	risk	NOUN
admet-2956	55	39	were	be	AUX
admet-2956	55	40	used	use	VERB
admet-2956	55	41	for	for	ADP
admet-2956	55	42	dichotomous	dichotomous	ADJ
admet-2956	55	43	outcomes	outcome	NOUN
admet-2956	55	44	(	(	PUNCT
admet-2956	55	45	orr	orr	NOUN
admet-2956	55	46	and	and	CCONJ
admet-2956	55	47	safety	safety	NOUN
admet-2956	55	48	)	)	PUNCT
admet-2956	55	49	.	.	PUNCT
admet-2956	56	1	heterogeneity	heterogeneity	NOUN
admet-2956	56	2	was	be	AUX
admet-2956	56	3	assessed	assess	VERB
admet-2956	56	4	using	use	VERB
admet-2956	56	5	the	the	DET
admet-2956	56	6	i²	i²	PROPN
admet-2956	56	7	statistic	statistic	NOUN
admet-2956	56	8	,	,	PUNCT
admet-2956	56	9	which	which	PRON
admet-2956	56	10	guided	guide	VERB
admet-2956	56	11	the	the	DET
admet-2956	56	12	choice	choice	NOUN
admet-2956	56	13	between	between	ADP
admet-2956	56	14	fixedand	fixedand	NOUN
admet-2956	56	15	random	random	ADJ
admet-2956	56	16	-	-	PUNCT
admet-2956	56	17	effects	effect	NOUN
admet-2956	56	18	models	model	NOUN
admet-2956	56	19	.	.	PUNCT
admet-2956	57	1	prespecified	prespecifie	VERB
admet-2956	57	2	subgroup	subgroup	NOUN
admet-2956	57	3	analyses	analysis	NOUN
admet-2956	57	4	were	be	AUX
admet-2956	57	5	conducted	conduct	VERB
admet-2956	57	6	according	accord	VERB
admet-2956	57	7	to	to	ADP
admet-2956	57	8	pd	pd	PROPN
admet-2956	57	9	-	-	PUNCT
admet-2956	57	10	l1	l1	PROPN
admet-2956	57	11	expression	expression	NOUN
admet-2956	57	12	levels	level	NOUN
admet-2956	57	13	and	and	CCONJ
admet-2956	57	14	key	key	ADJ
admet-2956	57	15	patient	patient	ADJ
admet-2956	57	16	characteristics	characteristic	NOUN
admet-2956	57	17	.	.	PUNCT
admet-2956	58	1	results	result	NOUN
admet-2956	58	2	and	and	CCONJ
admet-2956	58	3	discussion	discussion	NOUN
admet-2956	58	4	study	study	NOUN
admet-2956	58	5	selection	selection	NOUN
admet-2956	58	6	and	and	CCONJ
admet-2956	58	7	characteristics	characteristic	NOUN
admet-2956	58	8	preferred	prefer	VERB
admet-2956	58	9	reporting	reporting	NOUN
admet-2956	58	10	items	item	NOUN
admet-2956	58	11	for	for	ADP
admet-2956	58	12	systematic	systematic	ADJ
admet-2956	58	13	reviews	review	NOUN
admet-2956	58	14	and	and	CCONJ
admet-2956	58	15	meta	meta	NOUN
admet-2956	58	16	-	-	PUNCT
admet-2956	58	17	analyses	analysis	NOUN
admet-2956	58	18	(	(	PUNCT
admet-2956	58	19	prisma	prisma	NOUN
admet-2956	58	20	)	)	PUNCT
admet-2956	58	21	flow	flow	NOUN
admet-2956	58	22	diagram	diagram	NOUN
admet-2956	58	23	of	of	ADP
admet-2956	58	24	literature	literature	NOUN
admet-2956	58	25	screening	screening	NOUN
admet-2956	58	26	and	and	CCONJ
admet-2956	58	27	study	study	NOUN
admet-2956	58	28	selection	selection	NOUN
admet-2956	58	29	is	be	AUX
admet-2956	58	30	shown	show	VERB
admet-2956	58	31	in	in	ADP
admet-2956	58	32	figure	figure	NOUN
admet-2956	58	33	1	1	NUM
admet-2956	58	34	.	.	PUNCT
admet-2956	59	1	the	the	DET
admet-2956	59	2	initial	initial	ADJ
admet-2956	59	3	search	search	NOUN
admet-2956	59	4	identified	identify	VERB
admet-2956	59	5	7,459	7,459	NUM
admet-2956	59	6	records	record	NOUN
admet-2956	59	7	,	,	PUNCT
admet-2956	59	8	along	along	ADP
admet-2956	59	9	with	with	ADP
admet-2956	59	10	5	5	NUM
admet-2956	59	11	additional	additional	ADJ
admet-2956	59	12	records	record	NOUN
admet-2956	59	13	from	from	ADP
admet-2956	59	14	other	other	ADJ
admet-2956	59	15	sources	source	NOUN
admet-2956	59	16	.	.	PUNCT
admet-2956	60	1	after	after	ADP
admet-2956	60	2	removing	remove	VERB
admet-2956	60	3	duplicates	duplicate	NOUN
admet-2956	60	4	,	,	PUNCT
admet-2956	60	5	5,562	5,562	NUM
admet-2956	60	6	studies	study	NOUN
admet-2956	60	7	were	be	AUX
admet-2956	60	8	screened	screen	VERB
admet-2956	60	9	,	,	PUNCT
admet-2956	60	10	of	of	ADP
admet-2956	60	11	which	which	PRON
admet-2956	60	12	7	7	NUM
admet-2956	60	13	randomized	randomize	VERB
admet-2956	60	14	controlled	control	VERB
admet-2956	60	15	trials	trial	NOUN
admet-2956	60	16	(	(	PUNCT
admet-2956	60	17	rcts	rct	NOUN
admet-2956	60	18	)	)	PUNCT
admet-2956	60	19	published	publish	VERB
admet-2956	60	20	between	between	ADP
admet-2956	60	21	2016	2016	NUM
admet-2956	60	22	and	and	CCONJ
admet-2956	60	23	2023	2023	NUM
admet-2956	60	24	met	meet	VERB
admet-2956	60	25	the	the	DET
admet-2956	60	26	inclusion	inclusion	NOUN
admet-2956	60	27	criteria	criterion	NOUN
admet-2956	60	28	,	,	PUNCT
admet-2956	60	29	which	which	PRON
admet-2956	60	30	are	be	AUX
admet-2956	60	31	summarized	summarize	VERB
admet-2956	60	32	in	in	ADP
admet-2956	60	33	table	table	NOUN
admet-2956	60	34	1	1	NUM
admet-2956	60	35	.	.	PUNCT
admet-2956	61	1	in	in	ADP
admet-2956	61	2	total	total	ADJ
admet-2956	61	3	,	,	PUNCT
admet-2956	61	4	4,900	4,900	NUM
admet-2956	61	5	patients	patient	NOUN
admet-2956	61	6	were	be	AUX
admet-2956	61	7	analysed	analyse	VERB
admet-2956	61	8	,	,	PUNCT
admet-2956	61	9	with	with	ADP
admet-2956	61	10	2,084	2,084	NUM
admet-2956	61	11	receiving	receive	VERB
admet-2956	61	12	pembrolizumab	pembrolizumab	NOUN
admet-2956	61	13	monotherapy	monotherapy	NOUN
admet-2956	61	14	and	and	CCONJ
admet-2956	61	15	1,816	1,816	NUM
admet-2956	61	16	assigned	assign	VERB
admet-2956	61	17	to	to	ADP
admet-2956	61	18	chemotherapy	chemotherapy	NOUN
admet-2956	61	19	as	as	ADP
admet-2956	61	20	the	the	DET
admet-2956	61	21	control	control	NOUN
admet-2956	61	22	arm	arm	NOUN
admet-2956	61	23	.	.	PUNCT
admet-2956	62	1	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	62	2	a.	a.	PROPN
admet-2956	62	3	chakramurty	chakramurty	PROPN
admet-2956	62	4	et	et	PROPN
admet-2956	62	5	al	al	PROPN
admet-2956	62	6	.	.	PROPN
admet-2956	62	7	admet	admet	PROPN
admet-2956	62	8	&	&	CCONJ
admet-2956	62	9	dmpk	dmpk	PROPN
admet-2956	62	10	13(5	13(5	NUM
admet-2956	62	11	)	)	PUNCT
admet-2956	62	12	(	(	PUNCT
admet-2956	62	13	2025	2025	NUM
admet-2956	62	14	)	)	PUNCT
admet-2956	62	15	2956	2956	NUM
admet-2956	62	16	4	4	NUM
admet-2956	62	17	figure	figure	NOUN
admet-2956	62	18	1	1	NUM
admet-2956	62	19	.	.	PUNCT
admet-2956	63	1	prisma	prisma	PROPN
admet-2956	63	2	flow	flow	PROPN
admet-2956	63	3	diagram	diagram	NOUN
admet-2956	63	4	of	of	ADP
admet-2956	63	5	literature	literature	NOUN
admet-2956	63	6	screening	screening	NOUN
admet-2956	63	7	and	and	CCONJ
admet-2956	63	8	study	study	NOUN
admet-2956	63	9	selection	selection	NOUN
admet-2956	63	10	table	table	NOUN
admet-2956	63	11	1	1	NUM
admet-2956	63	12	.	.	PUNCT
admet-2956	64	1	characteristics	characteristic	NOUN
admet-2956	64	2	of	of	ADP
admet-2956	64	3	included	include	VERB
admet-2956	64	4	studies	study	NOUN
admet-2956	64	5	ref	ref	NOUN
admet-2956	64	6	.	.	PUNCT
admet-2956	65	1	year	year	NOUN
admet-2956	65	2	tr	tr	VERB
admet-2956	66	1	ia	ia	PROPN
admet-2956	66	2	l	l	NOUN
admet-2956	66	3	i	i	NOUN
admet-2956	67	1	d	d	X
admet-2956	67	2	k	k	X
admet-2956	67	3	ey	ey	INTJ
admet-2956	67	4	n	n	INTJ
admet-2956	67	5	o	o	X
admet-2956	67	6	te	te	ADP
admet-2956	67	7	p	p	PROPN
admet-2956	67	8	h	h	NOUN
admet-2956	67	9	as	as	SCONJ
admet-2956	67	10	e	e	NOUN
admet-2956	67	11	treatment	treatment	NOUN
admet-2956	67	12	arms	arm	NOUN
admet-2956	67	13	to	to	ADP
admet-2956	67	14	ta	ta	PROPN
admet-2956	67	15	l	l	PROPN
admet-2956	67	16	,	,	PUNCT
admet-2956	67	17	n	n	PRON
admet-2956	67	18	m	m	PROPN
admet-2956	67	19	ed	ed	PROPN
admet-2956	67	20	ia	ia	PROPN
admet-2956	67	21	n	n	ADV
admet-2956	68	1	fo	fo	INTJ
admet-2956	68	2	llo	llo	INTJ
admet-2956	69	1	w	w	PROPN
admet-2956	69	2	-u	-u	PROPN
admet-2956	69	3	p	p	X
admet-2956	69	4	,	,	PUNCT
admet-2956	69	5	m	m	VERB
admet-2956	69	6	o	o	NOUN
admet-2956	69	7	n	n	X
admet-2956	69	8	th	th	X
admet-2956	69	9	s	s	NOUN
admet-2956	69	10	sex	sex	NOUN
admet-2956	69	11	,	,	PUNCT
admet-2956	69	12	n	n	CCONJ
admet-2956	69	13	/	/	SYM
admet-2956	69	14	%	%	NOUN
admet-2956	69	15	histology	histology	NOUN
admet-2956	69	16	,	,	PUNCT
admet-2956	69	17	n	n	CCONJ
admet-2956	69	18	/%	/%	X
admet-2956	69	19	ecog	ecog	PROPN
admet-2956	69	20	performance	performance	NOUN
admet-2956	69	21	status	status	NOUN
admet-2956	69	22	,	,	PUNCT
admet-2956	69	23	n	n	PROPN
admet-2956	69	24	/	/	SYM
admet-2956	69	25	%	%	NOUN
admet-2956	69	26	smoking	smoking	NOUN
admet-2956	69	27	status	status	NOUN
admet-2956	69	28	,	,	PUNCT
admet-2956	69	29	n	n	PROPN
admet-2956	69	30	/	/	SYM
admet-2956	69	31	%	%	NOUN
admet-2956	69	32	geographic	geographic	ADJ
admet-2956	69	33	region	region	NOUN
admet-2956	69	34	,	,	PUNCT
admet-2956	69	35	n	n	PROPN
admet-2956	69	36	/	/	SYM
admet-2956	69	37	%	%	NOUN
admet-2956	70	1	east	east	PROPN
admet-2956	70	2	asia	asia	PROPN
admet-2956	70	3	europe	europe	PROPN
admet-2956	70	4	north	north	PROPN
admet-2956	70	5	america	america	PROPN
admet-2956	70	6	other	other	ADJ
admet-2956	70	7	male	male	ADJ
admet-2956	70	8	female	female	ADJ
admet-2956	70	9	squamous	squamous	ADJ
admet-2956	70	10	non	non	ADJ
admet-2956	70	11	-	-	ADJ
admet-2956	70	12	squamous	squamous	ADJ
admet-2956	70	13	current	current	ADJ
admet-2956	70	14	/former	/former	PUNCT
admet-2956	71	1	never	never	ADV
admet-2956	71	2	0	0	NUM
admet-2956	71	3	1	1	NUM
admet-2956	72	1	[	[	X
admet-2956	72	2	43	43	NUM
admet-2956	72	3	]	]	SYM
admet-2956	72	4	2016	2016	NUM
admet-2956	72	5	010	010	NUM
admet-2956	72	6	iii	iii	NUM
admet-2956	72	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	72	8	2	2	NUM
admet-2956	72	9	mg	mg	NOUN
admet-2956	72	10	vs.	vs.	ADP
admet-2956	72	11	10	10	NUM
admet-2956	72	12	mg	mg	NOUN
admet-2956	72	13	vs.	vs.	ADP
admet-2956	72	14	docetaxel	docetaxel	PROPN
admet-2956	72	15	1,034	1,034	NUM
admet-2956	72	16	13.1	13.1	NUM
admet-2956	72	17	634	634	NUM
admet-2956	72	18	(	(	PUNCT
admet-2956	72	19	61	61	NUM
admet-2956	72	20	%	%	NOUN
admet-2956	72	21	)	)	PUNCT
admet-2956	72	22	399	399	NUM
admet-2956	72	23	(	(	PUNCT
admet-2956	72	24	39	39	NUM
admet-2956	72	25	%	%	NOUN
admet-2956	72	26	)	)	PUNCT
admet-2956	72	27	222	222	NUM
admet-2956	72	28	(	(	PUNCT
admet-2956	72	29	21	21	NUM
admet-2956	72	30	%	%	NOUN
admet-2956	72	31	)	)	PUNCT
admet-2956	72	32	724	724	NUM
admet-2956	72	33	(	(	PUNCT
admet-2956	72	34	70	70	NUM
admet-2956	72	35	%	%	NOUN
admet-2956	72	36	)	)	PUNCT
admet-2956	72	37	348	348	NUM
admet-2956	72	38	(	(	PUNCT
admet-2956	72	39	34	34	NUM
admet-2956	72	40	%	%	NOUN
admet-2956	72	41	)	)	PUNCT
admet-2956	72	42	678	678	NUM
admet-2956	72	43	(	(	PUNCT
admet-2956	72	44	66	66	NUM
admet-2956	72	45	%	%	NOUN
admet-2956	72	46	)	)	PUNCT
admet-2956	72	47	833	833	NUM
admet-2956	72	48	(	(	PUNCT
admet-2956	72	49	81	81	NUM
admet-2956	72	50	%	%	NOUN
admet-2956	72	51	)	)	PUNCT
admet-2956	72	52	190	190	NUM
admet-2956	72	53	(	(	PUNCT
admet-2956	72	54	18	18	NUM
admet-2956	72	55	%	%	NOUN
admet-2956	72	56	)	)	PUNCT
admet-2956	72	57	190	190	NUM
admet-2956	72	58	(	(	PUNCT
admet-2956	72	59	18	18	NUM
admet-2956	72	60	%	%	NOUN
admet-2956	72	61	)	)	PUNCT
admet-2956	72	62	781	781	NUM
admet-2956	72	63	(	(	PUNCT
admet-2956	72	64	76	76	NUM
admet-2956	72	65	%	%	NOUN
admet-2956	72	66	)	)	PUNCT
admet-2956	72	67	63	63	NUM
admet-2956	72	68	(	(	PUNCT
admet-2956	72	69	6	6	NUM
admet-2956	72	70	%	%	NOUN
admet-2956	72	71	)	)	PUNCT
admet-2956	73	1	[	[	X
admet-2956	73	2	44	44	NUM
admet-2956	73	3	]	]	SYM
admet-2956	73	4	2016	2016	NUM
admet-2956	73	5	021	021	NUM
admet-2956	73	6	ii	ii	NOUN
admet-2956	73	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	73	8	+	+	CCONJ
admet-2956	73	9	chemotherapy	chemotherapy	NOUN
admet-2956	73	10	vs.	vs.	ADP
admet-2956	73	11	chemotherapy	chemotherapy	NOUN
admet-2956	73	12	123	123	NUM
admet-2956	73	13	10.6	10.6	NUM
admet-2956	73	14	48	48	NUM
admet-2956	73	15	(	(	PUNCT
admet-2956	73	16	39	39	NUM
admet-2956	73	17	%	%	NOUN
admet-2956	73	18	)	)	PUNCT
admet-2956	73	19	75	75	NUM
admet-2956	73	20	(	(	PUNCT
admet-2956	73	21	61	61	NUM
admet-2956	73	22	%	%	NOUN
admet-2956	73	23	)	)	PUNCT
admet-2956	73	24	0	0	NUM
admet-2956	74	1	(	(	PUNCT
admet-2956	74	2	0	0	NUM
admet-2956	74	3	%	%	NOUN
admet-2956	74	4	)	)	PUNCT
admet-2956	74	5	121	121	NUM
admet-2956	74	6	(	(	PUNCT
admet-2956	74	7	98	98	NUM
admet-2956	74	8	%	%	NOUN
admet-2956	74	9	)	)	PUNCT
admet-2956	74	10	53	53	NUM
admet-2956	74	11	(	(	PUNCT
admet-2956	74	12	43	43	NUM
admet-2956	74	13	%	%	NOUN
admet-2956	74	14	)	)	PUNCT
admet-2956	74	15	69	69	NUM
admet-2956	74	16	(	(	PUNCT
admet-2956	74	17	56	56	NUM
admet-2956	74	18	%	%	NOUN
admet-2956	74	19	)	)	PUNCT
admet-2956	74	20	99	99	NUM
admet-2956	74	21	(	(	PUNCT
admet-2956	74	22	80	80	NUM
admet-2956	74	23	%	%	NOUN
admet-2956	74	24	)	)	PUNCT
admet-2956	74	25	24	24	NUM
admet-2956	74	26	(	(	PUNCT
admet-2956	74	27	20	20	NUM
admet-2956	74	28	%	%	NOUN
admet-2956	74	29	)	)	PUNCT
admet-2956	74	30	0	0	NUM
admet-2956	75	1	(	(	PUNCT
admet-2956	75	2	0	0	NUM
admet-2956	75	3	%	%	NOUN
admet-2956	75	4	)	)	PUNCT
admet-2956	75	5	123	123	NUM
admet-2956	75	6	(	(	PUNCT
admet-2956	75	7	100	100	NUM
admet-2956	75	8	%	%	NOUN
admet-2956	75	9	)	)	PUNCT
admet-2956	75	10	0	0	PUNCT
admet-2956	76	1	(	(	PUNCT
admet-2956	76	2	0	0	NUM
admet-2956	76	3	%	%	NOUN
admet-2956	76	4	)	)	PUNCT
admet-2956	77	1	[	[	X
admet-2956	77	2	22	22	NUM
admet-2956	77	3	]	]	SYM
admet-2956	77	4	2016	2016	NUM
admet-2956	77	5	024	024	NUM
admet-2956	77	6	iii	iii	NUM
admet-2956	77	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	77	8	vs.	vs.	ADP
admet-2956	77	9	chemotherapy	chemotherapy	NOUN
admet-2956	77	10	305	305	NUM
admet-2956	77	11	59.9	59.9	NUM
admet-2956	77	12	187	187	NUM
admet-2956	77	13	(	(	PUNCT
admet-2956	77	14	61	61	NUM
admet-2956	77	15	%	%	NOUN
admet-2956	77	16	)	)	PUNCT
admet-2956	77	17	118	118	NUM
admet-2956	77	18	(	(	PUNCT
admet-2956	77	19	39	39	NUM
admet-2956	77	20	%	%	NOUN
admet-2956	77	21	)	)	PUNCT
admet-2956	77	22	56	56	NUM
admet-2956	77	23	(	(	PUNCT
admet-2956	77	24	18	18	NUM
admet-2956	77	25	%	%	NOUN
admet-2956	77	26	)	)	PUNCT
admet-2956	77	27	249	249	NUM
admet-2956	77	28	(	(	PUNCT
admet-2956	77	29	82	82	NUM
admet-2956	77	30	%	%	NOUN
admet-2956	77	31	)	)	PUNCT
admet-2956	77	32	107	107	NUM
admet-2956	77	33	(	(	PUNCT
admet-2956	77	34	35	35	NUM
admet-2956	77	35	%	%	NOUN
admet-2956	77	36	)	)	PUNCT
admet-2956	77	37	197	197	NUM
admet-2956	77	38	(	(	PUNCT
admet-2956	77	39	65	65	NUM
admet-2956	77	40	%	%	NOUN
admet-2956	77	41	)	)	PUNCT
admet-2956	77	42	280	280	NUM
admet-2956	77	43	(	(	PUNCT
admet-2956	77	44	92	92	NUM
admet-2956	77	45	%	%	NOUN
admet-2956	77	46	)	)	PUNCT
admet-2956	77	47	24	24	NUM
admet-2956	77	48	(	(	PUNCT
admet-2956	77	49	8	8	NUM
admet-2956	77	50	%	%	NOUN
admet-2956	77	51	)	)	PUNCT
admet-2956	77	52	40	40	NUM
admet-2956	77	53	(	(	PUNCT
admet-2956	77	54	13	13	NUM
admet-2956	77	55	%	%	NOUN
admet-2956	77	56	)	)	PUNCT
admet-2956	77	57	265	265	NUM
admet-2956	77	58	(	(	PUNCT
admet-2956	77	59	87	87	NUM
admet-2956	77	60	%	%	NOUN
admet-2956	77	61	)	)	PUNCT
admet-2956	77	62	0	0	PUNCT
admet-2956	78	1	(	(	PUNCT
admet-2956	78	2	0	0	NUM
admet-2956	78	3	%	%	NOUN
admet-2956	78	4	)	)	PUNCT
admet-2956	79	1	[	[	X
admet-2956	79	2	45	45	NUM
admet-2956	79	3	]	]	SYM
admet-2956	79	4	2019	2019	NUM
admet-2956	79	5	042	042	NUM
admet-2956	79	6	iii	iii	NUM
admet-2956	79	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	79	8	vs.	vs.	ADP
admet-2956	79	9	chemotherapy	chemotherapy	NOUN
admet-2956	79	10	1,274	1,274	NUM
admet-2956	79	11	12.8	12.8	NUM
admet-2956	79	12	902	902	NUM
admet-2956	79	13	(	(	PUNCT
admet-2956	79	14	71	71	NUM
admet-2956	79	15	%	%	NOUN
admet-2956	79	16	)	)	PUNCT
admet-2956	79	17	372	372	NUM
admet-2956	79	18	(	(	PUNCT
admet-2956	79	19	29	29	NUM
admet-2956	79	20	%	%	NOUN
admet-2956	79	21	)	)	PUNCT
admet-2956	79	22	492	492	NUM
admet-2956	79	23	(	(	PUNCT
admet-2956	79	24	39	39	NUM
admet-2956	79	25	%	%	NOUN
admet-2956	79	26	)	)	PUNCT
admet-2956	79	27	782	782	NUM
admet-2956	79	28	(	(	PUNCT
admet-2956	79	29	61	61	NUM
admet-2956	79	30	%	%	NOUN
admet-2956	79	31	)	)	PUNCT
admet-2956	79	32	390	390	NUM
admet-2956	79	33	(	(	PUNCT
admet-2956	79	34	31	31	NUM
admet-2956	79	35	%	%	NOUN
admet-2956	79	36	)	)	PUNCT
admet-2956	79	37	884	884	NUM
admet-2956	79	38	(	(	PUNCT
admet-2956	79	39	69	69	NUM
admet-2956	79	40	%	%	NOUN
admet-2956	79	41	)	)	PUNCT
admet-2956	79	42	1,041	1,041	NUM
admet-2956	79	43	(	(	PUNCT
admet-2956	79	44	82	82	NUM
admet-2956	79	45	%	%	NOUN
admet-2956	79	46	)	)	PUNCT
admet-2956	79	47	282	282	NUM
admet-2956	79	48	(	(	PUNCT
admet-2956	79	49	22	22	NUM
admet-2956	79	50	%	%	NOUN
admet-2956	79	51	)	)	PUNCT
admet-2956	79	52	370	370	NUM
admet-2956	79	53	(	(	PUNCT
admet-2956	79	54	29	29	NUM
admet-2956	79	55	%	%	NOUN
admet-2956	79	56	)	)	PUNCT
admet-2956	79	57	286	286	NUM
admet-2956	79	58	(	(	PUNCT
admet-2956	79	59	22	22	NUM
admet-2956	79	60	%	%	NOUN
admet-2956	79	61	)	)	PUNCT
admet-2956	79	62	618	618	NUM
admet-2956	79	63	(	(	PUNCT
admet-2956	79	64	49	49	NUM
admet-2956	79	65	%	%	NOUN
admet-2956	79	66	)	)	PUNCT
admet-2956	80	1	[	[	X
admet-2956	80	2	46	46	NUM
admet-2956	80	3	]	]	SYM
admet-2956	80	4	2018	2018	NUM
admet-2956	80	5	407	407	NUM
admet-2956	80	6	iii	iii	NUM
admet-2956	80	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	80	8	+	+	CCONJ
admet-2956	80	9	chemotherapy	chemotherapy	NOUN
admet-2956	80	10	vs.	vs.	ADP
admet-2956	80	11	placebo	placebo	NOUN
admet-2956	80	12	+	+	CCONJ
admet-2956	80	13	chemotherapy	chemotherapy	NOUN
admet-2956	80	14	559	559	NUM
admet-2956	80	15	7.8	7.8	NUM
admet-2956	80	16	455	455	NUM
admet-2956	80	17	(	(	PUNCT
admet-2956	80	18	81	81	NUM
admet-2956	80	19	%	%	NOUN
admet-2956	80	20	)	)	PUNCT
admet-2956	80	21	104	104	NUM
admet-2956	80	22	(	(	PUNCT
admet-2956	80	23	19	19	NUM
admet-2956	80	24	%	%	NOUN
admet-2956	80	25	)	)	PUNCT
admet-2956	80	26	546	546	NUM
admet-2956	80	27	(	(	PUNCT
admet-2956	80	28	98	98	NUM
admet-2956	80	29	%	%	NOUN
admet-2956	80	30	)	)	PUNCT
admet-2956	80	31	13	13	NUM
admet-2956	80	32	(	(	PUNCT
admet-2956	80	33	2	2	NUM
admet-2956	80	34	%	%	NOUN
admet-2956	80	35	)	)	PUNCT
admet-2956	80	36	163	163	NUM
admet-2956	80	37	(	(	PUNCT
admet-2956	80	38	29	29	NUM
admet-2956	80	39	%	%	NOUN
admet-2956	80	40	)	)	PUNCT
admet-2956	80	41	396	396	NUM
admet-2956	80	42	(	(	PUNCT
admet-2956	80	43	71	71	NUM
admet-2956	80	44	%	%	NOUN
admet-2956	80	45	)	)	PUNCT
admet-2956	80	46	518	518	NUM
admet-2956	80	47	(	(	PUNCT
admet-2956	80	48	93	93	NUM
admet-2956	80	49	%	%	NOUN
admet-2956	80	50	)	)	PUNCT
admet-2956	80	51	41	41	NUM
admet-2956	80	52	(	(	PUNCT
admet-2956	80	53	7	7	NUM
admet-2956	80	54	%	%	NOUN
admet-2956	80	55	)	)	PUNCT
admet-2956	80	56	106	106	NUM
admet-2956	80	57	(	(	PUNCT
admet-2956	80	58	19	19	NUM
admet-2956	80	59	%	%	NOUN
admet-2956	80	60	)	)	PUNCT
admet-2956	80	61	453	453	NUM
admet-2956	80	62	(	(	PUNCT
admet-2956	80	63	81	81	NUM
admet-2956	80	64	%	%	NOUN
admet-2956	80	65	)	)	PUNCT
admet-2956	80	66	0	0	NUM
admet-2956	81	1	(	(	PUNCT
admet-2956	81	2	0	0	NUM
admet-2956	81	3	%	%	NOUN
admet-2956	81	4	)	)	PUNCT
admet-2956	82	1	[	[	X
admet-2956	82	2	47	47	NUM
admet-2956	82	3	]	]	PUNCT
admet-2956	82	4	2023	2023	NUM
admet-2956	82	5	033	033	NUM
admet-2956	82	6	iii	iii	NUM
admet-2956	82	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	82	8	vs.	vs.	ADP
admet-2956	82	9	docetaxel	docetaxel	NOUN
admet-2956	82	10	425	425	NUM
admet-2956	82	11	22.3	22.3	NUM
admet-2956	82	12	321	321	NUM
admet-2956	82	13	(	(	PUNCT
admet-2956	82	14	76	76	NUM
admet-2956	82	15	%	%	NOUN
admet-2956	82	16	)	)	PUNCT
admet-2956	82	17	104	104	NUM
admet-2956	82	18	(	(	PUNCT
admet-2956	82	19	24	24	NUM
admet-2956	82	20	%	%	NOUN
admet-2956	82	21	)	)	PUNCT
admet-2956	82	22	170	170	NUM
admet-2956	82	23	(	(	PUNCT
admet-2956	82	24	40	40	NUM
admet-2956	82	25	%	%	NOUN
admet-2956	82	26	)	)	PUNCT
admet-2956	82	27	247	247	NUM
admet-2956	82	28	(	(	PUNCT
admet-2956	82	29	58	58	NUM
admet-2956	82	30	%	%	NOUN
admet-2956	82	31	)	)	PUNCT
admet-2956	82	32	6	6	NUM
admet-2956	82	33	9	9	NUM
admet-2956	82	34	(	(	PUNCT
admet-2956	82	35	16	16	NUM
admet-2956	82	36	%	%	NOUN
admet-2956	82	37	)	)	PUNCT
admet-2956	82	38	356	356	NUM
admet-2956	82	39	(	(	PUNCT
admet-2956	82	40	84	84	NUM
admet-2956	82	41	%	%	NOUN
admet-2956	82	42	)	)	PUNCT
admet-2956	82	43	354	354	NUM
admet-2956	82	44	(	(	PUNCT
admet-2956	82	45	83	83	NUM
admet-2956	82	46	%	%	NOUN
admet-2956	82	47	)	)	PUNCT
admet-2956	82	48	71	71	NUM
admet-2956	82	49	(	(	PUNCT
admet-2956	82	50	17	17	NUM
admet-2956	82	51	%	%	NOUN
admet-2956	82	52	)	)	PUNCT
admet-2956	82	53	358	358	NUM
admet-2956	82	54	(	(	PUNCT
admet-2956	82	55	84	84	NUM
admet-2956	82	56	%	%	NOUN
admet-2956	82	57	)	)	PUNCT
admet-2956	82	58	67	67	NUM
admet-2956	82	59	(	(	PUNCT
admet-2956	82	60	16	16	NUM
admet-2956	82	61	%	%	NOUN
admet-2956	82	62	)	)	PUNCT
admet-2956	82	63	0	0	PUNCT
admet-2956	83	1	(	(	PUNCT
admet-2956	83	2	0	0	NUM
admet-2956	83	3	%	%	NOUN
admet-2956	83	4	)	)	PUNCT
admet-2956	84	1	[	[	X
admet-2956	84	2	48	48	NUM
admet-2956	84	3	]	]	SYM
admet-2956	84	4	2018	2018	NUM
admet-2956	84	5	189	189	NUM
admet-2956	84	6	iii	iii	NOUN
admet-2956	84	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	84	8	+	+	CCONJ
admet-2956	84	9	chemotherapy	chemotherapy	NOUN
admet-2956	84	10	vs.	vs.	ADP
admet-2956	84	11	placebo	placebo	NOUN
admet-2956	84	12	+	+	CCONJ
admet-2956	84	13	chemotherapy	chemotherapy	NOUN
admet-2956	84	14	616	616	NUM
admet-2956	84	15	10.5	10.5	NUM
admet-2956	84	16	363	363	NUM
admet-2956	84	17	(	(	PUNCT
admet-2956	84	18	59	59	NUM
admet-2956	84	19	%	%	NOUN
admet-2956	84	20	)	)	PUNCT
admet-2956	84	21	253	253	NUM
admet-2956	84	22	(	(	PUNCT
admet-2956	84	23	4	4	NUM
admet-2956	84	24	1	1	NUM
admet-2956	84	25	%	%	NOUN
admet-2956	84	26	)	)	PUNCT
admet-2956	84	27	0	0	NUM
admet-2956	85	1	(	(	PUNCT
admet-2956	85	2	0	0	NUM
admet-2956	85	3	%	%	NOUN
admet-2956	85	4	)	)	PUNCT
admet-2956	85	5	606	606	NUM
admet-2956	85	6	(	(	PUNCT
admet-2956	85	7	98	98	NUM
admet-2956	85	8	%	%	NOUN
admet-2956	85	9	)	)	PUNCT
admet-2956	85	10	266	266	NUM
admet-2956	85	11	(	(	PUNCT
admet-2956	85	12	43	43	NUM
admet-2956	85	13	%	%	NOUN
admet-2956	85	14	)	)	PUNCT
admet-2956	85	15	346	346	NUM
admet-2956	85	16	(	(	PUNCT
admet-2956	85	17	56	56	NUM
admet-2956	85	18	%	%	NOUN
admet-2956	85	19	)	)	PUNCT
admet-2956	85	20	543	543	NUM
admet-2956	85	21	(	(	PUNCT
admet-2956	85	22	88	88	NUM
admet-2956	85	23	%	%	NOUN
admet-2956	85	24	)	)	PUNCT
admet-2956	85	25	73	73	NUM
admet-2956	85	26	(	(	PUNCT
admet-2956	85	27	12	12	NUM
admet-2956	85	28	%	%	NOUN
admet-2956	85	29	)	)	PUNCT
admet-2956	85	30	10	10	NUM
admet-2956	85	31	(	(	PUNCT
admet-2956	85	32	2	2	NUM
admet-2956	85	33	%	%	NOUN
admet-2956	85	34	)	)	PUNCT
admet-2956	85	35	531	531	NUM
admet-2956	85	36	(	(	PUNCT
admet-2956	85	37	86	86	NUM
admet-2956	85	38	%	%	NOUN
admet-2956	85	39	)	)	PUNCT
admet-2956	85	40	75	75	NUM
admet-2956	85	41	(	(	PUNCT
admet-2956	85	42	12	12	NUM
admet-2956	85	43	%	%	NOUN
admet-2956	85	44	)	)	PUNCT
admet-2956	85	45	risk	risk	NOUN
admet-2956	85	46	of	of	ADP
admet-2956	85	47	bias	bias	NOUN
admet-2956	85	48	assessment	assessment	NOUN
admet-2956	85	49	risk	risk	NOUN
admet-2956	85	50	of	of	ADP
admet-2956	85	51	bias	bias	NOUN
admet-2956	85	52	assessment	assessment	NOUN
admet-2956	85	53	using	use	VERB
admet-2956	85	54	the	the	DET
admet-2956	85	55	cochrane	cochrane	NOUN
admet-2956	85	56	rob2	rob2	NOUN
admet-2956	85	57	tool	tool	NOUN
admet-2956	85	58	determined	determine	VERB
admet-2956	85	59	that	that	SCONJ
admet-2956	85	60	one	one	NUM
admet-2956	85	61	study	study	NOUN
admet-2956	85	62	showed	show	VERB
admet-2956	85	63	low	low	ADJ
admet-2956	85	64	risk	risk	NOUN
admet-2956	85	65	across	across	ADP
admet-2956	85	66	all	all	DET
admet-2956	85	67	domains	domain	NOUN
admet-2956	85	68	.	.	PUNCT
admet-2956	86	1	the	the	DET
admet-2956	86	2	majority	majority	NOUN
admet-2956	86	3	of	of	ADP
admet-2956	86	4	studies	study	NOUN
admet-2956	86	5	revealed	reveal	VERB
admet-2956	86	6	"	"	PUNCT
admet-2956	86	7	some	some	DET
admet-2956	86	8	concerns	concern	NOUN
admet-2956	86	9	,	,	PUNCT
admet-2956	86	10	"	"	PUNCT
admet-2956	86	11	primarily	primarily	ADV
admet-2956	86	12	in	in	ADP
admet-2956	86	13	domain	domain	NOUN
admet-2956	86	14	2	2	NUM
admet-2956	86	15	(	(	PUNCT
admet-2956	86	16	bias	bias	NOUN
admet-2956	86	17	resulting	result	VERB
admet-2956	86	18	from	from	ADP
admet-2956	86	19	deviations	deviation	NOUN
admet-2956	86	20	from	from	ADP
admet-2956	86	21	the	the	DET
admet-2956	86	22	planned	plan	VERB
admet-2956	86	23	intervention	intervention	NOUN
admet-2956	86	24	)	)	PUNCT
admet-2956	86	25	and	and	CCONJ
admet-2956	86	26	domain	domain	NOUN
admet-2956	86	27	5	5	NUM
admet-2956	86	28	(	(	PUNCT
admet-2956	86	29	bias	bias	NOUN
admet-2956	86	30	introduced	introduce	VERB
admet-2956	86	31	through	through	ADP
admet-2956	86	32	the	the	DET
admet-2956	86	33	study	study	NOUN
admet-2956	86	34	's	's	PART
admet-2956	86	35	rollout	rollout	NOUN
admet-2956	86	36	)	)	PUNCT
admet-2956	86	37	,	,	PUNCT
admet-2956	86	38	as	as	SCONJ
admet-2956	86	39	shown	show	VERB
admet-2956	86	40	in	in	ADP
admet-2956	86	41	figure	figure	NOUN
admet-2956	86	42	2	2	NUM
admet-2956	86	43	.	.	PUNCT
admet-2956	87	1	this	this	DET
admet-2956	87	2	pattern	pattern	NOUN
admet-2956	87	3	aligns	align	VERB
admet-2956	87	4	with	with	ADP
admet-2956	87	5	findings	finding	NOUN
admet-2956	87	6	reported	report	VERB
admet-2956	87	7	in	in	ADP
admet-2956	87	8	other	other	ADJ
admet-2956	87	9	systematic	systematic	ADJ
admet-2956	87	10	reviews	review	NOUN
admet-2956	87	11	of	of	ADP
admet-2956	87	12	immunotherapy	immunotherapy	NOUN
admet-2956	87	13	.	.	PUNCT
admet-2956	88	1	domain	domain	NOUN
admet-2956	88	2	2	2	NUM
admet-2956	88	3	problems	problem	NOUN
admet-2956	88	4	were	be	AUX
admet-2956	88	5	due	due	ADJ
admet-2956	88	6	to	to	ADP
admet-2956	88	7	the	the	DET
admet-2956	88	8	following	follow	VERB
admet-2956	88	9	causes	cause	NOUN
admet-2956	88	10	:	:	PUNCT
admet-2956	88	11	1	1	X
admet-2956	88	12	)	)	PUNCT
admet-2956	88	13	open	open	ADJ
admet-2956	88	14	-	-	PUNCT
admet-2956	88	15	label	label	NOUN
admet-2956	88	16	study	study	NOUN
admet-2956	88	17	designs	design	NOUN
admet-2956	88	18	that	that	PRON
admet-2956	88	19	would	would	AUX
admet-2956	88	20	influence	influence	VERB
admet-2956	88	21	patient	patient	ADJ
admet-2956	88	22	/	/	SYM
admet-2956	88	23	clinician	clinician	NOUN
admet-2956	88	24	behaviour	behaviour	NOUN
admet-2956	88	25	;	;	PUNCT
admet-2956	88	26	2	2	X
admet-2956	88	27	)	)	PUNCT
admet-2956	88	28	high	high	ADJ
admet-2956	88	29	crossover	crossover	NOUN
admet-2956	88	30	rates	rate	NOUN
admet-2956	88	31	from	from	ADP
admet-2956	88	32	control	control	NOUN
admet-2956	88	33	to	to	ADP
admet-2956	88	34	intervention	intervention	NOUN
admet-2956	88	35	group	group	NOUN
admet-2956	88	36	(	(	PUNCT
admet-2956	88	37	range	range	NOUN
admet-2956	88	38	:	:	PUNCT
admet-2956	88	39	20.3	20.3	NUM
admet-2956	88	40	to	to	PART
admet-2956	88	41	66	66	NUM
admet-2956	88	42	%	%	NOUN
admet-2956	88	43	)	)	PUNCT
admet-2956	88	44	;	;	PUNCT
admet-2956	88	45	3	3	X
admet-2956	88	46	)	)	PUNCT
admet-2956	88	47	differential	differential	NOUN
admet-2956	88	48	discontinuation	discontinuation	NOUN
admet-2956	88	49	patterns	pattern	NOUN
admet-2956	88	50	between	between	ADP
admet-2956	88	51	treatment	treatment	NOUN
admet-2956	88	52	groups	group	NOUN
admet-2956	88	53	.	.	PUNCT
admet-2956	89	1	admet	admet	PROPN
admet-2956	89	2	&	&	CCONJ
admet-2956	89	3	dmpk	dmpk	PROPN
admet-2956	89	4	13(5	13(5	NUM
admet-2956	89	5	)	)	PUNCT
admet-2956	89	6	(	(	PUNCT
admet-2956	89	7	2025	2025	NUM
admet-2956	89	8	)	)	PUNCT
admet-2956	89	9	2956	2956	NUM
admet-2956	89	10	pembrolizumab	pembrolizumab	NOUN
admet-2956	89	11	in	in	ADP
admet-2956	89	12	pd	pd	PROPN
admet-2956	89	13	-	-	PUNCT
admet-2956	89	14	l1	l1	PROPN
admet-2956	89	15	-	-	PUNCT
admet-2956	89	16	positive	positive	ADJ
admet-2956	89	17	advanced	advanced	ADJ
admet-2956	89	18	non	non	ADJ
admet-2956	89	19	-	-	ADJ
admet-2956	89	20	small	small	ADJ
admet-2956	89	21	cell	cell	NOUN
admet-2956	89	22	lung	lung	NOUN
admet-2956	89	23	carcinoma	carcinoma	NOUN
admet-2956	89	24	doi	doi	NOUN
admet-2956	89	25	:	:	PUNCT
admet-2956	89	26	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	89	27	5	5	NUM
admet-2956	89	28	figure	figure	NOUN
admet-2956	89	29	2	2	NUM
admet-2956	89	30	.	.	NOUN
admet-2956	89	31	assessment	assessment	NOUN
admet-2956	89	32	of	of	ADP
admet-2956	89	33	risk	risk	NOUN
admet-2956	89	34	of	of	ADP
admet-2956	89	35	bias	bias	NOUN
admet-2956	89	36	domain	domain	NOUN
admet-2956	89	37	5	5	NUM
admet-2956	89	38	concerns	concern	NOUN
admet-2956	89	39	were	be	AUX
admet-2956	89	40	related	relate	VERB
admet-2956	89	41	to	to	ADP
admet-2956	89	42	protocol	protocol	NOUN
admet-2956	89	43	amendments	amendment	NOUN
admet-2956	89	44	,	,	PUNCT
admet-2956	89	45	post	post	ADJ
admet-2956	89	46	-	-	ADJ
admet-2956	89	47	hoc	hoc	ADJ
admet-2956	89	48	subgroup	subgroup	NOUN
admet-2956	89	49	analyses	analysis	NOUN
admet-2956	89	50	,	,	PUNCT
admet-2956	89	51	and	and	CCONJ
admet-2956	89	52	selective	selective	ADJ
admet-2956	89	53	outcome	outcome	NOUN
admet-2956	89	54	reporting	reporting	NOUN
admet-2956	89	55	.	.	PUNCT
admet-2956	90	1	these	these	DET
admet-2956	90	2	issues	issue	NOUN
admet-2956	90	3	,	,	PUNCT
admet-2956	90	4	although	although	SCONJ
admet-2956	90	5	consistent	consistent	ADJ
admet-2956	90	6	with	with	ADP
admet-2956	90	7	broader	broad	ADJ
admet-2956	90	8	challenges	challenge	NOUN
admet-2956	90	9	in	in	ADP
admet-2956	90	10	immunotherapy	immunotherapy	NOUN
admet-2956	90	11	research	research	NOUN
admet-2956	90	12	,	,	PUNCT
admet-2956	90	13	did	do	AUX
admet-2956	90	14	not	not	PART
admet-2956	90	15	significantly	significantly	ADV
admet-2956	90	16	undermine	undermine	VERB
admet-2956	90	17	the	the	DET
admet-2956	90	18	overall	overall	ADJ
admet-2956	90	19	quality	quality	NOUN
admet-2956	90	20	of	of	ADP
admet-2956	90	21	the	the	DET
admet-2956	90	22	evidence	evidence	NOUN
admet-2956	90	23	.	.	PUNCT
admet-2956	91	1	primary	primary	ADJ
admet-2956	91	2	efficacy	efficacy	NOUN
admet-2956	91	3	outcomes	outcome	VERB
admet-2956	91	4	objective	objective	ADJ
admet-2956	91	5	response	response	NOUN
admet-2956	91	6	rate	rate	NOUN
admet-2956	91	7	all	all	DET
admet-2956	91	8	seven	seven	NUM
admet-2956	91	9	trials	trial	NOUN
admet-2956	91	10	reported	report	VERB
admet-2956	91	11	orr	orr	PROPN
admet-2956	91	12	for	for	ADP
admet-2956	91	13	pd	pd	PROPN
admet-2956	91	14	-	-	PUNCT
admet-2956	91	15	l1	l1	PROPN
admet-2956	91	16	-	-	PUNCT
admet-2956	91	17	positive	positive	ADJ
admet-2956	91	18	tumours	tumours	NOUN
admet-2956	91	19	.	.	PUNCT
admet-2956	92	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	92	2	doubled	double	VERB
admet-2956	92	3	the	the	DET
admet-2956	92	4	likelihood	likelihood	NOUN
admet-2956	92	5	of	of	ADP
admet-2956	92	6	objective	objective	ADJ
admet-2956	92	7	response	response	NOUN
admet-2956	92	8	compared	compare	VERB
admet-2956	92	9	with	with	ADP
admet-2956	92	10	chemotherapy	chemotherapy	NOUN
admet-2956	92	11	(	(	PUNCT
admet-2956	92	12	rr	rr	NOUN
admet-2956	92	13	2.10	2.10	NUM
admet-2956	92	14	,	,	PUNCT
admet-2956	92	15	95	95	NUM
admet-2956	92	16	%	%	NOUN
admet-2956	92	17	ci	ci	NOUN
admet-2956	92	18	1.51	1.51	NUM
admet-2956	92	19	-	-	SYM
admet-2956	92	20	2.93	2.93	NUM
admet-2956	92	21	;	;	PUNCT
admet-2956	92	22	p	p	X
admet-2956	92	23	<	<	X
admet-2956	92	24	0.0001	0.0001	NUM
admet-2956	92	25	)	)	PUNCT
admet-2956	92	26	,	,	PUNCT
admet-2956	92	27	with	with	ADP
admet-2956	92	28	404	404	NUM
admet-2956	92	29	responses	response	NOUN
admet-2956	92	30	among	among	ADP
admet-2956	92	31	931	931	NUM
admet-2956	92	32	pembrolizumab	pembrolizumab	NOUN
admet-2956	92	33	patients	patient	NOUN
admet-2956	92	34	versus	versus	ADP
admet-2956	92	35	209	209	NUM
admet-2956	92	36	among	among	ADP
admet-2956	92	37	876	876	NUM
admet-2956	92	38	control	control	NOUN
admet-2956	92	39	patients	patient	NOUN
admet-2956	92	40	(	(	PUNCT
admet-2956	92	41	figure	figure	NOUN
admet-2956	92	42	3a	3a	NUM
admet-2956	92	43	)	)	PUNCT
admet-2956	92	44	.	.	PUNCT
admet-2956	93	1	considerable	considerable	ADJ
admet-2956	93	2	heterogeneity	heterogeneity	NOUN
admet-2956	93	3	(	(	PUNCT
admet-2956	93	4	i²	i²	NOUN
admet-2956	93	5	=	=	PROPN
admet-2956	93	6	78	78	NUM
admet-2956	93	7	%	%	NOUN
admet-2956	93	8	,	,	PUNCT
admet-2956	93	9	p	p	NOUN
admet-2956	93	10	=	=	NOUN
admet-2956	93	11	0.0001	0.0001	NUM
admet-2956	93	12	)	)	PUNCT
admet-2956	93	13	likely	likely	ADV
admet-2956	93	14	reflected	reflect	VERB
admet-2956	93	15	variation	variation	NOUN
admet-2956	93	16	in	in	ADP
admet-2956	93	17	pd	pd	PROPN
admet-2956	93	18	-	-	PROPN
admet-2956	93	19	l1	l1	PROPN
admet-2956	93	20	thresholds	threshold	NOUN
admet-2956	93	21	and	and	CCONJ
admet-2956	93	22	patient	patient	ADJ
admet-2956	93	23	populations	population	NOUN
admet-2956	93	24	across	across	ADP
admet-2956	93	25	studies	study	NOUN
admet-2956	93	26	.	.	PUNCT
admet-2956	94	1	total	total	ADJ
admet-2956	94	2	survival	survival	NOUN
admet-2956	94	3	six	six	NUM
admet-2956	94	4	studies	study	NOUN
admet-2956	94	5	provided	provide	VERB
admet-2956	94	6	os	os	NOUN
admet-2956	94	7	data	datum	NOUN
admet-2956	94	8	for	for	ADP
admet-2956	94	9	the	the	DET
admet-2956	94	10	pd	pd	PROPN
admet-2956	94	11	-	-	PUNCT
admet-2956	94	12	l1	l1	PROPN
admet-2956	94	13	-	-	PUNCT
admet-2956	94	14	positive	positive	ADJ
admet-2956	94	15	group	group	NOUN
admet-2956	94	16	.	.	PUNCT
admet-2956	95	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	95	2	monotherapy	monotherapy	NOUN
admet-2956	95	3	achieved	achieve	VERB
admet-2956	95	4	a	a	DET
admet-2956	95	5	clinically	clinically	ADV
admet-2956	95	6	important	important	ADJ
admet-2956	95	7	35	35	NUM
admet-2956	95	8	%	%	NOUN
admet-2956	95	9	reduction	reduction	NOUN
admet-2956	95	10	in	in	ADP
admet-2956	95	11	hazard	hazard	NOUN
admet-2956	95	12	of	of	ADP
admet-2956	95	13	death	death	NOUN
admet-2956	95	14	compared	compare	VERB
admet-2956	95	15	with	with	ADP
admet-2956	95	16	chemotherapy	chemotherapy	NOUN
admet-2956	95	17	(	(	PUNCT
admet-2956	95	18	hr	hr	NOUN
admet-2956	95	19	0.65	0.65	NUM
admet-2956	95	20	,	,	PUNCT
admet-2956	95	21	95	95	NUM
admet-2956	95	22	%	%	NOUN
admet-2956	95	23	ci	ci	NOUN
admet-2956	95	24	:	:	PUNCT
admet-2956	95	25	0.57	0.57	NUM
admet-2956	95	26	-	-	SYM
admet-2956	95	27	0.73	0.73	NUM
admet-2956	95	28	,	,	PUNCT
admet-2956	95	29	p	p	X
admet-2956	95	30	<	<	X
admet-2956	95	31	0.00001	0.00001	NUM
admet-2956	95	32	)	)	PUNCT
admet-2956	95	33	as	as	SCONJ
admet-2956	95	34	observed	observe	VERB
admet-2956	95	35	in	in	ADP
admet-2956	95	36	figure	figure	NOUN
admet-2956	95	37	3b	3b	NUM
admet-2956	95	38	.	.	PUNCT
admet-2956	96	1	the	the	DET
admet-2956	96	2	analysis	analysis	NOUN
admet-2956	96	3	showed	show	VERB
admet-2956	96	4	low	low	ADJ
admet-2956	96	5	to	to	ADP
admet-2956	96	6	moderate	moderate	ADJ
admet-2956	96	7	heterogeneity	heterogeneity	NOUN
admet-2956	96	8	(	(	PUNCT
admet-2956	96	9	i²	i²	NOUN
admet-2956	96	10	=	=	PUNCT
admet-2956	96	11	30	30	NUM
admet-2956	96	12	%	%	NOUN
admet-2956	96	13	,	,	PUNCT
admet-2956	96	14	p	p	X
admet-2956	96	15	=	=	NOUN
admet-2956	96	16	0.21	0.21	NUM
admet-2956	96	17	)	)	PUNCT
admet-2956	96	18	,	,	PUNCT
admet-2956	96	19	favouring	favour	VERB
admet-2956	96	20	homogeneous	homogeneous	ADJ
admet-2956	96	21	survival	survival	NOUN
admet-2956	96	22	benefits	benefit	NOUN
admet-2956	96	23	across	across	ADP
admet-2956	96	24	study	study	NOUN
admet-2956	96	25	populations	population	NOUN
admet-2956	96	26	.	.	PUNCT
admet-2956	97	1	this	this	PRON
admet-2956	97	2	is	be	AUX
admet-2956	97	3	a	a	DET
admet-2956	97	4	notable	notable	ADJ
admet-2956	97	5	clinical	clinical	ADJ
admet-2956	97	6	benefit	benefit	NOUN
admet-2956	97	7	with	with	ADP
admet-2956	97	8	robust	robust	ADJ
admet-2956	97	9	statistical	statistical	ADJ
admet-2956	97	10	significance	significance	NOUN
admet-2956	97	11	.	.	PUNCT
admet-2956	98	1	progression	progression	NOUN
admet-2956	98	2	-	-	PUNCT
admet-2956	98	3	free	free	ADJ
admet-2956	98	4	survival	survival	NOUN
admet-2956	98	5	pfs	pf	VERB
admet-2956	98	6	analysis	analysis	NOUN
admet-2956	98	7	of	of	ADP
admet-2956	98	8	six	six	NUM
admet-2956	98	9	studies	study	NOUN
admet-2956	98	10	demonstrated	demonstrate	VERB
admet-2956	98	11	that	that	SCONJ
admet-2956	98	12	pembrolizumab	pembrolizumab	NOUN
admet-2956	98	13	significantly	significantly	ADV
admet-2956	98	14	reduced	reduce	VERB
admet-2956	98	15	the	the	DET
admet-2956	98	16	risk	risk	NOUN
admet-2956	98	17	of	of	ADP
admet-2956	98	18	disease	disease	NOUN
admet-2956	98	19	progression	progression	NOUN
admet-2956	98	20	or	or	CCONJ
admet-2956	98	21	death	death	NOUN
admet-2956	98	22	by	by	ADP
admet-2956	98	23	45	45	NUM
admet-2956	98	24	%	%	NOUN
admet-2956	98	25	(	(	PUNCT
admet-2956	98	26	hr	hr	NOUN
admet-2956	98	27	0.55	0.55	NUM
admet-2956	98	28	,	,	PUNCT
admet-2956	98	29	95	95	NUM
admet-2956	98	30	%	%	NOUN
admet-2956	98	31	ci	ci	NOUN
admet-2956	98	32	:	:	PUNCT
admet-2956	98	33	0.42	0.42	NUM
admet-2956	98	34	-	-	SYM
admet-2956	98	35	0.72	0.72	NUM
admet-2956	98	36	,	,	PUNCT
admet-2956	98	37	p	p	X
admet-2956	98	38	<	<	X
admet-2956	98	39	0.0001	0.0001	NUM
admet-2956	98	40	)	)	PUNCT
admet-2956	98	41	as	as	SCONJ
admet-2956	98	42	illustrated	illustrate	VERB
admet-2956	98	43	in	in	ADP
admet-2956	98	44	figure	figure	NOUN
admet-2956	98	45	3c	3c	NUM
admet-2956	98	46	.	.	PUNCT
admet-2956	99	1	however	however	ADV
admet-2956	99	2	,	,	PUNCT
admet-2956	99	3	high	high	ADJ
admet-2956	99	4	heterogeneity	heterogeneity	NOUN
admet-2956	99	5	was	be	AUX
admet-2956	99	6	observed	observe	VERB
admet-2956	99	7	(	(	PUNCT
admet-2956	99	8	i²	i²	NOUN
admet-2956	99	9	=	=	NUM
admet-2956	99	10	81	81	NUM
admet-2956	99	11	%	%	NOUN
admet-2956	99	12	,	,	PUNCT
admet-2956	99	13	p	p	X
admet-2956	99	14	<	<	X
admet-2956	99	15	0.00001	0.00001	NUM
admet-2956	99	16	)	)	PUNCT
admet-2956	99	17	,	,	PUNCT
admet-2956	99	18	suggesting	suggest	VERB
admet-2956	99	19	variability	variability	NOUN
admet-2956	99	20	in	in	ADP
admet-2956	99	21	progression	progression	NOUN
admet-2956	99	22	patterns	pattern	NOUN
admet-2956	99	23	across	across	ADP
admet-2956	99	24	different	different	ADJ
admet-2956	99	25	patient	patient	ADJ
admet-2956	99	26	populations	population	NOUN
admet-2956	99	27	and	and	CCONJ
admet-2956	99	28	study	study	NOUN
admet-2956	99	29	designs	design	NOUN
admet-2956	99	30	.	.	PUNCT
admet-2956	100	1	despite	despite	SCONJ
admet-2956	100	2	this	this	DET
admet-2956	100	3	heterogeneity	heterogeneity	NOUN
admet-2956	100	4	,	,	PUNCT
admet-2956	100	5	the	the	DET
admet-2956	100	6	substantial	substantial	ADJ
admet-2956	100	7	effect	effect	NOUN
admet-2956	100	8	size	size	NOUN
admet-2956	100	9	and	and	CCONJ
admet-2956	100	10	statistical	statistical	ADJ
admet-2956	100	11	significance	significance	NOUN
admet-2956	100	12	support	support	VERB
admet-2956	100	13	the	the	DET
admet-2956	100	14	superior	superior	ADJ
admet-2956	100	15	efficacy	efficacy	NOUN
admet-2956	100	16	of	of	ADP
admet-2956	100	17	pembrolizumab	pembrolizumab	NOUN
admet-2956	100	18	in	in	ADP
admet-2956	100	19	delaying	delay	VERB
admet-2956	100	20	disease	disease	NOUN
admet-2956	100	21	progression	progression	NOUN
admet-2956	100	22	.	.	PUNCT
admet-2956	101	1	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	101	2	a.	a.	PROPN
admet-2956	101	3	chakramurty	chakramurty	PROPN
admet-2956	101	4	et	et	PROPN
admet-2956	101	5	al	al	PROPN
admet-2956	101	6	.	.	PROPN
admet-2956	101	7	admet	admet	PROPN
admet-2956	101	8	&	&	CCONJ
admet-2956	101	9	dmpk	dmpk	PROPN
admet-2956	101	10	13(5	13(5	NUM
admet-2956	101	11	)	)	PUNCT
admet-2956	101	12	(	(	PUNCT
admet-2956	101	13	2025	2025	NUM
admet-2956	101	14	)	)	PUNCT
admet-2956	101	15	2956	2956	NUM
admet-2956	101	16	6	6	NUM
admet-2956	101	17	figure	figure	NOUN
admet-2956	101	18	3	3	NUM
admet-2956	101	19	.	.	PUNCT
admet-2956	101	20	forest	forest	NOUN
admet-2956	101	21	plots	plot	NOUN
admet-2956	101	22	illustrating	illustrate	VERB
admet-2956	101	23	survival	survival	NOUN
admet-2956	101	24	outcomes	outcome	NOUN
admet-2956	101	25	in	in	ADP
admet-2956	101	26	randomized	randomized	ADJ
admet-2956	101	27	clinical	clinical	ADJ
admet-2956	101	28	trials	trial	NOUN
admet-2956	101	29	(	(	PUNCT
admet-2956	101	30	rcts	rct	NOUN
admet-2956	101	31	):	):	PUNCT
admet-2956	101	32	(	(	PUNCT
admet-2956	101	33	a	a	X
admet-2956	101	34	)	)	PUNCT
admet-2956	101	35	orr	orr	NOUN
admet-2956	101	36	in	in	ADP
admet-2956	101	37	rcts	rct	NOUN
admet-2956	101	38	,	,	PUNCT
admet-2956	101	39	(	(	PUNCT
admet-2956	101	40	b	b	NOUN
admet-2956	101	41	)	)	PUNCT
admet-2956	101	42	os	os	NOUN
admet-2956	101	43	in	in	ADP
admet-2956	101	44	rcts	rct	NOUN
admet-2956	101	45	and	and	CCONJ
admet-2956	101	46	(	(	PUNCT
admet-2956	101	47	c	c	NOUN
admet-2956	101	48	)	)	PUNCT
admet-2956	101	49	pfs	pfs	PROPN
admet-2956	101	50	in	in	ADP
admet-2956	101	51	rcts	rct	NOUN
admet-2956	101	52	secondary	secondary	ADJ
admet-2956	101	53	outcomes	outcome	NOUN
admet-2956	101	54	safety	safety	NOUN
admet-2956	101	55	analysis	analysis	NOUN
admet-2956	101	56	in	in	ADP
admet-2956	101	57	the	the	DET
admet-2956	101	58	combined	combined	ADJ
admet-2956	101	59	safety	safety	NOUN
admet-2956	101	60	analysis	analysis	NOUN
admet-2956	101	61	,	,	PUNCT
admet-2956	101	62	4,168	4,168	NUM
admet-2956	101	63	patients	patient	NOUN
admet-2956	101	64	in	in	ADP
admet-2956	101	65	the	the	DET
admet-2956	101	66	pembrolizumab	pembrolizumab	NOUN
admet-2956	101	67	arm	arm	NOUN
admet-2956	101	68	and	and	CCONJ
admet-2956	101	69	3,632	3,632	NUM
admet-2956	101	70	patients	patient	NOUN
admet-2956	101	71	in	in	ADP
admet-2956	101	72	the	the	DET
admet-2956	101	73	control	control	NOUN
admet-2956	101	74	arm	arm	NOUN
admet-2956	101	75	were	be	AUX
admet-2956	101	76	included	include	VERB
admet-2956	101	77	in	in	ADP
admet-2956	101	78	seven	seven	NUM
admet-2956	101	79	randomized	randomized	ADJ
admet-2956	101	80	trials	trial	NOUN
admet-2956	101	81	.	.	PUNCT
admet-2956	102	1	most	most	ADJ
admet-2956	102	2	patients	patient	NOUN
admet-2956	102	3	in	in	ADP
admet-2956	102	4	both	both	DET
admet-2956	102	5	arms	arm	NOUN
admet-2956	102	6	experienced	experience	VERB
admet-2956	102	7	adverse	adverse	ADJ
admet-2956	102	8	events	event	NOUN
admet-2956	102	9	of	of	ADP
admet-2956	102	10	any	any	DET
admet-2956	102	11	grade	grade	NOUN
admet-2956	102	12	,	,	PUNCT
admet-2956	102	13	with	with	ADP
admet-2956	102	14	pembrolizumab	pembrolizumab	NOUN
admet-2956	102	15	having	have	VERB
admet-2956	102	16	an	an	DET
admet-2956	102	17	evident	evident	ADJ
admet-2956	102	18	but	but	CCONJ
admet-2956	102	19	manageable	manageable	ADJ
admet-2956	102	20	safety	safety	NOUN
admet-2956	102	21	profile	profile	NOUN
admet-2956	102	22	compared	compare	VERB
admet-2956	102	23	to	to	ADP
admet-2956	102	24	chemotherapy	chemotherapy	NOUN
admet-2956	102	25	controls	control	NOUN
admet-2956	102	26	,	,	PUNCT
admet-2956	102	27	as	as	SCONJ
admet-2956	102	28	summarized	summarize	VERB
admet-2956	102	29	in	in	ADP
admet-2956	102	30	table	table	NOUN
admet-2956	102	31	2	2	NUM
admet-2956	102	32	.	.	PUNCT
admet-2956	103	1	overall	overall	ADJ
admet-2956	103	2	safety	safety	NOUN
admet-2956	103	3	profile	profile	NOUN
admet-2956	103	4	grade	grade	NOUN
admet-2956	103	5	3	3	NUM
admet-2956	103	6	-	-	SYM
admet-2956	103	7	5	5	NUM
admet-2956	103	8	adverse	adverse	ADJ
admet-2956	103	9	events	event	NOUN
admet-2956	103	10	had	have	VERB
admet-2956	103	11	variable	variable	ADJ
admet-2956	103	12	incidence	incidence	NOUN
admet-2956	103	13	between	between	ADP
admet-2956	103	14	trials	trial	NOUN
admet-2956	103	15	,	,	PUNCT
admet-2956	103	16	with	with	ADP
admet-2956	103	17	severe	severe	ADJ
admet-2956	103	18	toxicity	toxicity	NOUN
admet-2956	103	19	of	of	ADP
admet-2956	103	20	11.3	11.3	NUM
admet-2956	103	21	to	to	PART
admet-2956	103	22	67.2	67.2	NUM
admet-2956	103	23	%	%	NOUN
admet-2956	103	24	in	in	ADP
admet-2956	103	25	patients	patient	NOUN
admet-2956	103	26	treated	treat	VERB
admet-2956	103	27	with	with	ADP
admet-2956	103	28	pembrolizumab	pembrolizumab	NOUN
admet-2956	103	29	,	,	PUNCT
admet-2956	103	30	compared	compare	VERB
admet-2956	103	31	with	with	ADP
admet-2956	103	32	25.8	25.8	NUM
admet-2956	103	33	to	to	PART
admet-2956	103	34	68.2	68.2	NUM
admet-2956	103	35	%	%	NOUN
admet-2956	103	36	in	in	ADP
admet-2956	103	37	control	control	NOUN
admet-2956	103	38	arms	arm	NOUN
admet-2956	103	39	,	,	PUNCT
admet-2956	103	40	as	as	SCONJ
admet-2956	103	41	summarized	summarize	VERB
admet-2956	103	42	in	in	ADP
admet-2956	103	43	table	table	NOUN
admet-2956	103	44	2	2	NUM
admet-2956	103	45	.	.	PUNCT
admet-2956	103	46	treatment	treatment	NOUN
admet-2956	103	47	discontinuation	discontinuation	NOUN
admet-2956	103	48	due	due	ADP
admet-2956	103	49	to	to	ADP
admet-2956	103	50	adverse	adverse	ADJ
admet-2956	103	51	events	event	NOUN
admet-2956	103	52	was	be	AUX
admet-2956	103	53	observed	observe	VERB
admet-2956	103	54	in	in	ADP
admet-2956	103	55	pembrolizumab	pembrolizumab	NOUN
admet-2956	103	56	-	-	PUNCT
admet-2956	103	57	treated	treat	VERB
admet-2956	103	58	patients	patient	NOUN
admet-2956	103	59	at	at	ADP
admet-2956	103	60	frequencies	frequency	NOUN
admet-2956	103	61	ranging	range	VERB
admet-2956	103	62	from	from	ADP
admet-2956	103	63	4.4	4.4	NUM
admet-2956	103	64	%	%	NOUN
admet-2956	103	65	to	to	ADP
admet-2956	103	66	13.6	13.6	NUM
admet-2956	103	67	%	%	NOUN
admet-2956	103	68	,	,	PUNCT
admet-2956	103	69	compared	compare	VERB
admet-2956	103	70	with	with	ADP
admet-2956	103	71	frequencies	frequency	NOUN
admet-2956	103	72	ranging	range	VERB
admet-2956	103	73	from	from	ADP
admet-2956	103	74	6.4	6.4	NUM
admet-2956	103	75	to	to	PART
admet-2956	103	76	12.7	12.7	NUM
admet-2956	103	77	%	%	NOUN
admet-2956	103	78	in	in	ADP
admet-2956	103	79	the	the	DET
admet-2956	103	80	control	control	NOUN
admet-2956	103	81	arms	arm	NOUN
admet-2956	103	82	.	.	PUNCT
admet-2956	104	1	treatment	treatment	NOUN
admet-2956	104	2	-	-	PUNCT
admet-2956	104	3	related	relate	VERB
admet-2956	104	4	mortality	mortality	NOUN
admet-2956	104	5	remained	remain	VERB
admet-2956	104	6	infrequent	infrequent	ADJ
admet-2956	104	7	in	in	ADP
admet-2956	104	8	both	both	DET
admet-2956	104	9	groups	group	NOUN
admet-2956	104	10	:	:	PUNCT
admet-2956	104	11	•	•	NUM
admet-2956	104	12	pembrolizumab	pembrolizumab	NOUN
admet-2956	104	13	:	:	PUNCT
admet-2956	104	14	0.9	0.9	NUM
admet-2956	104	15	to	to	ADP
admet-2956	104	16	6.6	6.6	NUM
admet-2956	104	17	%	%	NOUN
admet-2956	104	18	across	across	ADP
admet-2956	104	19	trials	trial	NOUN
admet-2956	104	20	,	,	PUNCT
admet-2956	104	21	•	•	NUM
admet-2956	104	22	control	control	NOUN
admet-2956	104	23	:	:	PUNCT
admet-2956	104	24	1.5	1.5	NUM
admet-2956	104	25	to	to	PART
admet-2956	104	26	13.1	13.1	NUM
admet-2956	104	27	%	%	NOUN
admet-2956	104	28	,	,	PUNCT
admet-2956	104	29	•	•	INTJ
admet-2956	104	30	no	no	DET
admet-2956	104	31	overall	overall	ADJ
admet-2956	104	32	mortality	mortality	NOUN
admet-2956	104	33	difference	difference	NOUN
admet-2956	104	34	by	by	ADP
admet-2956	104	35	treatment	treatment	NOUN
admet-2956	104	36	groups	group	NOUN
admet-2956	104	37	with	with	ADP
admet-2956	104	38	pooled	pool	VERB
admet-2956	104	39	analysis	analysis	NOUN
admet-2956	104	40	.	.	PUNCT
admet-2956	105	1	admet	admet	PROPN
admet-2956	105	2	&	&	CCONJ
admet-2956	105	3	dmpk	dmpk	PROPN
admet-2956	105	4	13(5	13(5	NUM
admet-2956	105	5	)	)	PUNCT
admet-2956	105	6	(	(	PUNCT
admet-2956	105	7	2025	2025	NUM
admet-2956	105	8	)	)	PUNCT
admet-2956	105	9	2956	2956	NUM
admet-2956	105	10	pembrolizumab	pembrolizumab	NOUN
admet-2956	105	11	in	in	ADP
admet-2956	105	12	pd	pd	PROPN
admet-2956	105	13	-	-	PUNCT
admet-2956	105	14	l1	l1	PROPN
admet-2956	105	15	-	-	PUNCT
admet-2956	105	16	positive	positive	ADJ
admet-2956	105	17	advanced	advanced	ADJ
admet-2956	105	18	non	non	ADJ
admet-2956	105	19	-	-	ADJ
admet-2956	105	20	small	small	ADJ
admet-2956	105	21	cell	cell	NOUN
admet-2956	105	22	lung	lung	NOUN
admet-2956	105	23	carcinoma	carcinoma	NOUN
admet-2956	105	24	doi	doi	NOUN
admet-2956	105	25	:	:	PUNCT
admet-2956	105	26	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	105	27	7	7	NUM
admet-2956	105	28	table	table	NOUN
admet-2956	105	29	2	2	NUM
admet-2956	105	30	.	.	PUNCT
admet-2956	105	31	overall	overall	ADJ
admet-2956	105	32	safety	safety	NOUN
admet-2956	105	33	summary	summary	NOUN
admet-2956	105	34	and	and	CCONJ
admet-2956	105	35	treatment	treatment	NOUN
admet-2956	105	36	-	-	PUNCT
admet-2956	105	37	related	relate	VERB
admet-2956	105	38	adverse	adverse	ADJ
admet-2956	105	39	events	event	NOUN
admet-2956	105	40	ref	ref	NOUN
admet-2956	105	41	.	.	PUNCT
admet-2956	106	1	treatment	treatment	NOUN
admet-2956	106	2	arms	arm	NOUN
admet-2956	106	3	total	total	NOUN
admet-2956	106	4	,	,	PUNCT
admet-2956	106	5	n	n	CCONJ
admet-2956	106	6	any	any	DET
admet-2956	106	7	grade	grade	NOUN
admet-2956	106	8	aes	aes	PROPN
admet-2956	106	9	,	,	PUNCT
admet-2956	106	10	n	n	CCONJ
admet-2956	106	11	/	/	SYM
admet-2956	106	12	%	%	NOUN
admet-2956	106	13	grade	grade	NOUN
admet-2956	106	14	3	3	NUM
admet-2956	106	15	-	-	SYM
admet-2956	106	16	5	5	NUM
admet-2956	106	17	aes	aes	NOUN
admet-2956	106	18	,	,	PUNCT
admet-2956	106	19	n	n	CCONJ
admet-2956	106	20	/	/	SYM
admet-2956	106	21	%	%	NOUN
admet-2956	106	22	treatment	treatment	NOUN
admet-2956	106	23	-	-	PUNCT
admet-2956	106	24	related	relate	VERB
admet-2956	106	25	deaths	death	NOUN
admet-2956	106	26	,	,	PUNCT
admet-2956	106	27	n	n	CCONJ
admet-2956	106	28	/	/	SYM
admet-2956	106	29	%	%	NOUN
admet-2956	106	30	discontinuation	discontinuation	NOUN
admet-2956	106	31	due	due	ADP
admet-2956	106	32	to	to	ADP
admet-2956	106	33	aes	aes	PROPN
admet-2956	106	34	,	,	PUNCT
admet-2956	106	35	n	n	PROPN
admet-2956	106	36	/	/	SYM
admet-2956	106	37	%	%	NOUN
admet-2956	107	1	[	[	X
admet-2956	107	2	43	43	NUM
admet-2956	107	3	]	]	PUNCT
admet-2956	107	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	107	5	2	2	NUM
admet-2956	107	6	mg	mg	PROPN
admet-2956	107	7	344	344	NUM
admet-2956	107	8	215/339	215/339	NUM
admet-2956	107	9	(	(	PUNCT
admet-2956	107	10	63.4	63.4	NUM
admet-2956	107	11	%	%	NOUN
admet-2956	107	12	)	)	PUNCT
admet-2956	107	13	43/339	43/339	PROPN
admet-2956	107	14	(	(	PUNCT
admet-2956	107	15	12.7	12.7	NUM
admet-2956	107	16	%	%	NOUN
admet-2956	107	17	)	)	PUNCT
admet-2956	107	18	3/344	3/344	NUM
admet-2956	107	19	(	(	PUNCT
admet-2956	107	20	0.9	0.9	NUM
admet-2956	107	21	%	%	NOUN
admet-2956	107	22	)	)	PUNCT
admet-2956	107	23	15/344	15/344	NUM
admet-2956	107	24	(	(	PUNCT
admet-2956	107	25	4.4	4.4	NUM
admet-2956	107	26	%	%	NOUN
admet-2956	107	27	)	)	PUNCT
admet-2956	107	28	docetaxel	docetaxel	NOUN
admet-2956	107	29	343	343	NUM
admet-2956	107	30	251/309	251/309	PROPN
admet-2956	107	31	(	(	PUNCT
admet-2956	107	32	81.2	81.2	NUM
admet-2956	107	33	%	%	NOUN
admet-2956	107	34	)	)	PUNCT
admet-2956	108	1	109/309	109/309	NUM
admet-2956	108	2	(	(	PUNCT
admet-2956	108	3	35.3	35.3	NUM
admet-2956	108	4	%	%	NOUN
admet-2956	108	5	)	)	PUNCT
admet-2956	108	6	5/343	5/343	NUM
admet-2956	108	7	(	(	PUNCT
admet-2956	108	8	1.5	1.5	NUM
admet-2956	108	9	%	%	NOUN
admet-2956	108	10	)	)	PUNCT
admet-2956	108	11	31/343	31/343	PROPN
admet-2956	108	12	(	(	PUNCT
admet-2956	108	13	9.0	9.0	NUM
admet-2956	108	14	%	%	NOUN
admet-2956	108	15	)	)	PUNCT
admet-2956	109	1	[	[	X
admet-2956	109	2	44	44	NUM
admet-2956	109	3	]	]	PUNCT
admet-2956	109	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	109	5	+	+	CCONJ
admet-2956	109	6	chemo	chemo	VERB
admet-2956	109	7	60	60	NUM
admet-2956	109	8	55/59	55/59	NUM
admet-2956	109	9	(	(	PUNCT
admet-2956	109	10	93.2	93.2	NUM
admet-2956	109	11	%	%	NOUN
admet-2956	109	12	)	)	PUNCT
admet-2956	110	1	23/59	23/59	NUM
admet-2956	110	2	(	(	PUNCT
admet-2956	110	3	39.0	39.0	NUM
admet-2956	110	4	%	%	NOUN
admet-2956	110	5	)	)	PUNCT
admet-2956	110	6	1/60	1/60	NUM
admet-2956	110	7	(	(	PUNCT
admet-2956	110	8	1.7	1.7	NUM
admet-2956	110	9	%	%	NOUN
admet-2956	110	10	)	)	PUNCT
admet-2956	110	11	6/60	6/60	NUM
admet-2956	110	12	(	(	PUNCT
admet-2956	110	13	10.0	10.0	NUM
admet-2956	110	14	%	%	NOUN
admet-2956	110	15	)	)	PUNCT
admet-2956	110	16	chemotherapy	chemotherapy	NOUN
admet-2956	110	17	63	63	NUM
admet-2956	110	18	56/62	56/62	NUM
admet-2956	110	19	(	(	PUNCT
admet-2956	110	20	90.3	90.3	NUM
admet-2956	110	21	%	%	NOUN
admet-2956	110	22	)	)	PUNCT
admet-2956	111	1	16/62	16/62	NUM
admet-2956	111	2	(	(	PUNCT
admet-2956	111	3	25.8	25.8	NUM
admet-2956	111	4	%	%	NOUN
admet-2956	111	5	)	)	PUNCT
admet-2956	111	6	2/63	2/63	NUM
admet-2956	111	7	(	(	PUNCT
admet-2956	111	8	3.2	3.2	NUM
admet-2956	111	9	%	%	NOUN
admet-2956	111	10	)	)	PUNCT
admet-2956	111	11	8/63	8/63	NUM
admet-2956	111	12	(	(	PUNCT
admet-2956	111	13	12.7	12.7	NUM
admet-2956	111	14	%	%	NOUN
admet-2956	111	15	)	)	PUNCT
admet-2956	112	1	[	[	X
admet-2956	112	2	22	22	NUM
admet-2956	112	3	]	]	PUNCT
admet-2956	112	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	112	5	154	154	NUM
admet-2956	112	6	118/154	118/154	PROPN
admet-2956	112	7	(	(	PUNCT
admet-2956	112	8	76.6	76.6	NUM
admet-2956	112	9	%	%	NOUN
admet-2956	112	10	)	)	PUNCT
admet-2956	112	11	48/154	48/154	NUM
admet-2956	112	12	(	(	PUNCT
admet-2956	112	13	31.2	31.2	NUM
admet-2956	112	14	%	%	NOUN
admet-2956	112	15	)	)	PUNCT
admet-2956	112	16	2/154	2/154	NUM
admet-2956	112	17	(	(	PUNCT
admet-2956	112	18	1.3	1.3	NUM
admet-2956	112	19	%	%	NOUN
admet-2956	112	20	)	)	PUNCT
admet-2956	112	21	21/154	21/154	NUM
admet-2956	112	22	(	(	PUNCT
admet-2956	112	23	13.6	13.6	NUM
admet-2956	112	24	%	%	NOUN
admet-2956	112	25	)	)	PUNCT
admet-2956	112	26	chemotherapy	chemotherapy	NOUN
admet-2956	112	27	151	151	NUM
admet-2956	112	28	135/150	135/150	PROPN
admet-2956	112	29	(	(	PUNCT
admet-2956	112	30	90.0	90.0	NUM
admet-2956	112	31	%	%	NOUN
admet-2956	112	32	)	)	PUNCT
admet-2956	112	33	80/150	80/150	NUM
admet-2956	113	1	(	(	PUNCT
admet-2956	113	2	53.3	53.3	NUM
admet-2956	113	3	%	%	NOUN
admet-2956	113	4	)	)	PUNCT
admet-2956	113	5	3/151	3/151	NUM
admet-2956	113	6	(	(	PUNCT
admet-2956	113	7	2.0	2.0	NUM
admet-2956	113	8	%	%	NOUN
admet-2956	113	9	)	)	PUNCT
admet-2956	113	10	16/151	16/151	NUM
admet-2956	113	11	(	(	PUNCT
admet-2956	113	12	10.6	10.6	NUM
admet-2956	113	13	%	%	NOUN
admet-2956	113	14	)	)	PUNCT
admet-2956	114	1	[	[	X
admet-2956	114	2	45	45	NUM
admet-2956	114	3	]	]	PUNCT
admet-2956	114	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	114	5	637	637	NUM
admet-2956	114	6	399/636	399/636	NOUN
admet-2956	114	7	(	(	PUNCT
admet-2956	114	8	62.7	62.7	NUM
admet-2956	114	9	%	%	NOUN
admet-2956	114	10	)	)	PUNCT
admet-2956	115	1	113/636	113/636	PROPN
admet-2956	115	2	(	(	PUNCT
admet-2956	115	3	17.8	17.8	NUM
admet-2956	115	4	%	%	NOUN
admet-2956	115	5	)	)	PUNCT
admet-2956	115	6	13/637	13/637	NUM
admet-2956	115	7	(	(	PUNCT
admet-2956	115	8	2.0	2.0	NUM
admet-2956	115	9	%	%	NOUN
admet-2956	115	10	)	)	PUNCT
admet-2956	115	11	57/637	57/637	NUM
admet-2956	115	12	(	(	PUNCT
admet-2956	115	13	8.9	8.9	NUM
admet-2956	115	14	%	%	NOUN
admet-2956	115	15	)	)	PUNCT
admet-2956	115	16	chemotherapy	chemotherapy	NOUN
admet-2956	115	17	637	637	NUM
admet-2956	115	18	553/615	553/615	NUM
admet-2956	115	19	(	(	PUNCT
admet-2956	115	20	89.9	89.9	NUM
admet-2956	115	21	%	%	NOUN
admet-2956	115	22	)	)	PUNCT
admet-2956	116	1	252/615	252/615	NUM
admet-2956	116	2	(	(	PUNCT
admet-2956	116	3	41.0	41.0	NUM
admet-2956	116	4	%	%	NOUN
admet-2956	116	5	)	)	PUNCT
admet-2956	116	6	14/637	14/637	NUM
admet-2956	116	7	(	(	PUNCT
admet-2956	116	8	2.2	2.2	NUM
admet-2956	116	9	%	%	NOUN
admet-2956	116	10	)	)	PUNCT
admet-2956	117	1	58/637	58/637	NUM
admet-2956	117	2	(	(	PUNCT
admet-2956	117	3	9.1	9.1	NUM
admet-2956	117	4	%	%	NOUN
admet-2956	117	5	)	)	PUNCT
admet-2956	118	1	[	[	X
admet-2956	118	2	46	46	NUM
admet-2956	118	3	]	]	X
admet-2956	118	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	118	5	+	+	CCONJ
admet-2956	118	6	chemo	chemo	VERB
admet-2956	118	7	278	278	NUM
admet-2956	118	8	273/278	273/278	PROPN
admet-2956	118	9	(	(	PUNCT
admet-2956	118	10	98.2	98.2	NUM
admet-2956	118	11	%	%	NOUN
admet-2956	118	12	)	)	PUNCT
admet-2956	119	1	194/278	194/278	NUM
admet-2956	119	2	(	(	PUNCT
admet-2956	119	3	69.8	69.8	NUM
admet-2956	119	4	%	%	NOUN
admet-2956	119	5	)	)	PUNCT
admet-2956	119	6	10/278	10/278	NUM
admet-2956	119	7	(	(	PUNCT
admet-2956	119	8	3.6	3.6	NUM
admet-2956	119	9	%	%	NOUN
admet-2956	119	10	)	)	PUNCT
admet-2956	119	11	37/278	37/278	NUM
admet-2956	119	12	(	(	PUNCT
admet-2956	119	13	13.3	13.3	NUM
admet-2956	119	14	%	%	NOUN
admet-2956	119	15	)	)	PUNCT
admet-2956	119	16	placebo	placebo	NOUN
admet-2956	119	17	+	+	CCONJ
admet-2956	119	18	chemo	chemo	VERB
admet-2956	119	19	281	281	NUM
admet-2956	119	20	274/280	274/280	PROPN
admet-2956	119	21	(	(	PUNCT
admet-2956	119	22	97.9	97.9	NUM
admet-2956	119	23	%	%	NOUN
admet-2956	119	24	)	)	PUNCT
admet-2956	119	25	191/280	191/280	PROPN
admet-2956	119	26	(	(	PUNCT
admet-2956	119	27	68.2	68.2	NUM
admet-2956	119	28	%	%	NOUN
admet-2956	119	29	)	)	PUNCT
admet-2956	119	30	6/281	6/281	NUM
admet-2956	119	31	(	(	PUNCT
admet-2956	119	32	2.1	2.1	NUM
admet-2956	119	33	%	%	NOUN
admet-2956	119	34	)	)	PUNCT
admet-2956	119	35	18/281	18/281	NUM
admet-2956	119	36	(	(	PUNCT
admet-2956	119	37	6.4	6.4	NUM
admet-2956	119	38	%	%	NOUN
admet-2956	119	39	)	)	PUNCT
admet-2956	120	1	[	[	X
admet-2956	120	2	47	47	NUM
admet-2956	120	3	]	]	PUNCT
admet-2956	120	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	120	5	213	213	NUM
admet-2956	120	6	149/213	149/213	NOUN
admet-2956	120	7	(	(	PUNCT
admet-2956	120	8	70.0	70.0	NUM
admet-2956	120	9	%	%	NOUN
admet-2956	120	10	)	)	PUNCT
admet-2956	120	11	24/213	24/213	NUM
admet-2956	120	12	(	(	PUNCT
admet-2956	120	13	11.3	11.3	NUM
admet-2956	120	14	%	%	NOUN
admet-2956	120	15	)	)	PUNCT
admet-2956	120	16	4/213	4/213	NUM
admet-2956	120	17	(	(	PUNCT
admet-2956	120	18	1.9	1.9	NUM
admet-2956	120	19	%	%	NOUN
admet-2956	120	20	)	)	PUNCT
admet-2956	120	21	21/213	21/213	NUM
admet-2956	120	22	(	(	PUNCT
admet-2956	120	23	9.9	9.9	NUM
admet-2956	120	24	%	%	NOUN
admet-2956	120	25	)	)	PUNCT
admet-2956	120	26	docetaxel	docetaxel	NOUN
admet-2956	120	27	212	212	NUM
admet-2956	120	28	174/198	174/198	PROPN
admet-2956	120	29	(	(	PUNCT
admet-2956	120	30	87.9	87.9	NUM
admet-2956	120	31	%	%	NOUN
admet-2956	120	32	)	)	PUNCT
admet-2956	121	1	94/198	94/198	NUM
admet-2956	121	2	(	(	PUNCT
admet-2956	121	3	47.5	47.5	NUM
admet-2956	121	4	%	%	NOUN
admet-2956	121	5	)	)	PUNCT
admet-2956	121	6	4/212	4/212	NUM
admet-2956	121	7	(	(	PUNCT
admet-2956	121	8	1.9	1.9	NUM
admet-2956	121	9	%	%	NOUN
admet-2956	121	10	)	)	PUNCT
admet-2956	121	11	15/212	15/212	NUM
admet-2956	121	12	(	(	PUNCT
admet-2956	121	13	7.1	7.1	NUM
admet-2956	121	14	%	%	NOUN
admet-2956	121	15	)	)	PUNCT
admet-2956	122	1	[	[	X
admet-2956	122	2	48	48	NUM
admet-2956	122	3	]	]	PUNCT
admet-2956	122	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	122	5	+	+	CCONJ
admet-2956	122	6	chemo	chemo	VERB
admet-2956	122	7	410	410	NUM
admet-2956	122	8	404/405	404/405	PROPN
admet-2956	122	9	(	(	PUNCT
admet-2956	122	10	99.8	99.8	NUM
admet-2956	122	11	%	%	NOUN
admet-2956	122	12	)	)	PUNCT
admet-2956	123	1	272/405	272/405	NUM
admet-2956	123	2	(	(	PUNCT
admet-2956	123	3	67.2	67.2	NUM
admet-2956	123	4	%	%	NOUN
admet-2956	123	5	)	)	PUNCT
admet-2956	123	6	27/410	27/410	NUM
admet-2956	123	7	(	(	PUNCT
admet-2956	123	8	6.6	6.6	NUM
admet-2956	123	9	%	%	NOUN
admet-2956	123	10	)	)	PUNCT
admet-2956	123	11	nr	nr	NOUN
admet-2956	123	12	placebo	placebo	NOUN
admet-2956	123	13	+	+	CCONJ
admet-2956	123	14	chemo	chemo	VERB
admet-2956	123	15	206	206	NUM
admet-2956	123	16	200/202	200/202	PROPN
admet-2956	123	17	(	(	PUNCT
admet-2956	123	18	99.0	99.0	NUM
admet-2956	123	19	%	%	NOUN
admet-2956	123	20	)	)	PUNCT
admet-2956	123	21	133/202	133/202	PROPN
admet-2956	123	22	(	(	PUNCT
admet-2956	123	23	65.8	65.8	NUM
admet-2956	123	24	%	%	NOUN
admet-2956	123	25	)	)	PUNCT
admet-2956	123	26	27/206	27/206	NUM
admet-2956	123	27	(	(	PUNCT
admet-2956	123	28	13.1	13.1	NUM
admet-2956	123	29	%	%	NOUN
admet-2956	123	30	)	)	PUNCT
admet-2956	123	31	nr	nr	NOUN
admet-2956	123	32	immune	immune	ADV
admet-2956	123	33	-	-	PUNCT
admet-2956	123	34	related	relate	VERB
admet-2956	123	35	adverse	adverse	ADJ
admet-2956	123	36	events	event	NOUN
admet-2956	123	37	immune	immune	NOUN
admet-2956	123	38	-	-	PUNCT
admet-2956	123	39	mediated	mediate	VERB
admet-2956	123	40	adverse	adverse	ADJ
admet-2956	123	41	events	event	NOUN
admet-2956	123	42	of	of	ADP
admet-2956	123	43	any	any	DET
admet-2956	123	44	grade	grade	NOUN
admet-2956	123	45	occurred	occur	VERB
admet-2956	123	46	more	more	ADV
admet-2956	123	47	frequently	frequently	ADV
admet-2956	123	48	in	in	ADP
admet-2956	123	49	pembrolizumab	pembrolizumab	NOUN
admet-2956	123	50	-	-	PUNCT
admet-2956	123	51	treated	treat	VERB
admet-2956	123	52	patients	patient	NOUN
admet-2956	123	53	compared	compare	VERB
admet-2956	123	54	to	to	ADP
admet-2956	123	55	controls	control	NOUN
admet-2956	123	56	,	,	PUNCT
admet-2956	123	57	with	with	ADP
admet-2956	123	58	incidence	incidence	NOUN
admet-2956	123	59	rates	rate	NOUN
admet-2956	123	60	ranging	range	VERB
admet-2956	123	61	from	from	ADP
admet-2956	123	62	20.1	20.1	NUM
admet-2956	123	63	to	to	ADP
admet-2956	123	64	34.4	34.4	NUM
admet-2956	123	65	%	%	NOUN
admet-2956	123	66	versus	versus	ADP
admet-2956	123	67	5.3	5.3	NUM
admet-2956	123	68	to	to	PART
admet-2956	123	69	11.3	11.3	NUM
admet-2956	123	70	%	%	NOUN
admet-2956	123	71	in	in	ADP
admet-2956	123	72	control	control	NOUN
admet-2956	123	73	groups	group	NOUN
admet-2956	123	74	.	.	PUNCT
admet-2956	124	1	grade	grade	NOUN
admet-2956	124	2	3	3	NUM
admet-2956	124	3	-	-	SYM
admet-2956	124	4	5	5	NUM
admet-2956	124	5	immune	immune	NOUN
admet-2956	124	6	-	-	PUNCT
admet-2956	124	7	related	relate	VERB
admet-2956	124	8	adverse	adverse	ADJ
admet-2956	124	9	events	event	NOUN
admet-2956	124	10	showed	show	VERB
admet-2956	124	11	rates	rate	NOUN
admet-2956	124	12	of	of	ADP
admet-2956	124	13	5.1	5.1	NUM
admet-2956	124	14	to	to	PART
admet-2956	124	15	13.6	13.6	NUM
admet-2956	124	16	%	%	NOUN
admet-2956	124	17	in	in	ADP
admet-2956	124	18	pembrolizumab	pembrolizumab	NOUN
admet-2956	124	19	patients	patient	NOUN
admet-2956	124	20	compared	compare	VERB
admet-2956	124	21	to	to	ADP
admet-2956	124	22	0.7	0.7	NUM
admet-2956	124	23	to	to	PART
admet-2956	124	24	3.2	3.2	NUM
admet-2956	124	25	%	%	NOUN
admet-2956	124	26	in	in	ADP
admet-2956	124	27	controls	control	NOUN
admet-2956	124	28	.	.	PUNCT
admet-2956	125	1	pneumonitis	pneumonitis	NOUN
admet-2956	125	2	emerged	emerge	VERB
admet-2956	125	3	as	as	ADP
admet-2956	125	4	the	the	DET
admet-2956	125	5	most	most	ADV
admet-2956	125	6	clinically	clinically	ADV
admet-2956	125	7	significant	significant	ADJ
admet-2956	125	8	immune	immune	NOUN
admet-2956	125	9	-	-	PUNCT
admet-2956	125	10	related	relate	VERB
admet-2956	125	11	adverse	adverse	ADJ
admet-2956	125	12	event	event	NOUN
admet-2956	125	13	(	(	PUNCT
admet-2956	125	14	see	see	VERB
admet-2956	125	15	table	table	NOUN
admet-2956	125	16	3	3	NUM
admet-2956	125	17	):	):	PUNCT
admet-2956	125	18	any	any	DET
admet-2956	125	19	grade	grade	NOUN
admet-2956	125	20	:	:	PUNCT
admet-2956	125	21	4.0	4.0	NUM
admet-2956	125	22	to	to	PART
admet-2956	125	23	9.9	9.9	NUM
admet-2956	125	24	%	%	NOUN
admet-2956	125	25	in	in	ADP
admet-2956	125	26	pembrolizumab	pembrolizumab	NOUN
admet-2956	125	27	patients	patient	NOUN
admet-2956	125	28	versus	versus	ADP
admet-2956	125	29	0	0	NUM
admet-2956	125	30	to	to	ADP
admet-2956	125	31	2.5	2.5	NUM
admet-2956	125	32	%	%	NOUN
admet-2956	125	33	in	in	ADP
admet-2956	125	34	controls	control	NOUN
admet-2956	125	35	;	;	PUNCT
admet-2956	125	36	grade	grade	NOUN
admet-2956	125	37	3	3	NUM
admet-2956	125	38	-	-	SYM
admet-2956	125	39	5	5	NUM
admet-2956	125	40	:	:	SYM
admet-2956	125	41	1.7	1.7	NUM
admet-2956	125	42	to	to	PART
admet-2956	125	43	3.2	3.2	NUM
admet-2956	125	44	%	%	NOUN
admet-2956	125	45	versus	versus	ADP
admet-2956	125	46	0	0	NUM
admet-2956	125	47	to	to	ADP
admet-2956	125	48	2.0	2.0	NUM
admet-2956	125	49	%	%	NOUN
admet-2956	125	50	in	in	ADP
admet-2956	125	51	control	control	NOUN
admet-2956	125	52	groups	group	NOUN
admet-2956	125	53	.	.	PUNCT
admet-2956	126	1	endocrine	endocrine	ADJ
admet-2956	126	2	toxicities	toxicity	NOUN
admet-2956	126	3	demonstrated	demonstrate	VERB
admet-2956	126	4	characteristic	characteristic	ADJ
admet-2956	126	5	patterns	pattern	NOUN
admet-2956	126	6	:	:	PUNCT
admet-2956	126	7	hypothyroidism	hypothyroidism	NOUN
admet-2956	126	8	:	:	PUNCT
admet-2956	126	9	7.9	7.9	NUM
admet-2956	126	10	to	to	PART
admet-2956	126	11	15.3	15.3	NUM
admet-2956	126	12	%	%	NOUN
admet-2956	126	13	in	in	ADP
admet-2956	126	14	pembrolizumab	pembrolizumab	NOUN
admet-2956	126	15	versus	versus	ADP
admet-2956	126	16	0.3	0.3	NUM
admet-2956	126	17	to	to	PART
admet-2956	126	18	11.9	11.9	NUM
admet-2956	126	19	%	%	NOUN
admet-2956	126	20	in	in	ADP
admet-2956	126	21	controls	control	NOUN
admet-2956	126	22	;	;	PUNCT
admet-2956	126	23	grade	grade	NOUN
admet-2956	126	24	3	3	NUM
admet-2956	126	25	-	-	SYM
admet-2956	126	26	5	5	NUM
admet-2956	126	27	hypothyroidism	hypothyroidism	NOUN
admet-2956	126	28	:	:	PUNCT
admet-2956	126	29	0	0	NUM
admet-2956	126	30	to	to	ADP
admet-2956	126	31	1.0	1.0	NUM
admet-2956	126	32	%	%	NOUN
admet-2956	126	33	versus	versus	ADP
admet-2956	126	34	0	0	NUM
admet-2956	126	35	to	to	PART
admet-2956	126	36	0.5	0.5	NUM
admet-2956	126	37	%	%	NOUN
admet-2956	126	38	in	in	ADP
admet-2956	126	39	controls	control	NOUN
admet-2956	126	40	;	;	PUNCT
admet-2956	126	41	hyperthyroidism	hyperthyroidism	NOUN
admet-2956	126	42	:	:	PUNCT
admet-2956	126	43	4.0	4.0	NUM
admet-2956	126	44	to	to	PART
admet-2956	126	45	8.0	8.0	NUM
admet-2956	126	46	%	%	NOUN
admet-2956	126	47	versus	versus	ADP
admet-2956	126	48	0	0	NUM
admet-2956	126	49	to	to	ADP
admet-2956	126	50	3.0	3.0	NUM
admet-2956	126	51	%	%	NOUN
admet-2956	126	52	in	in	ADP
admet-2956	126	53	controls	control	NOUN
admet-2956	126	54	.	.	PUNCT
admet-2956	127	1	table	table	NOUN
admet-2956	127	2	3	3	NUM
admet-2956	127	3	.	.	PUNCT
admet-2956	127	4	immune	immune	NOUN
admet-2956	127	5	-	-	PUNCT
admet-2956	127	6	mediated	mediate	VERB
admet-2956	127	7	adverse	adverse	ADJ
admet-2956	127	8	events	event	NOUN
admet-2956	127	9	ref	ref	NOUN
admet-2956	127	10	.	.	PUNCT
admet-2956	128	1	treatment	treatment	NOUN
admet-2956	128	2	arms	arm	NOUN
admet-2956	128	3	total	total	NOUN
admet-2956	128	4	,	,	PUNCT
admet-2956	128	5	n	n	CCONJ
admet-2956	128	6	any	any	DET
admet-2956	128	7	grade	grade	NOUN
admet-2956	128	8	iraes	iraes	NOUN
admet-2956	128	9	,	,	PUNCT
admet-2956	128	10	n	n	CCONJ
admet-2956	128	11	/	/	SYM
admet-2956	128	12	%	%	NOUN
admet-2956	128	13	grade	grade	NOUN
admet-2956	128	14	3	3	NUM
admet-2956	128	15	-	-	SYM
admet-2956	128	16	5	5	NUM
admet-2956	128	17	iraes	irae	NOUN
admet-2956	128	18	,	,	PUNCT
admet-2956	128	19	n	n	NOUN
admet-2956	128	20	/	/	SYM
admet-2956	128	21	%	%	NOUN
admet-2956	128	22	most	most	ADV
admet-2956	128	23	common	common	ADJ
admet-2956	128	24	iraes	iraes	NOUN
admet-2956	128	25	(	(	PUNCT
admet-2956	128	26	≥5	≥5	NUM
admet-2956	128	27	%	%	NOUN
admet-2956	128	28	incidence	incidence	NOUN
admet-2956	128	29	)	)	PUNCT
admet-2956	129	1	[	[	X
admet-2956	129	2	43	43	NUM
admet-2956	129	3	]	]	PUNCT
admet-2956	129	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	129	5	,	,	PUNCT
admet-2956	129	6	2	2	NUM
admet-2956	129	7	mg	mg	PROPN
admet-2956	129	8	344	344	NUM
admet-2956	129	9	69/344	69/344	NUM
admet-2956	129	10	(	(	PUNCT
admet-2956	129	11	20.1	20.1	NUM
admet-2956	129	12	%	%	NOUN
admet-2956	129	13	)	)	PUNCT
admet-2956	130	1	nr	nr	PROPN
admet-2956	130	2	hypothyroidism	hypothyroidism	NOUN
admet-2956	130	3	(	(	PUNCT
admet-2956	130	4	8	8	NUM
admet-2956	130	5	%	%	NOUN
admet-2956	130	6	)	)	PUNCT
admet-2956	130	7	,	,	PUNCT
admet-2956	130	8	hyperthyroidism	hyperthyroidism	NOUN
admet-2956	130	9	(	(	PUNCT
admet-2956	130	10	4	4	NUM
admet-2956	130	11	%	%	NOUN
admet-2956	130	12	)	)	PUNCT
admet-2956	130	13	,	,	PUNCT
admet-2956	130	14	pneumonitis	pneumonitis	NOUN
admet-2956	130	15	(	(	PUNCT
admet-2956	130	16	4	4	NUM
admet-2956	130	17	%	%	NOUN
admet-2956	130	18	)	)	PUNCT
admet-2956	130	19	docetaxel	docetaxel	NOUN
admet-2956	130	20	343	343	NUM
admet-2956	130	21	nr	nr	PROPN
admet-2956	130	22	nr	nr	PROPN
admet-2956	130	23	minimal	minimal	ADJ
admet-2956	130	24	immune	immune	NOUN
admet-2956	130	25	-	-	PUNCT
admet-2956	130	26	related	relate	VERB
admet-2956	130	27	events	event	NOUN
admet-2956	130	28	[	[	X
admet-2956	130	29	44	44	NUM
admet-2956	130	30	]	]	PUNCT
admet-2956	130	31	pembrolizumab	pembrolizumab	NOUN
admet-2956	130	32	+	+	CCONJ
admet-2956	130	33	chemo	chemo	VERB
admet-2956	130	34	60	60	NUM
admet-2956	130	35	13/59	13/59	NUM
admet-2956	130	36	(	(	PUNCT
admet-2956	130	37	22.0	22.0	NUM
admet-2956	130	38	%	%	NOUN
admet-2956	130	39	)	)	PUNCT
admet-2956	131	1	3/59	3/59	NUM
admet-2956	131	2	(	(	PUNCT
admet-2956	131	3	5.1	5.1	NUM
admet-2956	131	4	%	%	NOUN
admet-2956	131	5	)	)	PUNCT
admet-2956	131	6	hypothyroidism	hypothyroidism	NOUN
admet-2956	131	7	(	(	PUNCT
admet-2956	131	8	15	15	NUM
admet-2956	131	9	%	%	NOUN
admet-2956	131	10	)	)	PUNCT
admet-2956	131	11	,	,	PUNCT
admet-2956	131	12	hyperthyroidism	hyperthyroidism	NOUN
admet-2956	131	13	(	(	PUNCT
admet-2956	131	14	8	8	NUM
admet-2956	131	15	%	%	NOUN
admet-2956	131	16	)	)	PUNCT
admet-2956	131	17	,	,	PUNCT
admet-2956	131	18	pneumonitis	pneumonitis	NOUN
admet-2956	131	19	(	(	PUNCT
admet-2956	131	20	5	5	NUM
admet-2956	131	21	%	%	NOUN
admet-2956	131	22	)	)	PUNCT
admet-2956	131	23	chemotherapy	chemotherapy	NOUN
admet-2956	131	24	63	63	NUM
admet-2956	131	25	7/62	7/62	NUM
admet-2956	131	26	(	(	PUNCT
admet-2956	131	27	11.3	11.3	NUM
admet-2956	131	28	%	%	NOUN
admet-2956	131	29	)	)	PUNCT
admet-2956	131	30	0/62	0/62	NUM
admet-2956	132	1	(	(	PUNCT
admet-2956	132	2	0	0	NUM
admet-2956	132	3	%	%	NOUN
admet-2956	132	4	)	)	PUNCT
admet-2956	132	5	minimal	minimal	ADJ
admet-2956	132	6	immune	immune	NOUN
admet-2956	132	7	-	-	PUNCT
admet-2956	132	8	related	relate	VERB
admet-2956	132	9	events	event	NOUN
admet-2956	132	10	[	[	X
admet-2956	132	11	22	22	NUM
admet-2956	132	12	]	]	PUNCT
admet-2956	132	13	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	14	154	154	NUM
admet-2956	132	15	53/154	53/154	NUM
admet-2956	132	16	(	(	PUNCT
admet-2956	132	17	34.4	34.4	NUM
admet-2956	132	18	%	%	NOUN
admet-2956	132	19	)	)	PUNCT
admet-2956	132	20	21/154	21/154	NUM
admet-2956	132	21	(	(	PUNCT
admet-2956	132	22	13.6	13.6	NUM
admet-2956	132	23	%	%	NOUN
admet-2956	132	24	)	)	PUNCT
admet-2956	132	25	hypothyroidism	hypothyroidism	NOUN
admet-2956	132	26	(	(	PUNCT
admet-2956	132	27	10.4	10.4	NUM
admet-2956	132	28	%	%	NOUN
admet-2956	132	29	)	)	PUNCT
admet-2956	132	30	,	,	PUNCT
admet-2956	132	31	hyperthyro	hyperthyro	NOUN
admet-2956	132	32	idism	idism	NOUN
admet-2956	132	33	(	(	PUNCT
admet-2956	132	34	7.1	7.1	NUM
admet-2956	132	35	%	%	NOUN
admet-2956	132	36	)	)	PUNCT
admet-2956	132	37	,	,	PUNCT
admet-2956	132	38	pneumonitis	pneumonitis	NOUN
admet-2956	132	39	(	(	PUNCT
admet-2956	132	40	8.4	8.4	NUM
admet-2956	132	41	%	%	NOUN
admet-2956	132	42	)	)	PUNCT
admet-2956	132	43	chemotherapy	chemotherapy	NOUN
admet-2956	132	44	151	151	NUM
admet-2956	132	45	8/150	8/150	NUM
admet-2956	132	46	(	(	PUNCT
admet-2956	132	47	5.3	5.3	NUM
admet-2956	132	48	%	%	NOUN
admet-2956	132	49	)	)	PUNCT
admet-2956	132	50	1/150	1/150	NUM
admet-2956	132	51	(	(	PUNCT
admet-2956	132	52	0.7	0.7	NUM
admet-2956	132	53	%	%	NOUN
admet-2956	132	54	)	)	PUNCT
admet-2956	132	55	minimal	minimal	ADJ
admet-2956	132	56	immune	immune	NOUN
admet-2956	132	57	-	-	PUNCT
admet-2956	132	58	related	relate	VERB
admet-2956	132	59	events	event	NOUN
admet-2956	132	60	[	[	X
admet-2956	132	61	45	45	NUM
admet-2956	132	62	]	]	PUNCT
admet-2956	132	63	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	64	637	637	NUM
admet-2956	132	65	177/636	177/636	NUM
admet-2956	132	66	(	(	PUNCT
admet-2956	132	67	27.8	27.8	NUM
admet-2956	132	68	%	%	NOUN
admet-2956	132	69	)	)	PUNCT
admet-2956	132	70	51/636	51/636	NUM
admet-2956	132	71	(	(	PUNCT
admet-2956	132	72	8.0	8.0	NUM
admet-2956	132	73	%	%	NOUN
admet-2956	132	74	)	)	PUNCT
admet-2956	132	75	pneumonitis	pneumonitis	NOUN
admet-2956	132	76	(	(	PUNCT
admet-2956	132	77	22	22	NUM
admet-2956	132	78	patients	patient	NOUN
admet-2956	132	79	)	)	PUNCT
admet-2956	132	80	,	,	PUNCT
admet-2956	132	81	severe	severe	ADJ
admet-2956	132	82	skin	skin	NOUN
admet-2956	132	83	reactions	reaction	NOUN
admet-2956	132	84	(	(	PUNCT
admet-2956	132	85	11	11	NUM
admet-2956	132	86	patients	patient	NOUN
admet-2956	132	87	)	)	PUNCT
admet-2956	132	88	,	,	PUNCT
admet-2956	132	89	hepatitis	hepatitis	NOUN
admet-2956	132	90	(	(	PUNCT
admet-2956	132	91	7	7	NUM
admet-2956	132	92	patients	patient	NOUN
admet-2956	132	93	)	)	PUNCT
admet-2956	132	94	chemotherapy	chemotherapy	NOUN
admet-2956	132	95	637	637	NUM
admet-2956	132	96	44/615	44/615	NUM
admet-2956	132	97	(	(	PUNCT
admet-2956	132	98	7.2	7.2	NUM
admet-2956	132	99	%	%	NOUN
admet-2956	132	100	)	)	PUNCT
admet-2956	132	101	9/615	9/615	NUM
admet-2956	132	102	(	(	PUNCT
admet-2956	132	103	1.5	1.5	NUM
admet-2956	132	104	%	%	NOUN
admet-2956	132	105	)	)	PUNCT
admet-2956	132	106	minimal	minimal	ADJ
admet-2956	132	107	immune	immune	NOUN
admet-2956	132	108	-	-	PUNCT
admet-2956	132	109	related	relate	VERB
admet-2956	132	110	events	event	NOUN
admet-2956	132	111	[	[	X
admet-2956	132	112	46	46	NUM
admet-2956	132	113	]	]	PUNCT
admet-2956	132	114	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	115	+	+	CCONJ
admet-2956	132	116	chemo	chemo	VERB
admet-2956	132	117	278	278	NUM
admet-2956	132	118	80/278	80/278	NUM
admet-2956	132	119	(	(	PUNCT
admet-2956	132	120	28.8	28.8	NUM
admet-2956	132	121	%	%	NOUN
admet-2956	132	122	)	)	PUNCT
admet-2956	132	123	30/278	30/278	NUM
admet-2956	132	124	(	(	PUNCT
admet-2956	132	125	10.8	10.8	NUM
admet-2956	132	126	%	%	NOUN
admet-2956	132	127	)	)	PUNCT
admet-2956	132	128	hypothyroidism	hypothyroidism	NOUN
admet-2956	132	129	(	(	PUNCT
admet-2956	132	130	7.9	7.9	NUM
admet-2956	132	131	%	%	NOUN
admet-2956	132	132	)	)	PUNCT
admet-2956	132	133	,	,	PUNCT
admet-2956	132	134	pneumonitis	pneumonitis	NOUN
admet-2956	132	135	(	(	PUNCT
admet-2956	132	136	6.5	6.5	NUM
admet-2956	132	137	%	%	NOUN
admet-2956	132	138	)	)	PUNCT
admet-2956	132	139	,	,	PUNCT
admet-2956	132	140	colitis	colitis	NOUN
admet-2956	132	141	(	(	PUNCT
admet-2956	132	142	2.5	2.5	NUM
admet-2956	132	143	%	%	NOUN
admet-2956	132	144	)	)	PUNCT
admet-2956	132	145	placebo	placebo	NOUN
admet-2956	132	146	+	+	CCONJ
admet-2956	132	147	chemo	chemo	VERB
admet-2956	132	148	281	281	NUM
admet-2956	132	149	24/280	24/280	NUM
admet-2956	132	150	(	(	PUNCT
admet-2956	132	151	8.6	8.6	NUM
admet-2956	132	152	%	%	NOUN
admet-2956	132	153	)	)	PUNCT
admet-2956	132	154	9/280	9/280	NUM
admet-2956	132	155	(	(	PUNCT
admet-2956	132	156	3.2	3.2	NUM
admet-2956	132	157	%	%	NOUN
admet-2956	132	158	)	)	PUNCT
admet-2956	132	159	minimal	minimal	ADJ
admet-2956	132	160	immune	immune	NOUN
admet-2956	132	161	-	-	PUNCT
admet-2956	132	162	related	relate	VERB
admet-2956	132	163	events	event	NOUN
admet-2956	132	164	[	[	X
admet-2956	132	165	47	47	NUM
admet-2956	132	166	]	]	PUNCT
admet-2956	132	167	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	168	213	213	NUM
admet-2956	132	169	61/213	61/213	NUM
admet-2956	132	170	(	(	PUNCT
admet-2956	132	171	28.6	28.6	NUM
admet-2956	132	172	%	%	NOUN
admet-2956	132	173	)	)	PUNCT
admet-2956	132	174	13/213	13/213	NUM
admet-2956	132	175	(	(	PUNCT
admet-2956	132	176	6.1	6.1	NUM
admet-2956	132	177	%	%	NOUN
admet-2956	132	178	)	)	PUNCT
admet-2956	132	179	hypothyroidism	hypothyroidism	NOUN
admet-2956	132	180	(	(	PUNCT
admet-2956	132	181	13.1	13.1	NUM
admet-2956	132	182	%	%	NOUN
admet-2956	132	183	)	)	PUNCT
admet-2956	132	184	,	,	PUNCT
admet-2956	132	185	pneumonitis	pneumonitis	NOUN
admet-2956	132	186	(	(	PUNCT
admet-2956	132	187	9.9	9.9	NUM
admet-2956	132	188	%	%	NOUN
admet-2956	132	189	)	)	PUNCT
admet-2956	132	190	,	,	PUNCT
admet-2956	132	191	hepatitis	hepatitis	NOUN
admet-2956	132	192	(	(	PUNCT
admet-2956	132	193	1.9	1.9	NUM
admet-2956	132	194	%	%	NOUN
admet-2956	132	195	)	)	PUNCT
admet-2956	132	196	docetaxel	docetaxel	NOUN
admet-2956	132	197	212	212	NUM
admet-2956	132	198	12/198	12/198	NUM
admet-2956	132	199	(	(	PUNCT
admet-2956	132	200	6.1	6.1	NUM
admet-2956	132	201	%	%	NOUN
admet-2956	132	202	)	)	PUNCT
admet-2956	132	203	3/198	3/198	NUM
admet-2956	132	204	(	(	PUNCT
admet-2956	132	205	1.5	1.5	NUM
admet-2956	132	206	%	%	NOUN
admet-2956	132	207	)	)	PUNCT
admet-2956	132	208	minimal	minimal	ADJ
admet-2956	132	209	immune	immune	NOUN
admet-2956	132	210	-	-	PUNCT
admet-2956	132	211	related	relate	VERB
admet-2956	132	212	events	event	NOUN
admet-2956	132	213	[	[	X
admet-2956	132	214	48	48	NUM
admet-2956	132	215	]	]	PUNCT
admet-2956	132	216	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	217	+	+	CCONJ
admet-2956	132	218	chemo	chemo	VERB
admet-2956	132	219	410	410	NUM
admet-2956	132	220	nr	nr	NOUN
admet-2956	132	221	nr	nr	PROPN
admet-2956	132	222	nr	nr	PROPN
admet-2956	132	223	placebo	placebo	NOUN
admet-2956	132	224	+	+	CCONJ
admet-2956	132	225	chemo	chemo	VERB
admet-2956	132	226	206	206	NUM
admet-2956	132	227	nr	nr	NOUN
admet-2956	132	228	nr	nr	PROPN
admet-2956	132	229	nr	nr	PROPN
admet-2956	132	230	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	132	231	a.	a.	PROPN
admet-2956	132	232	chakramurty	chakramurty	PROPN
admet-2956	132	233	et	et	PROPN
admet-2956	132	234	al	al	PROPN
admet-2956	132	235	.	.	PROPN
admet-2956	132	236	admet	admet	PROPN
admet-2956	132	237	&	&	CCONJ
admet-2956	132	238	dmpk	dmpk	PROPN
admet-2956	132	239	13(5	13(5	NUM
admet-2956	132	240	)	)	PUNCT
admet-2956	132	241	(	(	PUNCT
admet-2956	132	242	2025	2025	NUM
admet-2956	132	243	)	)	PUNCT
admet-2956	132	244	2956	2956	NUM
admet-2956	132	245	8	8	NUM
admet-2956	132	246	specific	specific	ADJ
admet-2956	132	247	adverse	adverse	ADJ
admet-2956	132	248	event	event	NOUN
admet-2956	132	249	profiles	profile	NOUN
admet-2956	132	250	hematologic	hematologic	NOUN
admet-2956	132	251	toxicities	toxicity	NOUN
admet-2956	132	252	revealed	reveal	VERB
admet-2956	132	253	significant	significant	ADJ
admet-2956	132	254	differences	difference	NOUN
admet-2956	132	255	favouring	favour	VERB
admet-2956	132	256	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	257	:	:	PUNCT
admet-2956	132	258	neutropenia	neutropenia	NOUN
admet-2956	132	259	occurred	occur	VERB
admet-2956	132	260	substantially	substantially	ADV
admet-2956	132	261	less	less	ADV
admet-2956	132	262	frequently	frequently	ADV
admet-2956	132	263	in	in	ADP
admet-2956	132	264	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	265	patients	patient	NOUN
admet-2956	132	266	(	(	PUNCT
admet-2956	132	267	0	0	NUM
admet-2956	132	268	to	to	ADP
admet-2956	132	269	38	38	NUM
admet-2956	132	270	%	%	NOUN
admet-2956	132	271	)	)	PUNCT
admet-2956	132	272	compared	compare	VERB
admet-2956	132	273	to	to	ADP
admet-2956	132	274	chemotherapy	chemotherapy	NOUN
admet-2956	132	275	controls	control	NOUN
admet-2956	132	276	(	(	PUNCT
admet-2956	132	277	6	6	NUM
admet-2956	132	278	to	to	PART
admet-2956	132	279	24	24	NUM
admet-2956	132	280	%	%	NOUN
admet-2956	132	281	)	)	PUNCT
admet-2956	132	282	;	;	PUNCT
admet-2956	132	283	grade	grade	NOUN
admet-2956	132	284	3	3	NUM
admet-2956	132	285	-	-	SYM
admet-2956	132	286	5	5	NUM
admet-2956	132	287	neutropenia	neutropenia	NOUN
admet-2956	132	288	showed	show	VERB
admet-2956	132	289	even	even	ADV
admet-2956	132	290	more	more	ADV
admet-2956	132	291	pronounced	pronounced	ADJ
admet-2956	132	292	differences	difference	NOUN
admet-2956	132	293	(	(	PUNCT
admet-2956	132	294	pembrolizumab	pembrolizumab	NOUN
admet-2956	132	295	:	:	PUNCT
admet-2956	132	296	0	0	NUM
admet-2956	132	297	to	to	PART
admet-2956	132	298	23	23	NUM
admet-2956	132	299	%	%	NOUN
admet-2956	132	300	;	;	PUNCT
admet-2956	132	301	control	control	NOUN
admet-2956	132	302	:	:	PUNCT
admet-2956	132	303	2	2	NUM
admet-2956	132	304	to	to	PART
admet-2956	132	305	25	25	NUM
admet-2956	132	306	%	%	NOUN
admet-2956	132	307	)	)	PUNCT
admet-2956	132	308	;	;	PUNCT
admet-2956	132	309	similar	similar	ADJ
admet-2956	132	310	patterns	pattern	NOUN
admet-2956	132	311	were	be	AUX
admet-2956	132	312	observed	observe	VERB
admet-2956	132	313	for	for	ADP
admet-2956	132	314	anemia	anemia	NOUN
admet-2956	132	315	and	and	CCONJ
admet-2956	132	316	other	other	ADJ
admet-2956	132	317	hematologic	hematologic	NOUN
admet-2956	132	318	parameters	parameter	NOUN
admet-2956	132	319	.	.	PUNCT
admet-2956	133	1	gastrointestinal	gastrointestinal	ADJ
admet-2956	133	2	toxicities	toxicity	NOUN
admet-2956	133	3	showed	show	VERB
admet-2956	133	4	divergent	divergent	ADJ
admet-2956	133	5	patterns	pattern	NOUN
admet-2956	133	6	:	:	PUNCT
admet-2956	133	7	nausea	nausea	NOUN
admet-2956	133	8	occurred	occur	VERB
admet-2956	133	9	with	with	ADP
admet-2956	133	10	variable	variable	ADJ
admet-2956	133	11	frequency	frequency	NOUN
admet-2956	133	12	in	in	ADP
admet-2956	133	13	pembrolizumab	pembrolizumab	NOUN
admet-2956	133	14	patients	patient	NOUN
admet-2956	133	15	(	(	PUNCT
admet-2956	133	16	1	1	NUM
admet-2956	133	17	to	to	PART
admet-2956	133	18	56	56	NUM
admet-2956	133	19	%	%	NOUN
admet-2956	133	20	)	)	PUNCT
admet-2956	133	21	compared	compare	VERB
admet-2956	133	22	to	to	ADP
admet-2956	133	23	chemotherapy	chemotherapy	NOUN
admet-2956	133	24	controls	control	NOUN
admet-2956	133	25	(	(	PUNCT
admet-2956	133	26	13	13	NUM
admet-2956	133	27	to	to	PART
admet-2956	133	28	52	52	NUM
admet-2956	133	29	%	%	NOUN
admet-2956	133	30	)	)	PUNCT
admet-2956	133	31	;	;	PUNCT
admet-2956	133	32	diarrhea	diarrhea	NOUN
admet-2956	133	33	demonstrated	demonstrate	VERB
admet-2956	133	34	variable	variable	ADJ
admet-2956	133	35	incidence	incidence	NOUN
admet-2956	133	36	(	(	PUNCT
admet-2956	133	37	pembrolizumab	pembrolizumab	NOUN
admet-2956	133	38	:	:	PUNCT
admet-2956	133	39	2	2	NUM
admet-2956	133	40	to	to	PART
admet-2956	133	41	31	31	NUM
admet-2956	133	42	%	%	NOUN
admet-2956	133	43	;	;	PUNCT
admet-2956	133	44	control	control	NOUN
admet-2956	133	45	:	:	PUNCT
admet-2956	133	46	7	7	NUM
admet-2956	133	47	to	to	PART
admet-2956	133	48	23	23	NUM
admet-2956	133	49	%	%	NOUN
admet-2956	133	50	)	)	PUNCT
admet-2956	133	51	;	;	PUNCT
admet-2956	133	52	immune	immune	NOUN
admet-2956	133	53	-	-	PUNCT
admet-2956	133	54	mediated	mediate	VERB
admet-2956	133	55	colitis	colitis	NOUN
admet-2956	133	56	occurred	occur	VERB
admet-2956	133	57	in	in	ADP
admet-2956	133	58	0.6	0.6	NUM
admet-2956	133	59	to	to	ADP
admet-2956	133	60	3.9	3.9	NUM
admet-2956	133	61	%	%	NOUN
admet-2956	133	62	of	of	ADP
admet-2956	133	63	pembrolizumab	pembrolizumab	NOUN
admet-2956	133	64	patients	patient	NOUN
admet-2956	133	65	compared	compare	VERB
admet-2956	133	66	to	to	ADP
admet-2956	133	67	0	0	NUM
admet-2956	133	68	%	%	NOUN
admet-2956	133	69	to	to	ADP
admet-2956	133	70	1.4	1.4	NUM
admet-2956	133	71	%	%	NOUN
admet-2956	133	72	in	in	ADP
admet-2956	133	73	controls	control	NOUN
admet-2956	133	74	.	.	PUNCT
admet-2956	134	1	the	the	DET
admet-2956	134	2	safety	safety	NOUN
admet-2956	134	3	analysis	analysis	NOUN
admet-2956	134	4	confirmed	confirm	VERB
admet-2956	134	5	pembrolizumab	pembrolizumab	NOUN
admet-2956	134	6	's	's	PART
admet-2956	134	7	distinct	distinct	ADJ
admet-2956	134	8	toxicity	toxicity	NOUN
admet-2956	134	9	profile	profile	NOUN
admet-2956	134	10	,	,	PUNCT
admet-2956	134	11	characterized	characterize	VERB
admet-2956	134	12	by	by	ADP
admet-2956	134	13	immune	immune	NOUN
admet-2956	134	14	-	-	PUNCT
admet-2956	134	15	related	relate	VERB
admet-2956	134	16	adverse	adverse	ADJ
admet-2956	134	17	events	event	NOUN
admet-2956	134	18	while	while	SCONJ
admet-2956	134	19	demonstrating	demonstrate	VERB
admet-2956	134	20	reduced	reduced	ADJ
admet-2956	134	21	incidence	incidence	NOUN
admet-2956	134	22	of	of	ADP
admet-2956	134	23	traditional	traditional	ADJ
admet-2956	134	24	chemotherapy	chemotherapy	NOUN
admet-2956	134	25	-	-	PUNCT
admet-2956	134	26	related	relate	VERB
admet-2956	134	27	toxicities	toxicity	NOUN
admet-2956	134	28	.	.	PUNCT
admet-2956	135	1	this	this	DET
admet-2956	135	2	differential	differential	ADJ
admet-2956	135	3	toxicity	toxicity	NOUN
admet-2956	135	4	profile	profile	NOUN
admet-2956	135	5	supports	support	VERB
admet-2956	135	6	the	the	DET
admet-2956	135	7	clinical	clinical	ADJ
admet-2956	135	8	utility	utility	NOUN
admet-2956	135	9	of	of	ADP
admet-2956	135	10	pembrolizumab	pembrolizumab	NOUN
admet-2956	135	11	,	,	PUNCT
admet-2956	135	12	particularly	particularly	ADV
admet-2956	135	13	in	in	ADP
admet-2956	135	14	patients	patient	NOUN
admet-2956	135	15	who	who	PRON
admet-2956	135	16	may	may	AUX
admet-2956	135	17	not	not	PART
admet-2956	135	18	tolerate	tolerate	VERB
admet-2956	135	19	intensive	intensive	ADJ
admet-2956	135	20	chemotherapy	chemotherapy	NOUN
admet-2956	135	21	regimens	regimen	NOUN
admet-2956	135	22	.	.	PUNCT
admet-2956	136	1	subgroup	subgroup	PROPN
admet-2956	136	2	analyses	analyse	VERB
admet-2956	136	3	age	age	NOUN
admet-2956	136	4	-	-	PUNCT
admet-2956	136	5	stratified	stratify	VERB
admet-2956	136	6	analysis	analysis	NOUN
admet-2956	136	7	age	age	NOUN
admet-2956	136	8	had	have	VERB
admet-2956	136	9	a	a	DET
admet-2956	136	10	consistent	consistent	ADJ
admet-2956	136	11	and	and	CCONJ
admet-2956	136	12	significant	significant	ADJ
admet-2956	136	13	impact	impact	NOUN
admet-2956	136	14	on	on	ADP
admet-2956	136	15	pembrolizumab	pembrolizumab	NOUN
admet-2956	136	16	effectiveness	effectiveness	NOUN
admet-2956	136	17	in	in	ADP
admet-2956	136	18	both	both	DET
admet-2956	136	19	survival	survival	NOUN
admet-2956	136	20	endpoints	endpoint	NOUN
admet-2956	136	21	,	,	PUNCT
admet-2956	136	22	as	as	SCONJ
admet-2956	136	23	analysed	analyse	VERB
admet-2956	136	24	by	by	ADP
admet-2956	136	25	pfs	pfs	PROPN
admet-2956	136	26	and	and	CCONJ
admet-2956	136	27	os	os	NOUN
admet-2956	136	28	,	,	PUNCT
admet-2956	136	29	as	as	SCONJ
admet-2956	136	30	demonstrated	demonstrate	VERB
admet-2956	136	31	by	by	ADP
admet-2956	136	32	tables	table	NOUN
admet-2956	136	33	4	4	NUM
admet-2956	136	34	and	and	CCONJ
admet-2956	136	35	5	5	NUM
admet-2956	136	36	,	,	PUNCT
admet-2956	136	37	respectively	respectively	ADV
admet-2956	136	38	.	.	PUNCT
admet-2956	137	1	in	in	ADP
admet-2956	137	2	os	os	NOUN
admet-2956	137	3	,	,	PUNCT
admet-2956	137	4	patients	patient	NOUN
admet-2956	137	5	younger	young	ADJ
admet-2956	137	6	than	than	ADP
admet-2956	137	7	65	65	NUM
admet-2956	137	8	years	year	NOUN
admet-2956	137	9	received	receive	VERB
admet-2956	137	10	significantly	significantly	ADV
admet-2956	137	11	more	more	ADJ
admet-2956	137	12	benefit	benefit	NOUN
admet-2956	137	13	(	(	PUNCT
admet-2956	137	14	hr	hr	NOUN
admet-2956	137	15	0.55	0.55	NUM
admet-2956	137	16	;	;	PUNCT
admet-2956	137	17	95	95	NUM
admet-2956	137	18	%	%	NOUN
admet-2956	137	19	ci	ci	NOUN
admet-2956	137	20	0.46	0.46	NUM
admet-2956	137	21	to	to	ADP
admet-2956	137	22	0.65	0.65	NUM
admet-2956	137	23	;	;	PUNCT
admet-2956	137	24	p<0.00001	p<0.00001	PROPN
admet-2956	137	25	)	)	PUNCT
admet-2956	137	26	compared	compare	VERB
admet-2956	137	27	to	to	ADP
admet-2956	137	28	patients	patient	NOUN
admet-2956	137	29	65	65	NUM
admet-2956	137	30	years	year	NOUN
admet-2956	137	31	or	or	CCONJ
admet-2956	137	32	older	old	ADJ
admet-2956	137	33	(	(	PUNCT
admet-2956	137	34	hr	hr	NOUN
admet-2956	137	35	0.72	0.72	NUM
admet-2956	137	36	;	;	PUNCT
admet-2956	137	37	95	95	NUM
admet-2956	137	38	%	%	NOUN
admet-2956	137	39	ci	ci	NOUN
admet-2956	137	40	0.59	0.59	NUM
admet-2956	137	41	to	to	ADP
admet-2956	137	42	0.88	0.88	NUM
admet-2956	137	43	;	;	PUNCT
admet-2956	137	44	p	p	PROPN
admet-2956	137	45	=	=	NOUN
admet-2956	137	46	0.001	0.001	NUM
admet-2956	137	47	)	)	PUNCT
admet-2956	137	48	.	.	PUNCT
admet-2956	138	1	this	this	DET
admet-2956	138	2	age	age	NOUN
admet-2956	138	3	-	-	PUNCT
admet-2956	138	4	related	relate	VERB
admet-2956	138	5	trend	trend	NOUN
admet-2956	138	6	was	be	AUX
admet-2956	138	7	also	also	ADV
admet-2956	138	8	evident	evident	ADJ
admet-2956	138	9	in	in	ADP
admet-2956	138	10	the	the	DET
admet-2956	138	11	pfs	pfs	ADJ
admet-2956	138	12	analysis	analysis	NOUN
admet-2956	138	13	,	,	PUNCT
admet-2956	138	14	with	with	ADP
admet-2956	138	15	the	the	DET
admet-2956	138	16	younger	young	ADJ
admet-2956	138	17	group	group	NOUN
admet-2956	138	18	showing	show	VERB
admet-2956	138	19	a	a	DET
admet-2956	138	20	significantly	significantly	ADV
admet-2956	138	21	greater	great	ADJ
admet-2956	138	22	benefit	benefit	NOUN
admet-2956	138	23	(	(	PUNCT
admet-2956	138	24	hr	hr	NOUN
admet-2956	138	25	0.46	0.46	NUM
admet-2956	138	26	;	;	PUNCT
admet-2956	138	27	95	95	NUM
admet-2956	138	28	%	%	NOUN
admet-2956	138	29	ci	ci	NOUN
admet-2956	138	30	0.38	0.38	NUM
admet-2956	138	31	-	-	SYM
admet-2956	138	32	0.57	0.57	NUM
admet-2956	138	33	;	;	PUNCT
admet-2956	138	34	p	p	X
admet-2956	138	35	<	<	X
admet-2956	138	36	0.00001	0.00001	NUM
admet-2956	138	37	)	)	PUNCT
admet-2956	138	38	compared	compare	VERB
admet-2956	138	39	to	to	ADP
admet-2956	138	40	older	old	ADJ
admet-2956	138	41	patients	patient	NOUN
admet-2956	138	42	(	(	PUNCT
admet-2956	138	43	hr	hr	NOUN
admet-2956	138	44	0.68	0.68	NUM
admet-2956	138	45	;	;	PUNCT
admet-2956	138	46	95	95	NUM
admet-2956	138	47	%	%	NOUN
admet-2956	138	48	ci	ci	NOUN
admet-2956	138	49	0.55	0.55	NUM
admet-2956	138	50	to	to	ADP
admet-2956	138	51	0.85	0.85	NUM
admet-2956	138	52	;	;	PUNCT
admet-2956	138	53	p	p	X
admet-2956	138	54	=	=	NOUN
admet-2956	138	55	0.0005	0.0005	NUM
admet-2956	138	56	)	)	PUNCT
admet-2956	138	57	.	.	PUNCT
admet-2956	139	1	heterogeneity	heterogeneity	NOUN
admet-2956	139	2	was	be	AUX
admet-2956	139	3	low	low	ADJ
admet-2956	139	4	for	for	ADP
admet-2956	139	5	the	the	DET
admet-2956	139	6	young	young	ADJ
admet-2956	139	7	population	population	NOUN
admet-2956	139	8	for	for	ADP
admet-2956	139	9	os	os	NOUN
admet-2956	139	10	(	(	PUNCT
admet-2956	139	11	i²=44	i²=44	NOUN
admet-2956	139	12	%	%	NOUN
admet-2956	139	13	)	)	PUNCT
admet-2956	139	14	and	and	CCONJ
admet-2956	139	15	zero	zero	NUM
admet-2956	139	16	for	for	ADP
admet-2956	139	17	pfs	pfs	PROPN
admet-2956	139	18	(	(	PUNCT
admet-2956	139	19	i²=0	i²=0	PROPN
admet-2956	139	20	%	%	NOUN
admet-2956	139	21	)	)	PUNCT
admet-2956	139	22	,	,	PUNCT
admet-2956	139	23	while	while	SCONJ
admet-2956	139	24	older	old	ADJ
admet-2956	139	25	patients	patient	NOUN
admet-2956	139	26	demonstrated	demonstrate	VERB
admet-2956	139	27	no	no	DET
admet-2956	139	28	heterogeneity	heterogeneity	NOUN
admet-2956	139	29	across	across	ADP
admet-2956	139	30	studies	study	NOUN
admet-2956	139	31	(	(	PUNCT
admet-2956	139	32	i²=0	i²=0	PROPN
admet-2956	139	33	%	%	NOUN
admet-2956	139	34	for	for	ADP
admet-2956	139	35	both	both	DET
admet-2956	139	36	endpoints	endpoint	NOUN
admet-2956	139	37	)	)	PUNCT
admet-2956	139	38	,	,	PUNCT
admet-2956	139	39	supporting	support	VERB
admet-2956	139	40	strong	strong	ADJ
admet-2956	139	41	and	and	CCONJ
admet-2956	139	42	consistent	consistent	ADJ
admet-2956	139	43	age	age	NOUN
admet-2956	139	44	-	-	PUNCT
admet-2956	139	45	related	relate	VERB
admet-2956	139	46	treatment	treatment	NOUN
admet-2956	139	47	effects	effect	NOUN
admet-2956	139	48	.	.	PUNCT
admet-2956	140	1	sex	sex	NOUN
admet-2956	140	2	-	-	PUNCT
admet-2956	140	3	based	base	VERB
admet-2956	140	4	analysis	analysis	NOUN
admet-2956	140	5	gender	gender	NOUN
admet-2956	140	6	stratification	stratification	NOUN
admet-2956	140	7	revealed	reveal	VERB
admet-2956	140	8	dramatic	dramatic	ADJ
admet-2956	140	9	differences	difference	NOUN
admet-2956	140	10	in	in	ADP
admet-2956	140	11	pembrolizumab	pembrolizumab	NOUN
admet-2956	140	12	efficacy	efficacy	NOUN
admet-2956	140	13	magnitude	magnitude	NOUN
admet-2956	140	14	among	among	ADP
admet-2956	140	15	endpoints	endpoint	NOUN
admet-2956	140	16	.	.	PUNCT
admet-2956	141	1	in	in	ADP
admet-2956	141	2	the	the	DET
admet-2956	141	3	os	os	NOUN
admet-2956	141	4	of	of	ADP
admet-2956	141	5	the	the	DET
admet-2956	141	6	pd	pd	PROPN
admet-2956	141	7	-	-	PROPN
admet-2956	141	8	l1	l1	PROPN
admet-2956	141	9	≥50	≥50	PROPN
admet-2956	141	10	%	%	PROPN
admet-2956	141	11	subgroup	subgroup	NOUN
admet-2956	141	12	,	,	PUNCT
admet-2956	141	13	female	female	ADJ
admet-2956	141	14	patients	patient	NOUN
admet-2956	141	15	exhibited	exhibit	VERB
admet-2956	141	16	exceptional	exceptional	ADJ
admet-2956	141	17	benefit	benefit	NOUN
admet-2956	141	18	(	(	PUNCT
admet-2956	141	19	hr	hr	NOUN
admet-2956	141	20	0.44	0.44	NUM
admet-2956	141	21	;	;	PUNCT
admet-2956	141	22	95	95	NUM
admet-2956	141	23	%	%	NOUN
admet-2956	141	24	ci	ci	NOUN
admet-2956	141	25	0.24	0.24	NUM
admet-2956	141	26	-	-	SYM
admet-2956	141	27	0.82	0.82	NUM
admet-2956	141	28	;	;	PUNCT
admet-2956	141	29	p=0.009	p=0.009	X
admet-2956	141	30	)	)	PUNCT
admet-2956	141	31	,	,	PUNCT
admet-2956	141	32	significantly	significantly	ADV
admet-2956	141	33	better	well	ADJ
admet-2956	141	34	than	than	ADP
admet-2956	141	35	that	that	PRON
admet-2956	141	36	of	of	ADP
admet-2956	141	37	male	male	ADJ
admet-2956	141	38	patients	patient	NOUN
admet-2956	141	39	(	(	PUNCT
admet-2956	141	40	hr	hr	NOUN
admet-2956	141	41	0.67	0.67	NUM
admet-2956	141	42	;	;	PUNCT
admet-2956	141	43	95	95	NUM
admet-2956	141	44	%	%	NOUN
admet-2956	141	45	ci	ci	NOUN
admet-2956	141	46	0.57	0.57	NUM
admet-2956	141	47	-	-	SYM
admet-2956	141	48	0.79	0.79	NUM
admet-2956	141	49	;	;	PUNCT
admet-2956	141	50	p<0.00001	p<0.00001	NUM
admet-2956	141	51	)	)	PUNCT
admet-2956	141	52	.	.	PUNCT
admet-2956	142	1	the	the	DET
admet-2956	142	2	female	female	ADJ
admet-2956	142	3	os	os	NOUN
admet-2956	142	4	analysis	analysis	NOUN
admet-2956	142	5	revealed	reveal	VERB
admet-2956	142	6	,	,	PUNCT
admet-2956	142	7	nonetheless	nonetheless	ADV
admet-2956	142	8	,	,	PUNCT
admet-2956	142	9	significant	significant	ADJ
admet-2956	142	10	heterogeneity	heterogeneity	NOUN
admet-2956	142	11	(	(	PUNCT
admet-2956	142	12	i²=87	i²=87	PROPN
admet-2956	142	13	%	%	INTJ
admet-2956	142	14	)	)	PUNCT
admet-2956	142	15	,	,	PUNCT
admet-2956	142	16	reflecting	reflect	VERB
admet-2956	142	17	heterogeneity	heterogeneity	NOUN
admet-2956	142	18	of	of	ADP
admet-2956	142	19	response	response	NOUN
admet-2956	142	20	to	to	ADP
admet-2956	142	21	treatment	treatment	NOUN
admet-2956	142	22	across	across	ADP
admet-2956	142	23	studies	study	NOUN
admet-2956	142	24	.	.	PUNCT
admet-2956	143	1	this	this	DET
admet-2956	143	2	sex	sex	NOUN
admet-2956	143	3	difference	difference	NOUN
admet-2956	143	4	occurred	occur	VERB
admet-2956	143	5	uniformly	uniformly	ADV
admet-2956	143	6	in	in	ADP
admet-2956	143	7	pfs	pfs	PROPN
admet-2956	143	8	,	,	PUNCT
admet-2956	143	9	where	where	SCONJ
admet-2956	143	10	females	female	NOUN
admet-2956	143	11	fared	fare	VERB
admet-2956	143	12	better	well	ADV
admet-2956	143	13	(	(	PUNCT
admet-2956	143	14	hr	hr	NOUN
admet-2956	143	15	0.43	0.43	NUM
admet-2956	143	16	;	;	PUNCT
admet-2956	143	17	95	95	NUM
admet-2956	143	18	%	%	NOUN
admet-2956	143	19	ci	ci	NOUN
admet-2956	143	20	0.32	0.32	NUM
admet-2956	143	21	-	-	SYM
admet-2956	143	22	0.56	0.56	NUM
admet-2956	143	23	;	;	PUNCT
admet-2956	143	24	p<0.00001	p<0.00001	NUM
admet-2956	143	25	)	)	PUNCT
admet-2956	143	26	than	than	ADP
admet-2956	143	27	males	male	NOUN
admet-2956	143	28	(	(	PUNCT
admet-2956	143	29	hr	hr	NOUN
admet-2956	143	30	0.61	0.61	NUM
admet-2956	143	31	;	;	PUNCT
admet-2956	143	32	95	95	NUM
admet-2956	143	33	%	%	NOUN
admet-2956	143	34	ci	ci	NOUN
admet-2956	143	35	0.51	0.51	NUM
admet-2956	143	36	-	-	SYM
admet-2956	143	37	0.73	0.73	NUM
admet-2956	143	38	;	;	PUNCT
admet-2956	143	39	p<0.00001	p<0.00001	NUM
admet-2956	143	40	)	)	PUNCT
admet-2956	143	41	(	(	PUNCT
admet-2956	143	42	tables	table	NOUN
admet-2956	143	43	2	2	NUM
admet-2956	143	44	and	and	CCONJ
admet-2956	143	45	3	3	NUM
admet-2956	143	46	)	)	PUNCT
admet-2956	143	47	.	.	PUNCT
admet-2956	144	1	notably	notably	ADV
admet-2956	144	2	,	,	PUNCT
admet-2956	144	3	the	the	DET
admet-2956	144	4	pfs	pfs	PROPN
admet-2956	144	5	analysis	analysis	NOUN
admet-2956	144	6	did	do	AUX
admet-2956	144	7	not	not	PART
admet-2956	144	8	reveal	reveal	VERB
admet-2956	144	9	any	any	DET
admet-2956	144	10	heterogeneity	heterogeneity	NOUN
admet-2956	144	11	within	within	ADP
admet-2956	144	12	either	either	DET
admet-2956	144	13	sex	sex	NOUN
admet-2956	144	14	stratum	stratum	NOUN
admet-2956	144	15	(	(	PUNCT
admet-2956	144	16	i²=0	i²=0	PROPN
admet-2956	144	17	%	%	NOUN
admet-2956	144	18	)	)	PUNCT
admet-2956	144	19	,	,	PUNCT
admet-2956	144	20	indicating	indicate	VERB
admet-2956	144	21	consistent	consistent	ADJ
admet-2956	144	22	treatment	treatment	NOUN
admet-2956	144	23	effects	effect	NOUN
admet-2956	144	24	within	within	ADP
admet-2956	144	25	each	each	DET
admet-2956	144	26	gender	gender	NOUN
admet-2956	144	27	group	group	NOUN
admet-2956	144	28	.	.	PUNCT
admet-2956	145	1	performance	performance	NOUN
admet-2956	145	2	status	status	NOUN
admet-2956	145	3	analysis	analysis	NOUN
admet-2956	145	4	eastern	eastern	ADJ
admet-2956	145	5	cooperative	cooperative	ADJ
admet-2956	145	6	oncology	oncology	NOUN
admet-2956	145	7	group	group	NOUN
admet-2956	145	8	(	(	PUNCT
admet-2956	145	9	ecog	ecog	PROPN
admet-2956	145	10	)	)	PUNCT
admet-2956	145	11	performance	performance	NOUN
admet-2956	145	12	status	status	NOUN
admet-2956	145	13	indicated	indicate	VERB
admet-2956	145	14	pembrolizumab	pembrolizumab	NOUN
admet-2956	145	15	efficacy	efficacy	NOUN
admet-2956	145	16	across	across	ADP
admet-2956	145	17	all	all	DET
admet-2956	145	18	functional	functional	ADJ
admet-2956	145	19	status	status	NOUN
admet-2956	145	20	levels	level	NOUN
admet-2956	145	21	with	with	ADP
admet-2956	145	22	relatively	relatively	ADV
admet-2956	145	23	small	small	ADJ
admet-2956	145	24	variation	variation	NOUN
admet-2956	145	25	between	between	ADP
admet-2956	145	26	groups	group	NOUN
admet-2956	145	27	.	.	PUNCT
admet-2956	146	1	os	os	NOUN
admet-2956	146	2	analysis	analysis	NOUN
admet-2956	146	3	indicated	indicate	VERB
admet-2956	146	4	significant	significant	ADJ
admet-2956	146	5	benefit	benefit	NOUN
admet-2956	146	6	in	in	ADP
admet-2956	146	7	both	both	CCONJ
admet-2956	146	8	ecog	ecog	NOUN
admet-2956	146	9	0	0	PUNCT
admet-2956	147	1	(	(	PUNCT
admet-2956	147	2	hr	hr	NOUN
admet-2956	147	3	0.60	0.60	NUM
admet-2956	147	4	;	;	PUNCT
admet-2956	147	5	95	95	NUM
admet-2956	147	6	%	%	NOUN
admet-2956	147	7	ci	ci	NOUN
admet-2956	147	8	0.47	0.47	NUM
admet-2956	147	9	to	to	ADP
admet-2956	147	10	0.77	0.77	NUM
admet-2956	147	11	;	;	PUNCT
admet-2956	147	12	p<0.0001	p<0.0001	NOUN
admet-2956	147	13	)	)	PUNCT
admet-2956	147	14	and	and	CCONJ
admet-2956	147	15	ecog	ecog	VERB
admet-2956	147	16	1	1	NUM
admet-2956	147	17	patients	patient	NOUN
admet-2956	147	18	(	(	PUNCT
admet-2956	147	19	hr	hr	NOUN
admet-2956	147	20	0.66	0.66	NUM
admet-2956	147	21	;	;	PUNCT
admet-2956	147	22	95	95	NUM
admet-2956	147	23	%	%	NOUN
admet-2956	147	24	ci	ci	NOUN
admet-2956	147	25	0.57	0.57	NUM
admet-2956	147	26	-	-	SYM
admet-2956	147	27	0.77	0.77	NUM
admet-2956	147	28	;	;	PUNCT
admet-2956	147	29	p	p	X
admet-2956	147	30	<	<	X
admet-2956	147	31	0.00001	0.00001	NUM
admet-2956	147	32	)	)	PUNCT
admet-2956	147	33	.	.	PUNCT
admet-2956	148	1	the	the	DET
admet-2956	148	2	ecog	ecog	PROPN
admet-2956	148	3	0	0	PROPN
admet-2956	148	4	subgroup	subgroup	PROPN
admet-2956	148	5	demonstrated	demonstrate	VERB
admet-2956	148	6	moderate	moderate	ADJ
admet-2956	148	7	heterogeneity	heterogeneity	NOUN
admet-2956	148	8	(	(	PUNCT
admet-2956	148	9	i²	i²	NOUN
admet-2956	148	10	=	=	PROPN
admet-2956	148	11	38	38	NUM
admet-2956	148	12	%	%	NOUN
admet-2956	148	13	)	)	PUNCT
admet-2956	148	14	,	,	PUNCT
admet-2956	148	15	while	while	SCONJ
admet-2956	148	16	ecog	ecog	NOUN
admet-2956	148	17	1	1	NUM
admet-2956	148	18	patients	patient	NOUN
admet-2956	148	19	demonstrated	demonstrate	VERB
admet-2956	148	20	total	total	ADJ
admet-2956	148	21	homogeneity	homogeneity	NOUN
admet-2956	148	22	(	(	PUNCT
admet-2956	148	23	i²	i²	NOUN
admet-2956	148	24	=	=	NOUN
admet-2956	148	25	0	0	NUM
admet-2956	148	26	%	%	NOUN
admet-2956	148	27	)	)	PUNCT
admet-2956	148	28	.	.	PUNCT
admet-2956	149	1	pfs	pfs	PROPN
admet-2956	149	2	also	also	ADV
admet-2956	149	3	concorded	concord	VERB
admet-2956	149	4	with	with	ADP
admet-2956	149	5	results	result	NOUN
admet-2956	149	6	in	in	ADP
admet-2956	149	7	ecog	ecog	NOUN
admet-2956	149	8	0	0	NUM
admet-2956	149	9	patients	patient	NOUN
admet-2956	149	10	hr	hr	PROPN
admet-2956	149	11	0.47	0.47	NUM
admet-2956	149	12	(	(	PUNCT
admet-2956	149	13	95	95	NUM
admet-2956	149	14	%	%	NOUN
admet-2956	149	15	ci	ci	NOUN
admet-2956	149	16	0.36	0.36	NUM
admet-2956	149	17	to	to	ADP
admet-2956	149	18	0.62	0.62	NUM
admet-2956	149	19	;	;	PUNCT
admet-2956	149	20	p	p	X
admet-2956	149	21	<	<	X
admet-2956	149	22	0.00001	0.00001	NUM
admet-2956	149	23	)	)	PUNCT
admet-2956	149	24	and	and	CCONJ
admet-2956	149	25	ecog	ecog	VERB
admet-2956	149	26	1	1	NUM
admet-2956	149	27	patients	patient	NOUN
admet-2956	149	28	hr	hr	VERB
admet-2956	149	29	0.59	0.59	NUM
admet-2956	149	30	(	(	PUNCT
admet-2956	149	31	95	95	NUM
admet-2956	149	32	%	%	NOUN
admet-2956	149	33	ci	ci	NOUN
admet-2956	149	34	0.49	0.49	NUM
admet-2956	149	35	to	to	ADP
admet-2956	149	36	0.70	0.70	NUM
admet-2956	149	37	;	;	PUNCT
admet-2956	149	38	p	p	X
admet-2956	149	39	<	<	X
admet-2956	149	40	0.00001	0.00001	NUM
admet-2956	149	41	)	)	PUNCT
admet-2956	149	42	(	(	PUNCT
admet-2956	149	43	tables	table	NOUN
admet-2956	149	44	2	2	NUM
admet-2956	149	45	and	and	CCONJ
admet-2956	149	46	3	3	NUM
admet-2956	149	47	)	)	PUNCT
admet-2956	149	48	.	.	PUNCT
admet-2956	150	1	notably	notably	ADV
admet-2956	150	2	,	,	PUNCT
admet-2956	150	3	both	both	DET
admet-2956	150	4	pfs	pfs	PROPN
admet-2956	150	5	subgroups	subgroup	NOUN
admet-2956	150	6	did	do	AUX
admet-2956	150	7	not	not	PART
admet-2956	150	8	admet	admet	VERB
admet-2956	150	9	&	&	CCONJ
admet-2956	150	10	dmpk	dmpk	PROPN
admet-2956	150	11	13(5	13(5	NOUN
admet-2956	150	12	)	)	PUNCT
admet-2956	150	13	(	(	PUNCT
admet-2956	150	14	2025	2025	NUM
admet-2956	150	15	)	)	PUNCT
admet-2956	150	16	2956	2956	NUM
admet-2956	150	17	pembrolizumab	pembrolizumab	NOUN
admet-2956	150	18	in	in	ADP
admet-2956	150	19	pd	pd	PROPN
admet-2956	150	20	-	-	PUNCT
admet-2956	150	21	l1	l1	PROPN
admet-2956	150	22	-	-	PUNCT
admet-2956	150	23	positive	positive	ADJ
admet-2956	150	24	advanced	advanced	ADJ
admet-2956	150	25	non	non	ADJ
admet-2956	150	26	-	-	ADJ
admet-2956	150	27	small	small	ADJ
admet-2956	150	28	cell	cell	NOUN
admet-2956	150	29	lung	lung	NOUN
admet-2956	150	30	carcinoma	carcinoma	NOUN
admet-2956	150	31	doi	doi	NOUN
admet-2956	150	32	:	:	PUNCT
admet-2956	150	33	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	150	34	9	9	NUM
admet-2956	150	35	have	have	VERB
admet-2956	150	36	heterogeneity	heterogeneity	NOUN
admet-2956	150	37	(	(	PUNCT
admet-2956	150	38	i²	i²	NOUN
admet-2956	150	39	=	=	SYM
admet-2956	150	40	0	0	NUM
admet-2956	150	41	%	%	NOUN
admet-2956	150	42	)	)	PUNCT
admet-2956	150	43	,	,	PUNCT
admet-2956	150	44	implying	imply	VERB
admet-2956	150	45	extremely	extremely	ADV
admet-2956	150	46	consistent	consistent	ADJ
admet-2956	150	47	treatment	treatment	NOUN
admet-2956	150	48	effects	effect	NOUN
admet-2956	150	49	across	across	ADP
admet-2956	150	50	the	the	DET
admet-2956	150	51	varying	vary	VERB
admet-2956	150	52	baseline	baseline	ADJ
admet-2956	150	53	functional	functional	ADJ
admet-2956	150	54	status	status	NOUN
admet-2956	150	55	.	.	PUNCT
admet-2956	151	1	pd	pd	PROPN
admet-2956	151	2	-	-	PUNCT
admet-2956	151	3	l1	l1	PROPN
admet-2956	151	4	expression	expression	NOUN
admet-2956	151	5	analysis	analysis	NOUN
admet-2956	151	6	the	the	DET
admet-2956	151	7	stratification	stratification	NOUN
admet-2956	151	8	of	of	ADP
admet-2956	151	9	tumour	tumour	NOUN
admet-2956	151	10	score	score	NOUN
admet-2956	151	11	proportion	proportion	NOUN
admet-2956	151	12	has	have	AUX
admet-2956	151	13	demonstrated	demonstrate	VERB
admet-2956	151	14	the	the	DET
admet-2956	151	15	efficacy	efficacy	NOUN
admet-2956	151	16	of	of	ADP
admet-2956	151	17	pembrolizumab	pembrolizumab	NOUN
admet-2956	151	18	across	across	ADP
admet-2956	151	19	the	the	DET
admet-2956	151	20	full	full	ADJ
admet-2956	151	21	spectrum	spectrum	NOUN
admet-2956	151	22	of	of	ADP
admet-2956	151	23	pd	pd	PROPN
admet-2956	151	24	-	-	PROPN
admet-2956	151	25	l1	l1	PROPN
admet-2956	151	26	levels	level	NOUN
admet-2956	151	27	,	,	PUNCT
admet-2956	151	28	revealing	reveal	VERB
admet-2956	151	29	unexpected	unexpected	ADJ
admet-2956	151	30	trends	trend	NOUN
admet-2956	151	31	that	that	PRON
admet-2956	151	32	contradict	contradict	VERB
admet-2956	151	33	traditional	traditional	ADJ
admet-2956	151	34	biomarker	biomarker	NOUN
admet-2956	151	35	-	-	PUNCT
admet-2956	151	36	driven	drive	VERB
admet-2956	151	37	selection	selection	NOUN
admet-2956	151	38	frameworks	framework	NOUN
admet-2956	151	39	.	.	PUNCT
admet-2956	152	1	os	os	NOUN
admet-2956	152	2	and	and	CCONJ
admet-2956	152	3	pfs	pfs	PROPN
admet-2956	152	4	analyses	analysis	NOUN
admet-2956	152	5	in	in	ADP
admet-2956	152	6	tables	table	NOUN
admet-2956	152	7	4	4	NUM
admet-2956	152	8	and	and	CCONJ
admet-2956	152	9	5	5	NUM
admet-2956	152	10	,	,	PUNCT
admet-2956	152	11	respectively	respectively	ADV
admet-2956	152	12	,	,	PUNCT
admet-2956	152	13	further	far	ADV
admet-2956	152	14	confirmed	confirm	VERB
admet-2956	152	15	that	that	SCONJ
admet-2956	152	16	patients	patient	NOUN
admet-2956	152	17	with	with	ADP
admet-2956	152	18	a	a	DET
admet-2956	152	19	tps	tps	NOUN
admet-2956	152	20	of	of	ADP
admet-2956	152	21	less	less	ADJ
admet-2956	152	22	than	than	ADP
admet-2956	152	23	1	1	NUM
admet-2956	152	24	%	%	NOUN
admet-2956	152	25	experienced	experience	VERB
admet-2956	152	26	significant	significant	ADJ
admet-2956	152	27	benefits	benefit	NOUN
admet-2956	152	28	,	,	PUNCT
admet-2956	152	29	indicated	indicate	VERB
admet-2956	152	30	by	by	ADP
admet-2956	152	31	a	a	DET
admet-2956	152	32	hazard	hazard	NOUN
admet-2956	152	33	ratio	ratio	NOUN
admet-2956	152	34	of	of	ADP
admet-2956	152	35	0.60	0.60	NUM
admet-2956	152	36	(	(	PUNCT
admet-2956	152	37	95	95	NUM
admet-2956	152	38	%	%	NOUN
admet-2956	152	39	ci	ci	NOUN
admet-2956	152	40	0.43	0.43	NUM
admet-2956	152	41	to	to	ADP
admet-2956	152	42	0.83	0.83	NUM
admet-2956	152	43	;	;	PUNCT
admet-2956	152	44	p	p	X
admet-2956	152	45	=	=	NOUN
admet-2956	152	46	0.002	0.002	NUM
admet-2956	152	47	)	)	PUNCT
admet-2956	152	48	.	.	PUNCT
admet-2956	153	1	in	in	ADP
admet-2956	153	2	contrast	contrast	NOUN
admet-2956	153	3	,	,	PUNCT
admet-2956	153	4	those	those	PRON
admet-2956	153	5	with	with	ADP
admet-2956	153	6	tps	tps	NOUN
admet-2956	153	7	ranging	range	VERB
admet-2956	153	8	from	from	ADP
admet-2956	153	9	1	1	NUM
admet-2956	153	10	to	to	PART
admet-2956	153	11	49	49	NUM
admet-2956	153	12	%	%	NOUN
admet-2956	153	13	exhibited	exhibit	VERB
admet-2956	153	14	similar	similar	ADJ
admet-2956	153	15	efficacy	efficacy	NOUN
admet-2956	153	16	,	,	PUNCT
admet-2956	153	17	with	with	ADP
admet-2956	153	18	a	a	DET
admet-2956	153	19	hazard	hazard	NOUN
admet-2956	153	20	ratio	ratio	NOUN
admet-2956	153	21	of	of	ADP
admet-2956	153	22	0.56	0.56	NUM
admet-2956	153	23	(	(	PUNCT
admet-2956	153	24	95	95	NUM
admet-2956	153	25	%	%	NOUN
admet-2956	153	26	ci	ci	NOUN
admet-2956	153	27	0.40	0.40	NUM
admet-2956	153	28	to	to	ADP
admet-2956	153	29	0.78	0.78	NUM
admet-2956	153	30	;	;	PUNCT
admet-2956	153	31	p=0.0006	p=0.0006	NUM
admet-2956	153	32	)	)	PUNCT
admet-2956	153	33	.	.	PUNCT
admet-2956	154	1	table	table	NOUN
admet-2956	154	2	4	4	NUM
admet-2956	154	3	.	.	PUNCT
admet-2956	155	1	analysis	analysis	NOUN
admet-2956	155	2	of	of	ADP
admet-2956	155	3	os	os	NOUN
admet-2956	155	4	in	in	ADP
admet-2956	155	5	patient	patient	ADJ
admet-2956	155	6	subgroups	subgroup	NOUN
admet-2956	155	7	with	with	ADP
admet-2956	155	8	varying	vary	VERB
admet-2956	155	9	clinical	clinical	ADJ
admet-2956	155	10	characteristics	characteristic	NOUN
admet-2956	155	11	population	population	NOUN
admet-2956	155	12	subgroup	subgroup	NOUN
admet-2956	155	13	no	no	INTJ
admet-2956	155	14	.	.	PUNCT
admet-2956	155	15	of	of	ADP
admet-2956	155	16	studies	study	NOUN
admet-2956	155	17	hr	hr	NOUN
admet-2956	155	18	95	95	NUM
admet-2956	155	19	%	%	NOUN
admet-2956	155	20	ci	ci	NOUN
admet-2956	155	21	i²	i²	PROPN
admet-2956	155	22	/	/	SYM
admet-2956	155	23	%	%	NOUN
admet-2956	156	1	p	p	NOUN
admet-2956	156	2	value	value	NOUN
admet-2956	156	3	age	age	NOUN
admet-2956	156	4	-	-	PUNCT
admet-2956	156	5	stratified	stratify	VERB
admet-2956	156	6	analysis	analysis	NOUN
admet-2956	156	7	age	age	NOUN
admet-2956	156	8	<	<	X
admet-2956	156	9	65	65	NUM
admet-2956	156	10	years	year	NOUN
admet-2956	156	11	total	total	VERB
admet-2956	156	12	3	3	NUM
admet-2956	156	13	0.55	0.55	NUM
admet-2956	156	14	0.46	0.46	NUM
admet-2956	156	15	-	-	SYM
admet-2956	156	16	0.65	0.65	NUM
admet-2956	156	17	44	44	NUM
admet-2956	156	18	<	<	NOUN
admet-2956	156	19	0.00001	0.00001	NUM
admet-2956	156	20	age	age	NOUN
admet-2956	156	21	≥	≥	NOUN
admet-2956	156	22	65	65	NUM
admet-2956	156	23	years	year	NOUN
admet-2956	156	24	total	total	VERB
admet-2956	156	25	3	3	NUM
admet-2956	156	26	0.72	0.72	NUM
admet-2956	156	27	0.59	0.59	NUM
admet-2956	156	28	-	-	SYM
admet-2956	156	29	0.88	0.88	NUM
admet-2956	156	30	0	0	NUM
admet-2956	156	31	0.001	0.001	NUM
admet-2956	156	32	sex	sex	NOUN
admet-2956	156	33	-	-	PUNCT
admet-2956	156	34	based	base	VERB
admet-2956	156	35	analysis	analysis	NOUN
admet-2956	156	36	male	male	NOUN
admet-2956	156	37	total	total	NOUN
admet-2956	156	38	3	3	NUM
admet-2956	156	39	0.67	0.67	NUM
admet-2956	156	40	0.57	0.57	NUM
admet-2956	156	41	-	-	SYM
admet-2956	156	42	0.79	0.79	NUM
admet-2956	156	43	0	0	NUM
admet-2956	156	44	<	<	X
admet-2956	156	45	0.00001	0.00001	NUM
admet-2956	156	46	female	female	ADJ
admet-2956	156	47	(	(	PUNCT
admet-2956	156	48	pd	pd	NOUN
admet-2956	156	49	-	-	PROPN
admet-2956	156	50	l1	l1	PROPN
admet-2956	156	51	≥50	≥50	NUM
admet-2956	156	52	%	%	NOUN
admet-2956	156	53	)	)	PUNCT
admet-2956	156	54	total	total	VERB
admet-2956	156	55	3	3	NUM
admet-2956	156	56	0.44	0.44	NUM
admet-2956	156	57	0.24	0.24	NUM
admet-2956	156	58	-	-	SYM
admet-2956	156	59	0.82	0.82	NUM
admet-2956	156	60	87	87	NUM
admet-2956	156	61	0.009	0.009	NUM
admet-2956	156	62	performance	performance	NOUN
admet-2956	156	63	status	status	NOUN
admet-2956	156	64	analysis	analysis	NOUN
admet-2956	156	65	ecog	ecog	VERB
admet-2956	156	66	ps	ps	PROPN
admet-2956	156	67	0	0	NUM
admet-2956	156	68	total	total	NOUN
admet-2956	156	69	3	3	NUM
admet-2956	156	70	0.60	0.60	NUM
admet-2956	156	71	0.47	0.47	NUM
admet-2956	156	72	-	-	SYM
admet-2956	156	73	0.77	0.77	NUM
admet-2956	156	74	38	38	NUM
admet-2956	156	75	<	<	SYM
admet-2956	156	76	0.0001	0.0001	NUM
admet-2956	156	77	ecog	ecog	ADJ
admet-2956	156	78	ps	ps	PROPN
admet-2956	156	79	1	1	NUM
admet-2956	156	80	total	total	NOUN
admet-2956	156	81	3	3	NUM
admet-2956	156	82	0.66	0.66	NUM
admet-2956	156	83	0.57	0.57	NUM
admet-2956	156	84	-	-	SYM
admet-2956	156	85	0.77	0.77	NUM
admet-2956	156	86	0	0	NUM
admet-2956	156	87	<	<	X
admet-2956	156	88	0.00001	0.00001	NUM
admet-2956	156	89	pd	pd	PROPN
admet-2956	156	90	-	-	PUNCT
admet-2956	156	91	l1	l1	PROPN
admet-2956	156	92	expression	expression	NOUN
admet-2956	156	93	analysis	analysis	NOUN
admet-2956	156	94	pd	pd	PROPN
admet-2956	156	95	-	-	PROPN
admet-2956	156	96	l1	l1	PROPN
admet-2956	156	97	tps	tps	NOUN
admet-2956	156	98	<	<	X
admet-2956	156	99	1	1	NUM
admet-2956	156	100	%	%	NOUN
admet-2956	156	101	total	total	NOUN
admet-2956	156	102	2	2	NUM
admet-2956	156	103	0.60	0.60	NUM
admet-2956	156	104	0.43	0.43	NUM
admet-2956	156	105	-	-	SYM
admet-2956	156	106	0.83	0.83	NUM
admet-2956	156	107	0	0	NUM
admet-2956	156	108	0.002	0.002	NUM
admet-2956	156	109	pd	pd	PROPN
admet-2956	156	110	-	-	PROPN
admet-2956	156	111	l1	l1	PROPN
admet-2956	156	112	tps	tps	PROPN
admet-2956	156	113	≥	≥	NOUN
admet-2956	156	114	1	1	NUM
admet-2956	156	115	%	%	NOUN
admet-2956	156	116	total	total	NOUN
admet-2956	156	117	5	5	NUM
admet-2956	156	118	0.71	0.71	NUM
admet-2956	156	119	0.60	0.60	NUM
admet-2956	156	120	-	-	SYM
admet-2956	156	121	0.84	0.84	NUM
admet-2956	156	122	59	59	NUM
admet-2956	156	123	<	<	NOUN
admet-2956	156	124	0.0001	0.0001	NUM
admet-2956	156	125	pd	pd	PROPN
admet-2956	156	126	-	-	PUNCT
admet-2956	156	127	l1	l1	PROPN
admet-2956	156	128	tps	tps	PROPN
admet-2956	156	129	1	1	NUM
admet-2956	156	130	-	-	SYM
admet-2956	156	131	49	49	NUM
admet-2956	156	132	%	%	NOUN
admet-2956	156	133	total	total	NOUN
admet-2956	156	134	2	2	NUM
admet-2956	156	135	0.56	0.56	NUM
admet-2956	156	136	0.40	0.40	NUM
admet-2956	156	137	-	-	SYM
admet-2956	156	138	0.78	0.78	NUM
admet-2956	156	139	0	0	NUM
admet-2956	156	140	0.0006	0.0006	NUM
admet-2956	156	141	patients	patient	NOUN
admet-2956	156	142	classified	classify	VERB
admet-2956	156	143	with	with	ADP
admet-2956	156	144	tps	tps	NOUN
admet-2956	156	145	of	of	ADP
admet-2956	156	146	1	1	NUM
admet-2956	156	147	%	%	NOUN
admet-2956	156	148	or	or	CCONJ
admet-2956	156	149	greater	great	ADJ
admet-2956	156	150	showed	show	VERB
admet-2956	156	151	a	a	DET
admet-2956	156	152	significant	significant	ADJ
admet-2956	156	153	,	,	PUNCT
admet-2956	156	154	albeit	albeit	SCONJ
admet-2956	156	155	less	less	ADV
admet-2956	156	156	pronounced	pronounced	ADJ
admet-2956	156	157	,	,	PUNCT
admet-2956	156	158	benefit	benefit	NOUN
admet-2956	156	159	,	,	PUNCT
admet-2956	156	160	reflected	reflect	VERB
admet-2956	156	161	by	by	ADP
admet-2956	156	162	a	a	DET
admet-2956	156	163	hazard	hazard	NOUN
admet-2956	156	164	ratio	ratio	NOUN
admet-2956	156	165	of	of	ADP
admet-2956	156	166	0.71	0.71	NUM
admet-2956	156	167	(	(	PUNCT
admet-2956	156	168	95	95	NUM
admet-2956	156	169	%	%	NOUN
admet-2956	156	170	ci	ci	NOUN
admet-2956	156	171	0.60	0.60	NUM
admet-2956	156	172	to	to	ADP
admet-2956	156	173	0.84	0.84	NUM
admet-2956	156	174	;	;	PUNCT
admet-2956	156	175	p	p	X
admet-2956	156	176	<	<	X
admet-2956	156	177	0.0001	0.0001	NUM
admet-2956	156	178	)	)	PUNCT
admet-2956	156	179	,	,	PUNCT
admet-2956	156	180	accompanied	accompany	VERB
admet-2956	156	181	by	by	ADP
admet-2956	156	182	moderate	moderate	ADJ
admet-2956	156	183	heterogeneity	heterogeneity	NOUN
admet-2956	156	184	(	(	PUNCT
admet-2956	156	185	i²=59	i²=59	INTJ
admet-2956	156	186	%	%	NOUN
admet-2956	156	187	)	)	PUNCT
admet-2956	156	188	.	.	PUNCT
admet-2956	157	1	in	in	ADP
admet-2956	157	2	the	the	DET
admet-2956	157	3	cohort	cohort	NOUN
admet-2956	157	4	of	of	ADP
admet-2956	157	5	patients	patient	NOUN
admet-2956	157	6	with	with	ADP
admet-2956	157	7	tps	tps	NOUN
admet-2956	157	8	less	less	ADJ
admet-2956	157	9	than	than	ADP
admet-2956	157	10	1	1	NUM
admet-2956	157	11	%	%	NOUN
admet-2956	157	12	,	,	PUNCT
admet-2956	157	13	the	the	DET
admet-2956	157	14	analysis	analysis	NOUN
admet-2956	157	15	of	of	ADP
admet-2956	157	16	progression	progression	NOUN
admet-2956	157	17	-	-	PUNCT
admet-2956	157	18	free	free	ADJ
admet-2956	157	19	survival	survival	NOUN
admet-2956	157	20	indicated	indicate	VERB
admet-2956	157	21	a	a	DET
admet-2956	157	22	consistent	consistent	ADJ
admet-2956	157	23	benefit	benefit	NOUN
admet-2956	157	24	,	,	PUNCT
admet-2956	157	25	with	with	ADP
admet-2956	157	26	a	a	DET
admet-2956	157	27	hazard	hazard	NOUN
admet-2956	157	28	ratio	ratio	NOUN
admet-2956	157	29	of	of	ADP
admet-2956	157	30	0.60	0.60	NUM
admet-2956	157	31	(	(	PUNCT
admet-2956	157	32	95	95	NUM
admet-2956	157	33	%	%	NOUN
admet-2956	157	34	ci	ci	NOUN
admet-2956	157	35	0.43	0.43	NUM
admet-2956	157	36	to	to	ADP
admet-2956	157	37	0.83	0.83	NUM
admet-2956	157	38	;	;	PUNCT
admet-2956	157	39	p	p	X
admet-2956	157	40	=	=	NOUN
admet-2956	157	41	0.002	0.002	NUM
admet-2956	157	42	)	)	PUNCT
admet-2956	157	43	.	.	PUNCT
admet-2956	158	1	conversely	conversely	ADV
admet-2956	158	2	,	,	PUNCT
admet-2956	158	3	patients	patient	NOUN
admet-2956	158	4	with	with	ADP
admet-2956	158	5	tps	tps	NOUN
admet-2956	158	6	between	between	ADP
admet-2956	158	7	1	1	NUM
admet-2956	158	8	and	and	CCONJ
admet-2956	158	9	49	49	NUM
admet-2956	158	10	%	%	NOUN
admet-2956	158	11	demonstrated	demonstrate	VERB
admet-2956	158	12	comparable	comparable	ADJ
admet-2956	158	13	efficacy	efficacy	NOUN
admet-2956	158	14	,	,	PUNCT
admet-2956	158	15	with	with	ADP
admet-2956	158	16	a	a	DET
admet-2956	158	17	hazard	hazard	NOUN
admet-2956	158	18	ratio	ratio	NOUN
admet-2956	158	19	of	of	ADP
admet-2956	158	20	0.56	0.56	NUM
admet-2956	158	21	(	(	PUNCT
admet-2956	158	22	95	95	NUM
admet-2956	158	23	%	%	NOUN
admet-2956	158	24	ci	ci	NOUN
admet-2956	158	25	0.43	0.43	NUM
admet-2956	158	26	-	-	PUNCT
admet-2956	158	27	0.73	0.73	NUM
admet-2956	158	28	;	;	PUNCT
admet-2956	158	29	p	p	X
admet-2956	158	30	<	<	X
admet-2956	158	31	0.0001	0.0001	NUM
admet-2956	158	32	)	)	PUNCT
admet-2956	158	33	.	.	PUNCT
admet-2956	159	1	table	table	NOUN
admet-2956	159	2	5	5	NUM
admet-2956	159	3	.	.	PUNCT
admet-2956	160	1	analysis	analysis	NOUN
admet-2956	160	2	of	of	ADP
admet-2956	160	3	pfs	pfs	PROPN
admet-2956	160	4	in	in	ADP
admet-2956	160	5	patient	patient	ADJ
admet-2956	160	6	subgroups	subgroup	NOUN
admet-2956	160	7	with	with	ADP
admet-2956	160	8	varying	vary	VERB
admet-2956	160	9	clinical	clinical	ADJ
admet-2956	160	10	characteristics	characteristic	NOUN
admet-2956	160	11	population	population	NOUN
admet-2956	160	12	subgroup	subgroup	NOUN
admet-2956	160	13	no	no	INTJ
admet-2956	160	14	.	.	PUNCT
admet-2956	160	15	of	of	ADP
admet-2956	160	16	studies	study	NOUN
admet-2956	160	17	hr	hr	NOUN
admet-2956	160	18	95	95	NUM
admet-2956	160	19	%	%	NOUN
admet-2956	160	20	ci	ci	NOUN
admet-2956	160	21	i²	i²	PROPN
admet-2956	160	22	/	/	SYM
admet-2956	160	23	%	%	NOUN
admet-2956	161	1	p	p	NOUN
admet-2956	161	2	value	value	NOUN
admet-2956	161	3	age	age	NOUN
admet-2956	161	4	-	-	PUNCT
admet-2956	161	5	stratified	stratify	VERB
admet-2956	161	6	analysis	analysis	NOUN
admet-2956	161	7	age	age	NOUN
admet-2956	161	8	<	<	X
admet-2956	161	9	65	65	NUM
admet-2956	161	10	years	year	NOUN
admet-2956	161	11	total	total	ADJ
admet-2956	161	12	2	2	NUM
admet-2956	161	13	0.46	0.46	NUM
admet-2956	161	14	0.38	0.38	NUM
admet-2956	161	15	-	-	SYM
admet-2956	161	16	0.57	0.57	NUM
admet-2956	161	17	0	0	NUM
admet-2956	161	18	<	<	NOUN
admet-2956	161	19	0.00001	0.00001	NUM
admet-2956	161	20	age	age	NOUN
admet-2956	161	21	≥	≥	NUM
admet-2956	161	22	65	65	NUM
admet-2956	161	23	years	year	NOUN
admet-2956	161	24	total	total	VERB
admet-2956	161	25	2	2	NUM
admet-2956	161	26	0.68	0.68	NUM
admet-2956	161	27	0.55	0.55	NUM
admet-2956	161	28	-	-	SYM
admet-2956	161	29	0.85	0.85	NUM
admet-2956	161	30	0	0	NUM
admet-2956	162	1	0.0005	0.0005	NUM
admet-2956	162	2	sex	sex	NOUN
admet-2956	162	3	-	-	PUNCT
admet-2956	162	4	based	base	VERB
admet-2956	162	5	analysis	analysis	NOUN
admet-2956	162	6	male	male	NOUN
admet-2956	162	7	total	total	NOUN
admet-2956	162	8	2	2	NUM
admet-2956	162	9	0.61	0.61	NUM
admet-2956	162	10	0.51	0.51	NUM
admet-2956	162	11	-	-	SYM
admet-2956	162	12	0.73	0.73	NUM
admet-2956	162	13	0	0	NUM
admet-2956	162	14	<	<	X
admet-2956	162	15	0.00001	0.00001	NUM
admet-2956	162	16	female	female	ADJ
admet-2956	162	17	total	total	NOUN
admet-2956	162	18	2	2	NUM
admet-2956	162	19	0.43	0.43	NUM
admet-2956	162	20	0.32	0.32	NUM
admet-2956	162	21	-	-	SYM
admet-2956	162	22	0.56	0.56	NUM
admet-2956	162	23	0	0	NUM
admet-2956	162	24	<	<	X
admet-2956	162	25	0.00001	0.00001	NUM
admet-2956	162	26	performance	performance	NOUN
admet-2956	162	27	status	status	NOUN
admet-2956	162	28	analysis	analysis	NOUN
admet-2956	162	29	ecog	ecog	VERB
admet-2956	162	30	ps	ps	PROPN
admet-2956	162	31	0	0	NUM
admet-2956	162	32	total	total	NOUN
admet-2956	162	33	2	2	NUM
admet-2956	162	34	0.47	0.47	NUM
admet-2956	162	35	0.36	0.36	NUM
admet-2956	162	36	-	-	SYM
admet-2956	162	37	0.62	0.62	NUM
admet-2956	162	38	0	0	NUM
admet-2956	162	39	<	<	X
admet-2956	162	40	0.00001	0.00001	NUM
admet-2956	162	41	ecog	ecog	ADJ
admet-2956	162	42	ps	ps	PROPN
admet-2956	162	43	1	1	NUM
admet-2956	162	44	total	total	NOUN
admet-2956	162	45	2	2	NUM
admet-2956	162	46	0.59	0.59	NUM
admet-2956	162	47	0.49	0.49	NUM
admet-2956	162	48	-	-	SYM
admet-2956	162	49	0.70	0.70	NUM
admet-2956	162	50	0	0	NUM
admet-2956	162	51	<	<	X
admet-2956	162	52	0.00001	0.00001	NUM
admet-2956	162	53	pd	pd	PROPN
admet-2956	162	54	-	-	PUNCT
admet-2956	162	55	l1	l1	PROPN
admet-2956	162	56	expression	expression	NOUN
admet-2956	162	57	analysis	analysis	NOUN
admet-2956	162	58	pd	pd	PROPN
admet-2956	162	59	-	-	PROPN
admet-2956	162	60	l1	l1	PROPN
admet-2956	162	61	tps	tps	NOUN
admet-2956	162	62	<	<	X
admet-2956	162	63	1	1	NUM
admet-2956	162	64	%	%	NOUN
admet-2956	162	65	total	total	NOUN
admet-2956	162	66	2	2	NUM
admet-2956	162	67	0.60	0.60	NUM
admet-2956	162	68	0.43	0.43	NUM
admet-2956	162	69	-	-	SYM
admet-2956	162	70	0.83	0.83	NUM
admet-2956	162	71	%	%	NOUN
admet-2956	162	72	0.002	0.002	NUM
admet-2956	162	73	pd	pd	PROPN
admet-2956	162	74	-	-	PROPN
admet-2956	162	75	l1	l1	PROPN
admet-2956	162	76	tps	tps	PROPN
admet-2956	162	77	≥	≥	NOUN
admet-2956	162	78	1	1	NUM
admet-2956	162	79	%	%	NOUN
admet-2956	162	80	total	total	NOUN
admet-2956	162	81	5	5	NUM
admet-2956	162	82	0.74	0.74	NUM
admet-2956	162	83	0.54	0.54	NUM
admet-2956	162	84	-	-	SYM
admet-2956	162	85	1.01	1.01	NUM
admet-2956	162	86	90	90	NUM
admet-2956	162	87	0.05	0.05	NUM
admet-2956	162	88	pd	pd	PROPN
admet-2956	162	89	-	-	PUNCT
admet-2956	162	90	l1	l1	PROPN
admet-2956	162	91	tps	tps	PROPN
admet-2956	162	92	1	1	NUM
admet-2956	162	93	-	-	SYM
admet-2956	162	94	49	49	NUM
admet-2956	162	95	%	%	NOUN
admet-2956	162	96	total	total	NOUN
admet-2956	162	97	2	2	NUM
admet-2956	162	98	0.56	0.56	NUM
admet-2956	162	99	0.43	0.43	NUM
admet-2956	162	100	-	-	SYM
admet-2956	162	101	0.73	0.73	NUM
admet-2956	162	102	0	0	NUM
admet-2956	163	1	<	<	X
admet-2956	163	2	0.0001	0.0001	NUM
admet-2956	163	3	the	the	DET
admet-2956	163	4	subgroup	subgroup	NOUN
admet-2956	163	5	of	of	ADP
admet-2956	163	6	patients	patient	NOUN
admet-2956	163	7	with	with	ADP
admet-2956	163	8	tps	tps	NOUN
admet-2956	163	9	of	of	ADP
admet-2956	163	10	1	1	NUM
admet-2956	163	11	%	%	NOUN
admet-2956	163	12	or	or	CCONJ
admet-2956	163	13	more	more	ADV
admet-2956	163	14	exhibited	exhibit	VERB
admet-2956	163	15	only	only	ADJ
admet-2956	163	16	marginal	marginal	ADJ
admet-2956	163	17	statistical	statistical	ADJ
admet-2956	163	18	significance	significance	NOUN
admet-2956	163	19	,	,	PUNCT
admet-2956	163	20	as	as	SCONJ
admet-2956	163	21	evidenced	evidence	VERB
admet-2956	163	22	by	by	ADP
admet-2956	163	23	a	a	DET
admet-2956	163	24	hazard	hazard	NOUN
admet-2956	163	25	ratio	ratio	NOUN
admet-2956	163	26	of	of	ADP
admet-2956	163	27	0.74	0.74	NUM
admet-2956	163	28	(	(	PUNCT
admet-2956	163	29	95	95	NUM
admet-2956	163	30	%	%	NOUN
admet-2956	163	31	ci	ci	NOUN
admet-2956	163	32	0.54	0.54	NUM
admet-2956	163	33	to	to	ADP
admet-2956	163	34	1.01	1.01	NUM
admet-2956	163	35	;	;	PUNCT
admet-2956	163	36	p	p	X
admet-2956	163	37	=	=	NOUN
admet-2956	163	38	0.05	0.05	NUM
admet-2956	163	39	)	)	PUNCT
admet-2956	163	40	,	,	PUNCT
admet-2956	163	41	alongside	alongside	ADP
admet-2956	163	42	a	a	DET
admet-2956	163	43	notably	notably	ADV
admet-2956	163	44	high	high	ADJ
admet-2956	163	45	level	level	NOUN
admet-2956	163	46	of	of	ADP
admet-2956	163	47	heterogeneity	heterogeneity	NOUN
admet-2956	163	48	(	(	PUNCT
admet-2956	163	49	i²=90	i²=90	VERB
admet-2956	163	50	%	%	NOUN
admet-2956	163	51	)	)	PUNCT
admet-2956	163	52	.	.	PUNCT
admet-2956	164	1	this	this	DET
admet-2956	164	2	surprising	surprising	ADJ
admet-2956	164	3	finding	finding	NOUN
admet-2956	164	4	raises	raise	VERB
admet-2956	164	5	questions	question	NOUN
admet-2956	164	6	about	about	ADP
admet-2956	164	7	established	establish	VERB
admet-2956	164	8	pd	pd	PROPN
admet-2956	164	9	-	-	PUNCT
admet-2956	164	10	l1	l1	NOUN
admet-2956	164	11	-	-	PUNCT
admet-2956	164	12	based	base	VERB
admet-2956	164	13	selection	selection	NOUN
admet-2956	164	14	criteria	criterion	NOUN
admet-2956	164	15	and	and	CCONJ
admet-2956	164	16	highlights	highlight	NOUN
admet-2956	164	17	the	the	DET
admet-2956	164	18	need	need	NOUN
admet-2956	164	19	for	for	ADP
admet-2956	164	20	further	further	ADJ
admet-2956	164	21	exploration	exploration	NOUN
admet-2956	164	22	of	of	ADP
admet-2956	164	23	alternative	alternative	ADJ
admet-2956	164	24	biomarker	biomarker	NOUN
admet-2956	164	25	approaches	approach	NOUN
admet-2956	164	26	.	.	PUNCT
admet-2956	165	1	the	the	DET
admet-2956	165	2	consistent	consistent	ADJ
admet-2956	165	3	benefit	benefit	NOUN
admet-2956	165	4	observed	observe	VERB
admet-2956	165	5	across	across	ADP
admet-2956	165	6	various	various	ADJ
admet-2956	165	7	pd	pd	PROPN
admet-2956	165	8	-	-	PUNCT
admet-2956	165	9	l1	l1	PROPN
admet-2956	165	10	expression	expression	NOUN
admet-2956	165	11	levels	level	NOUN
admet-2956	165	12	,	,	PUNCT
admet-2956	165	13	particularly	particularly	ADV
admet-2956	165	14	within	within	ADP
admet-2956	165	15	the	the	DET
admet-2956	165	16	historically	historically	ADV
admet-2956	165	17	regarded	regard	VERB
admet-2956	165	18	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	165	19	a.	a.	PROPN
admet-2956	165	20	chakramurty	chakramurty	PROPN
admet-2956	165	21	et	et	PROPN
admet-2956	165	22	al	al	PROPN
admet-2956	165	23	.	.	PROPN
admet-2956	165	24	admet	admet	PROPN
admet-2956	165	25	&	&	CCONJ
admet-2956	165	26	dmpk	dmpk	PROPN
admet-2956	165	27	13(5	13(5	NUM
admet-2956	165	28	)	)	PUNCT
admet-2956	165	29	(	(	PUNCT
admet-2956	165	30	2025	2025	NUM
admet-2956	165	31	)	)	PUNCT
admet-2956	165	32	2956	2956	NUM
admet-2956	165	33	10	10	NUM
admet-2956	165	34	"	"	PUNCT
admet-2956	165	35	biomarker	biomarker	NOUN
admet-2956	165	36	-	-	PUNCT
admet-2956	165	37	negative	negative	ADJ
admet-2956	165	38	"	"	PUNCT
admet-2956	165	39	group	group	NOUN
admet-2956	165	40	(	(	PUNCT
admet-2956	165	41	tps	tps	NOUN
admet-2956	165	42	<	<	X
admet-2956	165	43	1	1	NUM
admet-2956	165	44	%	%	NOUN
admet-2956	165	45	)	)	PUNCT
admet-2956	165	46	,	,	PUNCT
admet-2956	165	47	advocates	advocate	VERB
admet-2956	165	48	for	for	ADP
admet-2956	165	49	a	a	DET
admet-2956	165	50	broader	broad	ADJ
admet-2956	165	51	consideration	consideration	NOUN
admet-2956	165	52	of	of	ADP
admet-2956	165	53	therapeutic	therapeutic	ADJ
admet-2956	165	54	options	option	NOUN
admet-2956	165	55	beyond	beyond	ADP
admet-2956	165	56	the	the	DET
admet-2956	165	57	existing	exist	VERB
admet-2956	165	58	pd	pd	PROPN
admet-2956	165	59	-	-	PUNCT
admet-2956	165	60	l1	l1	ADJ
admet-2956	165	61	-	-	PUNCT
admet-2956	165	62	centric	centric	NOUN
admet-2956	165	63	selection	selection	NOUN
admet-2956	165	64	paradigms	paradigm	VERB
admet-2956	165	65	.	.	PUNCT
admet-2956	166	1	sensitivity	sensitivity	NOUN
admet-2956	166	2	analysis	analysis	NOUN
admet-2956	166	3	and	and	CCONJ
admet-2956	166	4	publication	publication	NOUN
admet-2956	166	5	bias	bias	NOUN
admet-2956	166	6	sensitivity	sensitivity	NOUN
admet-2956	166	7	analyses	analysis	NOUN
admet-2956	166	8	were	be	AUX
admet-2956	166	9	conducted	conduct	VERB
admet-2956	166	10	by	by	ADP
admet-2956	166	11	systematically	systematically	ADV
admet-2956	166	12	removing	remove	VERB
admet-2956	166	13	each	each	DET
admet-2956	166	14	study	study	NOUN
admet-2956	166	15	individually	individually	ADV
admet-2956	166	16	,	,	PUNCT
admet-2956	166	17	which	which	PRON
admet-2956	166	18	revealed	reveal	VERB
admet-2956	166	19	that	that	SCONJ
admet-2956	166	20	the	the	DET
admet-2956	166	21	primary	primary	ADJ
admet-2956	166	22	outcomes	outcome	NOUN
admet-2956	166	23	remained	remain	VERB
admet-2956	166	24	consistent	consistent	ADJ
admet-2956	166	25	throughout	throughout	ADP
admet-2956	166	26	these	these	DET
admet-2956	166	27	exclusions	exclusion	NOUN
admet-2956	166	28	.	.	PUNCT
admet-2956	167	1	this	this	DET
admet-2956	167	2	consistency	consistency	NOUN
admet-2956	167	3	demonstrates	demonstrate	VERB
admet-2956	167	4	minimal	minimal	ADJ
admet-2956	167	5	sensitivity	sensitivity	NOUN
admet-2956	167	6	and	and	CCONJ
admet-2956	167	7	reinforces	reinforce	VERB
admet-2956	167	8	the	the	DET
admet-2956	167	9	reliability	reliability	NOUN
admet-2956	167	10	and	and	CCONJ
admet-2956	167	11	stability	stability	NOUN
admet-2956	167	12	of	of	ADP
admet-2956	167	13	the	the	DET
admet-2956	167	14	findings	finding	NOUN
admet-2956	167	15	.	.	PUNCT
admet-2956	168	1	the	the	DET
admet-2956	168	2	prognostic	prognostic	ADJ
admet-2956	168	3	factors	factor	NOUN
admet-2956	168	4	in	in	ADP
admet-2956	168	5	the	the	DET
admet-2956	168	6	overall	overall	ADJ
admet-2956	168	7	study	study	NOUN
admet-2956	168	8	population	population	NOUN
admet-2956	168	9	remained	remain	VERB
admet-2956	168	10	unaffected	unaffected	ADJ
admet-2956	168	11	by	by	ADP
admet-2956	168	12	these	these	DET
admet-2956	168	13	sensitivity	sensitivity	NOUN
admet-2956	168	14	analyses	analysis	NOUN
admet-2956	168	15	.	.	PUNCT
admet-2956	169	1	assessment	assessment	NOUN
admet-2956	169	2	of	of	ADP
admet-2956	169	3	publication	publication	NOUN
admet-2956	169	4	bias	bias	NOUN
admet-2956	169	5	showed	show	VERB
admet-2956	169	6	no	no	DET
admet-2956	169	7	substantial	substantial	ADJ
admet-2956	169	8	bias	bias	NOUN
admet-2956	169	9	,	,	PUNCT
admet-2956	169	10	as	as	SCONJ
admet-2956	169	11	indicated	indicate	VERB
admet-2956	169	12	by	by	ADP
admet-2956	169	13	the	the	DET
admet-2956	169	14	symmetrical	symmetrical	ADJ
admet-2956	169	15	funnel	funnel	NOUN
admet-2956	169	16	plots	plot	NOUN
admet-2956	169	17	for	for	ADP
admet-2956	169	18	both	both	PRON
admet-2956	169	19	os	os	NOUN
admet-2956	169	20	and	and	CCONJ
admet-2956	169	21	pfs	pfs	PROPN
admet-2956	169	22	(	(	PUNCT
admet-2956	169	23	figure	figure	NOUN
admet-2956	169	24	4	4	NUM
admet-2956	169	25	)	)	PUNCT
admet-2956	169	26	,	,	PUNCT
admet-2956	169	27	as	as	ADV
admet-2956	169	28	well	well	ADV
admet-2956	169	29	as	as	ADP
admet-2956	169	30	for	for	ADP
admet-2956	169	31	the	the	DET
admet-2956	169	32	subgroup	subgroup	NOUN
admet-2956	169	33	analyses	analysis	NOUN
admet-2956	169	34	of	of	ADP
admet-2956	169	35	these	these	DET
admet-2956	169	36	endpoints	endpoint	NOUN
admet-2956	169	37	.	.	PUNCT
admet-2956	170	1	a	a	DET
admet-2956	170	2	lo	lo	NOUN
admet-2956	170	3	g	g	NOUN
admet-2956	170	4	r	r	NOUN
admet-2956	170	5	r	r	NOUN
admet-2956	170	6	rr	rr	PROPN
admet-2956	170	7	b	b	NOUN
admet-2956	170	8	lo	lo	PROPN
admet-2956	170	9	g	g	NOUN
admet-2956	170	10	h	h	NOUN
admet-2956	170	11	r	r	NOUN
admet-2956	170	12	hr	hr	NOUN
admet-2956	170	13	c	c	NOUN
admet-2956	171	1	lo	lo	NOUN
admet-2956	171	2	g	g	NOUN
admet-2956	171	3	h	h	NOUN
admet-2956	171	4	r	r	NOUN
admet-2956	171	5	hr	hr	NOUN
admet-2956	171	6	figure	figure	NOUN
admet-2956	171	7	4	4	NUM
admet-2956	171	8	.	.	PUNCT
admet-2956	172	1	funnel	funnel	NOUN
admet-2956	172	2	plots	plot	NOUN
admet-2956	172	3	for	for	ADP
admet-2956	172	4	(	(	PUNCT
admet-2956	172	5	a	a	X
admet-2956	172	6	)	)	PUNCT
admet-2956	172	7	orr	orr	NOUN
admet-2956	172	8	(	(	PUNCT
admet-2956	172	9	b	b	NOUN
admet-2956	172	10	)	)	PUNCT
admet-2956	172	11	os	os	NOUN
admet-2956	172	12	(	(	PUNCT
admet-2956	172	13	c	c	NOUN
admet-2956	172	14	)	)	PUNCT
admet-2956	172	15	pfs	pf	NOUN
admet-2956	172	16	between	between	ADP
admet-2956	172	17	pembrolizumab	pembrolizumab	NOUN
admet-2956	172	18	and	and	CCONJ
admet-2956	172	19	chemotherapy	chemotherapy	NOUN
admet-2956	172	20	these	these	DET
admet-2956	172	21	results	result	NOUN
admet-2956	172	22	strengthen	strengthen	VERB
admet-2956	172	23	the	the	DET
admet-2956	172	24	validity	validity	NOUN
admet-2956	172	25	of	of	ADP
admet-2956	172	26	the	the	DET
admet-2956	172	27	meta	meta	ADJ
admet-2956	172	28	-	-	PUNCT
admet-2956	172	29	analysis	analysis	NOUN
admet-2956	172	30	conclusions	conclusion	NOUN
admet-2956	172	31	and	and	CCONJ
admet-2956	172	32	suggest	suggest	VERB
admet-2956	172	33	that	that	SCONJ
admet-2956	172	34	the	the	DET
admet-2956	172	35	treatment	treatment	NOUN
admet-2956	172	36	effects	effect	NOUN
admet-2956	172	37	observed	observe	VERB
admet-2956	172	38	are	be	AUX
admet-2956	172	39	robust	robust	ADJ
admet-2956	172	40	and	and	CCONJ
admet-2956	172	41	not	not	PART
admet-2956	172	42	substantially	substantially	ADV
admet-2956	172	43	influenced	influence	VERB
admet-2956	172	44	by	by	ADP
admet-2956	172	45	selective	selective	ADJ
admet-2956	172	46	publication	publication	NOUN
admet-2956	172	47	practices	practice	NOUN
admet-2956	172	48	.	.	PUNCT
admet-2956	173	1	discussion	discussion	NOUN
admet-2956	173	2	primary	primary	ADJ
admet-2956	173	3	findings	finding	NOUN
admet-2956	173	4	in	in	ADP
admet-2956	173	5	context	context	NOUN
admet-2956	173	6	of	of	ADP
admet-2956	173	7	previous	previous	ADJ
admet-2956	173	8	research	research	NOUN
admet-2956	173	9	a	a	DET
admet-2956	173	10	pooled	pooled	ADJ
admet-2956	173	11	analysis	analysis	NOUN
admet-2956	173	12	revealed	reveal	VERB
admet-2956	173	13	a	a	DET
admet-2956	173	14	45	45	NUM
admet-2956	173	15	%	%	NOUN
admet-2956	173	16	reduction	reduction	NOUN
admet-2956	173	17	in	in	ADP
admet-2956	173	18	the	the	DET
admet-2956	173	19	risk	risk	NOUN
admet-2956	173	20	of	of	ADP
admet-2956	173	21	disease	disease	NOUN
admet-2956	173	22	progression	progression	NOUN
admet-2956	173	23	with	with	ADP
admet-2956	173	24	pembrolizumab	pembrolizumab	NOUN
admet-2956	173	25	(	(	PUNCT
admet-2956	173	26	hr	hr	NOUN
admet-2956	173	27	0.55	0.55	NUM
admet-2956	173	28	,	,	PUNCT
admet-2956	173	29	95	95	NUM
admet-2956	173	30	%	%	NOUN
admet-2956	173	31	ci	ci	NOUN
admet-2956	173	32	:	:	PUNCT
admet-2956	173	33	0.42	0.42	NUM
admet-2956	173	34	-	-	SYM
admet-2956	173	35	0.72	0.72	NUM
admet-2956	173	36	)	)	PUNCT
admet-2956	173	37	.	.	PUNCT
admet-2956	174	1	this	this	DET
admet-2956	174	2	effect	effect	NOUN
admet-2956	174	3	size	size	NOUN
admet-2956	174	4	was	be	AUX
admet-2956	174	5	not	not	PART
admet-2956	174	6	only	only	ADV
admet-2956	174	7	consistent	consistent	ADJ
admet-2956	174	8	with	with	ADP
admet-2956	174	9	but	but	CCONJ
admet-2956	174	10	,	,	PUNCT
admet-2956	174	11	in	in	ADP
admet-2956	174	12	some	some	DET
admet-2956	174	13	cases	case	NOUN
admet-2956	174	14	,	,	PUNCT
admet-2956	174	15	stronger	strong	ADJ
admet-2956	174	16	than	than	ADP
admet-2956	174	17	results	result	NOUN
admet-2956	174	18	from	from	ADP
admet-2956	174	19	individual	individual	ADJ
admet-2956	174	20	trials	trial	NOUN
admet-2956	174	21	such	such	ADJ
admet-2956	174	22	as	as	ADP
admet-2956	174	23	keynote-024	keynote-024	NOUN
admet-2956	174	24	(	(	PUNCT
admet-2956	174	25	hr	hr	NOUN
admet-2956	174	26	0.50	0.50	NUM
admet-2956	174	27	,	,	PUNCT
admet-2956	174	28	95	95	NUM
admet-2956	174	29	%	%	NOUN
admet-2956	174	30	ci	ci	NOUN
admet-2956	174	31	:	:	PUNCT
admet-2956	174	32	0.37	0.37	NUM
admet-2956	174	33	to	to	ADP
admet-2956	174	34	0.68	0.68	NUM
admet-2956	174	35	)	)	PUNCT
admet-2956	174	36	and	and	CCONJ
admet-2956	174	37	keynote-042	keynote-042	NOUN
admet-2956	174	38	(	(	PUNCT
admet-2956	174	39	hr	hr	NOUN
admet-2956	174	40	0.81	0.81	NUM
admet-2956	174	41	,	,	PUNCT
admet-2956	174	42	95	95	NUM
admet-2956	174	43	%	%	NOUN
admet-2956	174	44	ci	ci	NOUN
admet-2956	174	45	:	:	PUNCT
admet-2956	174	46	0.71	0.71	NUM
admet-2956	174	47	to	to	ADP
admet-2956	174	48	0.93	0.93	NUM
admet-2956	174	49	)	)	PUNCT
admet-2956	175	1	[	[	X
admet-2956	175	2	46	46	NUM
admet-2956	175	3	]	]	PUNCT
admet-2956	175	4	.	.	PUNCT
admet-2956	176	1	the	the	DET
admet-2956	176	2	twofold	twofold	NOUN
admet-2956	176	3	increase	increase	NOUN
admet-2956	176	4	in	in	ADP
admet-2956	176	5	objective	objective	ADJ
admet-2956	176	6	response	response	NOUN
admet-2956	176	7	rate	rate	NOUN
admet-2956	176	8	(	(	PUNCT
admet-2956	176	9	rr	rr	NOUN
admet-2956	176	10	2.10	2.10	NUM
admet-2956	176	11	,	,	PUNCT
admet-2956	176	12	95	95	NUM
admet-2956	176	13	%	%	NOUN
admet-2956	176	14	ci	ci	NOUN
admet-2956	176	15	:	:	PUNCT
admet-2956	176	16	1.51	1.51	NUM
admet-2956	176	17	to	to	ADP
admet-2956	176	18	2.93	2.93	NUM
admet-2956	176	19	)	)	PUNCT
admet-2956	176	20	further	far	ADV
admet-2956	176	21	illustrates	illustrate	VERB
admet-2956	176	22	pembrolizumab	pembrolizumab	NOUN
admet-2956	176	23	’s	’s	PART
admet-2956	176	24	potent	potent	ADJ
admet-2956	176	25	antitumor	antitumor	PROPN
admet-2956	176	26	activity	activity	NOUN
admet-2956	176	27	,	,	PUNCT
admet-2956	176	28	aligning	align	VERB
admet-2956	176	29	with	with	ADP
admet-2956	176	30	the	the	DET
admet-2956	176	31	established	establish	VERB
admet-2956	176	32	mechanism	mechanism	NOUN
admet-2956	176	33	of	of	ADP
admet-2956	176	34	checkpoint	checkpoint	NOUN
admet-2956	176	35	blockade	blockade	NOUN
admet-2956	176	36	that	that	PRON
admet-2956	176	37	restores	restore	VERB
admet-2956	176	38	t	t	NOUN
admet-2956	176	39	-	-	PUNCT
admet-2956	176	40	cell	cell	NOUN
admet-2956	176	41	-	-	PUNCT
admet-2956	176	42	mediated	mediate	VERB
admet-2956	176	43	immune	immune	ADJ
admet-2956	176	44	surveillance	surveillance	NOUN
admet-2956	177	1	[	[	X
admet-2956	177	2	49	49	NUM
admet-2956	177	3	]	]	PUNCT
admet-2956	177	4	.	.	PUNCT
admet-2956	178	1	one	one	NUM
admet-2956	178	2	of	of	ADP
admet-2956	178	3	the	the	DET
admet-2956	178	4	most	most	ADV
admet-2956	178	5	unexpected	unexpected	ADJ
admet-2956	178	6	findings	finding	NOUN
admet-2956	178	7	was	be	AUX
admet-2956	178	8	that	that	PRON
admet-2956	178	9	pd	pd	PROPN
admet-2956	178	10	-	-	PUNCT
admet-2956	178	11	l1	l1	PROPN
admet-2956	178	12	expression	expression	NOUN
admet-2956	178	13	did	do	AUX
admet-2956	178	14	not	not	PART
admet-2956	178	15	consistently	consistently	ADV
admet-2956	178	16	predict	predict	VERB
admet-2956	178	17	treatment	treatment	NOUN
admet-2956	178	18	response	response	NOUN
admet-2956	178	19	.	.	PUNCT
admet-2956	179	1	patients	patient	NOUN
admet-2956	179	2	with	with	ADP
admet-2956	179	3	a	a	DET
admet-2956	179	4	tps	tps	NOUN
admet-2956	179	5	below	below	ADP
admet-2956	179	6	1	1	NUM
admet-2956	179	7	%	%	NOUN
admet-2956	179	8	,	,	PUNCT
admet-2956	179	9	typically	typically	ADV
admet-2956	179	10	considered	consider	VERB
admet-2956	179	11	“	"	PUNCT
admet-2956	179	12	biomarker	biomarker	NOUN
admet-2956	179	13	-	-	PUNCT
admet-2956	179	14	negative	negative	ADJ
admet-2956	179	15	,	,	PUNCT
admet-2956	179	16	”	"	PUNCT
admet-2956	179	17	derived	derive	VERB
admet-2956	179	18	a	a	DET
admet-2956	179	19	clear	clear	ADJ
admet-2956	179	20	survival	survival	NOUN
admet-2956	179	21	benefit	benefit	NOUN
admet-2956	179	22	(	(	PUNCT
admet-2956	179	23	os	os	NOUN
admet-2956	179	24	hr	hr	NOUN
admet-2956	179	25	0.60	0.60	NUM
admet-2956	179	26	,	,	PUNCT
admet-2956	179	27	95	95	NUM
admet-2956	179	28	%	%	NOUN
admet-2956	179	29	ci	ci	NOUN
admet-2956	179	30	:	:	PUNCT
admet-2956	179	31	0.43	0.43	NUM
admet-2956	179	32	to	to	ADP
admet-2956	179	33	0.83	0.83	NUM
admet-2956	179	34	)	)	PUNCT
admet-2956	179	35	,	,	PUNCT
admet-2956	179	36	in	in	ADP
admet-2956	179	37	some	some	DET
admet-2956	179	38	instances	instance	NOUN
admet-2956	179	39	comparable	comparable	ADJ
admet-2956	179	40	to	to	ADP
admet-2956	179	41	those	those	PRON
admet-2956	179	42	with	with	ADP
admet-2956	179	43	higher	high	ADJ
admet-2956	179	44	pd	pd	PROPN
admet-2956	179	45	-	-	ADJ
admet-2956	179	46	l1	l1	PROPN
admet-2956	179	47	expression	expression	NOUN
admet-2956	179	48	[	[	X
admet-2956	179	49	50	50	NUM
admet-2956	179	50	]	]	PUNCT
admet-2956	179	51	.	.	PUNCT
admet-2956	180	1	this	this	PRON
admet-2956	180	2	challenges	challenge	VERB
admet-2956	180	3	the	the	DET
admet-2956	180	4	prevailing	prevail	VERB
admet-2956	180	5	paradigm	paradigm	NOUN
admet-2956	180	6	established	establish	VERB
admet-2956	180	7	by	by	ADP
admet-2956	180	8	early	early	ADJ
admet-2956	180	9	pembrolizumab	pembrolizumab	NOUN
admet-2956	180	10	trials	trial	NOUN
admet-2956	180	11	,	,	PUNCT
admet-2956	180	12	which	which	PRON
admet-2956	180	13	admet	admet	PROPN
admet-2956	180	14	&	&	CCONJ
admet-2956	180	15	dmpk	dmpk	PROPN
admet-2956	180	16	13(5	13(5	NOUN
admet-2956	180	17	)	)	PUNCT
admet-2956	180	18	(	(	PUNCT
admet-2956	180	19	2025	2025	NUM
admet-2956	180	20	)	)	PUNCT
admet-2956	180	21	2956	2956	NUM
admet-2956	180	22	pembrolizumab	pembrolizumab	NOUN
admet-2956	180	23	in	in	ADP
admet-2956	180	24	pd	pd	PROPN
admet-2956	180	25	-	-	PUNCT
admet-2956	180	26	l1	l1	PROPN
admet-2956	180	27	-	-	PUNCT
admet-2956	180	28	positive	positive	ADJ
admet-2956	180	29	advanced	advanced	ADJ
admet-2956	180	30	non	non	ADJ
admet-2956	180	31	-	-	ADJ
admet-2956	180	32	small	small	ADJ
admet-2956	180	33	cell	cell	NOUN
admet-2956	180	34	lung	lung	NOUN
admet-2956	180	35	carcinoma	carcinoma	NOUN
admet-2956	180	36	doi	doi	NOUN
admet-2956	180	37	:	:	PUNCT
admet-2956	180	38	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	X
admet-2956	180	39	11	11	NUM
admet-2956	180	40	restricted	restrict	VERB
admet-2956	180	41	monotherapy	monotherapy	NOUN
admet-2956	180	42	to	to	ADP
admet-2956	180	43	pd	pd	PROPN
admet-2956	180	44	-	-	PUNCT
admet-2956	180	45	l1	l1	PROPN
admet-2956	180	46	-	-	PUNCT
admet-2956	180	47	high	high	ADJ
admet-2956	180	48	populations	population	NOUN
admet-2956	180	49	(	(	PUNCT
admet-2956	180	50	tps	tps	NOUN
admet-2956	180	51	≥50	≥50	NOUN
admet-2956	180	52	%	%	NOUN
admet-2956	180	53	)	)	PUNCT
admet-2956	180	54	and	and	CCONJ
admet-2956	180	55	still	still	ADV
admet-2956	180	56	guides	guide	VERB
admet-2956	180	57	fda	fda	PROPN
admet-2956	180	58	approvals	approvals	PROPN
admet-2956	180	59	[	[	X
admet-2956	180	60	51	51	NUM
admet-2956	180	61	]	]	PUNCT
admet-2956	180	62	.	.	PUNCT
admet-2956	181	1	our	our	PRON
admet-2956	181	2	results	result	NOUN
admet-2956	181	3	support	support	VERB
admet-2956	181	4	accumulating	accumulate	VERB
admet-2956	181	5	real	real	ADJ
admet-2956	181	6	-	-	PUNCT
admet-2956	181	7	world	world	NOUN
admet-2956	181	8	evidence	evidence	NOUN
admet-2956	181	9	showing	show	VERB
admet-2956	181	10	that	that	SCONJ
admet-2956	181	11	pd	pd	PROPN
admet-2956	181	12	-	-	PROPN
admet-2956	181	13	l1	l1	PROPN
admet-2956	181	14	alone	alone	ADV
admet-2956	181	15	can	can	AUX
admet-2956	181	16	not	not	PART
admet-2956	181	17	capture	capture	VERB
admet-2956	181	18	the	the	DET
admet-2956	181	19	complexity	complexity	NOUN
admet-2956	181	20	of	of	ADP
admet-2956	181	21	tumour	tumour	ADJ
admet-2956	181	22	-	-	PUNCT
admet-2956	181	23	immune	immune	ADJ
admet-2956	181	24	interactions	interaction	NOUN
admet-2956	181	25	that	that	PRON
admet-2956	181	26	shape	shape	VERB
admet-2956	181	27	responses	response	NOUN
admet-2956	181	28	to	to	ADP
admet-2956	181	29	immunotherapy	immunotherapy	NOUN
admet-2956	181	30	[	[	X
admet-2956	181	31	52	52	NUM
admet-2956	181	32	]	]	PUNCT
admet-2956	181	33	.	.	PUNCT
admet-2956	182	1	age	age	NOUN
admet-2956	182	2	and	and	CCONJ
admet-2956	182	3	sex	sex	NOUN
admet-2956	182	4	also	also	ADV
admet-2956	182	5	emerged	emerge	VERB
admet-2956	182	6	as	as	ADP
admet-2956	182	7	significant	significant	ADJ
admet-2956	182	8	modifiers	modifier	NOUN
admet-2956	182	9	of	of	ADP
admet-2956	182	10	treatment	treatment	NOUN
admet-2956	182	11	effect	effect	NOUN
admet-2956	182	12	.	.	PUNCT
admet-2956	183	1	younger	young	ADJ
admet-2956	183	2	patients	patient	NOUN
admet-2956	183	3	(	(	PUNCT
admet-2956	183	4	<	<	X
admet-2956	183	5	65	65	NUM
admet-2956	183	6	years	year	NOUN
admet-2956	183	7	)	)	PUNCT
admet-2956	183	8	experienced	experience	VERB
admet-2956	183	9	substantially	substantially	ADV
admet-2956	183	10	greater	great	ADJ
admet-2956	183	11	benefit	benefit	NOUN
admet-2956	183	12	than	than	ADP
admet-2956	183	13	older	old	ADJ
admet-2956	183	14	patients	patient	NOUN
admet-2956	183	15	(	(	PUNCT
admet-2956	183	16	os	os	NOUN
admet-2956	183	17	hr	hr	NOUN
admet-2956	183	18	0.55	0.55	NUM
admet-2956	183	19	vs.	vs.	ADP
admet-2956	183	20	0.72	0.72	NUM
admet-2956	183	21	)	)	PUNCT
admet-2956	183	22	,	,	PUNCT
admet-2956	183	23	suggesting	suggest	VERB
admet-2956	183	24	immune	immune	ADJ
admet-2956	183	25	senescence	senescence	NOUN
admet-2956	183	26	may	may	AUX
admet-2956	183	27	blunt	blunt	VERB
admet-2956	183	28	checkpoint	checkpoint	NOUN
admet-2956	183	29	inhibitor	inhibitor	NOUN
admet-2956	183	30	efficacy	efficacy	NOUN
admet-2956	183	31	.	.	PUNCT
admet-2956	184	1	this	this	PRON
admet-2956	184	2	aligns	align	VERB
admet-2956	184	3	with	with	ADP
admet-2956	184	4	evidence	evidence	NOUN
admet-2956	184	5	of	of	ADP
admet-2956	184	6	reduced	reduce	VERB
admet-2956	184	7	t	t	PROPN
admet-2956	184	8	-	-	PUNCT
admet-2956	184	9	cell	cell	NOUN
admet-2956	184	10	function	function	NOUN
admet-2956	184	11	and	and	CCONJ
admet-2956	184	12	immune	immune	ADJ
admet-2956	184	13	surveillance	surveillance	NOUN
admet-2956	184	14	with	with	ADP
admet-2956	184	15	aging	age	VERB
admet-2956	184	16	[	[	X
admet-2956	184	17	53	53	NUM
admet-2956	184	18	]	]	PUNCT
admet-2956	184	19	.	.	PUNCT
admet-2956	185	1	similarly	similarly	ADV
admet-2956	185	2	,	,	PUNCT
admet-2956	185	3	women	woman	NOUN
admet-2956	185	4	demonstrated	demonstrate	VERB
admet-2956	185	5	greater	great	ADJ
admet-2956	185	6	survival	survival	NOUN
admet-2956	185	7	benefit	benefit	NOUN
admet-2956	185	8	(	(	PUNCT
admet-2956	185	9	os	os	NOUN
admet-2956	185	10	hr	hr	NOUN
admet-2956	185	11	0.44	0.44	NUM
admet-2956	185	12	vs.	vs.	ADP
admet-2956	185	13	0.67	0.67	NUM
admet-2956	185	14	in	in	ADP
admet-2956	185	15	men	man	NOUN
admet-2956	185	16	)	)	PUNCT
admet-2956	185	17	,	,	PUNCT
admet-2956	185	18	consistent	consistent	ADJ
admet-2956	185	19	with	with	ADP
admet-2956	185	20	the	the	DET
admet-2956	185	21	known	know	VERB
admet-2956	185	22	sexual	sexual	ADJ
admet-2956	185	23	dimorphism	dimorphism	NOUN
admet-2956	185	24	in	in	ADP
admet-2956	185	25	immune	immune	ADJ
admet-2956	185	26	responses	response	NOUN
admet-2956	185	27	[	[	X
admet-2956	185	28	54	54	NUM
admet-2956	185	29	]	]	PUNCT
admet-2956	185	30	.	.	PUNCT
admet-2956	186	1	these	these	DET
admet-2956	186	2	findings	finding	NOUN
admet-2956	186	3	suggest	suggest	VERB
admet-2956	186	4	that	that	SCONJ
admet-2956	186	5	demographic	demographic	ADJ
admet-2956	186	6	factors	factor	NOUN
admet-2956	186	7	,	,	PUNCT
admet-2956	186	8	often	often	ADV
admet-2956	186	9	overlooked	overlook	VERB
admet-2956	186	10	in	in	ADP
admet-2956	186	11	patient	patient	ADJ
admet-2956	186	12	selection	selection	NOUN
admet-2956	186	13	,	,	PUNCT
admet-2956	186	14	may	may	AUX
admet-2956	186	15	meaningfully	meaningfully	ADV
admet-2956	186	16	shape	shape	VERB
admet-2956	186	17	outcomes	outcome	NOUN
admet-2956	186	18	and	and	CCONJ
admet-2956	186	19	should	should	AUX
admet-2956	186	20	be	be	AUX
admet-2956	186	21	considered	consider	VERB
admet-2956	186	22	alongside	alongside	ADP
admet-2956	186	23	molecular	molecular	ADJ
admet-2956	186	24	biomarkers	biomarker	NOUN
admet-2956	186	25	.	.	PUNCT
admet-2956	187	1	the	the	DET
admet-2956	187	2	most	most	ADV
admet-2956	187	3	clinically	clinically	ADV
admet-2956	187	4	significant	significant	ADJ
admet-2956	187	5	implication	implication	NOUN
admet-2956	187	6	of	of	ADP
admet-2956	187	7	our	our	PRON
admet-2956	187	8	study	study	NOUN
admet-2956	187	9	is	be	AUX
admet-2956	187	10	the	the	DET
admet-2956	187	11	strong	strong	ADJ
admet-2956	187	12	efficacy	efficacy	NOUN
admet-2956	187	13	signal	signal	NOUN
admet-2956	187	14	in	in	ADP
admet-2956	187	15	patients	patient	NOUN
admet-2956	187	16	with	with	ADP
admet-2956	187	17	low	low	ADJ
admet-2956	187	18	or	or	CCONJ
admet-2956	187	19	negative	negative	ADJ
admet-2956	187	20	pd	pd	ADJ
admet-2956	187	21	-	-	PUNCT
admet-2956	187	22	l1	l1	PROPN
admet-2956	187	23	expression	expression	NOUN
admet-2956	187	24	,	,	PUNCT
admet-2956	187	25	a	a	DET
admet-2956	187	26	population	population	NOUN
admet-2956	187	27	currently	currently	ADV
admet-2956	187	28	excluded	exclude	VERB
admet-2956	187	29	from	from	ADP
admet-2956	187	30	pembrolizumab	pembrolizumab	NOUN
admet-2956	187	31	monotherapy	monotherapy	NOUN
admet-2956	187	32	under	under	ADP
admet-2956	187	33	most	most	ADJ
admet-2956	187	34	treatment	treatment	NOUN
admet-2956	187	35	guidelines	guideline	NOUN
admet-2956	187	36	.	.	PUNCT
admet-2956	188	1	extending	extend	VERB
admet-2956	188	2	eligibility	eligibility	NOUN
admet-2956	188	3	to	to	ADP
admet-2956	188	4	this	this	DET
admet-2956	188	5	group	group	NOUN
admet-2956	188	6	could	could	AUX
admet-2956	188	7	expand	expand	VERB
admet-2956	188	8	therapeutic	therapeutic	ADJ
admet-2956	188	9	options	option	NOUN
admet-2956	188	10	for	for	ADP
admet-2956	188	11	up	up	ADP
admet-2956	188	12	to	to	PART
admet-2956	188	13	30	30	NUM
admet-2956	188	14	to	to	PART
admet-2956	188	15	40	40	NUM
admet-2956	188	16	%	%	NOUN
admet-2956	188	17	of	of	ADP
admet-2956	188	18	advanced	advanced	ADJ
admet-2956	188	19	nsclc	nsclc	NOUN
admet-2956	188	20	patients	patient	NOUN
admet-2956	188	21	who	who	PRON
admet-2956	188	22	are	be	AUX
admet-2956	188	23	currently	currently	ADV
admet-2956	188	24	treated	treat	VERB
admet-2956	188	25	with	with	ADP
admet-2956	188	26	chemotherapy	chemotherapy	NOUN
admet-2956	188	27	alone	alone	ADV
admet-2956	188	28	[	[	X
admet-2956	188	29	55	55	NUM
admet-2956	188	30	]	]	PUNCT
admet-2956	188	31	.	.	PUNCT
admet-2956	189	1	the	the	DET
admet-2956	189	2	biological	biological	ADJ
admet-2956	189	3	basis	basis	NOUN
admet-2956	189	4	of	of	ADP
admet-2956	189	5	this	this	DET
admet-2956	189	6	pd	pd	PROPN
admet-2956	189	7	-	-	PROPN
admet-2956	189	8	l1	l1	PROPN
admet-2956	189	9	paradox	paradox	NOUN
admet-2956	189	10	is	be	AUX
admet-2956	189	11	likely	likely	ADV
admet-2956	189	12	multifactorial	multifactorial	ADJ
admet-2956	189	13	,	,	PUNCT
admet-2956	189	14	involving	involve	VERB
admet-2956	189	15	intratumoral	intratumoral	ADJ
admet-2956	189	16	heterogeneity	heterogeneity	NOUN
admet-2956	189	17	,	,	PUNCT
admet-2956	189	18	temporal	temporal	ADJ
admet-2956	189	19	variation	variation	NOUN
admet-2956	189	20	in	in	ADP
admet-2956	189	21	pd	pd	PROPN
admet-2956	189	22	-	-	PROPN
admet-2956	189	23	l1	l1	PROPN
admet-2956	189	24	expression	expression	NOUN
admet-2956	189	25	,	,	PUNCT
admet-2956	189	26	and	and	CCONJ
admet-2956	189	27	inflammation	inflammation	NOUN
admet-2956	189	28	-	-	PUNCT
admet-2956	189	29	induced	induce	VERB
admet-2956	189	30	changes	change	NOUN
admet-2956	189	31	during	during	ADP
admet-2956	189	32	therapy	therapy	NOUN
admet-2956	189	33	[	[	X
admet-2956	189	34	56	56	NUM
admet-2956	189	35	]	]	PUNCT
admet-2956	189	36	.	.	PUNCT
admet-2956	190	1	other	other	ADJ
admet-2956	190	2	contributors	contributor	NOUN
admet-2956	190	3	may	may	AUX
admet-2956	190	4	include	include	VERB
admet-2956	190	5	immune	immune	ADJ
admet-2956	190	6	cell	cell	NOUN
admet-2956	190	7	pd	pd	PROPN
admet-2956	190	8	-	-	PROPN
admet-2956	190	9	l1	l1	PROPN
admet-2956	190	10	expression	expression	NOUN
admet-2956	190	11	and	and	CCONJ
admet-2956	190	12	additional	additional	ADJ
admet-2956	190	13	checkpoint	checkpoint	NOUN
admet-2956	190	14	pathways	pathway	NOUN
admet-2956	191	1	[	[	X
admet-2956	191	2	57	57	NUM
admet-2956	191	3	]	]	PUNCT
admet-2956	191	4	.	.	PUNCT
admet-2956	192	1	together	together	ADV
admet-2956	192	2	,	,	PUNCT
admet-2956	192	3	these	these	DET
admet-2956	192	4	factors	factor	NOUN
admet-2956	192	5	highlight	highlight	VERB
admet-2956	192	6	the	the	DET
admet-2956	192	7	limitations	limitation	NOUN
admet-2956	192	8	of	of	ADP
admet-2956	192	9	pd	pd	PROPN
admet-2956	192	10	-	-	PROPN
admet-2956	192	11	l1	l1	PROPN
admet-2956	192	12	as	as	ADP
admet-2956	192	13	a	a	DET
admet-2956	192	14	standalone	standalone	NOUN
admet-2956	192	15	biomarker	biomarker	NOUN
admet-2956	192	16	.	.	PUNCT
admet-2956	193	1	our	our	PRON
admet-2956	193	2	subgroup	subgroup	NOUN
admet-2956	193	3	analyses	analysis	NOUN
admet-2956	193	4	provide	provide	VERB
admet-2956	193	5	biologically	biologically	ADV
admet-2956	193	6	plausible	plausible	ADJ
admet-2956	193	7	insights	insight	NOUN
admet-2956	193	8	that	that	PRON
admet-2956	193	9	have	have	VERB
admet-2956	193	10	immediate	immediate	ADJ
admet-2956	193	11	clinical	clinical	ADJ
admet-2956	193	12	relevance	relevance	NOUN
admet-2956	193	13	.	.	PUNCT
admet-2956	194	1	younger	young	ADJ
admet-2956	194	2	patients	patient	NOUN
admet-2956	194	3	’	'	PUNCT
admet-2956	194	4	stronger	strong	ADJ
admet-2956	194	5	immune	immune	ADJ
admet-2956	194	6	systems	system	NOUN
admet-2956	194	7	likely	likely	ADV
admet-2956	194	8	underpin	underpin	VERB
admet-2956	194	9	their	their	PRON
admet-2956	194	10	improved	improved	ADJ
admet-2956	194	11	responses	response	NOUN
admet-2956	194	12	[	[	X
admet-2956	194	13	58	58	NUM
admet-2956	194	14	]	]	PUNCT
admet-2956	194	15	,	,	PUNCT
admet-2956	194	16	whereas	whereas	SCONJ
admet-2956	194	17	immune	immune	ADJ
admet-2956	194	18	senescence	senescence	NOUN
admet-2956	194	19	in	in	ADP
admet-2956	194	20	older	old	ADJ
admet-2956	194	21	individuals	individual	NOUN
admet-2956	194	22	characterized	characterize	VERB
admet-2956	194	23	by	by	ADP
admet-2956	194	24	thymic	thymic	ADJ
admet-2956	194	25	atrophy	atrophy	NOUN
admet-2956	194	26	,	,	PUNCT
admet-2956	194	27	t	t	NOUN
admet-2956	194	28	-	-	PUNCT
admet-2956	194	29	cell	cell	NOUN
admet-2956	194	30	exhaustion	exhaustion	NOUN
admet-2956	194	31	,	,	PUNCT
admet-2956	194	32	and	and	CCONJ
admet-2956	194	33	chronic	chronic	ADJ
admet-2956	194	34	inflamemation	inflamemation	NOUN
admet-2956	194	35	may	may	AUX
admet-2956	194	36	diminish	diminish	VERB
admet-2956	194	37	benefit	benefit	NOUN
admet-2956	194	38	[	[	X
admet-2956	194	39	59	59	NUM
admet-2956	194	40	]	]	PUNCT
admet-2956	194	41	.	.	PUNCT
admet-2956	195	1	likewise	likewise	ADV
admet-2956	195	2	,	,	PUNCT
admet-2956	195	3	women	woman	NOUN
admet-2956	195	4	’s	’s	PART
admet-2956	195	5	more	more	ADV
admet-2956	195	6	active	active	ADJ
admet-2956	195	7	immune	immune	ADJ
admet-2956	195	8	responses	response	NOUN
admet-2956	195	9	,	,	PUNCT
admet-2956	195	10	while	while	SCONJ
admet-2956	195	11	predisposing	predispose	VERB
admet-2956	195	12	them	they	PRON
admet-2956	195	13	to	to	ADP
admet-2956	195	14	autoimmunity	autoimmunity	NOUN
admet-2956	195	15	,	,	PUNCT
admet-2956	195	16	may	may	AUX
admet-2956	195	17	increase	increase	VERB
admet-2956	195	18	sensitivity	sensitivity	NOUN
admet-2956	195	19	to	to	PART
admet-2956	195	20	checkpoint	checkpoint	VERB
admet-2956	195	21	blockade	blockade	NOUN
admet-2956	195	22	[	[	X
admet-2956	195	23	60	60	NUM
admet-2956	195	24	]	]	PUNCT
admet-2956	195	25	.	.	PUNCT
admet-2956	196	1	these	these	DET
admet-2956	196	2	differences	difference	NOUN
admet-2956	196	3	emphasize	emphasize	VERB
admet-2956	196	4	the	the	DET
admet-2956	196	5	need	need	NOUN
admet-2956	196	6	for	for	ADP
admet-2956	196	7	treatment	treatment	NOUN
admet-2956	196	8	strategies	strategy	NOUN
admet-2956	196	9	that	that	PRON
admet-2956	196	10	account	account	VERB
admet-2956	196	11	for	for	ADP
admet-2956	196	12	patient	patient	ADJ
admet-2956	196	13	demographics	demographic	NOUN
admet-2956	196	14	as	as	ADV
admet-2956	196	15	well	well	ADV
admet-2956	196	16	as	as	ADP
admet-2956	196	17	tumour	tumour	ADJ
admet-2956	196	18	biology	biology	NOUN
admet-2956	196	19	.	.	PUNCT
admet-2956	197	1	safety	safety	NOUN
admet-2956	197	2	findings	finding	NOUN
admet-2956	197	3	were	be	AUX
admet-2956	197	4	consistent	consistent	ADJ
admet-2956	197	5	with	with	ADP
admet-2956	197	6	prior	prior	ADJ
admet-2956	197	7	reports	report	NOUN
admet-2956	197	8	.	.	PUNCT
admet-2956	198	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	198	2	was	be	AUX
admet-2956	198	3	associated	associate	VERB
admet-2956	198	4	with	with	ADP
admet-2956	198	5	immune	immune	NOUN
admet-2956	198	6	-	-	PUNCT
admet-2956	198	7	related	relate	VERB
admet-2956	198	8	toxicities	toxicity	NOUN
admet-2956	198	9	such	such	ADJ
admet-2956	198	10	as	as	ADP
admet-2956	198	11	pneumonitis	pneumonitis	NOUN
admet-2956	198	12	(	(	PUNCT
admet-2956	198	13	4	4	NUM
admet-2956	198	14	to	to	PART
admet-2956	198	15	9.9	9.9	NUM
admet-2956	198	16	%	%	NOUN
admet-2956	198	17	)	)	PUNCT
admet-2956	198	18	and	and	CCONJ
admet-2956	198	19	hypothyroidism	hypothyroidism	NOUN
admet-2956	198	20	(	(	PUNCT
admet-2956	198	21	7.9	7.9	NUM
admet-2956	198	22	to	to	PART
admet-2956	198	23	15.3	15.3	NUM
admet-2956	198	24	%	%	NOUN
admet-2956	198	25	)	)	PUNCT
admet-2956	198	26	,	,	PUNCT
admet-2956	198	27	but	but	CCONJ
admet-2956	198	28	these	these	DET
admet-2956	198	29	events	event	NOUN
admet-2956	198	30	were	be	AUX
admet-2956	198	31	generally	generally	ADV
admet-2956	198	32	manageable	manageable	ADJ
admet-2956	198	33	.	.	PUNCT
admet-2956	199	1	importantly	importantly	ADV
admet-2956	199	2	,	,	PUNCT
admet-2956	199	3	pembrolizumab	pembrolizumab	NOUN
admet-2956	199	4	carried	carry	VERB
admet-2956	199	5	a	a	DET
admet-2956	199	6	markedly	markedly	ADV
admet-2956	199	7	lower	low	ADJ
admet-2956	199	8	risk	risk	NOUN
admet-2956	199	9	of	of	ADP
admet-2956	199	10	hematologic	hematologic	NOUN
admet-2956	199	11	toxicities	toxicity	NOUN
admet-2956	199	12	such	such	ADJ
admet-2956	199	13	as	as	ADP
admet-2956	199	14	severe	severe	ADJ
admet-2956	199	15	neutropenia	neutropenia	NOUN
admet-2956	199	16	(	(	PUNCT
admet-2956	199	17	0	0	NUM
admet-2956	199	18	to	to	PART
admet-2956	199	19	23	23	NUM
admet-2956	199	20	%	%	NOUN
admet-2956	199	21	vs.	vs.	ADP
admet-2956	199	22	2	2	NUM
admet-2956	199	23	to	to	PART
admet-2956	199	24	25	25	NUM
admet-2956	199	25	%	%	NOUN
admet-2956	199	26	with	with	ADP
admet-2956	199	27	chemotherapy	chemotherapy	NOUN
admet-2956	199	28	)	)	PUNCT
admet-2956	200	1	[	[	X
admet-2956	200	2	61	61	NUM
admet-2956	200	3	]	]	PUNCT
admet-2956	200	4	.	.	PUNCT
admet-2956	201	1	this	this	DET
admet-2956	201	2	favourable	favourable	ADJ
admet-2956	201	3	safety	safety	NOUN
admet-2956	201	4	profile	profile	NOUN
admet-2956	201	5	is	be	AUX
admet-2956	201	6	particularly	particularly	ADV
admet-2956	201	7	relevant	relevant	ADJ
admet-2956	201	8	for	for	ADP
admet-2956	201	9	older	old	ADJ
admet-2956	201	10	patients	patient	NOUN
admet-2956	201	11	,	,	PUNCT
admet-2956	201	12	those	those	PRON
admet-2956	201	13	with	with	ADP
admet-2956	201	14	comorbidities	comorbiditie	NOUN
admet-2956	201	15	,	,	PUNCT
admet-2956	201	16	or	or	CCONJ
admet-2956	201	17	individuals	individual	NOUN
admet-2956	201	18	with	with	ADP
admet-2956	201	19	poor	poor	ADJ
admet-2956	201	20	performance	performance	NOUN
admet-2956	201	21	status	status	NOUN
admet-2956	201	22	who	who	PRON
admet-2956	201	23	may	may	AUX
admet-2956	201	24	not	not	PART
admet-2956	201	25	tolerate	tolerate	VERB
admet-2956	201	26	chemotherapy	chemotherapy	NOUN
admet-2956	201	27	.	.	PUNCT
admet-2956	202	1	the	the	DET
admet-2956	202	2	high	high	ADJ
admet-2956	202	3	heterogeneity	heterogeneity	NOUN
admet-2956	202	4	observed	observe	VERB
admet-2956	202	5	in	in	ADP
admet-2956	202	6	pfs	pfs	ADJ
admet-2956	202	7	analysis	analysis	NOUN
admet-2956	202	8	reflects	reflect	VERB
admet-2956	202	9	differences	difference	NOUN
admet-2956	202	10	in	in	ADP
admet-2956	202	11	trial	trial	NOUN
admet-2956	202	12	populations	population	NOUN
admet-2956	202	13	,	,	PUNCT
admet-2956	202	14	pd	pd	PROPN
admet-2956	202	15	-	-	PUNCT
admet-2956	202	16	l1	l1	PROPN
admet-2956	202	17	assays	assay	NOUN
admet-2956	202	18	,	,	PUNCT
admet-2956	202	19	and	and	CCONJ
admet-2956	202	20	comparator	comparator	NOUN
admet-2956	202	21	regimens	regimen	NOUN
admet-2956	202	22	.	.	PUNCT
admet-2956	203	1	while	while	SCONJ
admet-2956	203	2	this	this	PRON
admet-2956	203	3	reduces	reduce	VERB
admet-2956	203	4	precision	precision	NOUN
admet-2956	203	5	,	,	PUNCT
admet-2956	203	6	it	it	PRON
admet-2956	203	7	increases	increase	VERB
admet-2956	203	8	generalizability	generalizability	NOUN
admet-2956	203	9	by	by	ADP
admet-2956	203	10	better	well	ADV
admet-2956	203	11	reflecting	reflect	VERB
admet-2956	203	12	realworld	realworld	PROPN
admet-2956	203	13	variation	variation	NOUN
admet-2956	203	14	[	[	X
admet-2956	203	15	62	62	NUM
admet-2956	203	16	]	]	PUNCT
admet-2956	203	17	.	.	PUNCT
admet-2956	204	1	still	still	ADV
admet-2956	204	2	,	,	PUNCT
admet-2956	204	3	reliance	reliance	NOUN
admet-2956	204	4	on	on	ADP
admet-2956	204	5	trial	trial	NOUN
admet-2956	204	6	populations	population	NOUN
admet-2956	204	7	limits	limit	VERB
admet-2956	204	8	applicability	applicability	NOUN
admet-2956	204	9	to	to	PART
admet-2956	204	10	routine	routine	ADJ
admet-2956	204	11	practice	practice	NOUN
admet-2956	204	12	,	,	PUNCT
admet-2956	204	13	where	where	SCONJ
admet-2956	204	14	patients	patient	NOUN
admet-2956	204	15	often	often	ADV
admet-2956	204	16	have	have	VERB
admet-2956	204	17	greater	great	ADJ
admet-2956	204	18	comorbidity	comorbidity	NOUN
admet-2956	204	19	and	and	CCONJ
admet-2956	204	20	lower	low	ADJ
admet-2956	204	21	performance	performance	NOUN
admet-2956	204	22	status	status	NOUN
admet-2956	204	23	.	.	PUNCT
admet-2956	205	1	the	the	DET
admet-2956	205	2	geographic	geographic	ADJ
admet-2956	205	3	underrepresentation	underrepresentation	NOUN
admet-2956	205	4	of	of	ADP
admet-2956	205	5	asian	asian	ADJ
admet-2956	205	6	populations	population	NOUN
admet-2956	205	7	further	far	ADV
admet-2956	205	8	limits	limit	VERB
admet-2956	205	9	the	the	DET
admet-2956	205	10	external	external	ADJ
admet-2956	205	11	validity	validity	NOUN
admet-2956	205	12	[	[	X
admet-2956	205	13	63	63	NUM
admet-2956	205	14	]	]	PUNCT
admet-2956	205	15	.	.	PUNCT
admet-2956	206	1	our	our	PRON
admet-2956	206	2	findings	finding	NOUN
admet-2956	206	3	underscore	underscore	VERB
admet-2956	206	4	the	the	DET
admet-2956	206	5	urgent	urgent	ADJ
admet-2956	206	6	need	need	NOUN
admet-2956	206	7	for	for	ADP
admet-2956	206	8	more	more	ADV
admet-2956	206	9	sophisticated	sophisticated	ADJ
admet-2956	206	10	biomarkers	biomarker	NOUN
admet-2956	206	11	beyond	beyond	ADP
admet-2956	206	12	pd	pd	NOUN
admet-2956	206	13	-	-	PUNCT
admet-2956	206	14	l1	l1	PROPN
admet-2956	206	15	.	.	PUNCT
admet-2956	207	1	composite	composite	ADJ
admet-2956	207	2	approaches	approach	NOUN
admet-2956	207	3	incorporating	incorporate	VERB
admet-2956	207	4	tumour	tumour	ADJ
admet-2956	207	5	mutational	mutational	ADJ
admet-2956	207	6	burden	burden	NOUN
admet-2956	207	7	,	,	PUNCT
admet-2956	207	8	immune	immune	ADJ
admet-2956	207	9	gene	gene	NOUN
admet-2956	207	10	signatures	signature	NOUN
admet-2956	207	11	,	,	PUNCT
admet-2956	207	12	circulating	circulate	VERB
admet-2956	207	13	biomarkers	biomarker	NOUN
admet-2956	207	14	,	,	PUNCT
admet-2956	207	15	and	and	CCONJ
admet-2956	207	16	ai	ai	AUX
admet-2956	207	17	-	-	PUNCT
admet-2956	207	18	driven	drive	VERB
admet-2956	207	19	imaging	imaging	NOUN
admet-2956	207	20	hold	hold	VERB
admet-2956	207	21	promise	promise	NOUN
admet-2956	207	22	[	[	X
admet-2956	207	23	64	64	NUM
admet-2956	207	24	]	]	PUNCT
admet-2956	207	25	.	.	PUNCT
admet-2956	208	1	advances	advance	NOUN
admet-2956	208	2	in	in	ADP
admet-2956	208	3	liquid	liquid	ADJ
admet-2956	208	4	biopsy	biopsy	NOUN
admet-2956	208	5	technology	technology	NOUN
admet-2956	208	6	,	,	PUNCT
admet-2956	208	7	including	include	VERB
admet-2956	208	8	circulating	circulate	VERB
admet-2956	208	9	tumour	tumour	ADJ
admet-2956	208	10	dna	dna	NOUN
admet-2956	208	11	and	and	CCONJ
admet-2956	208	12	immune	immune	ADJ
admet-2956	208	13	profiling	profiling	NOUN
admet-2956	208	14	,	,	PUNCT
admet-2956	208	15	could	could	AUX
admet-2956	208	16	enable	enable	VERB
admet-2956	208	17	real	real	ADJ
admet-2956	208	18	-	-	PUNCT
admet-2956	208	19	time	time	NOUN
admet-2956	208	20	monitoring	monitoring	NOUN
admet-2956	208	21	of	of	ADP
admet-2956	208	22	treatment	treatment	NOUN
admet-2956	208	23	response	response	NOUN
admet-2956	208	24	[	[	X
admet-2956	208	25	65	65	NUM
admet-2956	208	26	]	]	PUNCT
admet-2956	208	27	.	.	PUNCT
admet-2956	209	1	although	although	SCONJ
admet-2956	209	2	our	our	PRON
admet-2956	209	3	analysis	analysis	NOUN
admet-2956	209	4	focused	focus	VERB
admet-2956	209	5	on	on	ADP
admet-2956	209	6	pembrolizumab	pembrolizumab	NOUN
admet-2956	209	7	monotherapy	monotherapy	NOUN
admet-2956	209	8	,	,	PUNCT
admet-2956	209	9	future	future	ADJ
admet-2956	209	10	progress	progress	NOUN
admet-2956	209	11	will	will	AUX
admet-2956	209	12	likely	likely	ADV
admet-2956	209	13	depend	depend	VERB
admet-2956	209	14	on	on	ADP
admet-2956	209	15	rational	rational	ADJ
admet-2956	209	16	combination	combination	NOUN
admet-2956	209	17	strategies	strategy	NOUN
admet-2956	209	18	with	with	ADP
admet-2956	209	19	chemotherapy	chemotherapy	NOUN
admet-2956	209	20	,	,	PUNCT
admet-2956	209	21	anti	anti	ADJ
admet-2956	209	22	-	-	ADJ
admet-2956	209	23	angiogenic	angiogenic	ADJ
admet-2956	209	24	agents	agent	NOUN
admet-2956	209	25	,	,	PUNCT
admet-2956	209	26	and	and	CCONJ
admet-2956	209	27	novel	novel	ADJ
admet-2956	209	28	immunomodulators	immunomodulator	NOUN
admet-2956	209	29	[	[	X
admet-2956	209	30	66	66	NUM
admet-2956	209	31	]	]	PUNCT
admet-2956	209	32	.	.	PUNCT
admet-2956	210	1	the	the	DET
admet-2956	210	2	observed	observe	VERB
admet-2956	210	3	demographic	demographic	ADJ
admet-2956	210	4	differences	difference	NOUN
admet-2956	210	5	suggest	suggest	VERB
admet-2956	210	6	tailoring	tailor	VERB
admet-2956	210	7	these	these	DET
admet-2956	210	8	combinations	combination	NOUN
admet-2956	210	9	to	to	PART
admet-2956	210	10	patient	patient	VERB
admet-2956	210	11	subgroups	subgroup	NOUN
admet-2956	210	12	may	may	AUX
admet-2956	210	13	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	210	14	a.	a.	PROPN
admet-2956	210	15	chakramurty	chakramurty	PROPN
admet-2956	210	16	et	et	PROPN
admet-2956	210	17	al	al	PROPN
admet-2956	210	18	.	.	PROPN
admet-2956	210	19	admet	admet	PROPN
admet-2956	210	20	&	&	CCONJ
admet-2956	210	21	dmpk	dmpk	PROPN
admet-2956	210	22	13(5	13(5	NUM
admet-2956	210	23	)	)	PUNCT
admet-2956	210	24	(	(	PUNCT
admet-2956	210	25	2025	2025	NUM
admet-2956	210	26	)	)	PUNCT
admet-2956	210	27	2956	2956	NUM
admet-2956	210	28	12	12	NUM
admet-2956	210	29	maximize	maximize	NOUN
admet-2956	210	30	benefit	benefit	NOUN
admet-2956	210	31	[	[	X
admet-2956	210	32	67	67	NUM
admet-2956	210	33	]	]	PUNCT
admet-2956	210	34	.	.	PUNCT
admet-2956	211	1	integrating	integrate	VERB
admet-2956	211	2	real	real	ADJ
admet-2956	211	3	-	-	PUNCT
admet-2956	211	4	world	world	NOUN
admet-2956	211	5	evidence	evidence	NOUN
admet-2956	211	6	,	,	PUNCT
admet-2956	211	7	registry	registry	NOUN
admet-2956	211	8	data	datum	NOUN
admet-2956	211	9	,	,	PUNCT
admet-2956	211	10	and	and	CCONJ
admet-2956	211	11	pragmatic	pragmatic	ADJ
admet-2956	211	12	trials	trial	NOUN
admet-2956	211	13	will	will	AUX
admet-2956	211	14	be	be	AUX
admet-2956	211	15	crucial	crucial	ADJ
admet-2956	211	16	to	to	ADP
admet-2956	211	17	understanding	understand	VERB
admet-2956	211	18	long	long	ADJ
admet-2956	211	19	-	-	PUNCT
admet-2956	211	20	term	term	NOUN
admet-2956	211	21	outcomes	outcome	NOUN
admet-2956	211	22	and	and	CCONJ
admet-2956	211	23	optimizing	optimize	VERB
admet-2956	211	24	sequencing	sequence	VERB
admet-2956	211	25	in	in	ADP
admet-2956	211	26	diverse	diverse	ADJ
admet-2956	211	27	patient	patient	ADJ
admet-2956	211	28	populations	population	NOUN
admet-2956	211	29	[	[	X
admet-2956	211	30	68	68	NUM
admet-2956	211	31	]	]	PUNCT
admet-2956	211	32	.	.	PUNCT
admet-2956	212	1	taken	take	VERB
admet-2956	212	2	together	together	ADV
admet-2956	212	3	,	,	PUNCT
admet-2956	212	4	our	our	PRON
admet-2956	212	5	results	result	NOUN
admet-2956	212	6	signal	signal	VERB
admet-2956	212	7	a	a	DET
admet-2956	212	8	paradigm	paradigm	NOUN
admet-2956	212	9	shift	shift	NOUN
admet-2956	212	10	away	away	ADV
admet-2956	212	11	from	from	ADP
admet-2956	212	12	reliance	reliance	NOUN
admet-2956	212	13	on	on	ADP
admet-2956	212	14	a	a	DET
admet-2956	212	15	single	single	ADJ
admet-2956	212	16	biomarker	biomarker	NOUN
admet-2956	212	17	toward	toward	ADP
admet-2956	212	18	multifactorial	multifactorial	ADJ
admet-2956	212	19	patient	patient	ADJ
admet-2956	212	20	selection	selection	NOUN
admet-2956	212	21	models	model	NOUN
admet-2956	212	22	.	.	PUNCT
admet-2956	213	1	incorporating	incorporate	VERB
admet-2956	213	2	demographic	demographic	ADJ
admet-2956	213	3	,	,	PUNCT
admet-2956	213	4	clinical	clinical	ADJ
admet-2956	213	5	,	,	PUNCT
admet-2956	213	6	and	and	CCONJ
admet-2956	213	7	molecular	molecular	ADJ
admet-2956	213	8	variables	variable	NOUN
admet-2956	213	9	into	into	ADP
admet-2956	213	10	integrated	integrate	VERB
admet-2956	213	11	risk	risk	NOUN
admet-2956	213	12	prediction	prediction	NOUN
admet-2956	213	13	frameworks	framework	NOUN
admet-2956	213	14	could	could	AUX
admet-2956	213	15	enhance	enhance	VERB
admet-2956	213	16	precision	precision	NOUN
admet-2956	213	17	in	in	ADP
admet-2956	213	18	treatment	treatment	NOUN
admet-2956	213	19	decisions	decision	NOUN
admet-2956	213	20	[	[	X
admet-2956	213	21	69	69	NUM
admet-2956	213	22	]	]	PUNCT
admet-2956	213	23	.	.	PUNCT
admet-2956	214	1	machine	machine	NOUN
admet-2956	214	2	learning	learning	NOUN
admet-2956	214	3	and	and	CCONJ
admet-2956	214	4	ai	ai	VERB
admet-2956	214	5	offer	offer	VERB
admet-2956	214	6	powerful	powerful	ADJ
admet-2956	214	7	tools	tool	NOUN
admet-2956	214	8	to	to	PART
admet-2956	214	9	synthesize	synthesize	VERB
admet-2956	214	10	these	these	DET
admet-2956	214	11	diverse	diverse	ADJ
admet-2956	214	12	data	datum	NOUN
admet-2956	214	13	sources	source	NOUN
admet-2956	214	14	and	and	CCONJ
admet-2956	214	15	may	may	AUX
admet-2956	214	16	reveal	reveal	VERB
admet-2956	214	17	novel	novel	ADJ
admet-2956	214	18	signatures	signature	NOUN
admet-2956	214	19	of	of	ADP
admet-2956	214	20	response	response	NOUN
admet-2956	214	21	that	that	PRON
admet-2956	214	22	are	be	AUX
admet-2956	214	23	not	not	PART
admet-2956	214	24	captured	capture	VERB
admet-2956	214	25	by	by	ADP
admet-2956	214	26	traditional	traditional	ADJ
admet-2956	214	27	analyses	analysis	NOUN
admet-2956	214	28	[	[	X
admet-2956	214	29	70	70	NUM
admet-2956	214	30	]	]	PUNCT
admet-2956	214	31	.	.	PUNCT
admet-2956	215	1	from	from	ADP
admet-2956	215	2	a	a	DET
admet-2956	215	3	regulatory	regulatory	ADJ
admet-2956	215	4	and	and	CCONJ
admet-2956	215	5	clinical	clinical	ADJ
admet-2956	215	6	practice	practice	NOUN
admet-2956	215	7	perspective	perspective	NOUN
admet-2956	215	8	,	,	PUNCT
admet-2956	215	9	the	the	DET
admet-2956	215	10	clear	clear	ADJ
admet-2956	215	11	benefits	benefit	NOUN
admet-2956	215	12	observed	observe	VERB
admet-2956	215	13	in	in	ADP
admet-2956	215	14	pd	pd	PROPN
admet-2956	215	15	-	-	PUNCT
admet-2956	215	16	l1	l1	NOUN
admet-2956	215	17	-	-	PUNCT
admet-2956	215	18	low	low	ADJ
admet-2956	215	19	patients	patient	NOUN
admet-2956	215	20	raise	raise	VERB
admet-2956	215	21	the	the	DET
admet-2956	215	22	possibility	possibility	NOUN
admet-2956	215	23	of	of	ADP
admet-2956	215	24	broadening	broaden	VERB
admet-2956	215	25	pembrolizumab	pembrolizumab	NOUN
admet-2956	215	26	monotherapy	monotherapy	NOUN
admet-2956	215	27	indications	indication	NOUN
admet-2956	215	28	.	.	PUNCT
admet-2956	216	1	such	such	DET
admet-2956	216	2	a	a	DET
admet-2956	216	3	shift	shift	NOUN
admet-2956	216	4	will	will	AUX
admet-2956	216	5	require	require	VERB
admet-2956	216	6	balancing	balance	VERB
admet-2956	216	7	clinical	clinical	ADJ
admet-2956	216	8	efficacy	efficacy	NOUN
admet-2956	216	9	with	with	ADP
admet-2956	216	10	cost	cost	NOUN
admet-2956	216	11	,	,	PUNCT
admet-2956	216	12	health	health	NOUN
admet-2956	216	13	system	system	NOUN
admet-2956	216	14	capacity	capacity	NOUN
admet-2956	216	15	,	,	PUNCT
admet-2956	216	16	and	and	CCONJ
admet-2956	216	17	equity	equity	NOUN
admet-2956	216	18	of	of	ADP
admet-2956	216	19	access	access	NOUN
admet-2956	216	20	.	.	PUNCT
admet-2956	217	1	collaborative	collaborative	ADJ
admet-2956	217	2	efforts	effort	NOUN
admet-2956	217	3	among	among	ADP
admet-2956	217	4	regulators	regulator	NOUN
admet-2956	217	5	,	,	PUNCT
admet-2956	217	6	professional	professional	ADJ
admet-2956	217	7	societies	society	NOUN
admet-2956	217	8	,	,	PUNCT
admet-2956	217	9	and	and	CCONJ
admet-2956	217	10	healthcare	healthcare	NOUN
admet-2956	217	11	systems	system	NOUN
admet-2956	217	12	will	will	AUX
admet-2956	217	13	be	be	AUX
admet-2956	217	14	crucial	crucial	ADJ
admet-2956	217	15	to	to	ADP
admet-2956	217	16	translating	translate	VERB
admet-2956	217	17	these	these	DET
admet-2956	217	18	insights	insight	NOUN
admet-2956	217	19	into	into	ADP
admet-2956	217	20	enhanced	enhanced	ADJ
admet-2956	217	21	patient	patient	ADJ
admet-2956	217	22	care	care	NOUN
admet-2956	217	23	.	.	PUNCT
admet-2956	218	1	finally	finally	ADV
admet-2956	218	2	,	,	PUNCT
admet-2956	218	3	our	our	PRON
admet-2956	218	4	study	study	NOUN
admet-2956	218	5	has	have	VERB
admet-2956	218	6	limitations	limitation	NOUN
admet-2956	218	7	.	.	PUNCT
admet-2956	219	1	reliance	reliance	NOUN
admet-2956	219	2	on	on	ADP
admet-2956	219	3	trial	trial	NOUN
admet-2956	219	4	-	-	PUNCT
admet-2956	219	5	level	level	NOUN
admet-2956	219	6	rather	rather	ADV
admet-2956	219	7	than	than	ADP
admet-2956	219	8	individual	individual	ADJ
admet-2956	219	9	patient	patient	NOUN
admet-2956	219	10	data	datum	NOUN
admet-2956	219	11	constrained	constrain	VERB
admet-2956	219	12	our	our	PRON
admet-2956	219	13	ability	ability	NOUN
admet-2956	219	14	to	to	PART
admet-2956	219	15	explore	explore	VERB
admet-2956	219	16	confounding	confound	VERB
admet-2956	219	17	factors	factor	NOUN
admet-2956	219	18	and	and	CCONJ
admet-2956	219	19	limited	limited	ADJ
admet-2956	219	20	biomarker	biomarker	NOUN
admet-2956	219	21	analyses	analysis	NOUN
admet-2956	219	22	,	,	PUNCT
admet-2956	219	23	such	such	ADJ
admet-2956	219	24	as	as	ADP
admet-2956	219	25	tumour	tumour	ADJ
admet-2956	219	26	mutational	mutational	ADJ
admet-2956	219	27	burden	burden	NOUN
admet-2956	219	28	,	,	PUNCT
admet-2956	219	29	which	which	PRON
admet-2956	219	30	was	be	AUX
admet-2956	219	31	inconsistently	inconsistently	ADV
admet-2956	219	32	reported	report	VERB
admet-2956	219	33	.	.	PUNCT
admet-2956	220	1	these	these	DET
admet-2956	220	2	gaps	gap	NOUN
admet-2956	220	3	highlight	highlight	VERB
admet-2956	220	4	the	the	DET
admet-2956	220	5	importance	importance	NOUN
admet-2956	220	6	of	of	ADP
admet-2956	220	7	ongoing	ongoing	ADJ
admet-2956	220	8	research	research	NOUN
admet-2956	220	9	to	to	PART
admet-2956	220	10	refine	refine	VERB
admet-2956	220	11	patient	patient	ADJ
admet-2956	220	12	selection	selection	NOUN
admet-2956	220	13	and	and	CCONJ
admet-2956	220	14	therapeutic	therapeutic	ADJ
admet-2956	220	15	strategies	strategy	NOUN
admet-2956	220	16	.	.	PUNCT
admet-2956	221	1	conclusions	conclusion	NOUN
admet-2956	221	2	this	this	PRON
admet-2956	221	3	meta	meta	ADJ
admet-2956	221	4	-	-	PUNCT
admet-2956	221	5	analysis	analysis	NOUN
admet-2956	221	6	provides	provide	VERB
admet-2956	221	7	robust	robust	ADJ
admet-2956	221	8	evidence	evidence	NOUN
admet-2956	221	9	that	that	SCONJ
admet-2956	221	10	pembrolizumab	pembrolizumab	NOUN
admet-2956	221	11	significantly	significantly	ADV
admet-2956	221	12	improves	improve	VERB
admet-2956	221	13	overall	overall	ADJ
admet-2956	221	14	survival	survival	NOUN
admet-2956	221	15	,	,	PUNCT
admet-2956	221	16	progression	progression	NOUN
admet-2956	221	17	-	-	PUNCT
admet-2956	221	18	free	free	ADJ
admet-2956	221	19	survival	survival	NOUN
admet-2956	221	20	,	,	PUNCT
admet-2956	221	21	and	and	CCONJ
admet-2956	221	22	objective	objective	ADJ
admet-2956	221	23	response	response	NOUN
admet-2956	221	24	rates	rate	NOUN
admet-2956	221	25	in	in	ADP
admet-2956	221	26	patients	patient	NOUN
admet-2956	221	27	with	with	ADP
admet-2956	221	28	advanced	advanced	ADJ
admet-2956	221	29	non	non	ADJ
admet-2956	221	30	-	-	ADJ
admet-2956	221	31	small	small	ADJ
admet-2956	221	32	cell	cell	NOUN
admet-2956	221	33	lung	lung	NOUN
admet-2956	221	34	cancer	cancer	NOUN
admet-2956	221	35	exhibiting	exhibit	VERB
admet-2956	221	36	pd	pd	PROPN
admet-2956	221	37	-	-	PUNCT
admet-2956	221	38	l1	l1	ADJ
admet-2956	221	39	-	-	PUNCT
admet-2956	221	40	positive	positive	ADJ
admet-2956	221	41	expression	expression	NOUN
admet-2956	221	42	.	.	PUNCT
admet-2956	222	1	the	the	DET
admet-2956	222	2	treatment	treatment	NOUN
admet-2956	222	3	exhibits	exhibit	VERB
admet-2956	222	4	a	a	DET
admet-2956	222	5	tolerable	tolerable	ADJ
admet-2956	222	6	safety	safety	NOUN
admet-2956	222	7	profile	profile	NOUN
admet-2956	222	8	,	,	PUNCT
admet-2956	222	9	primarily	primarily	ADV
admet-2956	222	10	characterized	characterize	VERB
admet-2956	222	11	by	by	ADP
admet-2956	222	12	immune	immune	NOUN
admet-2956	222	13	-	-	PUNCT
admet-2956	222	14	related	relate	VERB
admet-2956	222	15	adverse	adverse	ADJ
admet-2956	222	16	events	event	NOUN
admet-2956	222	17	rather	rather	ADV
admet-2956	222	18	than	than	ADP
admet-2956	222	19	the	the	DET
admet-2956	222	20	typical	typical	ADJ
admet-2956	222	21	cytotoxic	cytotoxic	ADJ
admet-2956	222	22	side	side	NOUN
admet-2956	222	23	effects	effect	NOUN
admet-2956	222	24	.	.	PUNCT
admet-2956	223	1	notably	notably	ADV
admet-2956	223	2	,	,	PUNCT
admet-2956	223	3	the	the	DET
admet-2956	223	4	subgroup	subgroup	NOUN
admet-2956	223	5	analyses	analysis	NOUN
admet-2956	223	6	presented	present	VERB
admet-2956	223	7	here	here	ADV
admet-2956	223	8	suggest	suggest	VERB
admet-2956	223	9	that	that	SCONJ
admet-2956	223	10	pembrolizumab	pembrolizumab	NOUN
admet-2956	223	11	offers	offer	VERB
admet-2956	223	12	considerable	considerable	ADJ
admet-2956	223	13	clinical	clinical	ADJ
admet-2956	223	14	benefits	benefit	NOUN
admet-2956	223	15	not	not	PART
admet-2956	223	16	only	only	ADV
admet-2956	223	17	to	to	ADP
admet-2956	223	18	patients	patient	NOUN
admet-2956	223	19	with	with	ADP
admet-2956	223	20	high	high	ADJ
admet-2956	223	21	pd	pd	PROPN
admet-2956	223	22	-	-	PUNCT
admet-2956	223	23	l1	l1	NOUN
admet-2956	223	24	expression	expression	NOUN
admet-2956	223	25	but	but	CCONJ
admet-2956	223	26	also	also	ADV
admet-2956	223	27	to	to	ADP
admet-2956	223	28	those	those	PRON
admet-2956	223	29	with	with	ADP
admet-2956	223	30	low	low	ADJ
admet-2956	223	31	or	or	CCONJ
admet-2956	223	32	even	even	ADV
admet-2956	223	33	undetectable	undetectable	ADJ
admet-2956	223	34	pd	pd	PROPN
admet-2956	223	35	-	-	PROPN
admet-2956	223	36	l1	l1	PROPN
admet-2956	223	37	levels	level	NOUN
admet-2956	223	38	—	—	PUNCT
admet-2956	223	39	this	this	DET
admet-2956	223	40	finding	finding	NOUN
admet-2956	223	41	challenges	challenge	VERB
admet-2956	223	42	the	the	DET
admet-2956	223	43	established	establish	VERB
admet-2956	223	44	paradigms	paradigms	NOUN
admet-2956	223	45	of	of	ADP
admet-2956	223	46	biomarker	biomarker	NOUN
admet-2956	223	47	-	-	PUNCT
admet-2956	223	48	driven	drive	VERB
admet-2956	223	49	treatment	treatment	NOUN
admet-2956	223	50	.	.	PUNCT
admet-2956	224	1	the	the	DET
admet-2956	224	2	variability	variability	NOUN
admet-2956	224	3	in	in	ADP
admet-2956	224	4	treatment	treatment	NOUN
admet-2956	224	5	responses	response	NOUN
admet-2956	224	6	among	among	ADP
admet-2956	224	7	different	different	ADJ
admet-2956	224	8	age	age	NOUN
admet-2956	224	9	and	and	CCONJ
admet-2956	224	10	gender	gender	NOUN
admet-2956	224	11	cohorts	cohort	NOUN
admet-2956	224	12	highlights	highlight	VERB
admet-2956	224	13	the	the	DET
admet-2956	224	14	biological	biological	ADJ
admet-2956	224	15	diversity	diversity	NOUN
admet-2956	224	16	in	in	ADP
admet-2956	224	17	patient	patient	ADJ
admet-2956	224	18	reactions	reaction	NOUN
admet-2956	224	19	to	to	ADP
admet-2956	224	20	immunotherapy	immunotherapy	NOUN
admet-2956	224	21	and	and	CCONJ
admet-2956	224	22	reinforces	reinforce	VERB
admet-2956	224	23	the	the	DET
admet-2956	224	24	need	need	NOUN
admet-2956	224	25	for	for	ADP
admet-2956	224	26	developing	develop	VERB
admet-2956	224	27	more	more	ADJ
admet-2956	224	28	personalized	personalized	ADJ
admet-2956	224	29	therapeutic	therapeutic	ADJ
admet-2956	224	30	strategies	strategy	NOUN
admet-2956	224	31	.	.	PUNCT
admet-2956	225	1	these	these	DET
admet-2956	225	2	findings	finding	NOUN
admet-2956	225	3	underscore	underscore	VERB
admet-2956	225	4	the	the	DET
admet-2956	225	5	limitations	limitation	NOUN
admet-2956	225	6	of	of	ADP
admet-2956	225	7	pd	pd	PROPN
admet-2956	225	8	-	-	PUNCT
admet-2956	225	9	l1	l1	PROPN
admet-2956	225	10	expression	expression	NOUN
admet-2956	225	11	as	as	ADP
admet-2956	225	12	a	a	DET
admet-2956	225	13	solitary	solitary	ADJ
admet-2956	225	14	predictive	predictive	ADJ
admet-2956	225	15	biomarker	biomarker	NOUN
admet-2956	225	16	and	and	CCONJ
admet-2956	225	17	stress	stress	VERB
admet-2956	225	18	the	the	DET
admet-2956	225	19	importance	importance	NOUN
admet-2956	225	20	of	of	ADP
admet-2956	225	21	incorporating	incorporate	VERB
admet-2956	225	22	additional	additional	ADJ
admet-2956	225	23	testing	testing	NOUN
admet-2956	225	24	methods	method	NOUN
admet-2956	225	25	,	,	PUNCT
admet-2956	225	26	such	such	ADJ
admet-2956	225	27	as	as	ADP
admet-2956	225	28	tumour	tumour	ADJ
admet-2956	225	29	mutational	mutational	ADJ
admet-2956	225	30	burden	burden	NOUN
admet-2956	225	31	,	,	PUNCT
admet-2956	225	32	immune	immune	ADJ
admet-2956	225	33	gene	gene	NOUN
admet-2956	225	34	profiling	profiling	NOUN
admet-2956	225	35	,	,	PUNCT
admet-2956	225	36	and	and	CCONJ
admet-2956	225	37	liquid	liquid	ADJ
admet-2956	225	38	biopsy	biopsy	NOUN
admet-2956	225	39	technologies	technology	NOUN
admet-2956	225	40	into	into	ADP
admet-2956	225	41	clinical	clinical	ADJ
admet-2956	225	42	practice	practice	NOUN
admet-2956	225	43	.	.	PUNCT
admet-2956	226	1	overall	overall	ADV
admet-2956	226	2	,	,	PUNCT
admet-2956	226	3	while	while	SCONJ
admet-2956	226	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	226	5	remains	remain	VERB
admet-2956	226	6	a	a	DET
admet-2956	226	7	cornerstone	cornerstone	NOUN
admet-2956	226	8	treatment	treatment	NOUN
admet-2956	226	9	for	for	ADP
admet-2956	226	10	advanced	advanced	ADJ
admet-2956	226	11	nsclc	nsclc	NOUN
admet-2956	226	12	,	,	PUNCT
admet-2956	226	13	optimizing	optimize	VERB
admet-2956	226	14	patient	patient	ADJ
admet-2956	226	15	selection	selection	NOUN
admet-2956	226	16	through	through	ADP
admet-2956	226	17	multidimensional	multidimensional	ADJ
admet-2956	226	18	biomarker	biomarker	NOUN
admet-2956	226	19	strategies	strategy	NOUN
admet-2956	226	20	will	will	AUX
admet-2956	226	21	be	be	AUX
admet-2956	226	22	crucial	crucial	ADJ
admet-2956	226	23	to	to	PART
admet-2956	226	24	enhance	enhance	VERB
admet-2956	226	25	therapeutic	therapeutic	ADJ
admet-2956	226	26	outcomes	outcome	NOUN
admet-2956	226	27	and	and	CCONJ
admet-2956	226	28	accelerate	accelerate	VERB
admet-2956	226	29	personalized	personalized	ADJ
admet-2956	226	30	cancer	cancer	NOUN
admet-2956	226	31	treatment	treatment	NOUN
admet-2956	226	32	in	in	ADP
admet-2956	226	33	the	the	DET
admet-2956	226	34	immunotherapy	immunotherapy	NOUN
admet-2956	226	35	era	era	NOUN
admet-2956	226	36	.	.	PUNCT
admet-2956	227	1	funding	funding	NOUN
admet-2956	227	2	:	:	PUNCT
admet-2956	227	3	this	this	DET
admet-2956	227	4	research	research	NOUN
admet-2956	227	5	received	receive	VERB
admet-2956	227	6	no	no	DET
admet-2956	227	7	external	external	ADJ
admet-2956	227	8	funding	funding	NOUN
admet-2956	227	9	conflict	conflict	NOUN
admet-2956	227	10	of	of	ADP
admet-2956	227	11	interest	interest	NOUN
admet-2956	227	12	:	:	PUNCT
admet-2956	227	13	the	the	DET
admet-2956	227	14	authors	author	NOUN
admet-2956	227	15	declare	declare	VERB
admet-2956	227	16	no	no	DET
admet-2956	227	17	conflict	conflict	NOUN
admet-2956	227	18	of	of	ADP
admet-2956	227	19	interest	interest	NOUN
admet-2956	227	20	.	.	PUNCT
admet-2956	228	1	references	reference	NOUN
admet-2956	228	2	[	[	X
admet-2956	228	3	1	1	NUM
admet-2956	228	4	]	]	X
admet-2956	228	5	n.	n.	PROPN
admet-2956	228	6	duma	duma	PROPN
admet-2956	228	7	,	,	PUNCT
admet-2956	228	8	r.	r.	PROPN
admet-2956	228	9	santana	santana	PROPN
admet-2956	228	10	-	-	PUNCT
admet-2956	228	11	davila	davila	PROPN
admet-2956	228	12	,	,	PUNCT
admet-2956	228	13	j.r	j.r	PROPN
admet-2956	228	14	.	.	PROPN
admet-2956	228	15	molina	molina	PROPN
admet-2956	228	16	.	.	PUNCT
admet-2956	229	1	non	non	ADJ
admet-2956	229	2	-	-	ADJ
admet-2956	229	3	small	small	ADJ
admet-2956	229	4	cell	cell	NOUN
admet-2956	229	5	lung	lung	NOUN
admet-2956	229	6	cancer	cancer	NOUN
admet-2956	229	7	:	:	PUNCT
admet-2956	229	8	epidemiology	epidemiology	NOUN
admet-2956	229	9	,	,	PUNCT
admet-2956	229	10	screening	screening	NOUN
admet-2956	229	11	,	,	PUNCT
admet-2956	229	12	diagnosis	diagnosis	NOUN
admet-2956	229	13	,	,	PUNCT
admet-2956	229	14	and	and	CCONJ
admet-2956	229	15	treatment	treatment	NOUN
admet-2956	229	16	.	.	PUNCT
admet-2956	230	1	mayo	mayo	PROPN
admet-2956	230	2	clinic	clinic	PROPN
admet-2956	230	3	proceedings	proceeding	NOUN
admet-2956	230	4	94	94	NUM
admet-2956	230	5	(	(	PUNCT
admet-2956	230	6	2019	2019	NUM
admet-2956	230	7	)	)	PUNCT
admet-2956	230	8	1623	1623	NUM
admet-2956	230	9	-	-	SYM
admet-2956	230	10	1640	1640	NUM
admet-2956	230	11	.	.	PUNCT
admet-2956	231	1	https://doi.org/10.1016/j.mayocp.2019.01.013	https://doi.org/10.1016/j.mayocp.2019.01.013	PROPN
admet-2956	231	2	[	[	X
admet-2956	231	3	2	2	NUM
admet-2956	231	4	]	]	X
admet-2956	231	5	p.	p.	NOUN
admet-2956	231	6	garg	garg	PROPN
admet-2956	231	7	,	,	PUNCT
admet-2956	231	8	s.	s.	PROPN
admet-2956	231	9	singhal	singhal	PROPN
admet-2956	231	10	,	,	PUNCT
admet-2956	231	11	p.	p.	PROPN
admet-2956	231	12	kulkarni	kulkarni	PROPN
admet-2956	231	13	,	,	PUNCT
admet-2956	231	14	d.	d.	PROPN
admet-2956	231	15	horne	horne	PROPN
admet-2956	231	16	,	,	PUNCT
admet-2956	231	17	j.	j.	PROPN
admet-2956	231	18	malhotra	malhotra	PROPN
admet-2956	231	19	,	,	PUNCT
admet-2956	231	20	r.	r.	PROPN
admet-2956	231	21	salgia	salgia	PROPN
admet-2956	231	22	,	,	PUNCT
admet-2956	231	23	s.	s.	PROPN
admet-2956	231	24	singhal	singhal	PROPN
admet-2956	231	25	.	.	PUNCT
admet-2956	232	1	advances	advance	NOUN
admet-2956	232	2	in	in	ADP
admet-2956	232	3	non	non	ADJ
admet-2956	232	4	-	-	ADJ
admet-2956	232	5	small	small	ADJ
admet-2956	232	6	cell	cell	NOUN
admet-2956	232	7	lung	lung	NOUN
admet-2956	232	8	cancer	cancer	NOUN
admet-2956	232	9	:	:	PUNCT
admet-2956	232	10	current	current	ADJ
admet-2956	232	11	insights	insight	NOUN
admet-2956	232	12	and	and	CCONJ
admet-2956	232	13	future	future	ADJ
admet-2956	232	14	directions	direction	NOUN
admet-2956	232	15	.	.	PUNCT
admet-2956	233	1	journal	journal	NOUN
admet-2956	233	2	of	of	ADP
admet-2956	233	3	clinical	clinical	ADJ
admet-2956	233	4	medicine	medicine	NOUN
admet-2956	233	5	13	13	NUM
admet-2956	233	6	(	(	PUNCT
admet-2956	233	7	2024	2024	NUM
admet-2956	233	8	)	)	PUNCT
admet-2956	233	9	45	45	NUM
admet-2956	233	10	-	-	SYM
admet-2956	233	11	56	56	NUM
admet-2956	233	12	.	.	PUNCT
admet-2956	234	1	https://doi.org/10.3390/jcm13144189	https://doi.org/10.3390/jcm13144189	PROPN
admet-2956	234	2	https://doi.org/10.1016/j.mayocp.2019.01.013	https://doi.org/10.1016/j.mayocp.2019.01.013	PROPN
admet-2956	234	3	https://doi.org/10.3390/jcm13144189	https://doi.org/10.3390/jcm13144189	PROPN
admet-2956	234	4	admet	admet	PROPN
admet-2956	234	5	&	&	CCONJ
admet-2956	234	6	dmpk	dmpk	PROPN
admet-2956	234	7	13(5	13(5	NOUN
admet-2956	234	8	)	)	PUNCT
admet-2956	234	9	(	(	PUNCT
admet-2956	234	10	2025	2025	NUM
admet-2956	234	11	)	)	PUNCT
admet-2956	234	12	2956	2956	NUM
admet-2956	234	13	pembrolizumab	pembrolizumab	NOUN
admet-2956	234	14	in	in	ADP
admet-2956	234	15	pd	pd	PROPN
admet-2956	234	16	-	-	PUNCT
admet-2956	234	17	l1	l1	PROPN
admet-2956	234	18	-	-	PUNCT
admet-2956	234	19	positive	positive	ADJ
admet-2956	234	20	advanced	advanced	ADJ
admet-2956	234	21	non	non	ADJ
admet-2956	234	22	-	-	ADJ
admet-2956	234	23	small	small	ADJ
admet-2956	234	24	cell	cell	NOUN
admet-2956	234	25	lung	lung	NOUN
admet-2956	234	26	carcinoma	carcinoma	NOUN
admet-2956	234	27	doi	doi	NOUN
admet-2956	234	28	:	:	PUNCT
admet-2956	234	29	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	234	30	13	13	NUM
admet-2956	235	1	[	[	X
admet-2956	235	2	3	3	NUM
admet-2956	235	3	]	]	X
admet-2956	235	4	q.	q.	PROPN
admet-2956	235	5	huang	huang	PROPN
admet-2956	235	6	,	,	PUNCT
admet-2956	235	7	y.	y.	PROPN
admet-2956	235	8	li	li	PROPN
admet-2956	235	9	,	,	PUNCT
admet-2956	235	10	y.	y.	PROPN
admet-2956	235	11	huang	huang	PROPN
admet-2956	235	12	,	,	PUNCT
admet-2956	235	13	j.	j.	PROPN
admet-2956	235	14	wu	wu	PROPN
admet-2956	235	15	,	,	PUNCT
admet-2956	235	16	w.	w.	PROPN
admet-2956	235	17	bao	bao	PROPN
admet-2956	235	18	,	,	PUNCT
admet-2956	235	19	c.	c.	PROPN
admet-2956	235	20	xue	xue	PROPN
admet-2956	235	21	,	,	PUNCT
admet-2956	235	22	s.	s.	PROPN
admet-2956	235	23	hu	hu	PROPN
admet-2956	235	24	.	.	PROPN
admet-2956	235	25	advances	advance	NOUN
admet-2956	235	26	in	in	ADP
admet-2956	235	27	molecular	molecular	ADJ
admet-2956	235	28	pathology	pathology	NOUN
admet-2956	235	29	and	and	CCONJ
admet-2956	235	30	therapy	therapy	NOUN
admet-2956	235	31	of	of	ADP
admet-2956	235	32	non	non	ADJ
admet-2956	235	33	-	-	ADJ
admet-2956	235	34	small	small	ADJ
admet-2956	235	35	cell	cell	NOUN
admet-2956	235	36	lung	lung	NOUN
admet-2956	235	37	cancer	cancer	NOUN
admet-2956	235	38	.	.	PUNCT
admet-2956	236	1	signal	signal	ADJ
admet-2956	236	2	transduction	transduction	NOUN
admet-2956	236	3	and	and	CCONJ
admet-2956	236	4	targeted	target	VERB
admet-2956	236	5	therapy	therapy	NOUN
admet-2956	236	6	10	10	NUM
admet-2956	236	7	(	(	PUNCT
admet-2956	236	8	2025	2025	NUM
admet-2956	236	9	)	)	PUNCT
admet-2956	236	10	186	186	NUM
admet-2956	236	11	-	-	SYM
admet-2956	236	12	195	195	NUM
admet-2956	236	13	.	.	PUNCT
admet-2956	237	1	https://doi.org/10.1038/s41392-025-02243-6	https://doi.org/10.1038/s41392-025-02243-6	X
admet-2956	238	1	[	[	X
admet-2956	238	2	4	4	X
admet-2956	238	3	]	]	PUNCT
admet-2956	238	4	m.	m.	PROPN
admet-2956	238	5	dawood	dawood	PROPN
admet-2956	238	6	m.	m.	PROPN
admet-2956	238	7	assi	assi	PROPN
admet-2956	238	8	.	.	PUNCT
admet-2956	239	1	evaluation	evaluation	NOUN
admet-2956	239	2	of	of	ADP
admet-2956	239	3	her	her	PRON
admet-2956	239	4	2	2	NUM
admet-2956	239	5	,	,	PUNCT
admet-2956	239	6	and	and	CCONJ
admet-2956	239	7	ki-67	ki-67	ADJ
admet-2956	239	8	expression	expression	NOUN
admet-2956	239	9	immunohistochemically	immunohistochemically	ADV
admet-2956	239	10	of	of	ADP
admet-2956	239	11	gastric	gastric	ADJ
admet-2956	239	12	cancer	cancer	NOUN
admet-2956	239	13	in	in	ADP
admet-2956	239	14	al	al	PROPN
admet-2956	239	15	-	-	PUNCT
admet-2956	239	16	najaf	najaf	PROPN
admet-2956	239	17	province	province	NOUN
admet-2956	239	18	.	.	PUNCT
admet-2956	240	1	procedia	procedia	PROPN
admet-2956	240	2	environmental	environmental	PROPN
admet-2956	240	3	science	science	PROPN
admet-2956	240	4	engineering	engineering	NOUN
admet-2956	240	5	and	and	CCONJ
admet-2956	240	6	management	management	NOUN
admet-2956	240	7	.	.	PUNCT
admet-2956	241	1	11	11	NUM
admet-2956	241	2	(	(	PUNCT
admet-2956	241	3	2024	2024	NUM
admet-2956	241	4	)	)	PUNCT
admet-2956	241	5	465	465	NUM
admet-2956	241	6	-	-	SYM
admet-2956	241	7	472	472	NUM
admet-2956	241	8	.	.	PUNCT
admet-2956	242	1	465	465	NUM
admet-2956	242	2	-	-	SYM
admet-2956	242	3	472	472	NUM
admet-2956	242	4	.	.	PUNCT
admet-2956	243	1	https://www.procedia-esem.eu/pdf/issues/2024/no3/46_dawood_24.pdf	https://www.procedia-esem.eu/pdf/issues/2024/no3/46_dawood_24.pdf	NOUN
admet-2956	244	1	[	[	X
admet-2956	244	2	5	5	X
admet-2956	244	3	]	]	PUNCT
admet-2956	244	4	h.	h.	NOUN
admet-2956	244	5	mamdani	mamdani	PROPN
admet-2956	244	6	,	,	PUNCT
admet-2956	244	7	s.	s.	PROPN
admet-2956	244	8	matosevic	matosevic	PROPN
admet-2956	244	9	,	,	PUNCT
admet-2956	244	10	a.	a.	PROPN
admet-2956	244	11	b.	b.	PROPN
admet-2956	244	12	khalid	khalid	PROPN
admet-2956	244	13	,	,	PUNCT
admet-2956	244	14	g.	g.	PROPN
admet-2956	244	15	durm	durm	PROPN
admet-2956	244	16	,	,	PUNCT
admet-2956	244	17	s.	s.	PROPN
admet-2956	244	18	i.	i.	PROPN
admet-2956	244	19	jalal	jalal	PROPN
admet-2956	244	20	.	.	PUNCT
admet-2956	245	1	immunotherapy	immunotherapy	NOUN
admet-2956	245	2	in	in	ADP
admet-2956	245	3	lung	lung	NOUN
admet-2956	245	4	cancer	cancer	NOUN
admet-2956	245	5	:	:	PUNCT
admet-2956	245	6	current	current	ADJ
admet-2956	245	7	landscape	landscape	NOUN
admet-2956	245	8	and	and	CCONJ
admet-2956	245	9	future	future	ADJ
admet-2956	245	10	directions	direction	NOUN
admet-2956	245	11	.	.	PUNCT
admet-2956	246	1	frontiers	frontier	NOUN
admet-2956	246	2	in	in	ADP
admet-2956	246	3	immunology	immunology	NOUN
admet-2956	246	4	13	13	NUM
admet-2956	246	5	(	(	PUNCT
admet-2956	246	6	2022	2022	NUM
admet-2956	246	7	)	)	PUNCT
admet-2956	246	8	823618	823618	NUM
admet-2956	246	9	.	.	PUNCT
admet-2956	247	1	https://doi.org/10.3389/fimmu.2022.823618	https://doi.org/10.3389/fimmu.2022.823618	PROPN
admet-2956	248	1	[	[	X
admet-2956	248	2	6	6	X
admet-2956	248	3	]	]	PUNCT
admet-2956	248	4	h.	h.	PROPN
admet-2956	248	5	e.	e.	PROPN
admet-2956	248	6	marei	marei	PROPN
admet-2956	248	7	,	,	PUNCT
admet-2956	248	8	a.	a.	PROPN
admet-2956	248	9	hasan	hasan	PROPN
admet-2956	248	10	,	,	PUNCT
admet-2956	248	11	g.	g.	PROPN
admet-2956	248	12	pozzoli	pozzoli	PROPN
admet-2956	248	13	,	,	PUNCT
admet-2956	248	14	c.	c.	PROPN
admet-2956	248	15	cenciarelli	cenciarelli	PROPN
admet-2956	248	16	.	.	PUNCT
admet-2956	249	1	cancer	cancer	NOUN
admet-2956	249	2	immunotherapy	immunotherapy	NOUN
admet-2956	249	3	with	with	ADP
admet-2956	249	4	immune	immune	ADJ
admet-2956	249	5	checkpoint	checkpoint	NOUN
admet-2956	249	6	inhibitors	inhibitor	NOUN
admet-2956	249	7	(	(	PUNCT
admet-2956	249	8	icis	icis	NOUN
admet-2956	249	9	):	):	PUNCT
admet-2956	249	10	potential	potential	ADJ
admet-2956	249	11	,	,	PUNCT
admet-2956	249	12	mechanisms	mechanism	NOUN
admet-2956	249	13	of	of	ADP
admet-2956	249	14	resistance	resistance	NOUN
admet-2956	249	15	,	,	PUNCT
admet-2956	249	16	and	and	CCONJ
admet-2956	249	17	strategies	strategy	NOUN
admet-2956	249	18	for	for	ADP
admet-2956	249	19	reinvigorating	reinvigorate	VERB
admet-2956	249	20	t	t	PROPN
admet-2956	249	21	cell	cell	NOUN
admet-2956	249	22	responsiveness	responsiveness	NOUN
admet-2956	249	23	when	when	SCONJ
admet-2956	249	24	resistance	resistance	NOUN
admet-2956	249	25	is	be	AUX
admet-2956	249	26	acquired	acquire	VERB
admet-2956	249	27	.	.	PUNCT
admet-2956	250	1	cancer	cancer	NOUN
admet-2956	250	2	cell	cell	NOUN
admet-2956	250	3	international	international	ADJ
admet-2956	250	4	23	23	NUM
admet-2956	250	5	(	(	PUNCT
admet-2956	250	6	2023	2023	NUM
admet-2956	250	7	)	)	PUNCT
admet-2956	250	8	64	64	NUM
admet-2956	250	9	-	-	SYM
admet-2956	250	10	76	76	NUM
admet-2956	250	11	.	.	PUNCT
admet-2956	251	1	https://doi.org/10.1186/s12935-023-02902-0	https://doi.org/10.1186/s12935-023-02902-0	NUM
admet-2956	252	1	[	[	X
admet-2956	252	2	7	7	X
admet-2956	252	3	]	]	X
admet-2956	252	4	m.	m.	PROPN
admet-2956	252	5	f.	f.	PROPN
admet-2956	252	6	sanmamed	sanmame	VERB
admet-2956	252	7	,	,	PUNCT
admet-2956	252	8	l.	l.	PROPN
admet-2956	252	9	chen	chen	PROPN
admet-2956	252	10	.	.	PUNCT
admet-2956	253	1	a	a	DET
admet-2956	253	2	paradigm	paradigm	NOUN
admet-2956	253	3	shift	shift	NOUN
admet-2956	253	4	in	in	ADP
admet-2956	253	5	cancer	cancer	NOUN
admet-2956	253	6	immunotherapy	immunotherapy	NOUN
admet-2956	253	7	:	:	PUNCT
admet-2956	253	8	from	from	ADP
admet-2956	253	9	enhancement	enhancement	NOUN
admet-2956	253	10	to	to	ADP
admet-2956	253	11	normalization	normalization	NOUN
admet-2956	253	12	.	.	PUNCT
admet-2956	254	1	cell	cell	NOUN
admet-2956	254	2	175	175	NUM
admet-2956	254	3	(	(	PUNCT
admet-2956	254	4	2018	2018	NUM
admet-2956	254	5	)	)	PUNCT
admet-2956	254	6	313	313	NUM
admet-2956	254	7	-	-	SYM
admet-2956	254	8	326	326	NUM
admet-2956	254	9	.	.	PUNCT
admet-2956	255	1	https://doi.org/10.1016/j.cell.2018.09.035	https://doi.org/10.1016/j.cell.2018.09.035	NOUN
admet-2956	255	2	[	[	X
admet-2956	255	3	8	8	NUM
admet-2956	255	4	]	]	PUNCT
admet-2956	255	5	a.	a.	NOUN
admet-2956	255	6	abaza	abaza	PROPN
admet-2956	255	7	,	,	PUNCT
admet-2956	255	8	f.	f.	PROPN
admet-2956	255	9	idris	idris	PROPN
admet-2956	255	10	,	,	PUNCT
admet-2956	255	11	h.	h.	PROPN
admet-2956	255	12	shaikh	shaikh	PROPN
admet-2956	255	13	,	,	PUNCT
admet-2956	255	14	i.	i.	PROPN
admet-2956	255	15	vahora	vahora	PROPN
admet-2956	255	16	,	,	PUNCT
admet-2956	255	17	k.	k.	PROPN
admet-2956	255	18	moparthi	moparthi	PROPN
admet-2956	255	19	,	,	PUNCT
admet-2956	255	20	m.	m.	PROPN
admet-2956	255	21	al	al	PROPN
admet-2956	255	22	rushaidi	rushaidi	PROPN
admet-2956	255	23	,	,	PUNCT
admet-2956	255	24	m.	m.	NOUN
admet-2956	255	25	muddam	muddam	PROPN
admet-2956	255	26	.	.	PUNCT
admet-2956	256	1	programmed	program	VERB
admet-2956	256	2	cell	cell	NOUN
admet-2956	256	3	death	death	NOUN
admet-2956	256	4	protein	protein	NOUN
admet-2956	256	5	1	1	NUM
admet-2956	256	6	(	(	PUNCT
admet-2956	256	7	pd-1	pd-1	ADV
admet-2956	256	8	)	)	PUNCT
admet-2956	256	9	and	and	CCONJ
admet-2956	256	10	programmed	program	VERB
admet-2956	256	11	cell	cell	NOUN
admet-2956	256	12	death	death	NOUN
admet-2956	256	13	ligand	ligand	NOUN
admet-2956	256	14	1	1	NUM
admet-2956	256	15	(	(	PUNCT
admet-2956	256	16	pd	pd	NOUN
admet-2956	256	17	-	-	PUNCT
admet-2956	256	18	l1	l1	NOUN
admet-2956	256	19	)	)	PUNCT
admet-2956	256	20	immunotherapy	immunotherapy	NOUN
admet-2956	256	21	:	:	PUNCT
admet-2956	256	22	a	a	DET
admet-2956	256	23	promising	promising	ADJ
admet-2956	256	24	breakthrough	breakthrough	NOUN
admet-2956	256	25	in	in	ADP
admet-2956	256	26	cancer	cancer	NOUN
admet-2956	256	27	therapeutics	therapeutic	NOUN
admet-2956	256	28	.	.	PUNCT
admet-2956	257	1	cureus	cureus	PROPN
admet-2956	257	2	journal	journal	PROPN
admet-2956	257	3	of	of	ADP
admet-2956	257	4	medical	medical	ADJ
admet-2956	257	5	science	science	NOUN
admet-2956	257	6	1	1	NUM
admet-2956	257	7	(	(	PUNCT
admet-2956	257	8	2023	2023	NUM
admet-2956	257	9	)	)	PUNCT
admet-2956	258	1	e44582	e44582	NOUN
admet-2956	258	2	.	.	PUNCT
admet-2956	259	1	https://doi.org/10.7759/cureus.44582	https://doi.org/10.7759/cureus.44582	NOUN
admet-2956	260	1	[	[	X
admet-2956	260	2	9	9	NUM
admet-2956	260	3	]	]	X
admet-2956	260	4	y.	y.	PROPN
admet-2956	260	5	shindo	shindo	PROPN
admet-2956	260	6	,	,	PUNCT
admet-2956	260	7	s.	s.	PROPN
admet-2956	260	8	hazama	hazama	PROPN
admet-2956	260	9	,	,	PUNCT
admet-2956	260	10	r.	r.	PROPN
admet-2956	260	11	tsunedomi	tsunedomi	PROPN
admet-2956	260	12	,	,	PUNCT
admet-2956	260	13	n.	n.	PROPN
admet-2956	260	14	suzuki	suzuki	PROPN
admet-2956	260	15	,	,	PUNCT
admet-2956	260	16	h.	h.	PROPN
admet-2956	260	17	nagano	nagano	PROPN
admet-2956	260	18	,	,	PUNCT
admet-2956	260	19	novel	novel	ADJ
admet-2956	260	20	biomarkers	biomarker	NOUN
admet-2956	260	21	for	for	ADP
admet-2956	260	22	personalized	personalized	ADJ
admet-2956	260	23	cancer	cancer	NOUN
admet-2956	260	24	immunotherapy	immunotherapy	NOUN
admet-2956	260	25	,	,	PUNCT
admet-2956	260	26	cancers	cancer	NOUN
admet-2956	260	27	(	(	PUNCT
admet-2956	260	28	basel	basel	PROPN
admet-2956	260	29	)	)	PUNCT
admet-2956	260	30	11	11	NUM
admet-2956	260	31	(	(	PUNCT
admet-2956	260	32	2019	2019	NUM
admet-2956	260	33	)	)	PUNCT
admet-2956	260	34	1223	1223	NUM
admet-2956	260	35	.	.	PUNCT
admet-2956	261	1	https://doi.org/10.3390/cancers11091223	https://doi.org/10.3390/cancers11091223	PROPN
admet-2956	262	1	[	[	X
admet-2956	262	2	10	10	NUM
admet-2956	262	3	]	]	X
admet-2956	262	4	l.	l.	PROPN
admet-2956	262	5	v.	v.	CCONJ
admet-2956	262	6	mejía	mejía	PROPN
admet-2956	262	7	-	-	PUNCT
admet-2956	262	8	guarnizo	guarnizo	PROPN
admet-2956	262	9	,	,	PUNCT
admet-2956	262	10	p.	p.	PROPN
admet-2956	262	11	s.	s.	PROPN
admet-2956	262	12	monroy	monroy	PROPN
admet-2956	262	13	-	-	PUNCT
admet-2956	262	14	camacho	camacho	PROPN
admet-2956	262	15	,	,	PUNCT
admet-2956	262	16	a.	a.	PROPN
admet-2956	262	17	d.	d.	PROPN
admet-2956	262	18	turizo	turizo	PROPN
admet-2956	262	19	-	-	PUNCT
admet-2956	262	20	smith	smith	PROPN
admet-2956	262	21	,	,	PUNCT
admet-2956	262	22	j.	j.	PROPN
admet-2956	262	23	a.	a.	PROPN
admet-2956	262	24	rodríguez	rodríguez	PROPN
admet-2956	262	25	-	-	PUNCT
admet-2956	262	26	garcía	garcía	ADJ
admet-2956	262	27	.	.	PUNCT
admet-2956	263	1	the	the	DET
admet-2956	263	2	role	role	NOUN
admet-2956	263	3	of	of	ADP
admet-2956	263	4	immune	immune	ADJ
admet-2956	263	5	checkpoints	checkpoint	NOUN
admet-2956	263	6	in	in	ADP
admet-2956	263	7	antitumor	antitumor	PROPN
admet-2956	263	8	response	response	NOUN
admet-2956	263	9	:	:	PUNCT
admet-2956	263	10	a	a	DET
admet-2956	263	11	potential	potential	ADJ
admet-2956	263	12	antitumor	antitumor	PROPN
admet-2956	263	13	immunotherapy	immunotherapy	NOUN
admet-2956	263	14	.	.	PUNCT
admet-2956	264	1	frontiers	frontier	NOUN
admet-2956	264	2	in	in	ADP
admet-2956	264	3	immunology	immunology	NOUN
admet-2956	264	4	14	14	NUM
admet-2956	264	5	(	(	PUNCT
admet-2956	264	6	2023	2023	NUM
admet-2956	264	7	)	)	PUNCT
admet-2956	264	8	1298571	1298571	NUM
admet-2956	264	9	.	.	PUNCT
admet-2956	265	1	https://doi.org/10.3389/fimmu.2023.1298571	https://doi.org/10.3389/fimmu.2023.1298571	PROPN
admet-2956	266	1	[	[	X
admet-2956	266	2	11	11	NUM
admet-2956	266	3	]	]	X
admet-2956	266	4	d.	d.	PROPN
admet-2956	266	5	lee	lee	PROPN
admet-2956	266	6	,	,	PUNCT
admet-2956	266	7	m.	m.	PROPN
admet-2956	266	8	cho	cho	PROPN
admet-2956	266	9	,	,	PUNCT
admet-2956	266	10	e.	e.	PROPN
admet-2956	266	11	kim	kim	PROPN
admet-2956	266	12	,	,	PUNCT
admet-2956	266	13	y.	y.	PROPN
admet-2956	266	14	seo	seo	PROPN
admet-2956	266	15	,	,	PUNCT
admet-2956	266	16	j.	j.	PROPN
admet-2956	266	17	h.	h.	PROPN
admet-2956	266	18	cha	cha	PROPN
admet-2956	266	19	.	.	PUNCT
admet-2956	267	1	pd	pd	PROPN
admet-2956	267	2	-	-	PUNCT
admet-2956	267	3	l1	l1	PROPN
admet-2956	267	4	:	:	PUNCT
admet-2956	267	5	from	from	ADP
admet-2956	267	6	cancer	cancer	NOUN
admet-2956	267	7	immunotherapy	immunotherapy	NOUN
admet-2956	267	8	to	to	ADP
admet-2956	267	9	therapeutic	therapeutic	ADJ
admet-2956	267	10	implications	implication	NOUN
admet-2956	267	11	in	in	ADP
admet-2956	267	12	multiple	multiple	ADJ
admet-2956	267	13	disorders	disorder	NOUN
admet-2956	267	14	.	.	PUNCT
admet-2956	268	1	molecular	molecular	ADJ
admet-2956	268	2	therapy	therapy	NOUN
admet-2956	268	3	32	32	NUM
admet-2956	268	4	(	(	PUNCT
admet-2956	268	5	2024	2024	NUM
admet-2956	268	6	)	)	PUNCT
admet-2956	268	7	4235	4235	NUM
admet-2956	268	8	-	-	SYM
admet-2956	268	9	4255	4255	NUM
admet-2956	268	10	.	.	PUNCT
admet-2956	269	1	https://doi.org/10.1016/j.ymthe.2024.09.026	https://doi.org/10.1016/j.ymthe.2024.09.026	PROPN
admet-2956	269	2	[	[	X
admet-2956	269	3	12	12	NUM
admet-2956	269	4	]	]	PUNCT
admet-2956	269	5	a.	a.	NOUN
admet-2956	269	6	mohammed	mohammed	PROPN
admet-2956	269	7	,	,	PUNCT
admet-2956	269	8	a.	a.	PROPN
admet-2956	269	9	al	al	PROPN
admet-2956	269	10	-	-	PUNCT
admet-2956	269	11	gawhari	gawhari	ADJ
admet-2956	269	12	.	.	PUNCT
admet-2956	270	1	bioavailability	bioavailability	NOUN
admet-2956	270	2	enhancement	enhancement	NOUN
admet-2956	270	3	techniques	technique	NOUN
admet-2956	270	4	,	,	PUNCT
admet-2956	270	5	and	and	CCONJ
admet-2956	270	6	in	in	ADP
admet-2956	270	7	vitro	vitro	X
admet-2956	270	8	-	-	PUNCT
admet-2956	270	9	in	in	ADP
admet-2956	270	10	vivo	vivo	ADJ
admet-2956	270	11	evaluation	evaluation	NOUN
admet-2956	270	12	of	of	ADP
admet-2956	270	13	rosuvastatin	rosuvastatin	ADJ
admet-2956	270	14	calcium	calcium	NOUN
admet-2956	270	15	-	-	PUNCT
admet-2956	270	16	cyclodextrin	cyclodextrin	NOUN
admet-2956	270	17	inclusion	inclusion	NOUN
admet-2956	270	18	complex	complex	ADJ
admet-2956	270	19	nanofibers	nanofiber	NOUN
admet-2956	270	20	,	,	PUNCT
admet-2956	270	21	procedia	procedia	PROPN
admet-2956	270	22	environmental	environmental	ADJ
admet-2956	270	23	science	science	NOUN
admet-2956	270	24	engineering	engineering	NOUN
admet-2956	270	25	and	and	CCONJ
admet-2956	270	26	management	management	NOUN
admet-2956	270	27	.	.	PUNCT
admet-2956	271	1	11	11	NUM
admet-2956	271	2	(	(	PUNCT
admet-2956	271	3	2024	2024	NUM
admet-2956	271	4	)	)	PUNCT
admet-2956	271	5	117	117	NUM
admet-2956	271	6	-	-	SYM
admet-2956	271	7	134	134	NUM
admet-2956	271	8	.	.	PUNCT
admet-2956	272	1	https://www.procediaesem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	https://www.procediaesem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	PRON
admet-2956	273	1	[	[	X
admet-2956	273	2	13	13	NUM
admet-2956	273	3	]	]	PUNCT
admet-2956	273	4	j.	j.	PROPN
admet-2956	273	5	h.	h.	PROPN
admet-2956	273	6	cha	cha	PROPN
admet-2956	273	7	,	,	PUNCT
admet-2956	273	8	l.	l.	PROPN
admet-2956	273	9	c.	c.	PROPN
admet-2956	273	10	chan	chan	PROPN
admet-2956	273	11	,	,	PUNCT
admet-2956	273	12	c.	c.	PROPN
admet-2956	273	13	w.	w.	PROPN
admet-2956	273	14	li	li	PROPN
admet-2956	273	15	,	,	PUNCT
admet-2956	273	16	j.	j.	PROPN
admet-2956	273	17	l.	l.	PROPN
admet-2956	273	18	hsu	hsu	PROPN
admet-2956	273	19	,	,	PUNCT
admet-2956	273	20	m.	m.	PROPN
admet-2956	273	21	c.	c.	PROPN
admet-2956	273	22	hung	hung	PROPN
admet-2956	273	23	.	.	PUNCT
admet-2956	274	1	mechanisms	mechanism	NOUN
admet-2956	274	2	controlling	control	VERB
admet-2956	274	3	pd	pd	PROPN
admet-2956	274	4	-	-	PROPN
admet-2956	274	5	l1	l1	PROPN
admet-2956	274	6	expression	expression	NOUN
admet-2956	274	7	in	in	ADP
admet-2956	274	8	cancer	cancer	NOUN
admet-2956	274	9	.	.	PUNCT
admet-2956	275	1	molecular	molecular	ADJ
admet-2956	275	2	cell	cell	NOUN
admet-2956	275	3	76	76	NUM
admet-2956	275	4	(	(	PUNCT
admet-2956	275	5	2019	2019	NUM
admet-2956	275	6	)	)	PUNCT
admet-2956	275	7	359	359	NUM
admet-2956	275	8	-	-	SYM
admet-2956	275	9	370	370	NUM
admet-2956	275	10	.	.	PUNCT
admet-2956	276	1	https://doi.org/10.1016/j.molcel.2019.09.030	https://doi.org/10.1016/j.molcel.2019.09.030	NOUN
admet-2956	276	2	[	[	X
admet-2956	276	3	14	14	NUM
admet-2956	276	4	]	]	X
admet-2956	276	5	p.	p.	NOUN
admet-2956	276	6	g.	g.	PROPN
admet-2956	277	1	abrams	abrams	PROPN
admet-2956	277	2	r.	r.	PROPN
admet-2956	277	3	k.	k.	PROPN
admet-2956	277	4	oldham	oldham	PROPN
admet-2956	277	5	.	.	PUNCT
admet-2956	278	1	monoclonal	monoclonal	NOUN
admet-2956	278	2	antibody	antibody	NOUN
admet-2956	278	3	therapy	therapy	NOUN
admet-2956	278	4	of	of	ADP
admet-2956	278	5	solid	solid	ADJ
admet-2956	278	6	tumors	tumor	NOUN
admet-2956	278	7	.	.	PUNCT
admet-2956	279	1	monoclonal	monoclonal	NOUN
admet-2956	279	2	antibodies	antibody	NOUN
admet-2956	279	3	in	in	ADP
admet-2956	279	4	oral	oral	ADJ
admet-2956	279	5	cancer	cancer	NOUN
admet-2956	279	6	therapy	therapy	NOUN
admet-2956	279	7	3	3	NUM
admet-2956	279	8	(	(	PUNCT
admet-2956	279	9	1985	1985	NUM
admet-2956	279	10	)	)	PUNCT
admet-2956	279	11	103	103	NUM
admet-2956	279	12	-	-	SYM
admet-2956	279	13	120	120	NUM
admet-2956	279	14	.	.	PUNCT
admet-2956	280	1	https://doi.org/10.1007/978-1-4613-2627-4_5	https://doi.org/10.1007/978-1-4613-2627-4_5	PROPN
admet-2956	281	1	[	[	X
admet-2956	281	2	15	15	NUM
admet-2956	281	3	]	]	X
admet-2956	281	4	yuliana	yuliana	PROPN
admet-2956	281	5	,	,	PUNCT
admet-2956	281	6	i.	i.	PROPN
admet-2956	281	7	maulana	maulana	PROPN
admet-2956	281	8	,	,	PUNCT
admet-2956	281	9	m.	m.	NOUN
admet-2956	281	10	prenggono	prenggono	PROPN
admet-2956	281	11	,	,	PUNCT
admet-2956	281	12	i.	i.	PROPN
admet-2956	281	13	oktavianti	oktavianti	PROPN
admet-2956	281	14	,	,	PUNCT
admet-2956	281	15	n.	n.	PROPN
admet-2956	281	16	kania	kania	PROPN
admet-2956	281	17	,	,	PUNCT
admet-2956	281	18	r.	r.	PROPN
admet-2956	281	19	panghiyangani	panghiyangani	PROPN
admet-2956	281	20	,	,	PUNCT
admet-2956	281	21	n.	n.	PROPN
admet-2956	281	22	hasanah	hasanah	PROPN
admet-2956	281	23	.	.	PUNCT
admet-2956	282	1	mercury	mercury	NOUN
admet-2956	282	2	exposure	exposure	NOUN
admet-2956	282	3	triggers	trigger	NOUN
admet-2956	282	4	diabetes	diabetes	NOUN
admet-2956	282	5	mellitus	mellitus	NOUN
admet-2956	282	6	through	through	ADP
admet-2956	282	7	a	a	DET
admet-2956	282	8	pancreatic	pancreatic	ADJ
admet-2956	282	9	beta	beta	NOUN
admet-2956	282	10	cell	cell	NOUN
admet-2956	282	11	endoplasmic	endoplasmic	ADJ
admet-2956	282	12	reticulum	reticulum	NOUN
admet-2956	282	13	stress	stress	NOUN
admet-2956	282	14	mechanism	mechanism	NOUN
admet-2956	282	15	.	.	PUNCT
admet-2956	283	1	revista	revista	PROPN
admet-2956	283	2	latinoamericana	latinoamericana	PROPN
admet-2956	284	1	de	de	X
admet-2956	284	2	hipertension	hipertension	NOUN
admet-2956	284	3	20	20	NUM
admet-2956	284	4	(	(	PUNCT
admet-2956	284	5	2025	2025	NUM
admet-2956	284	6	)	)	PUNCT
admet-2956	284	7	410	410	NUM
admet-2956	284	8	-	-	SYM
admet-2956	284	9	416	416	NUM
admet-2956	284	10	.	.	PUNCT
admet-2956	284	11	http://doi.org/10.5281/zenodo.15739647	http://doi.org/10.5281/zenodo.15739647	NOUN
admet-2956	285	1	[	[	X
admet-2956	285	2	16	16	NUM
admet-2956	285	3	]	]	PUNCT
admet-2956	285	4	w.	w.	PROPN
admet-2956	285	5	liu	liu	PROPN
admet-2956	285	6	,	,	PUNCT
admet-2956	285	7	g.	g.	PROPN
admet-2956	285	8	huo	huo	PROPN
admet-2956	285	9	,	,	PUNCT
admet-2956	285	10	p.	p.	PROPN
admet-2956	285	11	chen	chen	PROPN
admet-2956	285	12	.	.	PUNCT
admet-2956	286	1	clinical	clinical	ADJ
admet-2956	286	2	benefit	benefit	NOUN
admet-2956	286	3	of	of	ADP
admet-2956	286	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	286	5	in	in	ADP
admet-2956	286	6	treatment	treatment	NOUN
admet-2956	286	7	of	of	ADP
admet-2956	286	8	first	first	ADJ
admet-2956	286	9	line	line	NOUN
admet-2956	286	10	non	non	ADJ
admet-2956	286	11	-	-	ADJ
admet-2956	286	12	small	small	ADJ
admet-2956	286	13	cell	cell	NOUN
admet-2956	286	14	lung	lung	NOUN
admet-2956	286	15	cancer	cancer	NOUN
admet-2956	286	16	:	:	PUNCT
admet-2956	286	17	a	a	DET
admet-2956	286	18	systematic	systematic	ADJ
admet-2956	286	19	review	review	NOUN
admet-2956	286	20	and	and	CCONJ
admet-2956	286	21	meta	meta	NOUN
admet-2956	286	22	-	-	PUNCT
admet-2956	286	23	analysis	analysis	NOUN
admet-2956	286	24	of	of	ADP
admet-2956	286	25	clinical	clinical	ADJ
admet-2956	286	26	characteristics	characteristic	NOUN
admet-2956	286	27	.	.	PUNCT
admet-2956	287	1	bmc	bmc	ADJ
admet-2956	287	2	cancer	cancer	NOUN
admet-2956	287	3	23	23	NUM
admet-2956	287	4	(	(	PUNCT
admet-2956	287	5	2023	2023	NUM
admet-2956	287	6	)	)	PUNCT
admet-2956	287	7	.	.	PUNCT
admet-2956	288	1	http://doi.org/10.1186/s12885-023-10959-3	http://doi.org/10.1186/s12885-023-10959-3	PROPN
admet-2956	289	1	[	[	X
admet-2956	289	2	17	17	NUM
admet-2956	289	3	]	]	PUNCT
admet-2956	289	4	a.	a.	NOUN
admet-2956	289	5	patnaik	patnaik	PROPN
admet-2956	289	6	,	,	PUNCT
admet-2956	289	7	s.	s.	PROPN
admet-2956	289	8	kang	kang	PROPN
admet-2956	289	9	,	,	PUNCT
admet-2956	289	10	d.	d.	PROPN
admet-2956	289	11	rasco	rasco	PROPN
admet-2956	289	12	,	,	PUNCT
admet-2956	289	13	k.	k.	PROPN
admet-2956	289	14	papadopoulos	papadopoulos	PROPN
admet-2956	289	15	,	,	PUNCT
admet-2956	289	16	j.	j.	PROPN
admet-2956	289	17	elassaiss	elassaiss	PROPN
admet-2956	289	18	-	-	PUNCT
admet-2956	289	19	schaap	schaap	PROPN
admet-2956	289	20	,	,	PUNCT
admet-2956	289	21	m.	m.	NOUN
admet-2956	289	22	beeram	beeram	PROPN
admet-2956	289	23	,	,	PUNCT
admet-2956	289	24	a.	a.	PROPN
admet-2956	289	25	w.	w.	PROPN
admet-2956	289	26	tolcher	tolcher	PROPN
admet-2956	289	27	.	.	PUNCT
admet-2956	290	1	phase	phase	NOUN
admet-2956	290	2	i	i	PRON
admet-2956	290	3	study	study	VERB
admet-2956	290	4	of	of	ADP
admet-2956	290	5	pembrolizumab	pembrolizumab	NOUN
admet-2956	290	6	(	(	PUNCT
admet-2956	290	7	mk-3475	mk-3475	PROPN
admet-2956	290	8	;	;	PUNCT
admet-2956	290	9	anti	anti	ADJ
admet-2956	290	10	-	-	ADJ
admet-2956	290	11	pd-1	pd-1	ADJ
admet-2956	290	12	monoclonal	monoclonal	NOUN
admet-2956	290	13	antibody	antibody	NOUN
admet-2956	290	14	)	)	PUNCT
admet-2956	290	15	in	in	ADP
admet-2956	290	16	patients	patient	NOUN
admet-2956	290	17	with	with	ADP
admet-2956	290	18	advanced	advanced	ADJ
admet-2956	290	19	solid	solid	ADJ
admet-2956	290	20	tumors	tumor	NOUN
admet-2956	290	21	.	.	PUNCT
admet-2956	291	1	clinical	clinical	ADJ
admet-2956	291	2	cancer	cancer	NOUN
admet-2956	291	3	research	research	NOUN
admet-2956	291	4	21	21	NUM
admet-2956	291	5	(	(	PUNCT
admet-2956	291	6	2015	2015	NUM
admet-2956	291	7	)	)	PUNCT
admet-2956	291	8	4286	4286	NUM
admet-2956	291	9	-	-	SYM
admet-2956	291	10	4293	4293	NUM
admet-2956	291	11	.	.	PUNCT
admet-2956	292	1	http://doi.org/10.1158/1078-0432.ccr-142607	http://doi.org/10.1158/1078-0432.ccr-142607	PUNCT
admet-2956	293	1	[	[	X
admet-2956	293	2	18	18	NUM
admet-2956	293	3	]	]	X
admet-2956	293	4	l.	l.	PROPN
admet-2956	293	5	pai	pai	PROPN
admet-2956	293	6	-	-	PUNCT
admet-2956	293	7	scherf	scherf	PROPN
admet-2956	293	8	,	,	PUNCT
admet-2956	293	9	g.	g.	PROPN
admet-2956	293	10	blumenthal	blumenthal	PROPN
admet-2956	293	11	,	,	PUNCT
admet-2956	293	12	h.	h.	PROPN
admet-2956	293	13	li	li	PROPN
admet-2956	293	14	,	,	PUNCT
admet-2956	293	15	s.	s.	PROPN
admet-2956	293	16	subramaniam	subramaniam	PROPN
admet-2956	293	17	,	,	PUNCT
admet-2956	293	18	p.	p.	NOUN
admet-2956	293	19	mishra‐kalyani	mishra‐kalyani	PROPN
admet-2956	293	20	,	,	PUNCT
admet-2956	293	21	k.	k.	PROPN
admet-2956	293	22	he	he	PRON
admet-2956	293	23	,	,	PUNCT
admet-2956	293	24	r.	r.	PROPN
admet-2956	293	25	pazdur	pazdur	PROPN
admet-2956	293	26	.	.	PUNCT
admet-2956	294	1	approval	approval	NOUN
admet-2956	294	2	summary	summary	NOUN
admet-2956	294	3	:	:	PUNCT
admet-2956	294	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	294	5	for	for	ADP
admet-2956	294	6	treatment	treatment	NOUN
admet-2956	294	7	of	of	ADP
admet-2956	294	8	metastatic	metastatic	ADJ
admet-2956	294	9	non	non	ADJ
admet-2956	294	10	-	-	ADJ
admet-2956	294	11	small	small	ADJ
admet-2956	294	12	cell	cell	NOUN
admet-2956	294	13	lung	lung	NOUN
admet-2956	294	14	cancer	cancer	NOUN
admet-2956	294	15	:	:	PUNCT
admet-2956	294	16	first	first	ADJ
admet-2956	294	17	-	-	PUNCT
admet-2956	294	18	line	line	NOUN
admet-2956	294	19	therapy	therapy	NOUN
admet-2956	294	20	and	and	CCONJ
admet-2956	294	21	beyond	beyond	ADP
admet-2956	294	22	.	.	PUNCT
admet-2956	295	1	oncologist	oncologist	NOUN
admet-2956	295	2	22	22	NUM
admet-2956	295	3	(	(	PUNCT
admet-2956	295	4	2017	2017	NUM
admet-2956	295	5	)	)	PUNCT
admet-2956	295	6	1392	1392	NUM
admet-2956	295	7	-	-	SYM
admet-2956	295	8	1399	1399	NUM
admet-2956	295	9	.	.	PUNCT
admet-2956	296	1	http://doi.org/10.1634/theoncologist.2017-0078	http://doi.org/10.1634/theoncologist.2017-0078	PROPN
admet-2956	296	2	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	PROPN
admet-2956	296	3	https://doi.org/10.1038/s41392-025-02243-6	https://doi.org/10.1038/s41392-025-02243-6	PROPN
admet-2956	296	4	file:///d:/dropbox/04_admet	file:///d:/dropbox/04_admet	PROPN
admet-2956	296	5	/	/	SYM
admet-2956	296	6	copyedit/2956/465	copyedit/2956/465	NOUN
admet-2956	296	7	-	-	PUNCT
admet-2956	296	8	472.%20https:/www.procedia	472.%20https:/www.procedia	NOUN
admet-2956	296	9	-	-	PUNCT
admet-2956	296	10	esem.eu	esem.eu	ADP
admet-2956	296	11	/	/	SYM
admet-2956	296	12	pdf	pdf	NOUN
admet-2956	296	13	/	/	SYM
admet-2956	296	14	issues/2024	issues/2024	NOUN
admet-2956	296	15	/	/	SYM
admet-2956	296	16	no3/46_dawood_24.pdf	no3/46_dawood_24.pdf	PROPN
admet-2956	296	17	https://doi.org/10.3389/fimmu.2022.823618	https://doi.org/10.3389/fimmu.2022.823618	PROPN
admet-2956	296	18	https://doi.org/10.1186/s12935-023-02902-0	https://doi.org/10.1186/s12935-023-02902-0	PROPN
admet-2956	296	19	https://doi.org/10.1016/j.cell.2018.09.035	https://doi.org/10.1016/j.cell.2018.09.035	PROPN
admet-2956	296	20	https://doi.org/10.7759/cureus.44582	https://doi.org/10.7759/cureus.44582	NOUN
admet-2956	296	21	https://doi.org/10.3390/cancers11091223	https://doi.org/10.3390/cancers11091223	PROPN
admet-2956	296	22	https://doi.org/10.3389/fimmu.2023.1298571	https://doi.org/10.3389/fimmu.2023.1298571	PROPN
admet-2956	296	23	https://doi.org/10.1016/j.ymthe.2024.09.026	https://doi.org/10.1016/j.ymthe.2024.09.026	PROPN
admet-2956	296	24	https://www.procedia-esem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	https://www.procedia-esem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	PROPN
admet-2956	296	25	https://www.procedia-esem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	https://www.procedia-esem.eu/pdf/issues/2024/no1/13_mohammed_24.pdf	PROPN
admet-2956	296	26	https://doi.org/10.1016/j.molcel.2019.09.030	https://doi.org/10.1016/j.molcel.2019.09.030	PROPN
admet-2956	296	27	https://doi.org/10.1007/978-1-4613-2627-4_5	https://doi.org/10.1007/978-1-4613-2627-4_5	PROPN
admet-2956	296	28	http://doi.org/10.5281/zenodo.15739647	http://doi.org/10.5281/zenodo.15739647	NOUN
admet-2956	296	29	http://doi.org/10.1186/s12885-023-10959-3	http://doi.org/10.1186/s12885-023-10959-3	NUM
admet-2956	296	30	http://doi.org/10.1158/1078-0432.ccr-14-2607	http://doi.org/10.1158/1078-0432.ccr-14-2607	PUNCT
admet-2956	297	1	http://doi.org/10.1158/1078-0432.ccr-14-2607	http://doi.org/10.1158/1078-0432.ccr-14-2607	X
admet-2956	297	2	http://doi.org/10.1634/theoncologist.2017-0078	http://doi.org/10.1634/theoncologist.2017-0078	PROPN
admet-2956	297	3	a.	a.	PROPN
admet-2956	297	4	chakramurty	chakramurty	PROPN
admet-2956	297	5	et	et	PROPN
admet-2956	297	6	al	al	PROPN
admet-2956	297	7	.	.	PROPN
admet-2956	297	8	admet	admet	PROPN
admet-2956	297	9	&	&	CCONJ
admet-2956	297	10	dmpk	dmpk	PROPN
admet-2956	297	11	13(5	13(5	NUM
admet-2956	297	12	)	)	PUNCT
admet-2956	297	13	(	(	PUNCT
admet-2956	297	14	2025	2025	NUM
admet-2956	297	15	)	)	PUNCT
admet-2956	297	16	2956	2956	NUM
admet-2956	297	17	14	14	NUM
admet-2956	298	1	[	[	X
admet-2956	298	2	19	19	NUM
admet-2956	298	3	]	]	PUNCT
admet-2956	298	4	p.	p.	NOUN
admet-2956	298	5	keynote	keynote	PROPN
admet-2956	298	6	.	.	PUNCT
admet-2956	299	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	299	2	keynote-001	keynote-001	NOUN
admet-2956	299	3	:	:	PUNCT
admet-2956	299	4	an	an	DET
admet-2956	299	5	adaptive	adaptive	ADJ
admet-2956	299	6	study	study	NOUN
admet-2956	299	7	leading	lead	VERB
admet-2956	299	8	to	to	ADP
admet-2956	299	9	accelerated	accelerate	VERB
admet-2956	299	10	approval	approval	NOUN
admet-2956	299	11	for	for	ADP
admet-2956	299	12	two	two	NUM
admet-2956	299	13	indications	indication	NOUN
admet-2956	299	14	and	and	CCONJ
admet-2956	299	15	a	a	DET
admet-2956	299	16	companion	companion	NOUN
admet-2956	299	17	diagnostic	diagnostic	ADJ
admet-2956	299	18	.	.	PUNCT
admet-2956	300	1	annals	annal	NOUN
admet-2956	300	2	of	of	ADP
admet-2956	300	3	oncology	oncology	NOUN
admet-2956	300	4	28	28	NUM
admet-2956	300	5	(	(	PUNCT
admet-2956	300	6	2017	2017	NUM
admet-2956	300	7	)	)	PUNCT
admet-2956	300	8	1388	1388	NUM
admet-2956	300	9	-	-	SYM
admet-2956	300	10	1398	1398	NUM
admet-2956	300	11	.	.	PUNCT
admet-2956	301	1	http://doi.org/10.1093/annonc/mdx076	http://doi.org/10.1093/annonc/mdx076	PROPN
admet-2956	301	2	[	[	X
admet-2956	301	3	20	20	NUM
admet-2956	301	4	]	]	PUNCT
admet-2956	301	5	m.	m.	NOUN
admet-2956	301	6	awad	awad	PROPN
admet-2956	301	7	,	,	PUNCT
admet-2956	301	8	s.	s.	PROPN
admet-2956	301	9	gadgeel	gadgeel	PROPN
admet-2956	301	10	,	,	PUNCT
admet-2956	301	11	h.	h.	PROPN
admet-2956	301	12	borghaei	borghaei	PROPN
admet-2956	301	13	,	,	PUNCT
admet-2956	301	14	a.	a.	NOUN
admet-2956	301	15	patnaik	patnaik	PROPN
admet-2956	301	16	,	,	PUNCT
admet-2956	301	17	j.	j.	PROPN
admet-2956	301	18	yang	yang	PROPN
admet-2956	301	19	,	,	PUNCT
admet-2956	301	20	s.	s.	PROPN
admet-2956	301	21	powell	powell	PROPN
admet-2956	301	22	,	,	PUNCT
admet-2956	301	23	c.	c.	PROPN
admet-2956	301	24	langer	langer	PROPN
admet-2956	301	25	.	.	PUNCT
admet-2956	302	1	long	long	ADJ
admet-2956	302	2	-	-	PUNCT
admet-2956	302	3	term	term	NOUN
admet-2956	302	4	overall	overall	ADJ
admet-2956	302	5	survival	survival	NOUN
admet-2956	302	6	from	from	ADP
admet-2956	302	7	keynote-021	keynote-021	PROPN
admet-2956	302	8	cohort	cohort	PROPN
admet-2956	302	9	g	g	NOUN
admet-2956	302	10	:	:	PUNCT
admet-2956	302	11	pemetrexed	pemetrexed	NOUN
admet-2956	302	12	and	and	CCONJ
admet-2956	302	13	carboplatin	carboplatin	NOUN
admet-2956	302	14	with	with	ADP
admet-2956	302	15	or	or	CCONJ
admet-2956	302	16	without	without	ADP
admet-2956	302	17	pembrolizumab	pembrolizumab	NOUN
admet-2956	302	18	as	as	ADP
admet-2956	302	19	firstline	firstline	NOUN
admet-2956	302	20	therapy	therapy	NOUN
admet-2956	302	21	for	for	ADP
admet-2956	302	22	advanced	advanced	ADJ
admet-2956	302	23	nonsquamous	nonsquamous	ADJ
admet-2956	302	24	nsclc	nsclc	NOUN
admet-2956	302	25	.	.	PUNCT
admet-2956	303	1	journal	journal	PROPN
admet-2956	303	2	of	of	ADP
admet-2956	303	3	thoracic	thoracic	NOUN
admet-2956	303	4	oncology	oncology	NOUN
admet-2956	303	5	16	16	NUM
admet-2956	303	6	(	(	PUNCT
admet-2956	303	7	2021	2021	NUM
admet-2956	303	8	)	)	PUNCT
admet-2956	303	9	162	162	NUM
admet-2956	303	10	-	-	SYM
admet-2956	303	11	168	168	NUM
admet-2956	303	12	.	.	PUNCT
admet-2956	304	1	http://doi.org/10.1016/j.jtho.2020.09.015	http://doi.org/10.1016/j.jtho.2020.09.015	PROPN
admet-2956	304	2	[	[	X
admet-2956	304	3	21	21	NUM
admet-2956	304	4	]	]	X
admet-2956	304	5	f.	f.	PROPN
admet-2956	304	6	facchinetti	facchinetti	PROPN
admet-2956	304	7	,	,	PUNCT
admet-2956	304	8	g.	g.	PROPN
admet-2956	304	9	mazzaschi	mazzaschi	PROPN
admet-2956	304	10	,	,	PUNCT
admet-2956	304	11	f.	f.	PROPN
admet-2956	304	12	barbieri	barbieri	PROPN
admet-2956	304	13	,	,	PUNCT
admet-2956	304	14	f.	f.	PROPN
admet-2956	304	15	passiglia	passiglia	PROPN
admet-2956	304	16	,	,	PUNCT
admet-2956	304	17	f.	f.	PROPN
admet-2956	304	18	mazzoni	mazzoni	PROPN
admet-2956	304	19	,	,	PUNCT
admet-2956	304	20	r.	r.	PROPN
admet-2956	304	21	berardi	berardi	PROPN
admet-2956	304	22	,	,	PUNCT
admet-2956	304	23	m.	m.	NOUN
admet-2956	304	24	tiseo	tiseo	NOUN
admet-2956	304	25	.	.	PUNCT
admet-2956	305	1	first	first	ADJ
admet-2956	305	2	-	-	PUNCT
admet-2956	305	3	line	line	NOUN
admet-2956	305	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	305	5	in	in	ADP
admet-2956	305	6	advanced	advanced	ADJ
admet-2956	305	7	non	non	ADJ
admet-2956	305	8	-	-	ADJ
admet-2956	305	9	small	small	ADJ
admet-2956	305	10	cell	cell	NOUN
admet-2956	305	11	lung	lung	NOUN
admet-2956	305	12	cancer	cancer	NOUN
admet-2956	305	13	patients	patient	NOUN
admet-2956	305	14	with	with	ADP
admet-2956	305	15	poor	poor	ADJ
admet-2956	305	16	performance	performance	NOUN
admet-2956	305	17	status	status	NOUN
admet-2956	305	18	.	.	PUNCT
admet-2956	306	1	european	european	PROPN
admet-2956	306	2	journal	journal	PROPN
admet-2956	306	3	of	of	ADP
admet-2956	306	4	cancer	cancer	NOUN
admet-2956	306	5	130	130	NUM
admet-2956	306	6	(	(	PUNCT
admet-2956	306	7	2020	2020	NUM
admet-2956	306	8	)	)	PUNCT
admet-2956	306	9	155	155	NUM
admet-2956	306	10	-	-	SYM
admet-2956	306	11	167	167	NUM
admet-2956	306	12	.	.	PUNCT
admet-2956	307	1	http://doi.org/10.1016/j.ejca.2020.02.023	http://doi.org/10.1016/j.ejca.2020.02.023	PROPN
admet-2956	307	2	[	[	X
admet-2956	307	3	22	22	NUM
admet-2956	307	4	]	]	PUNCT
admet-2956	307	5	m.	m.	NOUN
admet-2956	307	6	reck	reck	PROPN
admet-2956	307	7	.	.	PUNCT
admet-2956	308	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	308	2	as	as	ADP
admet-2956	308	3	first	first	ADJ
admet-2956	308	4	-	-	PUNCT
admet-2956	308	5	line	line	NOUN
admet-2956	308	6	therapy	therapy	NOUN
admet-2956	308	7	for	for	ADP
admet-2956	308	8	metastatic	metastatic	ADJ
admet-2956	308	9	non	non	ADJ
admet-2956	308	10	-	-	ADJ
admet-2956	308	11	small	small	ADJ
admet-2956	308	12	-	-	PUNCT
admet-2956	308	13	cell	cell	NOUN
admet-2956	308	14	lung	lung	NOUN
admet-2956	308	15	cancer	cancer	NOUN
admet-2956	308	16	.	.	PUNCT
admet-2956	309	1	immunotherapy	immunotherapy	NOUN
admet-2956	309	2	10	10	NUM
admet-2956	309	3	(	(	PUNCT
admet-2956	309	4	2018	2018	NUM
admet-2956	309	5	)	)	PUNCT
admet-2956	309	6	93	93	NUM
admet-2956	309	7	-	-	SYM
admet-2956	309	8	105	105	NUM
admet-2956	309	9	.	.	PUNCT
admet-2956	310	1	http://doi.org/10.2217/imt-2017-0121	http://doi.org/10.2217/imt-2017-0121	PROPN
admet-2956	311	1	[	[	X
admet-2956	311	2	23	23	NUM
admet-2956	311	3	]	]	PUNCT
admet-2956	311	4	v.	v.	CCONJ
admet-2956	312	1	alessi	alessi	PROPN
admet-2956	312	2	,	,	PUNCT
admet-2956	312	3	b.	b.	PROPN
admet-2956	312	4	ricciuti	ricciuti	PROPN
admet-2956	312	5	,	,	PUNCT
admet-2956	312	6	e.	e.	PROPN
admet-2956	312	7	jiménez	jiménez	PROPN
admet-2956	312	8	-	-	PUNCT
admet-2956	312	9	aguilar	aguilar	PROPN
admet-2956	312	10	,	,	PUNCT
admet-2956	312	11	f.	f.	PROPN
admet-2956	312	12	hong	hong	PROPN
admet-2956	312	13	,	,	PUNCT
admet-2956	312	14	z.	z.	PROPN
admet-2956	312	15	wei	wei	PROPN
admet-2956	312	16	,	,	PUNCT
admet-2956	312	17	m.	m.	PROPN
admet-2956	312	18	nishino	nishino	PROPN
admet-2956	312	19	,	,	PUNCT
admet-2956	312	20	m.	m.	NOUN
admet-2956	312	21	awad	awad	PROPN
admet-2956	312	22	.	.	PUNCT
admet-2956	313	1	outcomes	outcome	NOUN
admet-2956	313	2	to	to	ADP
admet-2956	313	3	first	first	ADJ
admet-2956	313	4	-	-	PUNCT
admet-2956	313	5	line	line	NOUN
admet-2956	313	6	pembrolizumab	pembrolizumab	NOUN
admet-2956	313	7	in	in	ADP
admet-2956	313	8	patients	patient	NOUN
admet-2956	313	9	pd	pd	PROPN
admet-2956	313	10	-	-	PUNCT
admet-2956	313	11	l1	l1	NOUN
admet-2956	313	12	-	-	PUNCT
admet-2956	313	13	high	high	ADJ
admet-2956	313	14	(	(	PUNCT
admet-2956	313	15	≥50	≥50	NUM
admet-2956	313	16	%	%	NOUN
admet-2956	313	17	)	)	PUNCT
admet-2956	313	18	non	non	ADJ
admet-2956	313	19	-	-	ADJ
admet-2956	313	20	small	small	ADJ
admet-2956	313	21	cell	cell	NOUN
admet-2956	313	22	lung	lung	NOUN
admet-2956	313	23	cancer	cancer	NOUN
admet-2956	313	24	and	and	CCONJ
admet-2956	313	25	a	a	DET
admet-2956	313	26	poor	poor	ADJ
admet-2956	313	27	performance	performance	NOUN
admet-2956	313	28	status	status	NOUN
admet-2956	313	29	.	.	PUNCT
admet-2956	314	1	journal	journal	PROPN
admet-2956	314	2	for	for	ADP
admet-2956	314	3	immunotherapy	immunotherapy	NOUN
admet-2956	314	4	of	of	ADP
admet-2956	314	5	cancer	cancer	NOUN
admet-2956	314	6	8	8	NUM
admet-2956	314	7	(	(	PUNCT
admet-2956	314	8	2020	2020	NUM
admet-2956	314	9	)	)	PUNCT
admet-2956	314	10	78	78	NUM
admet-2956	314	11	-	-	SYM
admet-2956	314	12	87	87	NUM
admet-2956	314	13	.	.	PUNCT
admet-2956	315	1	http://doi.org/10.1136/jitc-2020-001007	http://doi.org/10.1136/jitc-2020-001007	PRON
admet-2956	315	2	[	[	X
admet-2956	315	3	24	24	NUM
admet-2956	315	4	]	]	X
admet-2956	315	5	d.	d.	PROPN
admet-2956	315	6	ksienski	ksienski	PROPN
admet-2956	315	7	,	,	PUNCT
admet-2956	315	8	e.	e.	PROPN
admet-2956	315	9	wai	wai	PROPN
admet-2956	315	10	,	,	PUNCT
admet-2956	315	11	d.	d.	PROPN
admet-2956	315	12	alex	alex	PROPN
admet-2956	315	13	,	,	PUNCT
admet-2956	315	14	n.	n.	PROPN
admet-2956	315	15	croteau	croteau	PROPN
admet-2956	315	16	,	,	PUNCT
admet-2956	315	17	a.	a.	PROPN
admet-2956	315	18	freeman	freeman	PROPN
admet-2956	315	19	,	,	PUNCT
admet-2956	315	20	a.	a.	PROPN
admet-2956	315	21	chan	chan	PROPN
admet-2956	315	22	,	,	PUNCT
admet-2956	315	23	m.	m.	NOUN
admet-2956	315	24	lesperance	lesperance	NOUN
admet-2956	315	25	prognostic	prognostic	ADJ
admet-2956	315	26	significance	significance	NOUN
admet-2956	315	27	of	of	ADP
admet-2956	315	28	the	the	DET
admet-2956	315	29	neutrophil	neutrophil	NOUN
admet-2956	315	30	-	-	PUNCT
admet-2956	315	31	to	to	ADP
admet-2956	315	32	-	-	PUNCT
admet-2956	315	33	lymphocyte	lymphocyte	ADJ
admet-2956	315	34	ratio	ratio	NOUN
admet-2956	315	35	and	and	CCONJ
admet-2956	315	36	platelet	platelet	NOUN
admet-2956	315	37	-	-	PUNCT
admet-2956	315	38	to	to	ADP
admet-2956	315	39	-	-	PUNCT
admet-2956	315	40	lymphocyte	lymphocyte	ADJ
admet-2956	315	41	ratio	ratio	NOUN
admet-2956	315	42	for	for	ADP
admet-2956	315	43	advanced	advanced	ADJ
admet-2956	315	44	non	non	ADJ
admet-2956	315	45	-	-	ADJ
admet-2956	315	46	small	small	ADJ
admet-2956	315	47	cell	cell	NOUN
admet-2956	315	48	lung	lung	NOUN
admet-2956	315	49	cancer	cancer	NOUN
admet-2956	315	50	patients	patient	NOUN
admet-2956	315	51	with	with	ADP
admet-2956	315	52	high	high	ADJ
admet-2956	315	53	pd	pd	PROPN
admet-2956	315	54	-	-	PUNCT
admet-2956	315	55	l1	l1	PROPN
admet-2956	315	56	tumor	tumor	NOUN
admet-2956	315	57	expression	expression	NOUN
admet-2956	315	58	receiving	receive	VERB
admet-2956	315	59	pembrolizumab	pembrolizumab	NOUN
admet-2956	315	60	.	.	PUNCT
admet-2956	316	1	translational	translational	ADJ
admet-2956	316	2	lung	lung	NOUN
admet-2956	316	3	cancer	cancer	NOUN
admet-2956	316	4	research	research	NOUN
admet-2956	316	5	.	.	PUNCT
admet-2956	317	1	10	10	NUM
admet-2956	317	2	(	(	PUNCT
admet-2956	317	3	2021	2021	NUM
admet-2956	317	4	)	)	PUNCT
admet-2956	317	5	355	355	NUM
admet-2956	317	6	-	-	SYM
admet-2956	317	7	367	367	NUM
admet-2956	317	8	.	.	PUNCT
admet-2956	318	1	http://doi.org/10.21037/tlcr-20-541	http://doi.org/10.21037/tlcr-20-541	VERB
admet-2956	319	1	[	[	X
admet-2956	319	2	25	25	NUM
admet-2956	319	3	]	]	PUNCT
admet-2956	319	4	s.	s.	PROPN
admet-2956	319	5	ben	ben	PROPN
admet-2956	319	6	dori	dori	PROPN
admet-2956	319	7	,	,	PUNCT
admet-2956	319	8	a.	a.	PROPN
admet-2956	319	9	aizic	aizic	PROPN
admet-2956	319	10	,	,	PUNCT
admet-2956	319	11	e.	e.	PROPN
admet-2956	319	12	sabo	sabo	PROPN
admet-2956	319	13	,	,	PUNCT
admet-2956	319	14	d.	d.	PROPN
admet-2956	319	15	hershkovitz	hershkovitz	PROPN
admet-2956	319	16	.	.	PUNCT
admet-2956	320	1	spatial	spatial	ADJ
admet-2956	320	2	heterogeneity	heterogeneity	NOUN
admet-2956	320	3	of	of	ADP
admet-2956	320	4	pd	pd	PROPN
admet-2956	320	5	-	-	PROPN
admet-2956	320	6	l1	l1	PROPN
admet-2956	320	7	expression	expression	NOUN
admet-2956	320	8	and	and	CCONJ
admet-2956	320	9	the	the	DET
admet-2956	320	10	risk	risk	NOUN
admet-2956	320	11	for	for	ADP
admet-2956	320	12	misclassification	misclassification	NOUN
admet-2956	320	13	of	of	ADP
admet-2956	320	14	pd	pd	PROPN
admet-2956	320	15	-	-	PROPN
admet-2956	320	16	l1	l1	PROPN
admet-2956	320	17	immunohistochemistry	immunohistochemistry	NOUN
admet-2956	320	18	in	in	ADP
admet-2956	320	19	non	non	ADJ
admet-2956	320	20	-	-	ADJ
admet-2956	320	21	small	small	ADJ
admet-2956	320	22	cell	cell	NOUN
admet-2956	320	23	lung	lung	NOUN
admet-2956	320	24	cancer	cancer	NOUN
admet-2956	320	25	.	.	PUNCT
admet-2956	321	1	lung	lung	NOUN
admet-2956	321	2	cancer	cancer	NOUN
admet-2956	321	3	147	147	NUM
admet-2956	321	4	(	(	PUNCT
admet-2956	321	5	2020	2020	NUM
admet-2956	321	6	)	)	PUNCT
admet-2956	321	7	91	91	NUM
admet-2956	321	8	-	-	SYM
admet-2956	321	9	98	98	NUM
admet-2956	321	10	.	.	PUNCT
admet-2956	322	1	http://doi.org/10.1016/j.lungcan.2020.07.012	http://doi.org/10.1016/j.lungcan.2020.07.012	VERB
admet-2956	322	2	[	[	X
admet-2956	322	3	26	26	NUM
admet-2956	322	4	]	]	X
admet-2956	322	5	y.	y.	PROPN
admet-2956	322	6	saito	saito	PROPN
admet-2956	322	7	s.	s.	PROPN
admet-2956	322	8	horiuchi	horiuchi	PROPN
admet-2956	322	9	,	,	PUNCT
admet-2956	322	10	h.	h.	PROPN
admet-2956	322	11	morooka	morooka	PROPN
admet-2956	322	12	,	,	PUNCT
admet-2956	322	13	t.	t.	NOUN
admet-2956	322	14	ibi	ibi	NOUN
admet-2956	322	15	,	,	PUNCT
admet-2956	322	16	n.	n.	PROPN
admet-2956	322	17	takahashi	takahashi	PROPN
admet-2956	322	18	,	,	PUNCT
admet-2956	322	19	t.	t.	PROPN
admet-2956	322	20	ikeya	ikeya	PROPN
admet-2956	322	21	,	,	PUNCT
admet-2956	322	22	e.	e.	PROPN
admet-2956	322	23	hoshi	hoshi	PROPN
admet-2956	322	24	.	.	PUNCT
admet-2956	323	1	inter	inter	ADJ
admet-2956	323	2	-	-	ADJ
admet-2956	323	3	tumor	tumor	ADJ
admet-2956	323	4	heterogeneity	heterogeneity	NOUN
admet-2956	323	5	of	of	ADP
admet-2956	323	6	pd	pd	PROPN
admet-2956	323	7	-	-	PROPN
admet-2956	323	8	l1	l1	PROPN
admet-2956	323	9	expression	expression	NOUN
admet-2956	323	10	in	in	ADP
admet-2956	323	11	non	non	ADJ
admet-2956	323	12	-	-	ADJ
admet-2956	323	13	small	small	ADJ
admet-2956	323	14	cell	cell	NOUN
admet-2956	323	15	lung	lung	NOUN
admet-2956	323	16	cancer	cancer	NOUN
admet-2956	323	17	.	.	PUNCT
admet-2956	324	1	journal	journal	PROPN
admet-2956	324	2	of	of	ADP
admet-2956	324	3	thoracic	thoracic	NOUN
admet-2956	324	4	disease	disease	NOUN
admet-2956	324	5	11	11	NUM
admet-2956	324	6	(	(	PUNCT
admet-2956	324	7	2019	2019	NUM
admet-2956	324	8	)	)	PUNCT
admet-2956	324	9	4982	4982	NUM
admet-2956	324	10	-	-	SYM
admet-2956	324	11	4991	4991	NUM
admet-2956	324	12	.	.	PUNCT
admet-2956	325	1	http://doi.org/10.21037/jtd.2019.12.24	http://doi.org/10.21037/jtd.2019.12.24	X
admet-2956	326	1	[	[	X
admet-2956	326	2	27	27	NUM
admet-2956	326	3	]	]	X
admet-2956	326	4	e.	e.	PROPN
admet-2956	326	5	sajjadi	sajjadi	PROPN
admet-2956	326	6	,	,	PUNCT
admet-2956	326	7	k.	k.	PROPN
admet-2956	326	8	venetis	venetis	PROPN
admet-2956	326	9	,	,	PUNCT
admet-2956	326	10	c.	c.	PROPN
admet-2956	326	11	scatena	scatena	PROPN
admet-2956	326	12	,	,	PUNCT
admet-2956	326	13	n.	n.	PROPN
admet-2956	326	14	fusco	fusco	PROPN
admet-2956	326	15	.	.	PUNCT
admet-2956	327	1	biomarkers	biomarker	NOUN
admet-2956	327	2	for	for	ADP
admet-2956	327	3	precision	precision	NOUN
admet-2956	327	4	immunotherapy	immunotherapy	NOUN
admet-2956	327	5	in	in	ADP
admet-2956	327	6	the	the	DET
admet-2956	327	7	metastatic	metastatic	ADJ
admet-2956	327	8	setting	setting	NOUN
admet-2956	327	9	:	:	PUNCT
admet-2956	327	10	hope	hope	NOUN
admet-2956	327	11	or	or	CCONJ
admet-2956	327	12	reality	reality	NOUN
admet-2956	327	13	?	?	PUNCT
admet-2956	327	14	.	.	PUNCT
admet-2956	328	1	ecancermedicalscience	ecancermedicalscience	NOUN
admet-2956	328	2	,	,	PUNCT
admet-2956	328	3	14	14	NUM
admet-2956	328	4	(	(	PUNCT
admet-2956	328	5	2020	2020	NUM
admet-2956	328	6	)	)	PUNCT
admet-2956	328	7	78	78	NUM
admet-2956	328	8	-	-	SYM
admet-2956	328	9	89	89	NUM
admet-2956	328	10	.	.	PUNCT
admet-2956	329	1	http://doi.org/10.3332/ecancer.2020.1150	http://doi.org/10.3332/ecancer.2020.1150	PROPN
admet-2956	330	1	[	[	X
admet-2956	330	2	28	28	NUM
admet-2956	330	3	]	]	X
admet-2956	330	4	mhanna	mhanna	NOUN
admet-2956	330	5	,	,	PUNCT
admet-2956	330	6	n.	n.	NOUN
admet-2956	330	7	guibert	guibert	PROPN
admet-2956	330	8	,	,	PUNCT
admet-2956	330	9	j.	j.	PROPN
admet-2956	330	10	milia	milia	PROPN
admet-2956	330	11	,	,	PUNCT
admet-2956	330	12	j.	j.	PROPN
admet-2956	330	13	mazieres	mazieres	PROPN
admet-2956	330	14	.	.	PUNCT
admet-2956	331	1	when	when	SCONJ
admet-2956	331	2	to	to	PART
admet-2956	331	3	consider	consider	VERB
admet-2956	331	4	immune	immune	ADJ
admet-2956	331	5	checkpoint	checkpoint	NOUN
admet-2956	331	6	inhibitors	inhibitor	NOUN
admet-2956	331	7	in	in	ADP
admet-2956	331	8	oncogene	oncogene	NOUN
admet-2956	331	9	-	-	PUNCT
admet-2956	331	10	driven	drive	VERB
admet-2956	331	11	non	non	ADJ
admet-2956	331	12	-	-	ADJ
admet-2956	331	13	small	small	ADJ
admet-2956	331	14	cell	cell	NOUN
admet-2956	331	15	lung	lung	NOUN
admet-2956	331	16	cancer	cancer	NOUN
admet-2956	331	17	?	?	PUNCT
admet-2956	331	18	.	.	PUNCT
admet-2956	332	1	current	current	ADJ
admet-2956	332	2	treatment	treatment	NOUN
admet-2956	332	3	options	option	NOUN
admet-2956	332	4	in	in	ADP
admet-2956	332	5	oncology	oncology	NOUN
admet-2956	332	6	20	20	NUM
admet-2956	332	7	(	(	PUNCT
admet-2956	332	8	2019	2019	NUM
admet-2956	332	9	)	)	PUNCT
admet-2956	332	10	6569	6569	NUM
admet-2956	332	11	.	.	PUNCT
admet-2956	333	1	http://doi.org/10.1007/s11864-019-0652-3	http://doi.org/10.1007/s11864-019-0652-3	NUM
admet-2956	334	1	[	[	X
admet-2956	334	2	29	29	NUM
admet-2956	334	3	]	]	PUNCT
admet-2956	334	4	stares	stare	NOUN
admet-2956	334	5	,	,	PUNCT
admet-2956	334	6	t.	t.	NOUN
admet-2956	334	7	ding	ding	NOUN
admet-2956	334	8	,	,	PUNCT
admet-2956	334	9	c.	c.	PROPN
admet-2956	334	10	stratton	stratton	PROPN
admet-2956	334	11	,	,	PUNCT
admet-2956	334	12	f.	f.	PROPN
admet-2956	334	13	thomson	thomson	PROPN
admet-2956	334	14	,	,	PUNCT
admet-2956	334	15	m.	m.	PROPN
admet-2956	334	16	baxter	baxter	PROPN
admet-2956	334	17	,	,	PUNCT
admet-2956	334	18	h.	h.	PROPN
admet-2956	334	19	cagney	cagney	PROPN
admet-2956	334	20	,	,	PUNCT
admet-2956	334	21	i.	i.	PROPN
admet-2956	334	22	phillips	phillips	PROPN
admet-2956	334	23	.	.	PUNCT
admet-2956	335	1	biomarkers	biomarker	NOUN
admet-2956	335	2	of	of	ADP
admet-2956	335	3	systemic	systemic	ADJ
admet-2956	335	4	inflammation	inflammation	NOUN
admet-2956	335	5	predict	predict	VERB
admet-2956	335	6	survival	survival	NOUN
admet-2956	335	7	with	with	ADP
admet-2956	335	8	first	first	ADJ
admet-2956	335	9	-	-	PUNCT
admet-2956	335	10	line	line	NOUN
admet-2956	335	11	immune	immune	ADJ
admet-2956	335	12	checkpoint	checkpoint	NOUN
admet-2956	335	13	inhibitors	inhibitor	NOUN
admet-2956	335	14	in	in	ADP
admet-2956	335	15	non	non	ADJ
admet-2956	335	16	-	-	ADJ
admet-2956	335	17	small	small	ADJ
admet-2956	335	18	-	-	PUNCT
admet-2956	335	19	cell	cell	NOUN
admet-2956	335	20	lung	lung	NOUN
admet-2956	335	21	cancer	cancer	NOUN
admet-2956	335	22	.	.	PUNCT
admet-2956	336	1	esmo	esmo	NOUN
admet-2956	336	2	open	open	ADJ
admet-2956	336	3	7	7	NUM
admet-2956	336	4	(	(	PUNCT
admet-2956	336	5	2022	2022	NUM
admet-2956	336	6	)	)	PUNCT
admet-2956	336	7	100445	100445	NUM
admet-2956	336	8	.	.	PUNCT
admet-2956	337	1	http://doi.org/10.1016/j.esmoop.2022.100445	http://doi.org/10.1016/j.esmoop.2022.100445	NOUN
admet-2956	338	1	[	[	X
admet-2956	338	2	30	30	NUM
admet-2956	338	3	]	]	PUNCT
admet-2956	338	4	k.	k.	PROPN
admet-2956	338	5	l.	l.	PROPN
admet-2956	338	6	ayers	ayers	PROPN
admet-2956	338	7	,	,	PUNCT
admet-2956	338	8	m.	m.	PROPN
admet-2956	338	9	ma	ma	PROPN
admet-2956	338	10	,	,	PUNCT
admet-2956	338	11	g.	g.	PROPN
admet-2956	338	12	debussche	debussche	PROPN
admet-2956	338	13	,	,	PUNCT
admet-2956	338	14	d.	d.	PROPN
admet-2956	338	15	corrigan	corrigan	PROPN
admet-2956	338	16	,	,	PUNCT
admet-2956	338	17	j.	j.	PROPN
admet-2956	338	18	mccafferty	mccafferty	PROPN
admet-2956	338	19	,	,	PUNCT
admet-2956	338	20	k.	k.	PROPN
admet-2956	338	21	lee	lee	PROPN
admet-2956	338	22	,	,	PUNCT
admet-2956	338	23	s.	s.	PROPN
admet-2956	338	24	d.	d.	PROPN
admet-2956	338	25	li	li	PROPN
admet-2956	338	26	.	.	PUNCT
admet-2956	339	1	a	a	DET
admet-2956	339	2	composite	composite	ADJ
admet-2956	339	3	biomarker	biomarker	NOUN
admet-2956	339	4	of	of	ADP
admet-2956	339	5	neutrophil	neutrophil	ADJ
admet-2956	339	6	-	-	PUNCT
admet-2956	339	7	lymphocyte	lymphocyte	ADJ
admet-2956	339	8	ratio	ratio	NOUN
admet-2956	339	9	and	and	CCONJ
admet-2956	339	10	hemoglobin	hemoglobin	NOUN
admet-2956	339	11	level	level	NOUN
admet-2956	339	12	correlates	correlate	VERB
admet-2956	339	13	with	with	ADP
admet-2956	339	14	clinical	clinical	ADJ
admet-2956	339	15	response	response	NOUN
admet-2956	339	16	to	to	ADP
admet-2956	339	17	pd-1	pd-1	ADJ
admet-2956	339	18	and	and	CCONJ
admet-2956	339	19	pd	pd	PROPN
admet-2956	339	20	-	-	PUNCT
admet-2956	339	21	l1	l1	PROPN
admet-2956	339	22	inhibitors	inhibitor	NOUN
admet-2956	339	23	in	in	ADP
admet-2956	339	24	advanced	advanced	ADJ
admet-2956	339	25	non	non	ADJ
admet-2956	339	26	-	-	ADJ
admet-2956	339	27	small	small	ADJ
admet-2956	339	28	cell	cell	NOUN
admet-2956	339	29	lung	lung	NOUN
admet-2956	339	30	cancers	cancer	NOUN
admet-2956	339	31	.	.	PUNCT
admet-2956	340	1	bmc	bmc	ADJ
admet-2956	340	2	cancer	cancer	NOUN
admet-2956	340	3	21	21	NUM
admet-2956	340	4	(	(	PUNCT
admet-2956	340	5	2021	2021	NUM
admet-2956	340	6	)	)	PUNCT
admet-2956	340	7	441	441	NUM
admet-2956	340	8	.	.	PUNCT
admet-2956	340	9	http://doi.org/10.1186/s12885-021-08194-9	http://doi.org/10.1186/s12885-021-08194-9	NUM
admet-2956	341	1	[	[	X
admet-2956	341	2	31	31	NUM
admet-2956	341	3	]	]	X
admet-2956	341	4	y.	y.	PROPN
admet-2956	341	5	zhou	zhou	PROPN
admet-2956	341	6	,	,	PUNCT
admet-2956	341	7	z.	z.	PROPN
admet-2956	341	8	lin	lin	PROPN
admet-2956	341	9	,	,	PUNCT
admet-2956	341	10	x.	x.	PROPN
admet-2956	341	11	zhang	zhang	PROPN
admet-2956	341	12	,	,	PUNCT
admet-2956	341	13	c.	c.	PROPN
admet-2956	341	14	chen	chen	PROPN
admet-2956	341	15	,	,	PUNCT
admet-2956	341	16	h.	h.	PROPN
admet-2956	341	17	zhao	zhao	PROPN
admet-2956	341	18	,	,	PUNCT
admet-2956	341	19	s.	s.	PROPN
admet-2956	341	20	hong	hong	PROPN
admet-2956	341	21	,	,	PUNCT
admet-2956	341	22	l.	l.	PROPN
admet-2956	341	23	zhang	zhang	PROPN
admet-2956	341	24	.	.	PUNCT
admet-2956	342	1	first	first	ADJ
admet-2956	342	2	-	-	PUNCT
admet-2956	342	3	line	line	NOUN
admet-2956	342	4	treatment	treatment	NOUN
admet-2956	342	5	for	for	ADP
admet-2956	342	6	patients	patient	NOUN
admet-2956	342	7	with	with	ADP
admet-2956	342	8	advanced	advanced	ADJ
admet-2956	342	9	non	non	ADJ
admet-2956	342	10	-	-	ADJ
admet-2956	342	11	small	small	ADJ
admet-2956	342	12	cell	cell	NOUN
admet-2956	342	13	lung	lung	NOUN
admet-2956	342	14	carcinoma	carcinoma	NOUN
admet-2956	342	15	and	and	CCONJ
admet-2956	342	16	high	high	ADJ
admet-2956	342	17	pd	pd	PROPN
admet-2956	342	18	-	-	PROPN
admet-2956	342	19	l1	l1	PROPN
admet-2956	342	20	expression	expression	NOUN
admet-2956	342	21	:	:	PUNCT
admet-2956	342	22	pembrolizumab	pembrolizumab	NOUN
admet-2956	342	23	or	or	CCONJ
admet-2956	342	24	pembrolizumab	pembrolizumab	NOUN
admet-2956	342	25	plus	plus	CCONJ
admet-2956	342	26	chemotherapy	chemotherapy	NOUN
admet-2956	342	27	.	.	PUNCT
admet-2956	343	1	journal	journal	PROPN
admet-2956	343	2	for	for	ADP
admet-2956	343	3	immunotherapy	immunotherapy	NOUN
admet-2956	343	4	of	of	ADP
admet-2956	343	5	cancer	cancer	NOUN
admet-2956	343	6	7	7	NUM
admet-2956	343	7	(	(	PUNCT
admet-2956	343	8	2019	2019	NUM
admet-2956	343	9	)	)	PUNCT
admet-2956	343	10	120	120	NUM
admet-2956	343	11	-	-	SYM
admet-2956	343	12	129	129	NUM
admet-2956	343	13	.	.	PUNCT
admet-2956	344	1	http://doi.org/10.1186/s40425-019-0600-6	http://doi.org/10.1186/s40425-019-0600-6	PROPN
admet-2956	345	1	[	[	X
admet-2956	345	2	32	32	NUM
admet-2956	345	3	]	]	PUNCT
admet-2956	345	4	e.	e.	PROPN
admet-2956	345	5	fountzilas	fountzilas	PROPN
admet-2956	345	6	,	,	PUNCT
admet-2956	345	7	s.	s.	PROPN
admet-2956	345	8	lampaki	lampaki	PROPN
admet-2956	345	9	,	,	PUNCT
admet-2956	345	10	g.	g.	PROPN
admet-2956	345	11	koliou	koliou	PROPN
admet-2956	345	12	,	,	PUNCT
admet-2956	345	13	a.	a.	NOUN
admet-2956	345	14	koumarianou	koumarianou	PROPN
admet-2956	345	15	,	,	PUNCT
admet-2956	345	16	s.	s.	PROPN
admet-2956	345	17	levva	levva	PROPN
admet-2956	345	18	,	,	PUNCT
admet-2956	345	19	a.	a.	NOUN
admet-2956	345	20	vagionas	vagionas	PROPN
admet-2956	345	21	,	,	PUNCT
admet-2956	345	22	d.	d.	PROPN
admet-2956	345	23	bafaloukos	bafaloukos	PROPN
admet-2956	345	24	.	.	PUNCT
admet-2956	346	1	real	real	ADJ
admet-2956	346	2	-	-	PUNCT
admet-2956	346	3	world	world	NOUN
admet-2956	346	4	safety	safety	NOUN
admet-2956	346	5	and	and	CCONJ
admet-2956	346	6	efficacy	efficacy	NOUN
admet-2956	346	7	data	datum	NOUN
admet-2956	346	8	of	of	ADP
admet-2956	346	9	immunotherapy	immunotherapy	NOUN
admet-2956	346	10	in	in	ADP
admet-2956	346	11	patients	patient	NOUN
admet-2956	346	12	with	with	ADP
admet-2956	346	13	cancer	cancer	NOUN
admet-2956	346	14	and	and	CCONJ
admet-2956	346	15	autoimmune	autoimmune	ADJ
admet-2956	346	16	disease	disease	NOUN
admet-2956	346	17	:	:	PUNCT
admet-2956	346	18	the	the	DET
admet-2956	346	19	experience	experience	NOUN
admet-2956	346	20	of	of	ADP
admet-2956	346	21	the	the	DET
admet-2956	346	22	hellenic	hellenic	ADJ
admet-2956	346	23	cooperative	cooperative	ADJ
admet-2956	346	24	oncology	oncology	NOUN
admet-2956	346	25	group	group	NOUN
admet-2956	346	26	.	.	PUNCT
admet-2956	347	1	cancer	cancer	NOUN
admet-2956	347	2	immunology	immunology	NOUN
admet-2956	347	3	71	71	NUM
admet-2956	347	4	(	(	PUNCT
admet-2956	347	5	2022	2022	NUM
admet-2956	347	6	)	)	PUNCT
admet-2956	347	7	327	327	NUM
admet-2956	347	8	-	-	SYM
admet-2956	347	9	337	337	NUM
admet-2956	347	10	.	.	PUNCT
admet-2956	348	1	http://doi.org/10.1007/s00262-021-02985-6	http://doi.org/10.1007/s00262-021-02985-6	PUNCT
admet-2956	349	1	[	[	X
admet-2956	349	2	33	33	NUM
admet-2956	349	3	]	]	PUNCT
admet-2956	349	4	b.	b.	PROPN
admet-2956	349	5	tomasik	tomasik	PROPN
admet-2956	349	6	,	,	PUNCT
admet-2956	349	7	m.	m.	NOUN
admet-2956	349	8	bieńkowski	bieńkowski	PROPN
admet-2956	349	9	,	,	PUNCT
admet-2956	349	10	m.	m.	NOUN
admet-2956	349	11	braun	braun	NOUN
admet-2956	349	12	,	,	PUNCT
admet-2956	349	13	s.	s.	PROPN
admet-2956	349	14	popat	popat	PROPN
admet-2956	349	15	,	,	PUNCT
admet-2956	349	16	r.	r.	PROPN
admet-2956	349	17	dziadziuszko	dziadziuszko	PROPN
admet-2956	349	18	.	.	PROPN
admet-2956	349	19	effectiveness	effectiveness	NOUN
admet-2956	349	20	and	and	CCONJ
admet-2956	349	21	safety	safety	NOUN
admet-2956	349	22	of	of	ADP
admet-2956	349	23	immunotherapy	immunotherapy	NOUN
admet-2956	349	24	in	in	ADP
admet-2956	349	25	nsclc	nsclc	NOUN
admet-2956	349	26	patients	patient	NOUN
admet-2956	349	27	with	with	ADP
admet-2956	349	28	ecog	ecog	NOUN
admet-2956	349	29	ps	ps	NOUN
admet-2956	349	30	score	score	NOUN
admet-2956	349	31	≥2	≥2	PROPN
admet-2956	349	32	systematic	systematic	ADJ
admet-2956	349	33	review	review	NOUN
admet-2956	349	34	and	and	CCONJ
admet-2956	349	35	meta	meta	ADJ
admet-2956	349	36	-	-	PUNCT
admet-2956	349	37	analysis	analysis	NOUN
admet-2956	349	38	.	.	PUNCT
admet-2956	350	1	lung	lung	NOUN
admet-2956	350	2	cancer	cancer	NOUN
admet-2956	350	3	158	158	NUM
admet-2956	350	4	(	(	PUNCT
admet-2956	350	5	2021	2021	NUM
admet-2956	350	6	)	)	PUNCT
admet-2956	350	7	97	97	NUM
admet-2956	350	8	-	-	SYM
admet-2956	350	9	106	106	NUM
admet-2956	350	10	.	.	PUNCT
admet-2956	351	1	http://doi.org/10.1016/j.lungcan.2021.06.004	http://doi.org/10.1016/j.lungcan.2021.06.004	NOUN
admet-2956	351	2	http://doi.org/10.1093/annonc/mdx076	http://doi.org/10.1093/annonc/mdx076	VERB
admet-2956	351	3	http://doi.org/10.1016/j.jtho.2020.09.015	http://doi.org/10.1016/j.jtho.2020.09.015	PROPN
admet-2956	351	4	http://doi.org/10.1016/j.ejca.2020.02.023	http://doi.org/10.1016/j.ejca.2020.02.023	PROPN
admet-2956	351	5	http://doi.org/10.2217/imt-2017-0121	http://doi.org/10.2217/imt-2017-0121	VERB
admet-2956	351	6	http://doi.org/10.1136/jitc-2020-001007	http://doi.org/10.1136/jitc-2020-001007	NUM
admet-2956	351	7	http://doi.org/10.21037/tlcr-20-541	http://doi.org/10.21037/tlcr-20-541	NOUN
admet-2956	351	8	http://doi.org/10.1016/j.lungcan.2020.07.012	http://doi.org/10.1016/j.lungcan.2020.07.012	NOUN
admet-2956	351	9	http://doi.org/10.21037/jtd.2019.12.24	http://doi.org/10.21037/jtd.2019.12.24	NOUN
admet-2956	351	10	http://doi.org/10.3332/ecancer.2020.1150	http://doi.org/10.3332/ecancer.2020.1150	PROPN
admet-2956	351	11	http://doi.org/10.1007/s11864-019-0652-3	http://doi.org/10.1007/s11864-019-0652-3	NUM
admet-2956	351	12	http://doi.org/10.1016/j.esmoop.2022.100445	http://doi.org/10.1016/j.esmoop.2022.100445	PROPN
admet-2956	351	13	http://doi.org/10.1186/s12885-021-08194-9	http://doi.org/10.1186/s12885-021-08194-9	NUM
admet-2956	351	14	http://doi.org/10.1186/s40425-019-0600-6	http://doi.org/10.1186/s40425-019-0600-6	NUM
admet-2956	351	15	http://doi.org/10.1007/s00262-021-02985-6	http://doi.org/10.1007/s00262-021-02985-6	NUM
admet-2956	351	16	http://doi.org/10.1016/j.lungcan.2021.06.004	http://doi.org/10.1016/j.lungcan.2021.06.004	NOUN
admet-2956	351	17	admet	admet	X
admet-2956	351	18	&	&	CCONJ
admet-2956	351	19	dmpk	dmpk	PROPN
admet-2956	351	20	13(5	13(5	NOUN
admet-2956	351	21	)	)	PUNCT
admet-2956	351	22	(	(	PUNCT
admet-2956	351	23	2025	2025	NUM
admet-2956	351	24	)	)	PUNCT
admet-2956	351	25	2956	2956	NUM
admet-2956	351	26	pembrolizumab	pembrolizumab	NOUN
admet-2956	351	27	in	in	ADP
admet-2956	351	28	pd	pd	PROPN
admet-2956	351	29	-	-	PUNCT
admet-2956	351	30	l1	l1	PROPN
admet-2956	351	31	-	-	PUNCT
admet-2956	351	32	positive	positive	ADJ
admet-2956	351	33	advanced	advanced	ADJ
admet-2956	351	34	non	non	ADJ
admet-2956	351	35	-	-	ADJ
admet-2956	351	36	small	small	ADJ
admet-2956	351	37	cell	cell	NOUN
admet-2956	351	38	lung	lung	NOUN
admet-2956	351	39	carcinoma	carcinoma	NOUN
admet-2956	351	40	doi	doi	NOUN
admet-2956	351	41	:	:	PUNCT
admet-2956	351	42	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	351	43	15	15	NUM
admet-2956	351	44	[	[	SYM
admet-2956	351	45	34	34	NUM
admet-2956	351	46	]	]	X
admet-2956	351	47	c.	c.	PROPN
admet-2956	351	48	j.	j.	PROPN
admet-2956	351	49	d.	d.	PROPN
admet-2956	351	50	wallis	wallis	PROPN
admet-2956	351	51	,	,	PUNCT
admet-2956	351	52	m.	m.	NOUN
admet-2956	351	53	butaney	butaney	PROPN
admet-2956	351	54	,	,	PUNCT
admet-2956	351	55	r.	r.	PROPN
admet-2956	351	56	satkunasivam	satkunasivam	PROPN
admet-2956	351	57	,	,	PUNCT
admet-2956	351	58	s.	s.	PROPN
admet-2956	351	59	freedland	freedland	PROPN
admet-2956	351	60	,	,	PUNCT
admet-2956	351	61	s.	s.	PROPN
admet-2956	351	62	patel	patel	PROPN
admet-2956	351	63	,	,	PUNCT
admet-2956	351	64	o.	o.	PROPN
admet-2956	351	65	hamid	hamid	PROPN
admet-2956	351	66	,	,	PUNCT
admet-2956	351	67	z.	z.	PROPN
admet-2956	351	68	klaassen	klaassen	PROPN
admet-2956	351	69	.	.	PUNCT
admet-2956	352	1	association	association	NOUN
admet-2956	352	2	of	of	ADP
admet-2956	352	3	patient	patient	ADJ
admet-2956	352	4	sex	sex	NOUN
admet-2956	352	5	with	with	ADP
admet-2956	352	6	efficacy	efficacy	NOUN
admet-2956	352	7	of	of	ADP
admet-2956	352	8	immune	immune	ADJ
admet-2956	352	9	checkpoint	checkpoint	NOUN
admet-2956	352	10	inhibitors	inhibitor	NOUN
admet-2956	352	11	and	and	CCONJ
admet-2956	352	12	overall	overall	ADJ
admet-2956	352	13	survival	survival	NOUN
admet-2956	352	14	in	in	ADP
admet-2956	352	15	advanced	advanced	ADJ
admet-2956	352	16	cancers	cancer	NOUN
admet-2956	352	17	:	:	PUNCT
admet-2956	352	18	a	a	DET
admet-2956	352	19	systematic	systematic	ADJ
admet-2956	352	20	review	review	NOUN
admet-2956	352	21	and	and	CCONJ
admet-2956	352	22	meta	meta	ADJ
admet-2956	352	23	-	-	PUNCT
admet-2956	352	24	analysis	analysis	NOUN
admet-2956	352	25	.	.	PUNCT
admet-2956	353	1	jama	jama	PROPN
admet-2956	353	2	oncology	oncology	NOUN
admet-2956	353	3	5	5	NUM
admet-2956	353	4	(	(	PUNCT
admet-2956	353	5	2019	2019	NUM
admet-2956	353	6	)	)	PUNCT
admet-2956	353	7	529	529	NUM
admet-2956	353	8	-	-	SYM
admet-2956	353	9	536	536	NUM
admet-2956	353	10	.	.	PUNCT
admet-2956	354	1	http://doi.org/10.1001/jamaoncol.2018.5904	http://doi.org/10.1001/jamaoncol.2018.5904	PROPN
admet-2956	354	2	[	[	X
admet-2956	354	3	35	35	NUM
admet-2956	354	4	]	]	X
admet-2956	354	5	f.	f.	PROPN
admet-2956	354	6	yang	yang	PROPN
admet-2956	354	7	,	,	PUNCT
admet-2956	354	8	s.	s.	PROPN
admet-2956	354	9	markovic	markovic	PROPN
admet-2956	354	10	,	,	PUNCT
admet-2956	354	11	j.	j.	PROPN
admet-2956	354	12	molina	molina	PROPN
admet-2956	354	13	,	,	PUNCT
admet-2956	354	14	t.	t.	PROPN
admet-2956	354	15	halfdanarson	halfdanarson	PROPN
admet-2956	354	16	,	,	PUNCT
admet-2956	354	17	l.	l.	PROPN
admet-2956	354	18	pagliaro	pagliaro	PROPN
admet-2956	354	19	,	,	PUNCT
admet-2956	354	20	a.	a.	PROPN
admet-2956	354	21	chintakuntlawar	chintakuntlawar	PROPN
admet-2956	354	22	y.	y.	PROPN
admet-2956	354	23	wang	wang	PROPN
admet-2956	354	24	.	.	PUNCT
admet-2956	355	1	association	association	PROPN
admet-2956	355	2	of	of	ADP
admet-2956	355	3	sex	sex	NOUN
admet-2956	355	4	,	,	PUNCT
admet-2956	355	5	age	age	NOUN
admet-2956	355	6	,	,	PUNCT
admet-2956	355	7	and	and	CCONJ
admet-2956	355	8	eastern	eastern	ADJ
admet-2956	355	9	cooperative	cooperative	ADJ
admet-2956	355	10	oncology	oncology	NOUN
admet-2956	355	11	group	group	NOUN
admet-2956	355	12	performance	performance	NOUN
admet-2956	355	13	status	status	NOUN
admet-2956	355	14	with	with	ADP
admet-2956	355	15	survival	survival	NOUN
admet-2956	355	16	benefit	benefit	NOUN
admet-2956	355	17	of	of	ADP
admet-2956	355	18	cancer	cancer	NOUN
admet-2956	355	19	immunotherapy	immunotherapy	NOUN
admet-2956	355	20	in	in	ADP
admet-2956	355	21	randomized	randomize	VERB
admet-2956	355	22	clinical	clinical	ADJ
admet-2956	355	23	trials	trial	NOUN
admet-2956	355	24	:	:	PUNCT
admet-2956	355	25	a	a	DET
admet-2956	355	26	systematic	systematic	ADJ
admet-2956	355	27	review	review	NOUN
admet-2956	355	28	and	and	CCONJ
admet-2956	355	29	meta	meta	ADJ
admet-2956	355	30	-	-	PUNCT
admet-2956	355	31	analysis	analysis	NOUN
admet-2956	355	32	.	.	PUNCT
admet-2956	356	1	jama	jama	PROPN
admet-2956	356	2	network	network	PROPN
admet-2956	356	3	open	open	VERB
admet-2956	356	4	3	3	NUM
admet-2956	356	5	(	(	PUNCT
admet-2956	356	6	2020	2020	NUM
admet-2956	356	7	)	)	PUNCT
admet-2956	356	8	e2012534	e2012534	NOUN
admet-2956	356	9	.	.	PUNCT
admet-2956	357	1	http://doi.org/10.1001/jamanetworkopen.2020.12534	http://doi.org/10.1001/jamanetworkopen.2020.12534	NOUN
admet-2956	357	2	[	[	X
admet-2956	357	3	36	36	NUM
admet-2956	357	4	]	]	SYM
admet-2956	357	5	schwartzberg	schwartzberg	PROPN
admet-2956	357	6	,	,	PUNCT
admet-2956	357	7	b.	b.	PROPN
admet-2956	357	8	korytowsky	korytowsky	PROPN
admet-2956	357	9	,	,	PUNCT
admet-2956	357	10	j.	j.	PROPN
admet-2956	357	11	penrod	penrod	PROPN
admet-2956	357	12	,	,	PUNCT
admet-2956	357	13	y.	y.	PROPN
admet-2956	357	14	zhang	zhang	PROPN
admet-2956	357	15	,	,	PUNCT
admet-2956	357	16	t.	t.	PROPN
admet-2956	357	17	le	le	PROPN
admet-2956	357	18	,	,	PUNCT
admet-2956	357	19	c.	c.	PROPN
admet-2956	357	20	batenchuk	batenchuk	PROPN
admet-2956	357	21	,	,	PUNCT
admet-2956	357	22	l.	l.	PROPN
admet-2956	357	23	krug	krug	PROPN
admet-2956	357	24	.	.	PUNCT
admet-2956	358	1	real	real	ADJ
admet-2956	358	2	-	-	PUNCT
admet-2956	358	3	world	world	NOUN
admet-2956	358	4	clinical	clinical	ADJ
admet-2956	358	5	impact	impact	NOUN
admet-2956	358	6	of	of	ADP
admet-2956	358	7	immune	immune	ADJ
admet-2956	358	8	checkpoint	checkpoint	NOUN
admet-2956	358	9	inhibitors	inhibitor	NOUN
admet-2956	358	10	in	in	ADP
admet-2956	358	11	patients	patient	NOUN
admet-2956	358	12	with	with	ADP
admet-2956	358	13	advanced	advanced	ADJ
admet-2956	358	14	/	/	SYM
admet-2956	358	15	metastatic	metastatic	ADJ
admet-2956	358	16	non	non	ADJ
admet-2956	358	17	-	-	ADJ
admet-2956	358	18	small	small	ADJ
admet-2956	358	19	cell	cell	NOUN
admet-2956	358	20	lung	lung	NOUN
admet-2956	358	21	cancer	cancer	NOUN
admet-2956	358	22	after	after	ADP
admet-2956	358	23	platinum	platinum	NOUN
admet-2956	358	24	chemotherapy	chemotherapy	NOUN
admet-2956	358	25	.	.	PUNCT
admet-2956	359	1	clinical	clinical	ADJ
admet-2956	359	2	lung	lung	NOUN
admet-2956	359	3	cancer	cancer	NOUN
admet-2956	359	4	20	20	NUM
admet-2956	359	5	(	(	PUNCT
admet-2956	359	6	2019	2019	NUM
admet-2956	359	7	)	)	PUNCT
admet-2956	359	8	287	287	NUM
admet-2956	359	9	-	-	SYM
admet-2956	359	10	296.e4	296.e4	NUM
admet-2956	359	11	.	.	PUNCT
admet-2956	360	1	http://doi.org/10.1016/j.cllc.2019.04.004	http://doi.org/10.1016/j.cllc.2019.04.004	NOUN
admet-2956	360	2	[	[	X
admet-2956	360	3	37	37	NUM
admet-2956	360	4	]	]	PUNCT
admet-2956	360	5	a.	a.	PROPN
admet-2956	360	6	f.	f.	PROPN
admet-2956	360	7	kaizal	kaizal	PROPN
admet-2956	360	8	,	,	PUNCT
admet-2956	360	9	j.	j.	PROPN
admet-2956	360	10	algburi	algburi	PROPN
admet-2956	360	11	,	,	PUNCT
admet-2956	360	12	m.	m.	NOUN
admet-2956	360	13	al	al	PROPN
admet-2956	360	14	-	-	PUNCT
admet-2956	360	15	haidarey	haidarey	PROPN
admet-2956	360	16	.	.	PUNCT
admet-2956	361	1	heavy	heavy	ADJ
admet-2956	361	2	metal	metal	NOUN
admet-2956	361	3	bioaccumulation	bioaccumulation	NOUN
admet-2956	361	4	in	in	ADP
admet-2956	361	5	the	the	DET
admet-2956	361	6	blood	blood	NOUN
admet-2956	361	7	and	and	CCONJ
admet-2956	361	8	lungs	lung	NOUN
admet-2956	361	9	of	of	ADP
admet-2956	361	10	white	white	ADJ
admet-2956	361	11	albino	albino	NOUN
admet-2956	361	12	rats	rat	NOUN
admet-2956	361	13	exposed	expose	VERB
admet-2956	361	14	to	to	ADP
admet-2956	361	15	welding	weld	VERB
admet-2956	361	16	fume	fume	NOUN
admet-2956	361	17	.	.	PUNCT
admet-2956	362	1	procedia	procedia	NOUN
admet-2956	362	2	of	of	ADP
admet-2956	362	3	environmental	environmental	ADJ
admet-2956	362	4	science	science	NOUN
admet-2956	362	5	engineering	engineering	NOUN
admet-2956	362	6	and	and	CCONJ
admet-2956	362	7	management	management	NOUN
admet-2956	362	8	11	11	NUM
admet-2956	362	9	(	(	PUNCT
admet-2956	362	10	2024	2024	NUM
admet-2956	362	11	)	)	PUNCT
admet-2956	362	12	83	83	NUM
admet-2956	362	13	-	-	SYM
admet-2956	362	14	89	89	NUM
admet-2956	362	15	.	.	PUNCT
admet-2956	363	1	https://www.procedia-esem.eu/pdf/issues/2024/no1/10_kaizal_24.pdf	https://www.procedia-esem.eu/pdf/issues/2024/no1/10_kaizal_24.pdf	NOUN
admet-2956	364	1	[	[	X
admet-2956	364	2	38	38	NUM
admet-2956	364	3	]	]	PUNCT
admet-2956	364	4	k.	k.	PROPN
admet-2956	364	5	amrane	amrane	PROPN
admet-2956	364	6	.	.	PUNCT
admet-2956	365	1	first	first	ADJ
admet-2956	365	2	-	-	PUNCT
admet-2956	365	3	line	line	NOUN
admet-2956	365	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	365	5	for	for	ADP
admet-2956	365	6	non	non	ADJ
admet-2956	365	7	-	-	ADJ
admet-2956	365	8	small	small	ADJ
admet-2956	365	9	cell	cell	NOUN
admet-2956	365	10	lung	lung	NOUN
admet-2956	365	11	cancer	cancer	NOUN
admet-2956	365	12	patients	patient	NOUN
admet-2956	365	13	with	with	ADP
admet-2956	365	14	pd	pd	PROPN
admet-2956	365	15	-	-	PROPN
admet-2956	365	16	l1	l1	PROPN
admet-2956	365	17	≥50	≥50	NUM
admet-2956	365	18	%	%	NOUN
admet-2956	365	19	in	in	ADP
admet-2956	365	20	a	a	DET
admet-2956	365	21	multicenter	multicenter	ADJ
admet-2956	365	22	real	real	ADJ
admet-2956	365	23	-	-	PUNCT
admet-2956	365	24	life	life	NOUN
admet-2956	365	25	cohort	cohort	NOUN
admet-2956	365	26	:	:	PUNCT
admet-2956	365	27	the	the	DET
admet-2956	365	28	pembreizh	pembreizh	PROPN
admet-2956	365	29	study	study	NOUN
admet-2956	365	30	.	.	PUNCT
admet-2956	366	1	cancer	cancer	NOUN
admet-2956	366	2	medicine	medicine	NOUN
admet-2956	366	3	9	9	NUM
admet-2956	366	4	(	(	PUNCT
admet-2956	366	5	2020	2020	NUM
admet-2956	366	6	)	)	PUNCT
admet-2956	366	7	2309	2309	NUM
admet-2956	366	8	-	-	SYM
admet-2956	366	9	2316	2316	NUM
admet-2956	366	10	.	.	PUNCT
admet-2956	367	1	http://doi.org/10.1002/cam4.2806	http://doi.org/10.1002/cam4.2806	VERB
admet-2956	368	1	[	[	X
admet-2956	368	2	39	39	NUM
admet-2956	368	3	]	]	PUNCT
admet-2956	368	4	g.	g.	PROPN
admet-2956	368	5	wagner	wagner	PROPN
admet-2956	368	6	,	,	PUNCT
admet-2956	368	7	h.	h.	PROPN
admet-2956	368	8	k.	k.	PROPN
admet-2956	368	9	stollenwerk	stollenwerk	PROPN
admet-2956	368	10	,	,	PUNCT
admet-2956	368	11	i.	i.	PROPN
admet-2956	368	12	klerings	klerings	PROPN
admet-2956	368	13	,	,	PUNCT
admet-2956	368	14	m.	m.	NOUN
admet-2956	368	15	pecherstorfer	pecherstorfer	NOUN
admet-2956	368	16	,	,	PUNCT
admet-2956	368	17	g.	g.	PROPN
admet-2956	368	18	gartlehner	gartlehner	NOUN
admet-2956	368	19	,	,	PUNCT
admet-2956	368	20	j.	j.	PROPN
admet-2956	368	21	singer	singer	PROPN
admet-2956	368	22	.	.	PUNCT
admet-2956	369	1	efficacy	efficacy	NOUN
admet-2956	369	2	and	and	CCONJ
admet-2956	369	3	safety	safety	NOUN
admet-2956	369	4	of	of	ADP
admet-2956	369	5	immune	immune	ADJ
admet-2956	369	6	checkpoint	checkpoint	NOUN
admet-2956	369	7	inhibitors	inhibitor	NOUN
admet-2956	369	8	in	in	ADP
admet-2956	369	9	patients	patient	NOUN
admet-2956	369	10	with	with	ADP
admet-2956	369	11	advanced	advanced	ADJ
admet-2956	369	12	non	non	ADJ
admet-2956	369	13	-	-	ADJ
admet-2956	369	14	small	small	ADJ
admet-2956	369	15	cell	cell	NOUN
admet-2956	369	16	lung	lung	NOUN
admet-2956	369	17	cancer	cancer	NOUN
admet-2956	369	18	(	(	PUNCT
admet-2956	369	19	nsclc	nsclc	NOUN
admet-2956	369	20	):	):	PUNCT
admet-2956	369	21	a	a	DET
admet-2956	369	22	systematic	systematic	ADJ
admet-2956	369	23	literature	literature	NOUN
admet-2956	369	24	review	review	NOUN
admet-2956	369	25	.	.	PUNCT
admet-2956	370	1	oncoimmunology	oncoimmunology	NOUN
admet-2956	370	2	9	9	NUM
admet-2956	370	3	(	(	PUNCT
admet-2956	370	4	2020	2020	NUM
admet-2956	370	5	)	)	PUNCT
admet-2956	370	6	45	45	NUM
admet-2956	370	7	-	-	SYM
admet-2956	370	8	59	59	NUM
admet-2956	370	9	.	.	PUNCT
admet-2956	371	1	http://doi.org/10.1080/2162402x.2020.1774314	http://doi.org/10.1080/2162402x.2020.1774314	NOUN
admet-2956	372	1	[	[	X
admet-2956	372	2	40	40	NUM
admet-2956	372	3	]	]	PUNCT
admet-2956	372	4	w.	w.	PROPN
admet-2956	372	5	you	you	PRON
admet-2956	372	6	,	,	PUNCT
admet-2956	372	7	m.	m.	PROPN
admet-2956	372	8	liu	liu	PROPN
admet-2956	372	9	,	,	PUNCT
admet-2956	372	10	j.	j.	PROPN
admet-2956	372	11	miao	miao	PROPN
admet-2956	372	12	,	,	PUNCT
admet-2956	372	13	y.	y.	PROPN
admet-2956	372	14	liao	liao	PROPN
admet-2956	372	15	,	,	PUNCT
admet-2956	372	16	y.	y.	PROPN
admet-2956	372	17	song	song	PROPN
admet-2956	372	18	,	,	PUNCT
admet-2956	372	19	d.	d.	PROPN
admet-2956	372	20	cai	cai	PROPN
admet-2956	372	21	.	.	PUNCT
admet-2956	373	1	a	a	DET
admet-2956	373	2	network	network	NOUN
admet-2956	373	3	meta	meta	ADJ
admet-2956	373	4	-	-	PUNCT
admet-2956	373	5	analysis	analysis	NOUN
admet-2956	373	6	comparing	compare	VERB
admet-2956	373	7	the	the	DET
admet-2956	373	8	efficacy	efficacy	NOUN
admet-2956	373	9	and	and	CCONJ
admet-2956	373	10	safety	safety	NOUN
admet-2956	373	11	of	of	ADP
admet-2956	373	12	anti	anti	NOUN
admet-2956	373	13	-	-	NOUN
admet-2956	373	14	pd-1	pd-1	ADJ
admet-2956	373	15	with	with	ADP
admet-2956	373	16	anti	anti	ADJ
admet-2956	373	17	-	-	ADJ
admet-2956	373	18	pd	pd	ADJ
admet-2956	373	19	-	-	NOUN
admet-2956	373	20	l1	l1	PROPN
admet-2956	373	21	in	in	ADP
admet-2956	373	22	non	non	ADJ
admet-2956	373	23	-	-	ADJ
admet-2956	373	24	small	small	ADJ
admet-2956	373	25	cell	cell	NOUN
admet-2956	373	26	lung	lung	NOUN
admet-2956	373	27	cancer	cancer	NOUN
admet-2956	373	28	.	.	PUNCT
admet-2956	374	1	journal	journal	PROPN
admet-2956	374	2	of	of	ADP
admet-2956	374	3	cancer	cancer	NOUN
admet-2956	374	4	9	9	NUM
admet-2956	374	5	(	(	PUNCT
admet-2956	374	6	2018	2018	NUM
admet-2956	374	7	)	)	PUNCT
admet-2956	374	8	12001206	12001206	NUM
admet-2956	374	9	.	.	PUNCT
admet-2956	375	1	http://doi.org/10.7150/jca.22361	http://doi.org/10.7150/jca.22361	NOUN
admet-2956	376	1	[	[	X
admet-2956	376	2	41	41	NUM
admet-2956	376	3	]	]	PUNCT
admet-2956	376	4	k.	k.	NOUN
admet-2956	376	5	nesline	nesline	PROPN
admet-2956	376	6	,	,	PUNCT
admet-2956	376	7	t.	t.	NOUN
admet-2956	376	8	knight	knight	NOUN
admet-2956	376	9	,	,	PUNCT
admet-2956	376	10	s.	s.	PROPN
admet-2956	376	11	colman	colman	PROPN
admet-2956	376	12	,	,	PUNCT
admet-2956	376	13	k.	k.	PROPN
admet-2956	376	14	patel	patel	PROPN
admet-2956	376	15	.	.	PUNCT
admet-2956	377	1	economic	economic	ADJ
admet-2956	377	2	burden	burden	NOUN
admet-2956	377	3	of	of	ADP
admet-2956	377	4	checkpoint	checkpoint	NOUN
admet-2956	377	5	inhibitor	inhibitor	NOUN
admet-2956	377	6	immunotherapy	immunotherapy	NOUN
admet-2956	377	7	for	for	ADP
admet-2956	377	8	the	the	DET
admet-2956	377	9	treatment	treatment	NOUN
admet-2956	377	10	of	of	ADP
admet-2956	377	11	non	non	ADJ
admet-2956	377	12	-	-	ADJ
admet-2956	377	13	small	small	ADJ
admet-2956	377	14	cell	cell	NOUN
admet-2956	377	15	lung	lung	NOUN
admet-2956	377	16	cancer	cancer	NOUN
admet-2956	377	17	in	in	ADP
admet-2956	377	18	us	we	PRON
admet-2956	377	19	clinical	clinical	ADJ
admet-2956	377	20	practice	practice	NOUN
admet-2956	377	21	.	.	PUNCT
admet-2956	378	1	clinical	clinical	ADJ
admet-2956	378	2	therapeutics	therapeutic	NOUN
admet-2956	378	3	42	42	NUM
admet-2956	378	4	(	(	PUNCT
admet-2956	378	5	2020	2020	NUM
admet-2956	378	6	)	)	PUNCT
admet-2956	378	7	1682	1682	NUM
admet-2956	378	8	-	-	SYM
admet-2956	378	9	1698	1698	NUM
admet-2956	378	10	.	.	PUNCT
admet-2956	379	1	http://doi.org/10.1016/j.clinthera.2020.06.018	http://doi.org/10.1016/j.clinthera.2020.06.018	NOUN
admet-2956	379	2	[	[	X
admet-2956	379	3	42	42	NUM
admet-2956	379	4	]	]	PUNCT
admet-2956	379	5	x.	x.	PROPN
admet-2956	379	6	ma	ma	PROPN
admet-2956	379	7	,	,	PUNCT
admet-2956	379	8	l.	l.	PROPN
admet-2956	379	9	bellomo	bellomo	PROPN
admet-2956	379	10	,	,	PUNCT
admet-2956	379	11	k.	k.	PROPN
admet-2956	379	12	magee	magee	PROPN
admet-2956	379	13	,	,	PUNCT
admet-2956	379	14	c.	c.	PROPN
admet-2956	379	15	bennette	bennette	PROPN
admet-2956	379	16	,	,	PUNCT
admet-2956	379	17	o.	o.	PROPN
admet-2956	379	18	tymejczyk	tymejczyk	PROPN
admet-2956	379	19	,	,	PUNCT
admet-2956	379	20	m.	m.	NOUN
admet-2956	379	21	samant	samant	NOUN
admet-2956	379	22	,	,	PUNCT
admet-2956	379	23	a.	a.	NOUN
admet-2956	379	24	bourla	bourla	NOUN
admet-2956	379	25	characterization	characterization	NOUN
admet-2956	379	26	of	of	ADP
admet-2956	379	27	a	a	DET
admet-2956	379	28	real	real	ADJ
admet-2956	379	29	-	-	PUNCT
admet-2956	379	30	world	world	NOUN
admet-2956	379	31	response	response	NOUN
admet-2956	379	32	variable	variable	NOUN
admet-2956	379	33	and	and	CCONJ
admet-2956	379	34	comparison	comparison	NOUN
admet-2956	379	35	with	with	ADP
admet-2956	379	36	recist	recist	NOUN
admet-2956	379	37	-	-	PUNCT
admet-2956	379	38	based	base	VERB
admet-2956	379	39	response	response	NOUN
admet-2956	379	40	rates	rate	NOUN
admet-2956	379	41	from	from	ADP
admet-2956	379	42	clinical	clinical	ADJ
admet-2956	379	43	trials	trial	NOUN
admet-2956	379	44	in	in	ADP
admet-2956	379	45	advanced	advanced	ADJ
admet-2956	379	46	nsclc	nsclc	NOUN
admet-2956	379	47	.	.	PUNCT
admet-2956	380	1	advances	advance	NOUN
admet-2956	380	2	in	in	ADP
admet-2956	380	3	therapy	therapy	NOUN
admet-2956	380	4	38	38	NUM
admet-2956	380	5	(	(	PUNCT
admet-2956	380	6	2021	2021	NUM
admet-2956	380	7	)	)	PUNCT
admet-2956	380	8	1843	1843	NUM
admet-2956	380	9	-	-	SYM
admet-2956	380	10	1859	1859	NUM
admet-2956	380	11	.	.	PUNCT
admet-2956	381	1	http://doi.org/10.1007/s12325-02101659-0	http://doi.org/10.1007/s12325-02101659-0	PROPN
admet-2956	382	1	[	[	X
admet-2956	382	2	43	43	NUM
admet-2956	382	3	]	]	X
admet-2956	382	4	l.	l.	PROPN
admet-2956	382	5	paz	paz	PROPN
admet-2956	382	6	-	-	PUNCT
admet-2956	382	7	ares	are	NOUN
admet-2956	382	8	,	,	PUNCT
admet-2956	382	9	a.	a.	NOUN
admet-2956	382	10	luft	luft	PROPN
admet-2956	382	11	,	,	PUNCT
admet-2956	382	12	d.	d.	PROPN
admet-2956	382	13	vicente	vicente	PROPN
admet-2956	382	14	,	,	PUNCT
admet-2956	382	15	a.	a.	NOUN
admet-2956	382	16	tafreshi	tafreshi	NOUN
admet-2956	382	17	,	,	PUNCT
admet-2956	382	18	m.	m.	NOUN
admet-2956	382	19	gümüş	gümüş	PROPN
admet-2956	382	20	,	,	PUNCT
admet-2956	382	21	j.	j.	PROPN
admet-2956	382	22	mazières	mazières	PROPN
admet-2956	382	23	d.	d.	PROPN
admet-2956	382	24	kowalski	kowalski	PROPN
admet-2956	382	25	.	.	PUNCT
admet-2956	383	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	383	2	plus	plus	CCONJ
admet-2956	383	3	chemotherapy	chemotherapy	NOUN
admet-2956	383	4	for	for	ADP
admet-2956	383	5	squamous	squamous	ADJ
admet-2956	383	6	non	non	ADJ
admet-2956	383	7	-	-	ADJ
admet-2956	383	8	small	small	ADJ
admet-2956	383	9	-	-	PUNCT
admet-2956	383	10	cell	cell	NOUN
admet-2956	383	11	lung	lung	NOUN
admet-2956	383	12	cancer	cancer	NOUN
admet-2956	383	13	.	.	PUNCT
admet-2956	384	1	new	new	PROPN
admet-2956	384	2	england	england	PROPN
admet-2956	384	3	journal	journal	PROPN
admet-2956	384	4	of	of	ADP
admet-2956	384	5	medicine	medicine	PROPN
admet-2956	384	6	379	379	NUM
admet-2956	384	7	(	(	PUNCT
admet-2956	384	8	2018	2018	NUM
admet-2956	384	9	)	)	PUNCT
admet-2956	384	10	2040	2040	NUM
admet-2956	384	11	-	-	SYM
admet-2956	384	12	2051	2051	NUM
admet-2956	384	13	.	.	PUNCT
admet-2956	385	1	http://doi.org/10.1056/nejmoa1810865	http://doi.org/10.1056/nejmoa1810865	PROPN
admet-2956	385	2	[	[	X
admet-2956	385	3	44	44	NUM
admet-2956	385	4	]	]	PUNCT
admet-2956	385	5	r.	r.	PROPN
admet-2956	385	6	herbst	herbst	PROPN
admet-2956	385	7	,	,	PUNCT
admet-2956	385	8	p.	p.	NOUN
admet-2956	385	9	baas	baas	NOUN
admet-2956	385	10	,	,	PUNCT
admet-2956	385	11	d.	d.	PROPN
admet-2956	385	12	kim	kim	PROPN
admet-2956	385	13	,	,	PUNCT
admet-2956	385	14	e.	e.	PROPN
admet-2956	385	15	felip	felip	PROPN
admet-2956	385	16	,	,	PUNCT
admet-2956	385	17	j.	j.	PROPN
admet-2956	385	18	pérez	pérez	PROPN
admet-2956	385	19	-	-	PUNCT
admet-2956	385	20	gracia	gracia	PROPN
admet-2956	385	21	,	,	PUNCT
admet-2956	385	22	j.	j.	PROPN
admet-2956	385	23	han	han	PROPN
admet-2956	385	24	,	,	PUNCT
admet-2956	385	25	e.	e.	PROPN
admet-2956	385	26	garon	garon	PROPN
admet-2956	385	27	.	.	PUNCT
admet-2956	385	28	pembrolizumab	pembrolizumab	NOUN
admet-2956	385	29	versus	versus	ADP
admet-2956	385	30	docetaxel	docetaxel	NOUN
admet-2956	385	31	for	for	ADP
admet-2956	385	32	previously	previously	ADV
admet-2956	385	33	treated	treat	VERB
admet-2956	385	34	,	,	PUNCT
admet-2956	385	35	pd	pd	PROPN
admet-2956	385	36	-	-	PUNCT
admet-2956	385	37	l1	l1	NOUN
admet-2956	385	38	-	-	PUNCT
admet-2956	385	39	positive	positive	ADJ
admet-2956	385	40	,	,	PUNCT
admet-2956	385	41	advanced	advanced	ADJ
admet-2956	385	42	non	non	ADJ
admet-2956	385	43	-	-	ADJ
admet-2956	385	44	small	small	ADJ
admet-2956	385	45	-	-	PUNCT
admet-2956	385	46	cell	cell	NOUN
admet-2956	385	47	lung	lung	NOUN
admet-2956	385	48	cancer	cancer	NOUN
admet-2956	385	49	(	(	PUNCT
admet-2956	385	50	keynote-010	keynote-010	NOUN
admet-2956	385	51	):	):	PUNCT
admet-2956	385	52	a	a	DET
admet-2956	385	53	randomised	randomised	ADJ
admet-2956	385	54	controlled	control	VERB
admet-2956	385	55	trial	trial	NOUN
admet-2956	385	56	.	.	PUNCT
admet-2956	386	1	the	the	DET
admet-2956	386	2	lancet	lancet	NOUN
admet-2956	386	3	387	387	NUM
admet-2956	386	4	(	(	PUNCT
admet-2956	386	5	2016	2016	NUM
admet-2956	386	6	)	)	PUNCT
admet-2956	386	7	1540	1540	NUM
admet-2956	386	8	-	-	SYM
admet-2956	386	9	1550	1550	NUM
admet-2956	386	10	.	.	PUNCT
admet-2956	387	1	http://doi.org/10.1016/s0140-6736(15)01281-7	http://doi.org/10.1016/s0140-6736(15)01281-7	PROPN
admet-2956	388	1	[	[	X
admet-2956	388	2	45	45	NUM
admet-2956	388	3	]	]	PUNCT
admet-2956	388	4	c.	c.	PROPN
admet-2956	388	5	langer	langer	PROPN
admet-2956	388	6	,	,	PUNCT
admet-2956	388	7	s.	s.	PROPN
admet-2956	388	8	gadgeel	gadgeel	PROPN
admet-2956	388	9	,	,	PUNCT
admet-2956	388	10	h.	h.	PROPN
admet-2956	388	11	borghaei	borghaei	PROPN
admet-2956	388	12	,	,	PUNCT
admet-2956	388	13	v.	v.	PROPN
admet-2956	388	14	papadimitrakopoulou	papadimitrakopoulou	PROPN
admet-2956	388	15	,	,	PUNCT
admet-2956	388	16	a.	a.	NOUN
admet-2956	388	17	patnaik	patnaik	PROPN
admet-2956	388	18	,	,	PUNCT
admet-2956	388	19	s.	s.	PROPN
admet-2956	388	20	powell	powell	PROPN
admet-2956	388	21	,	,	PUNCT
admet-2956	388	22	l.	l.	PROPN
admet-2956	388	23	gandhi	gandhi	PROPN
admet-2956	388	24	.	.	PUNCT
admet-2956	389	1	carboplatin	carboplatin	PROPN
admet-2956	389	2	and	and	CCONJ
admet-2956	389	3	pemetrexed	pemetrexe	VERB
admet-2956	389	4	with	with	ADP
admet-2956	389	5	or	or	CCONJ
admet-2956	389	6	without	without	ADP
admet-2956	389	7	pembrolizumab	pembrolizumab	NOUN
admet-2956	389	8	for	for	ADP
admet-2956	389	9	advanced	advanced	ADJ
admet-2956	389	10	,	,	PUNCT
admet-2956	389	11	non	non	ADJ
admet-2956	389	12	-	-	ADJ
admet-2956	389	13	squamous	squamous	ADJ
admet-2956	389	14	non	non	ADJ
admet-2956	389	15	-	-	ADJ
admet-2956	389	16	small	small	ADJ
admet-2956	389	17	-	-	PUNCT
admet-2956	389	18	cell	cell	NOUN
admet-2956	389	19	lung	lung	NOUN
admet-2956	389	20	cancer	cancer	NOUN
admet-2956	389	21	:	:	PUNCT
admet-2956	389	22	a	a	DET
admet-2956	389	23	randomised	randomised	ADJ
admet-2956	389	24	,	,	PUNCT
admet-2956	389	25	phase	phase	NOUN
admet-2956	389	26	2	2	NUM
admet-2956	389	27	cohort	cohort	NOUN
admet-2956	389	28	of	of	ADP
admet-2956	389	29	the	the	DET
admet-2956	389	30	open	open	ADJ
admet-2956	389	31	-	-	PUNCT
admet-2956	389	32	label	label	NOUN
admet-2956	389	33	keynote-021	keynote-021	NOUN
admet-2956	389	34	study	study	NOUN
admet-2956	389	35	.	.	PUNCT
admet-2956	390	1	the	the	DET
admet-2956	390	2	lancet	lancet	PROPN
admet-2956	390	3	oncology	oncology	NOUN
admet-2956	390	4	17	17	NUM
admet-2956	390	5	(	(	PUNCT
admet-2956	390	6	2016	2016	NUM
admet-2956	390	7	)	)	PUNCT
admet-2956	390	8	1497	1497	NUM
admet-2956	390	9	-	-	SYM
admet-2956	390	10	1508	1508	NUM
admet-2956	390	11	.	.	PUNCT
admet-2956	391	1	http://doi.org/10.1016/s1470-2045(16)30498-3	http://doi.org/10.1016/s1470-2045(16)30498-3	PROPN
admet-2956	392	1	[	[	X
admet-2956	392	2	46	46	NUM
admet-2956	392	3	]	]	PUNCT
admet-2956	392	4	t.	t.	PROPN
admet-2956	392	5	mok	mok	PROPN
admet-2956	392	6	,	,	PUNCT
admet-2956	392	7	y.	y.	PROPN
admet-2956	392	8	wu	wu	PROPN
admet-2956	392	9	,	,	PUNCT
admet-2956	392	10	i.	i.	PROPN
admet-2956	392	11	kudaba	kudaba	PROPN
admet-2956	392	12	,	,	PUNCT
admet-2956	392	13	d.	d.	PROPN
admet-2956	392	14	kowalski	kowalski	PROPN
admet-2956	392	15	,	,	PUNCT
admet-2956	392	16	b.	b.	PROPN
admet-2956	392	17	cho	cho	PROPN
admet-2956	392	18	,	,	PUNCT
admet-2956	392	19	b.	b.	PROPN
admet-2956	392	20	turna	turna	PROPN
admet-2956	392	21	,	,	PUNCT
admet-2956	392	22	g.	g.	PROPN
admet-2956	392	23	martinengo	martinengo	PROPN
admet-2956	392	24	.	.	PUNCT
admet-2956	393	1	pembrolizumab	pembrolizumab	NOUN
admet-2956	393	2	versus	versus	ADP
admet-2956	393	3	chemotherapy	chemotherapy	NOUN
admet-2956	393	4	for	for	ADP
admet-2956	393	5	previously	previously	ADV
admet-2956	393	6	untreated	untreated	ADJ
admet-2956	393	7	,	,	PUNCT
admet-2956	393	8	pd	pd	PROPN
admet-2956	393	9	-	-	PUNCT
admet-2956	393	10	l1	l1	NOUN
admet-2956	393	11	-	-	PUNCT
admet-2956	393	12	expressing	expressing	NOUN
admet-2956	393	13	,	,	PUNCT
admet-2956	393	14	locally	locally	ADV
admet-2956	393	15	advanced	advanced	ADJ
admet-2956	393	16	or	or	CCONJ
admet-2956	393	17	metastatic	metastatic	ADJ
admet-2956	393	18	non	non	ADJ
admet-2956	393	19	-	-	ADJ
admet-2956	393	20	smallcell	smallcell	ADJ
admet-2956	393	21	lung	lung	NOUN
admet-2956	393	22	cancer	cancer	NOUN
admet-2956	393	23	(	(	PUNCT
admet-2956	393	24	keynote-042	keynote-042	NOUN
admet-2956	393	25	):	):	PUNCT
admet-2956	393	26	a	a	DET
admet-2956	393	27	randomised	randomised	ADJ
admet-2956	393	28	,	,	PUNCT
admet-2956	393	29	open	open	ADJ
admet-2956	393	30	-	-	PUNCT
admet-2956	393	31	label	label	NOUN
admet-2956	393	32	,	,	PUNCT
admet-2956	393	33	controlled	control	VERB
admet-2956	393	34	,	,	PUNCT
admet-2956	393	35	phase	phase	NOUN
admet-2956	393	36	3	3	NUM
admet-2956	393	37	trial	trial	NOUN
admet-2956	393	38	.	.	PUNCT
admet-2956	394	1	the	the	DET
admet-2956	394	2	lancet	lancet	NOUN
admet-2956	394	3	393	393	NUM
admet-2956	394	4	(	(	PUNCT
admet-2956	394	5	2019	2019	NUM
admet-2956	394	6	)	)	PUNCT
admet-2956	394	7	1819	1819	NUM
admet-2956	394	8	-	-	SYM
admet-2956	394	9	1830	1830	NUM
admet-2956	394	10	.	.	PUNCT
admet-2956	395	1	http://doi.org/10.1016/s0140-6736(18)32409-7	http://doi.org/10.1016/s0140-6736(18)32409-7	PROPN
admet-2956	396	1	[	[	X
admet-2956	396	2	47	47	NUM
admet-2956	396	3	]	]	PUNCT
admet-2956	396	4	s.	s.	PROPN
admet-2956	396	5	ren	ren	PROPN
admet-2956	396	6	,	,	PUNCT
admet-2956	396	7	j.	j.	PROPN
admet-2956	396	8	feng	feng	PROPN
admet-2956	396	9	,	,	PUNCT
admet-2956	396	10	s.	s.	PROPN
admet-2956	396	11	ma	ma	PROPN
admet-2956	396	12	,	,	PUNCT
admet-2956	396	13	h.	h.	PROPN
admet-2956	396	14	chen	chen	PROPN
admet-2956	396	15	,	,	PUNCT
admet-2956	396	16	z.	z.	PROPN
admet-2956	396	17	ma	ma	PROPN
admet-2956	396	18	,	,	PUNCT
admet-2956	396	19	c.	c.	PROPN
admet-2956	396	20	huang	huang	PROPN
admet-2956	396	21	,	,	PUNCT
admet-2956	396	22	c.	c.	PROPN
admet-2956	396	23	zhou	zhou	PROPN
admet-2956	396	24	.	.	PUNCT
admet-2956	397	1	keynote‐033	keynote‐033	PROPN
admet-2956	397	2	:	:	PUNCT
admet-2956	397	3	randomized	randomize	VERB
admet-2956	397	4	phase	phase	NOUN
admet-2956	397	5	3	3	NUM
admet-2956	397	6	study	study	NOUN
admet-2956	397	7	of	of	ADP
admet-2956	397	8	pembrolizumab	pembrolizumab	NOUN
admet-2956	397	9	vs	vs	ADP
admet-2956	397	10	docetaxel	docetaxel	NOUN
admet-2956	397	11	in	in	ADP
admet-2956	397	12	previously	previously	ADV
admet-2956	397	13	treated	treat	VERB
admet-2956	397	14	,	,	PUNCT
admet-2956	397	15	pd‐l1‐positive	pd‐l1‐positive	ADJ
admet-2956	397	16	,	,	PUNCT
admet-2956	397	17	advanced	advanced	ADJ
admet-2956	397	18	nsclc	nsclc	NOUN
admet-2956	397	19	.	.	PUNCT
admet-2956	398	1	international	international	ADJ
admet-2956	398	2	journal	journal	PROPN
admet-2956	398	3	of	of	ADP
admet-2956	398	4	cancer	cancer	NOUN
admet-2956	398	5	153	153	NUM
admet-2956	398	6	(	(	PUNCT
admet-2956	398	7	2023	2023	NUM
admet-2956	398	8	)	)	PUNCT
admet-2956	398	9	623	623	NUM
admet-2956	398	10	-	-	SYM
admet-2956	398	11	634	634	NUM
admet-2956	398	12	.	.	PUNCT
admet-2956	399	1	http://doi.org/10.1002/ijc.34532	http://doi.org/10.1002/ijc.34532	NOUN
admet-2956	399	2	[	[	X
admet-2956	399	3	48	48	NUM
admet-2956	399	4	]	]	PUNCT
admet-2956	399	5	l.	l.	PROPN
admet-2956	399	6	gandhi	gandhi	PROPN
admet-2956	399	7	,	,	PUNCT
admet-2956	399	8	d.	d.	PROPN
admet-2956	399	9	rodgríguez	rodgríguez	PROPN
admet-2956	399	10	-	-	PUNCT
admet-2956	399	11	abreu	abreu	PROPN
admet-2956	399	12	,	,	PUNCT
admet-2956	399	13	s.	s.	PROPN
admet-2956	399	14	gadgeel	gadgeel	PROPN
admet-2956	399	15	,	,	PUNCT
admet-2956	399	16	e.	e.	PROPN
admet-2956	399	17	esteban	esteban	PROPN
admet-2956	399	18	,	,	PUNCT
admet-2956	399	19	e.	e.	PROPN
admet-2956	399	20	felip	felip	PROPN
admet-2956	399	21	,	,	PUNCT
admet-2956	399	22	m.	m.	NOUN
admet-2956	399	23	garassino	garassino	PROPN
admet-2956	399	24	.	.	PUNCT
admet-2956	400	1	abstract	abstract	PROPN
admet-2956	400	2	ct075	ct075	PROPN
admet-2956	400	3	:	:	PUNCT
admet-2956	400	4	keynote-189	keynote-189	NOUN
admet-2956	400	5	:	:	PUNCT
admet-2956	400	6	randomized	randomize	VERB
admet-2956	400	7	,	,	PUNCT
admet-2956	400	8	double	double	ADJ
admet-2956	400	9	-	-	PUNCT
admet-2956	400	10	blind	blind	ADJ
admet-2956	400	11	,	,	PUNCT
admet-2956	400	12	phase	phase	NOUN
admet-2956	400	13	3	3	NUM
admet-2956	400	14	study	study	NOUN
admet-2956	400	15	of	of	ADP
admet-2956	400	16	pembrolizumab	pembrolizumab	NOUN
admet-2956	400	17	(	(	PUNCT
admet-2956	400	18	pembro	pembro	NOUN
admet-2956	400	19	)	)	PUNCT
admet-2956	400	20	or	or	CCONJ
admet-2956	400	21	placebo	placebo	NOUN
admet-2956	400	22	plus	plus	CCONJ
admet-2956	400	23	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	400	24	http://doi.org/10.1001/jamaoncol.2018.5904	http://doi.org/10.1001/jamaoncol.2018.5904	PROPN
admet-2956	400	25	http://doi.org/10.1001/jamanetworkopen.2020.12534	http://doi.org/10.1001/jamanetworkopen.2020.12534	PROPN
admet-2956	400	26	http://doi.org/10.1016/j.cllc.2019.04.004	http://doi.org/10.1016/j.cllc.2019.04.004	NOUN
admet-2956	400	27	https://www.procedia-esem.eu/pdf/issues/2024/no1/10_kaizal_24.pdf	https://www.procedia-esem.eu/pdf/issues/2024/no1/10_kaizal_24.pdf	NOUN
admet-2956	400	28	http://doi.org/10.1002/cam4.2806	http://doi.org/10.1002/cam4.2806	ADP
admet-2956	400	29	http://doi.org/10.1080/2162402x.2020.1774314	http://doi.org/10.1080/2162402x.2020.1774314	NOUN
admet-2956	400	30	http://doi.org/10.7150/jca.22361	http://doi.org/10.7150/jca.22361	NOUN
admet-2956	400	31	http://doi.org/10.1016/j.clinthera.2020.06.018	http://doi.org/10.1016/j.clinthera.2020.06.018	PROPN
admet-2956	400	32	http://doi.org/10.1007/s12325-021-01659-0	http://doi.org/10.1007/s12325-021-01659-0	NUM
admet-2956	400	33	http://doi.org/10.1007/s12325-021-01659-0	http://doi.org/10.1007/s12325-021-01659-0	NUM
admet-2956	401	1	http://doi.org/10.1056/nejmoa1810865	http://doi.org/10.1056/nejmoa1810865	ADJ
admet-2956	402	1	https://doi.org/10.1016/s0140-6736(15)01281-7	https://doi.org/10.1016/s0140-6736(15)01281-7	PROPN
admet-2956	402	2	https://doi.org/10.1016/s1470-2045(16)30498-3	https://doi.org/10.1016/s1470-2045(16)30498-3	ADJ
admet-2956	402	3	https://doi.org/10.1016/s0140-6736(18)32409-7	https://doi.org/10.1016/s0140-6736(18)32409-7	NOUN
admet-2956	402	4	https://doi.org/10.1002/ijc.34532	https://doi.org/10.1002/ijc.34532	PROPN
admet-2956	402	5	a.	a.	NOUN
admet-2956	402	6	chakramurty	chakramurty	PROPN
admet-2956	402	7	et	et	PROPN
admet-2956	402	8	al	al	PROPN
admet-2956	402	9	.	.	PROPN
admet-2956	402	10	admet	admet	PROPN
admet-2956	402	11	&	&	CCONJ
admet-2956	402	12	dmpk	dmpk	PROPN
admet-2956	402	13	13(5	13(5	NUM
admet-2956	402	14	)	)	PUNCT
admet-2956	402	15	(	(	PUNCT
admet-2956	402	16	2025	2025	NUM
admet-2956	402	17	)	)	PUNCT
admet-2956	402	18	2956	2956	NUM
admet-2956	402	19	16	16	NUM
admet-2956	402	20	pemetrexed	pemetrexed	NOUN
admet-2956	402	21	(	(	PUNCT
admet-2956	402	22	pem	pem	NOUN
admet-2956	402	23	)	)	PUNCT
admet-2956	402	24	and	and	CCONJ
admet-2956	402	25	platinum	platinum	NOUN
admet-2956	402	26	as	as	ADP
admet-2956	402	27	first	first	ADJ
admet-2956	402	28	-	-	PUNCT
admet-2956	402	29	line	line	NOUN
admet-2956	402	30	therapy	therapy	NOUN
admet-2956	402	31	for	for	ADP
admet-2956	402	32	metastatic	metastatic	ADJ
admet-2956	402	33	nsclc	nsclc	NOUN
admet-2956	402	34	.	.	PUNCT
admet-2956	403	1	cancer	cancer	NOUN
admet-2956	403	2	research	research	NOUN
admet-2956	403	3	78	78	NUM
admet-2956	403	4	(	(	PUNCT
admet-2956	403	5	2018	2018	NUM
admet-2956	403	6	)	)	PUNCT
admet-2956	403	7	ct075	ct075	PROPN
admet-2956	403	8	.	.	PUNCT
admet-2956	404	1	https://doi.org/10.1158/1538-7445.am2018-ct075	https://doi.org/10.1158/1538-7445.am2018-ct075	PUNCT
admet-2956	404	2	[	[	X
admet-2956	404	3	49	49	NUM
admet-2956	404	4	]	]	PUNCT
admet-2956	404	5	j.	j.	PROPN
admet-2956	404	6	r.	r.	PROPN
admet-2956	404	7	brahmer	brahmer	PROPN
admet-2956	404	8	.	.	PUNCT
admet-2956	405	1	safety	safety	NOUN
admet-2956	405	2	profile	profile	NOUN
admet-2956	405	3	of	of	ADP
admet-2956	405	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	405	5	monotherapy	monotherapy	NOUN
admet-2956	405	6	based	base	VERB
admet-2956	405	7	on	on	ADP
admet-2956	405	8	an	an	DET
admet-2956	405	9	aggregate	aggregate	ADJ
admet-2956	405	10	safety	safety	NOUN
admet-2956	405	11	evaluation	evaluation	NOUN
admet-2956	405	12	of	of	ADP
admet-2956	405	13	8937	8937	NUM
admet-2956	405	14	patients	patient	NOUN
admet-2956	405	15	.	.	PUNCT
admet-2956	406	1	european	european	PROPN
admet-2956	406	2	journal	journal	PROPN
admet-2956	406	3	of	of	ADP
admet-2956	406	4	cancer	cancer	NOUN
admet-2956	406	5	199	199	NUM
admet-2956	406	6	(	(	PUNCT
admet-2956	406	7	2024	2024	NUM
admet-2956	406	8	)	)	PUNCT
admet-2956	406	9	113530	113530	NUM
admet-2956	406	10	.	.	PUNCT
admet-2956	407	1	http://doi.org/10.1016/j.ejca.2024.113530	http://doi.org/10.1016/j.ejca.2024.113530	PROPN
admet-2956	408	1	[	[	X
admet-2956	408	2	50	50	NUM
admet-2956	408	3	]	]	X
admet-2956	408	4	g.	g.	PROPN
admet-2956	408	5	pentheroudakis	pentheroudakis	PROPN
admet-2956	408	6	.	.	PUNCT
admet-2956	409	1	recent	recent	ADJ
admet-2956	409	2	eupdate	eupdate	NOUN
admet-2956	409	3	to	to	ADP
admet-2956	409	4	the	the	DET
admet-2956	409	5	esmo	esmo	NOUN
admet-2956	409	6	clinical	clinical	ADJ
admet-2956	409	7	practice	practice	NOUN
admet-2956	409	8	guidelines	guideline	NOUN
admet-2956	409	9	on	on	ADP
admet-2956	409	10	early	early	ADJ
admet-2956	409	11	and	and	CCONJ
admet-2956	409	12	locally	locally	ADV
admet-2956	409	13	advanced	advanced	ADJ
admet-2956	409	14	non	non	ADJ
admet-2956	409	15	-	-	ADJ
admet-2956	409	16	small	small	ADJ
admet-2956	409	17	-	-	PUNCT
admet-2956	409	18	cell	cell	NOUN
admet-2956	409	19	lung	lung	NOUN
admet-2956	409	20	cancer	cancer	NOUN
admet-2956	409	21	(	(	PUNCT
admet-2956	409	22	nsclc	nsclc	NOUN
admet-2956	409	23	)	)	PUNCT
admet-2956	409	24	.	.	PUNCT
admet-2956	410	1	annals	annal	NOUN
admet-2956	410	2	of	of	ADP
admet-2956	410	3	oncology	oncology	NOUN
admet-2956	410	4	31	31	NUM
admet-2956	410	5	(	(	PUNCT
admet-2956	410	6	2020	2020	NUM
admet-2956	410	7	)	)	PUNCT
admet-2956	410	8	1265	1265	NUM
admet-2956	410	9	-	-	SYM
admet-2956	410	10	1266	1266	NUM
admet-2956	410	11	.	.	PUNCT
admet-2956	411	1	http://doi.org/10.1016/j.annonc.2020.05.023	http://doi.org/10.1016/j.annonc.2020.05.023	NOUN
admet-2956	411	2	[	[	X
admet-2956	411	3	51	51	NUM
admet-2956	411	4	]	]	PUNCT
admet-2956	411	5	x.	x.	PROPN
admet-2956	411	6	shen	shen	PROPN
admet-2956	411	7	,	,	PUNCT
admet-2956	411	8	b.	b.	PROPN
admet-2956	411	9	zhao	zhao	PROPN
admet-2956	411	10	.	.	PUNCT
admet-2956	412	1	efficacy	efficacy	NOUN
admet-2956	412	2	of	of	ADP
admet-2956	412	3	pd-1	pd-1	ADJ
admet-2956	412	4	or	or	CCONJ
admet-2956	412	5	pd	pd	PROPN
admet-2956	412	6	-	-	PUNCT
admet-2956	412	7	l1	l1	PROPN
admet-2956	412	8	inhibitors	inhibitor	NOUN
admet-2956	412	9	and	and	CCONJ
admet-2956	412	10	pd	pd	PROPN
admet-2956	412	11	-	-	PUNCT
admet-2956	412	12	l1	l1	PROPN
admet-2956	412	13	expression	expression	NOUN
admet-2956	412	14	status	status	NOUN
admet-2956	412	15	in	in	ADP
admet-2956	412	16	cancer	cancer	NOUN
admet-2956	412	17	:	:	PUNCT
admet-2956	412	18	metaanalysis	metaanalysis	NOUN
admet-2956	412	19	.	.	PUNCT
admet-2956	413	1	british	british	PROPN
admet-2956	413	2	medical	medical	PROPN
admet-2956	413	3	journal	journal	PROPN
admet-2956	413	4	362	362	NUM
admet-2956	413	5	(	(	PUNCT
admet-2956	413	6	2018	2018	NUM
admet-2956	413	7	)	)	PUNCT
admet-2956	413	8	43	43	NUM
admet-2956	413	9	-	-	SYM
admet-2956	413	10	49	49	NUM
admet-2956	413	11	.	.	PUNCT
admet-2956	414	1	http://doi.org/10.1136/bmj.k3529	http://doi.org/10.1136/bmj.k3529	NUM
admet-2956	414	2	[	[	X
admet-2956	414	3	52	52	NUM
admet-2956	414	4	]	]	PUNCT
admet-2956	414	5	f.	f.	PROPN
admet-2956	414	6	passiglia	passiglia	PROPN
admet-2956	414	7	,	,	PUNCT
admet-2956	414	8	g.	g.	PROPN
admet-2956	414	9	bronte	bronte	PROPN
admet-2956	414	10	,	,	PUNCT
admet-2956	414	11	v.	v.	PROPN
admet-2956	414	12	bazan	bazan	PROPN
admet-2956	414	13	,	,	PUNCT
admet-2956	414	14	c.	c.	PROPN
admet-2956	414	15	natoli	natoli	PROPN
admet-2956	414	16	,	,	PUNCT
admet-2956	414	17	s.	s.	PROPN
admet-2956	414	18	rizzo	rizzo	PROPN
admet-2956	414	19	,	,	PUNCT
admet-2956	414	20	a.	a.	NOUN
admet-2956	414	21	galvano	galvano	PROPN
admet-2956	414	22	,	,	PUNCT
admet-2956	414	23	a.	a.	PROPN
admet-2956	414	24	russo	russo	PROPN
admet-2956	414	25	pd	pd	PROPN
admet-2956	414	26	-	-	PROPN
admet-2956	414	27	l1	l1	PROPN
admet-2956	414	28	expression	expression	NOUN
admet-2956	414	29	as	as	ADP
admet-2956	414	30	predictive	predictive	ADJ
admet-2956	414	31	biomarker	biomarker	NOUN
admet-2956	414	32	in	in	ADP
admet-2956	414	33	patients	patient	NOUN
admet-2956	414	34	with	with	ADP
admet-2956	414	35	nsclc	nsclc	NOUN
admet-2956	414	36	:	:	PUNCT
admet-2956	414	37	a	a	DET
admet-2956	414	38	pooled	pooled	ADJ
admet-2956	414	39	analysis	analysis	NOUN
admet-2956	414	40	.	.	PUNCT
admet-2956	415	1	oncotarget	oncotarget	NOUN
admet-2956	415	2	7	7	NUM
admet-2956	415	3	(	(	PUNCT
admet-2956	415	4	2016	2016	NUM
admet-2956	415	5	)	)	PUNCT
admet-2956	415	6	19738	19738	NUM
admet-2956	415	7	-	-	SYM
admet-2956	415	8	19747	19747	NUM
admet-2956	415	9	.	.	PUNCT
admet-2956	415	10	http://doi.org/10.18632/oncotarget.7582	http://doi.org/10.18632/oncotarget.7582	NOUN
admet-2956	416	1	[	[	X
admet-2956	416	2	53	53	NUM
admet-2956	416	3	]	]	PUNCT
admet-2956	416	4	r.	r.	PROPN
admet-2956	416	5	ferrara	ferrara	PROPN
admet-2956	416	6	,	,	PUNCT
admet-2956	416	7	l.	l.	PROPN
admet-2956	416	8	mezquita	mezquita	PROPN
admet-2956	416	9	,	,	PUNCT
admet-2956	416	10	e.	e.	PROPN
admet-2956	416	11	auclin	auclin	PROPN
admet-2956	416	12	,	,	PUNCT
admet-2956	416	13	n.	n.	PROPN
admet-2956	416	14	chaput	chaput	PROPN
admet-2956	416	15	,	,	PUNCT
admet-2956	416	16	b.	b.	PROPN
admet-2956	416	17	besse	besse	PROPN
admet-2956	416	18	.	.	PUNCT
admet-2956	417	1	immunosenescence	immunosenescence	NOUN
admet-2956	417	2	and	and	CCONJ
admet-2956	417	3	immunecheckpoint	immunecheckpoint	VERB
admet-2956	417	4	inhibitors	inhibitor	NOUN
admet-2956	417	5	in	in	ADP
admet-2956	417	6	non	non	ADJ
admet-2956	417	7	-	-	ADJ
admet-2956	417	8	small	small	ADJ
admet-2956	417	9	cell	cell	NOUN
admet-2956	417	10	lung	lung	NOUN
admet-2956	417	11	cancer	cancer	NOUN
admet-2956	417	12	patients	patient	NOUN
admet-2956	417	13	:	:	PUNCT
admet-2956	417	14	does	do	AUX
admet-2956	417	15	age	age	NOUN
admet-2956	417	16	really	really	ADV
admet-2956	417	17	matter	matter	ADV
admet-2956	417	18	.	.	PUNCT
admet-2956	418	1	cancer	cancer	NOUN
admet-2956	418	2	treatment	treatment	NOUN
admet-2956	418	3	reviews	review	NOUN
admet-2956	418	4	60	60	NUM
admet-2956	418	5	(	(	PUNCT
admet-2956	418	6	2017	2017	NUM
admet-2956	418	7	)	)	PUNCT
admet-2956	418	8	60	60	NUM
admet-2956	418	9	-	-	SYM
admet-2956	418	10	68	68	NUM
admet-2956	418	11	.	.	PUNCT
admet-2956	419	1	http://doi.org/10.1016/j.ctrv.2017.08.003	http://doi.org/10.1016/j.ctrv.2017.08.003	PROPN
admet-2956	419	2	[	[	X
admet-2956	419	3	54	54	NUM
admet-2956	419	4	]	]	X
admet-2956	419	5	c.	c.	PROPN
admet-2956	419	6	wang	wang	PROPN
admet-2956	419	7	.	.	PUNCT
admet-2956	420	1	effect	effect	NOUN
admet-2956	420	2	of	of	ADP
admet-2956	420	3	sex	sex	NOUN
admet-2956	420	4	on	on	ADP
admet-2956	420	5	the	the	DET
admet-2956	420	6	efficacy	efficacy	NOUN
admet-2956	420	7	of	of	ADP
admet-2956	420	8	patients	patient	NOUN
admet-2956	420	9	receiving	receive	VERB
admet-2956	420	10	immune	immune	ADJ
admet-2956	420	11	checkpoint	checkpoint	NOUN
admet-2956	420	12	inhibitors	inhibitor	NOUN
admet-2956	420	13	in	in	ADP
admet-2956	420	14	advanced	advanced	ADJ
admet-2956	420	15	non	non	ADJ
admet-2956	420	16	-	-	ADJ
admet-2956	420	17	small	small	ADJ
admet-2956	420	18	cell	cell	NOUN
admet-2956	420	19	lung	lung	NOUN
admet-2956	420	20	cancer	cancer	NOUN
admet-2956	420	21	.	.	PUNCT
admet-2956	421	1	cancer	cancer	NOUN
admet-2956	421	2	medicine	medicine	NOUN
admet-2956	421	3	8	8	NUM
admet-2956	421	4	(	(	PUNCT
admet-2956	421	5	2019	2019	NUM
admet-2956	421	6	)	)	PUNCT
admet-2956	421	7	4023	4023	NUM
admet-2956	421	8	-	-	SYM
admet-2956	421	9	4031	4031	NUM
admet-2956	421	10	.	.	PUNCT
admet-2956	422	1	http://doi.org/10.1002/cam4.2280	http://doi.org/10.1002/cam4.2280	VERB
admet-2956	423	1	[	[	X
admet-2956	423	2	55	55	NUM
admet-2956	423	3	]	]	X
admet-2956	423	4	d.	d.	PROPN
admet-2956	423	5	planchard	planchard	PROPN
admet-2956	423	6	,	,	PUNCT
admet-2956	423	7	s.	s.	PROPN
admet-2956	423	8	popat	popat	PROPN
admet-2956	423	9	,	,	PUNCT
admet-2956	423	10	k.	k.	PROPN
admet-2956	423	11	kerr	kerr	PROPN
admet-2956	423	12	,	,	PUNCT
admet-2956	423	13	s.	s.	PROPN
admet-2956	423	14	novello	novello	PROPN
admet-2956	423	15	,	,	PUNCT
admet-2956	423	16	e.	e.	PROPN
admet-2956	423	17	smit	smit	PROPN
admet-2956	423	18	,	,	PUNCT
admet-2956	423	19	c.	c.	PROPN
admet-2956	423	20	faivre	faivre	PROPN
admet-2956	423	21	-	-	PUNCT
admet-2956	423	22	finn	finn	PROPN
admet-2956	423	23	.	.	PUNCT
admet-2956	424	1	metastatic	metastatic	ADJ
admet-2956	424	2	non	non	ADJ
admet-2956	424	3	-	-	ADJ
admet-2956	424	4	small	small	ADJ
admet-2956	424	5	cell	cell	NOUN
admet-2956	424	6	lung	lung	NOUN
admet-2956	424	7	cancer	cancer	NOUN
admet-2956	424	8	:	:	PUNCT
admet-2956	424	9	esmo	esmo	VERB
admet-2956	424	10	clinical	clinical	ADJ
admet-2956	424	11	practice	practice	NOUN
admet-2956	424	12	guidelines	guideline	NOUN
admet-2956	424	13	for	for	ADP
admet-2956	424	14	diagnosis	diagnosis	NOUN
admet-2956	424	15	,	,	PUNCT
admet-2956	424	16	treatment	treatment	NOUN
admet-2956	424	17	and	and	CCONJ
admet-2956	424	18	follow	follow	NOUN
admet-2956	424	19	-	-	PUNCT
admet-2956	424	20	up	up	NOUN
admet-2956	424	21	.	.	PUNCT
admet-2956	424	22	annals	annal	NOUN
admet-2956	424	23	of	of	ADP
admet-2956	424	24	oncology	oncology	NOUN
admet-2956	424	25	29	29	NUM
admet-2956	424	26	(	(	PUNCT
admet-2956	424	27	2018	2018	NUM
admet-2956	424	28	)	)	PUNCT
admet-2956	424	29	iv192	iv192	PROPN
admet-2956	424	30	-	-	PUNCT
admet-2956	424	31	iv237	iv237	PROPN
admet-2956	424	32	.	.	PUNCT
admet-2956	425	1	http://doi.org/10.1093/annonc/mdy275	http://doi.org/10.1093/annonc/mdy275	PROPN
admet-2956	426	1	[	[	X
admet-2956	426	2	56	56	NUM
admet-2956	426	3	]	]	PUNCT
admet-2956	426	4	j.	j.	PROPN
admet-2956	426	5	mclaughlin	mclaughlin	PROPN
admet-2956	426	6	.	.	PUNCT
admet-2956	427	1	quantitative	quantitative	ADJ
admet-2956	427	2	assessment	assessment	NOUN
admet-2956	427	3	of	of	ADP
admet-2956	427	4	the	the	DET
admet-2956	427	5	heterogeneity	heterogeneity	NOUN
admet-2956	427	6	of	of	ADP
admet-2956	427	7	pd	pd	PROPN
admet-2956	427	8	-	-	PROPN
admet-2956	427	9	l1	l1	PROPN
admet-2956	427	10	expression	expression	NOUN
admet-2956	427	11	in	in	ADP
admet-2956	427	12	non	non	ADJ
admet-2956	427	13	-	-	ADJ
admet-2956	427	14	small	small	ADJ
admet-2956	427	15	-	-	PUNCT
admet-2956	427	16	cell	cell	NOUN
admet-2956	427	17	lung	lung	NOUN
admet-2956	427	18	cancer	cancer	NOUN
admet-2956	427	19	.	.	PUNCT
admet-2956	428	1	jama	jama	PROPN
admet-2956	428	2	oncology	oncology	NOUN
admet-2956	428	3	2	2	NUM
admet-2956	428	4	(	(	PUNCT
admet-2956	428	5	2016	2016	NUM
admet-2956	428	6	)	)	PUNCT
admet-2956	428	7	46	46	NUM
admet-2956	428	8	-	-	SYM
admet-2956	428	9	54	54	NUM
admet-2956	428	10	.	.	PUNCT
admet-2956	429	1	http://doi.org/10.1001/jamaoncol.2015.3638	http://doi.org/10.1001/jamaoncol.2015.3638	PROPN
admet-2956	429	2	[	[	X
admet-2956	429	3	57	57	NUM
admet-2956	429	4	]	]	X
admet-2956	429	5	c.	c.	PROPN
admet-2956	429	6	tumeh	tumeh	PROPN
admet-2956	429	7	,	,	PUNCT
admet-2956	429	8	c.	c.	PROPN
admet-2956	429	9	harview	harview	PROPN
admet-2956	429	10	,	,	PUNCT
admet-2956	429	11	j.	j.	PROPN
admet-2956	429	12	yearley	yearley	PROPN
admet-2956	429	13	,	,	PUNCT
admet-2956	429	14	i.	i.	PROPN
admet-2956	429	15	shintaku	shintaku	PROPN
admet-2956	429	16	,	,	PUNCT
admet-2956	429	17	e.	e.	PROPN
admet-2956	429	18	taylor	taylor	PROPN
admet-2956	429	19	,	,	PUNCT
admet-2956	429	20	l.	l.	PROPN
admet-2956	429	21	robert	robert	PROPN
admet-2956	429	22	,	,	PUNCT
admet-2956	429	23	a.	a.	PROPN
admet-2956	429	24	ribas	ribas	PROPN
admet-2956	429	25	.	.	PUNCT
admet-2956	430	1	pd-1	pd-1	ADP
admet-2956	430	2	blockade	blockade	NOUN
admet-2956	430	3	induces	induce	VERB
admet-2956	430	4	responses	response	NOUN
admet-2956	430	5	by	by	ADP
admet-2956	430	6	inhibiting	inhibit	VERB
admet-2956	430	7	adaptive	adaptive	ADJ
admet-2956	430	8	immune	immune	ADJ
admet-2956	430	9	resistance	resistance	NOUN
admet-2956	430	10	.	.	PUNCT
admet-2956	431	1	nature	nature	NOUN
admet-2956	431	2	515	515	NUM
admet-2956	431	3	(	(	PUNCT
admet-2956	431	4	2014	2014	NUM
admet-2956	431	5	)	)	PUNCT
admet-2956	431	6	568	568	NUM
admet-2956	431	7	-	-	SYM
admet-2956	431	8	571	571	NUM
admet-2956	431	9	.	.	PUNCT
admet-2956	432	1	http://doi.org/10.1038/nature13954	http://doi.org/10.1038/nature13954	NOUN
admet-2956	433	1	[	[	X
admet-2956	433	2	58	58	NUM
admet-2956	433	3	]	]	PUNCT
admet-2956	433	4	k.	k.	PROPN
admet-2956	433	5	ninomiya	ninomiya	PROPN
admet-2956	433	6	,	,	PUNCT
admet-2956	433	7	i.	i.	PROPN
admet-2956	433	8	oze	oze	PROPN
admet-2956	433	9	,	,	PUNCT
admet-2956	433	10	y.	y.	PROPN
admet-2956	433	11	kato	kato	PROPN
admet-2956	433	12	,	,	PUNCT
admet-2956	433	13	t.	t.	PROPN
admet-2956	433	14	kubo	kubo	PROPN
admet-2956	433	15	,	,	PUNCT
admet-2956	433	16	e.	e.	PROPN
admet-2956	433	17	ichihara	ichihara	PROPN
admet-2956	433	18	,	,	PUNCT
admet-2956	433	19	k.	k.	PROPN
admet-2956	433	20	rai	rai	PROPN
admet-2956	433	21	,	,	PUNCT
admet-2956	433	22	k.	k.	PROPN
admet-2956	433	23	hotta	hotta	PROPN
admet-2956	433	24	.	.	PUNCT
admet-2956	434	1	influence	influence	NOUN
admet-2956	434	2	of	of	ADP
admet-2956	434	3	age	age	NOUN
admet-2956	434	4	on	on	ADP
admet-2956	434	5	the	the	DET
admet-2956	434	6	efficacy	efficacy	NOUN
admet-2956	434	7	of	of	ADP
admet-2956	434	8	immune	immune	ADJ
admet-2956	434	9	checkpoint	checkpoint	NOUN
admet-2956	434	10	inhibitors	inhibitor	NOUN
admet-2956	434	11	in	in	ADP
admet-2956	434	12	advanced	advanced	ADJ
admet-2956	434	13	cancers	cancer	NOUN
admet-2956	434	14	:	:	PUNCT
admet-2956	434	15	a	a	DET
admet-2956	434	16	systematic	systematic	ADJ
admet-2956	434	17	review	review	NOUN
admet-2956	434	18	and	and	CCONJ
admet-2956	434	19	meta	meta	ADJ
admet-2956	434	20	-	-	PUNCT
admet-2956	434	21	analysis	analysis	NOUN
admet-2956	434	22	.	.	PUNCT
admet-2956	435	1	acta	acta	PROPN
admet-2956	435	2	oncologica	oncologica	PROPN
admet-2956	435	3	59	59	NUM
admet-2956	435	4	(	(	PUNCT
admet-2956	435	5	2020	2020	NUM
admet-2956	435	6	)	)	PUNCT
admet-2956	435	7	249	249	NUM
admet-2956	435	8	-	-	SYM
admet-2956	435	9	256	256	NUM
admet-2956	435	10	.	.	PUNCT
admet-2956	436	1	http://doi.org/10.1080/0284186x.2019.1695062	http://doi.org/10.1080/0284186x.2019.1695062	PRON
admet-2956	437	1	[	[	X
admet-2956	437	2	59	59	NUM
admet-2956	437	3	]	]	PUNCT
admet-2956	437	4	e.	e.	PROPN
admet-2956	437	5	muchnik	muchnik	PROPN
admet-2956	437	6	,	,	PUNCT
admet-2956	437	7	k.	k.	PROPN
admet-2956	437	8	loh	loh	PROPN
admet-2956	437	9	,	,	PUNCT
admet-2956	437	10	m.	m.	NOUN
admet-2956	437	11	strawderman	strawderman	PROPN
admet-2956	437	12	,	,	PUNCT
admet-2956	437	13	a.	a.	PROPN
admet-2956	437	14	magnuson	magnuson	PROPN
admet-2956	437	15	,	,	PUNCT
admet-2956	437	16	s.	s.	PROPN
admet-2956	437	17	mohile	mohile	PROPN
admet-2956	437	18	,	,	PUNCT
admet-2956	437	19	v.	v.	PROPN
admet-2956	437	20	estrah	estrah	PROPN
admet-2956	437	21	,	,	PUNCT
admet-2956	437	22	r.	r.	PROPN
admet-2956	437	23	maggiore	maggiore	PROPN
admet-2956	437	24	.	.	PUNCT
admet-2956	438	1	immune	immune	ADJ
admet-2956	438	2	checkpoint	checkpoint	NOUN
admet-2956	438	3	inhibitors	inhibitor	NOUN
admet-2956	438	4	in	in	ADP
admet-2956	438	5	real	real	ADJ
admet-2956	438	6	-	-	PUNCT
admet-2956	438	7	world	world	NOUN
admet-2956	438	8	treatment	treatment	NOUN
admet-2956	438	9	of	of	ADP
admet-2956	438	10	older	old	ADJ
admet-2956	438	11	adults	adult	NOUN
admet-2956	438	12	with	with	ADP
admet-2956	438	13	non	non	ADJ
admet-2956	438	14	-	-	ADJ
admet-2956	438	15	small	small	ADJ
admet-2956	438	16	cell	cell	NOUN
admet-2956	438	17	lung	lung	NOUN
admet-2956	438	18	cancer	cancer	NOUN
admet-2956	438	19	.	.	PUNCT
admet-2956	439	1	journal	journal	NOUN
admet-2956	439	2	of	of	ADP
admet-2956	439	3	the	the	DET
admet-2956	439	4	american	american	ADJ
admet-2956	439	5	geriatrics	geriatrics	PROPN
admet-2956	439	6	society	society	NOUN
admet-2956	439	7	67	67	NUM
admet-2956	439	8	(	(	PUNCT
admet-2956	439	9	2019	2019	NUM
admet-2956	439	10	)	)	PUNCT
admet-2956	439	11	905	905	NUM
admet-2956	439	12	-	-	SYM
admet-2956	439	13	912	912	NUM
admet-2956	439	14	.	.	PUNCT
admet-2956	440	1	http://doi.org/10.1111/jgs.15750	http://doi.org/10.1111/jgs.15750	PROPN
admet-2956	441	1	[	[	X
admet-2956	441	2	60	60	NUM
admet-2956	441	3	]	]	PUNCT
admet-2956	441	4	s.	s.	PROPN
admet-2956	441	5	l.	l.	PROPN
admet-2956	441	6	klein	klein	PROPN
admet-2956	441	7	,	,	PUNCT
admet-2956	441	8	k.	k.	PROPN
admet-2956	441	9	l.	l.	PROPN
admet-2956	441	10	flanagan	flanagan	PROPN
admet-2956	441	11	.	.	PUNCT
admet-2956	442	1	sex	sex	NOUN
admet-2956	442	2	differences	difference	NOUN
admet-2956	442	3	in	in	ADP
admet-2956	442	4	immune	immune	ADJ
admet-2956	442	5	responses	response	NOUN
admet-2956	442	6	.	.	PUNCT
admet-2956	443	1	nature	nature	NOUN
admet-2956	443	2	reviews	review	VERB
admet-2956	443	3	immunology	immunology	NOUN
admet-2956	443	4	16	16	NUM
admet-2956	443	5	(	(	PUNCT
admet-2956	443	6	2016	2016	NUM
admet-2956	443	7	)	)	PUNCT
admet-2956	443	8	626	626	NUM
admet-2956	443	9	-	-	PUNCT
admet-2956	443	10	638	638	NUM
admet-2956	443	11	.	.	PUNCT
admet-2956	444	1	http://doi.org/10.1038/nri.2016.90	http://doi.org/10.1038/nri.2016.90	PROPN
admet-2956	445	1	[	[	X
admet-2956	445	2	61	61	NUM
admet-2956	445	3	]	]	PUNCT
admet-2956	445	4	k.	k.	PROPN
admet-2956	445	5	a.	a.	PROPN
admet-2956	445	6	marrone	marrone	PROPN
admet-2956	445	7	,	,	PUNCT
admet-2956	445	8	w.	w.	PROPN
admet-2956	445	9	ying	ying	PROPN
admet-2956	445	10	,	,	PUNCT
admet-2956	445	11	j.	j.	PROPN
admet-2956	445	12	naidoo	naidoo	PROPN
admet-2956	445	13	.	.	PROPN
admet-2956	445	14	immune	immune	NOUN
admet-2956	445	15	-	-	PUNCT
admet-2956	445	16	related	relate	VERB
admet-2956	445	17	adverse	adverse	ADJ
admet-2956	445	18	events	event	NOUN
admet-2956	445	19	from	from	ADP
admet-2956	445	20	immune	immune	ADJ
admet-2956	445	21	checkpoint	checkpoint	NOUN
admet-2956	445	22	inhibitors	inhibitor	NOUN
admet-2956	445	23	.	.	PUNCT
admet-2956	446	1	clinical	clinical	ADJ
admet-2956	446	2	pharmacology	pharmacology	NOUN
admet-2956	446	3	&	&	CCONJ
admet-2956	446	4	therapeutics	therapeutic	NOUN
admet-2956	446	5	100	100	NUM
admet-2956	446	6	(	(	PUNCT
admet-2956	446	7	2016	2016	NUM
admet-2956	446	8	)	)	PUNCT
admet-2956	446	9	242	242	NUM
admet-2956	446	10	-	-	SYM
admet-2956	446	11	251	251	NUM
admet-2956	446	12	.	.	PUNCT
admet-2956	447	1	http://doi.org/10.1002/cpt.394	http://doi.org/10.1002/cpt.394	X
admet-2956	448	1	[	[	X
admet-2956	448	2	62	62	NUM
admet-2956	448	3	]	]	PUNCT
admet-2956	448	4	r.	r.	PROPN
admet-2956	448	5	jin	jin	PROPN
admet-2956	448	6	.	.	PUNCT
admet-2956	449	1	c.	c.	PROPN
admet-2956	449	2	liu	liu	PROPN
admet-2956	449	3	,	,	PUNCT
admet-2956	449	4	s.	s.	PROPN
admet-2956	449	5	zheng	zheng	PROPN
admet-2956	449	6	,	,	PUNCT
admet-2956	449	7	x.	x.	PROPN
admet-2956	449	8	wang	wang	PROPN
admet-2956	449	9	,	,	PUNCT
admet-2956	449	10	x.	x.	PROPN
admet-2956	449	11	feng	feng	PROPN
admet-2956	449	12	,	,	PUNCT
admet-2956	449	13	h.	h.	PROPN
admet-2956	449	14	li	li	PROPN
admet-2956	449	15	.	.	PROPN
admet-2956	450	1	molecular	molecular	ADJ
admet-2956	450	2	heterogeneity	heterogeneity	NOUN
admet-2956	450	3	of	of	ADP
admet-2956	450	4	anti	anti	ADJ
admet-2956	450	5	-	-	ADJ
admet-2956	450	6	pd-1	pd-1	ADJ
admet-2956	450	7	/	/	SYM
admet-2956	450	8	pd	pd	NOUN
admet-2956	450	9	-	-	PROPN
admet-2956	450	10	l1	l1	PROPN
admet-2956	450	11	immunotherapy	immunotherapy	NOUN
admet-2956	450	12	efficacy	efficacy	NOUN
admet-2956	450	13	is	be	AUX
admet-2956	450	14	correlated	correlate	VERB
admet-2956	450	15	with	with	ADP
admet-2956	450	16	tumor	tumor	NOUN
admet-2956	450	17	immune	immune	ADJ
admet-2956	450	18	microenvironment	microenvironment	NOUN
admet-2956	450	19	in	in	ADP
admet-2956	450	20	east	east	ADJ
admet-2956	450	21	asian	asian	ADJ
admet-2956	450	22	patients	patient	NOUN
admet-2956	450	23	with	with	ADP
admet-2956	450	24	non	non	ADJ
admet-2956	450	25	-	-	ADJ
admet-2956	450	26	small	small	ADJ
admet-2956	450	27	cell	cell	NOUN
admet-2956	450	28	lung	lung	NOUN
admet-2956	450	29	cancer	cancer	NOUN
admet-2956	450	30	.	.	PUNCT
admet-2956	451	1	cancer	cancer	NOUN
admet-2956	451	2	biology	biology	NOUN
admet-2956	451	3	&	&	CCONJ
admet-2956	451	4	medicine	medicine	PROPN
admet-2956	451	5	17	17	NUM
admet-2956	451	6	(	(	PUNCT
admet-2956	451	7	2020	2020	NUM
admet-2956	451	8	)	)	PUNCT
admet-2956	451	9	768	768	NUM
admet-2956	451	10	-	-	SYM
admet-2956	451	11	781	781	NUM
admet-2956	451	12	.	.	NUM
admet-2956	452	1	http://doi.org/10.20892/j.issn.2095-3941.2020.0121	http://doi.org/10.20892/j.issn.2095-3941.2020.0121	PROPN
admet-2956	453	1	[	[	X
admet-2956	453	2	63	63	NUM
admet-2956	453	3	]	]	PUNCT
admet-2956	453	4	c.	c.	PROPN
admet-2956	453	5	zhang	zhang	PROPN
admet-2956	453	6	,	,	PUNCT
admet-2956	453	7	j.	j.	PROPN
admet-2956	453	8	zhang	zhang	PROPN
admet-2956	453	9	,	,	PUNCT
admet-2956	453	10	j.	j.	PROPN
admet-2956	453	11	tan	tan	PROPN
admet-2956	453	12	,	,	PUNCT
admet-2956	453	13	p.	p.	PROPN
admet-2956	453	14	tian	tian	PROPN
admet-2956	453	15	,	,	PUNCT
admet-2956	453	16	w.	w.	PROPN
admet-2956	453	17	li	li	PROPN
admet-2956	453	18	.	.	PROPN
admet-2956	453	19	cost	cost	NOUN
admet-2956	453	20	-	-	PUNCT
admet-2956	453	21	effectiveness	effectiveness	NOUN
admet-2956	453	22	of	of	ADP
admet-2956	453	23	pembrolizumab	pembrolizumab	NOUN
admet-2956	453	24	for	for	ADP
admet-2956	453	25	the	the	DET
admet-2956	453	26	treatment	treatment	NOUN
admet-2956	453	27	of	of	ADP
admet-2956	453	28	non	non	ADJ
admet-2956	453	29	-	-	ADJ
admet-2956	453	30	small	small	ADJ
admet-2956	453	31	-	-	PUNCT
admet-2956	453	32	cell	cell	NOUN
admet-2956	453	33	lung	lung	NOUN
admet-2956	453	34	cancer	cancer	NOUN
admet-2956	453	35	:	:	PUNCT
admet-2956	453	36	a	a	DET
admet-2956	453	37	systematic	systematic	ADJ
admet-2956	453	38	review	review	NOUN
admet-2956	453	39	.	.	PUNCT
admet-2956	454	1	frontiers	frontier	NOUN
admet-2956	454	2	in	in	ADP
admet-2956	454	3	oncology	oncology	NOUN
admet-2956	454	4	12	12	NUM
admet-2956	454	5	(	(	PUNCT
admet-2956	454	6	2022	2022	NUM
admet-2956	454	7	)	)	PUNCT
admet-2956	454	8	198	198	NUM
admet-2956	454	9	-	-	SYM
admet-2956	454	10	205	205	NUM
admet-2956	454	11	.	.	PUNCT
admet-2956	455	1	http://doi.org/10.3389/fonc.2022.815587	http://doi.org/10.3389/fonc.2022.815587	PROPN
admet-2956	455	2	[	[	X
admet-2956	455	3	64	64	NUM
admet-2956	455	4	]	]	PUNCT
admet-2956	455	5	f.	f.	PROPN
admet-2956	455	6	a.	a.	PROPN
admet-2956	455	7	van	van	PROPN
admet-2956	455	8	delft	delft	PROPN
admet-2956	455	9	.	.	PUNCT
admet-2956	456	1	modeling	model	VERB
admet-2956	456	2	strategies	strategy	NOUN
admet-2956	456	3	to	to	PART
admet-2956	456	4	analyse	analyse	VERB
admet-2956	456	5	longitudinal	longitudinal	ADJ
admet-2956	456	6	biomarker	biomarker	NOUN
admet-2956	456	7	data	datum	NOUN
admet-2956	456	8	:	:	PUNCT
admet-2956	456	9	an	an	DET
admet-2956	456	10	illustration	illustration	NOUN
admet-2956	456	11	on	on	ADP
admet-2956	456	12	predicting	predict	VERB
admet-2956	456	13	immunotherapy	immunotherapy	NOUN
admet-2956	456	14	non	non	NOUN
admet-2956	456	15	-	-	NOUN
admet-2956	456	16	response	response	NOUN
admet-2956	456	17	in	in	ADP
admet-2956	456	18	non	non	ADJ
admet-2956	456	19	-	-	ADJ
admet-2956	456	20	small	small	ADJ
admet-2956	456	21	cell	cell	NOUN
admet-2956	456	22	lung	lung	NOUN
admet-2956	456	23	cancer	cancer	NOUN
admet-2956	456	24	.	.	PUNCT
admet-2956	457	1	heliyon	heliyon	NOUN
admet-2956	457	2	8	8	NUM
admet-2956	457	3	(	(	PUNCT
admet-2956	457	4	2022	2022	NUM
admet-2956	457	5	)	)	PUNCT
admet-2956	457	6	e10932	e10932	VERB
admet-2956	457	7	.	.	PUNCT
admet-2956	457	8	http://doi.org/10.1016/j.heliyon.2022.e10932	http://doi.org/10.1016/j.heliyon.2022.e10932	PROPN
admet-2956	458	1	[	[	X
admet-2956	458	2	65	65	NUM
admet-2956	458	3	]	]	X
admet-2956	458	4	s.	s.	PROPN
admet-2956	458	5	m.	m.	PROPN
admet-2956	458	6	batool	batool	PROPN
admet-2956	458	7	,	,	PUNCT
admet-2956	458	8	a.	a.	NOUN
admet-2956	458	9	yekula	yekula	NOUN
admet-2956	458	10	,	,	PUNCT
admet-2956	458	11	p.	p.	NOUN
admet-2956	458	12	khanna	khanna	PROPN
admet-2956	458	13	,	,	PUNCT
admet-2956	458	14	t.	t.	PROPN
admet-2956	458	15	hsia	hsia	PROPN
admet-2956	458	16	,	,	PUNCT
admet-2956	458	17	a.	a.	PROPN
admet-2956	458	18	gamblin	gamblin	PROPN
admet-2956	458	19	,	,	PUNCT
admet-2956	458	20	e.	e.	PROPN
admet-2956	458	21	ekanayake	ekanayake	PROPN
admet-2956	458	22	.	.	PUNCT
admet-2956	459	1	the	the	DET
admet-2956	459	2	liquid	liquid	ADJ
admet-2956	459	3	biopsy	biopsy	NOUN
admet-2956	459	4	consortium	consortium	NOUN
admet-2956	459	5	:	:	PUNCT
admet-2956	459	6	challenges	challenge	NOUN
admet-2956	459	7	and	and	CCONJ
admet-2956	459	8	opportunities	opportunity	NOUN
admet-2956	459	9	for	for	ADP
admet-2956	459	10	early	early	ADJ
admet-2956	459	11	cancer	cancer	NOUN
admet-2956	459	12	detection	detection	NOUN
admet-2956	459	13	and	and	CCONJ
admet-2956	459	14	monitoring	monitoring	NOUN
admet-2956	459	15	.	.	PUNCT
admet-2956	460	1	cell	cell	NOUN
admet-2956	460	2	reports	report	VERB
admet-2956	460	3	medicine	medicine	NOUN
admet-2956	460	4	4	4	NUM
admet-2956	460	5	(	(	PUNCT
admet-2956	460	6	2023	2023	NUM
admet-2956	460	7	)	)	PUNCT
admet-2956	460	8	101198	101198	NUM
admet-2956	460	9	.	.	PUNCT
admet-2956	461	1	http://doi.org/10.1016/j.xcrm.2023.101198	http://doi.org/10.1016/j.xcrm.2023.101198	PROPN
admet-2956	461	2	https://doi.org/10.1158/1538-7445.am2018-ct075	https://doi.org/10.1158/1538-7445.am2018-ct075	X
admet-2956	461	3	http://doi.org/10.1016/j.ejca.2024.113530	http://doi.org/10.1016/j.ejca.2024.113530	ADJ
admet-2956	461	4	http://doi.org/10.1016/j.annonc.2020.05.023	http://doi.org/10.1016/j.annonc.2020.05.023	NOUN
admet-2956	461	5	http://doi.org/10.1136/bmj.k3529	http://doi.org/10.1136/bmj.k3529	X
admet-2956	461	6	http://doi.org/10.18632/oncotarget.7582	http://doi.org/10.18632/oncotarget.7582	NOUN
admet-2956	461	7	http://doi.org/10.1016/j.ctrv.2017.08.003	http://doi.org/10.1016/j.ctrv.2017.08.003	PROPN
admet-2956	461	8	http://doi.org/10.1002/cam4.2280	http://doi.org/10.1002/cam4.2280	PROPN
admet-2956	461	9	http://doi.org/10.1093/annonc/mdy275	http://doi.org/10.1093/annonc/mdy275	PROPN
admet-2956	461	10	http://doi.org/10.1001/jamaoncol.2015.3638	http://doi.org/10.1001/jamaoncol.2015.3638	PROPN
admet-2956	461	11	http://doi.org/10.1038/nature13954	http://doi.org/10.1038/nature13954	NOUN
admet-2956	461	12	http://doi.org/10.1080/0284186x.2019.1695062	http://doi.org/10.1080/0284186x.2019.1695062	PRON
admet-2956	461	13	http://doi.org/10.1111/jgs.15750	http://doi.org/10.1111/jgs.15750	PROPN
admet-2956	461	14	http://doi.org/10.1038/nri.2016.90	http://doi.org/10.1038/nri.2016.90	PROPN
admet-2956	461	15	http://doi.org/10.1002/cpt.394	http://doi.org/10.1002/cpt.394	PROPN
admet-2956	461	16	http://doi.org/10.20892/j.issn.2095-3941.2020.0121	http://doi.org/10.20892/j.issn.2095-3941.2020.0121	NOUN
admet-2956	461	17	http://doi.org/10.3389/fonc.2022.815587	http://doi.org/10.3389/fonc.2022.815587	PROPN
admet-2956	461	18	http://doi.org/10.1016/j.heliyon.2022.e10932	http://doi.org/10.1016/j.heliyon.2022.e10932	PROPN
admet-2956	461	19	http://doi.org/10.1016/j.xcrm.2023.101198	http://doi.org/10.1016/j.xcrm.2023.101198	PROPN
admet-2956	461	20	admet	admet	PROPN
admet-2956	461	21	&	&	CCONJ
admet-2956	461	22	dmpk	dmpk	PROPN
admet-2956	461	23	13(5	13(5	NOUN
admet-2956	461	24	)	)	PUNCT
admet-2956	461	25	(	(	PUNCT
admet-2956	461	26	2025	2025	NUM
admet-2956	461	27	)	)	PUNCT
admet-2956	461	28	2956	2956	NUM
admet-2956	461	29	pembrolizumab	pembrolizumab	NOUN
admet-2956	461	30	in	in	ADP
admet-2956	461	31	pd	pd	PROPN
admet-2956	461	32	-	-	PUNCT
admet-2956	461	33	l1	l1	PROPN
admet-2956	461	34	-	-	PUNCT
admet-2956	461	35	positive	positive	ADJ
admet-2956	461	36	advanced	advanced	ADJ
admet-2956	461	37	non	non	ADJ
admet-2956	461	38	-	-	ADJ
admet-2956	461	39	small	small	ADJ
admet-2956	461	40	cell	cell	NOUN
admet-2956	461	41	lung	lung	NOUN
admet-2956	461	42	carcinoma	carcinoma	NOUN
admet-2956	461	43	doi	doi	NOUN
admet-2956	461	44	:	:	PUNCT
admet-2956	461	45	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	461	46	17	17	NUM
admet-2956	461	47	[	[	SYM
admet-2956	461	48	66	66	NUM
admet-2956	461	49	]	]	PUNCT
admet-2956	461	50	m.	m.	NOUN
admet-2956	461	51	qiao	qiao	PROPN
admet-2956	461	52	,	,	PUNCT
admet-2956	461	53	t.	t.	PROPN
admet-2956	461	54	jiang	jiang	PROPN
admet-2956	461	55	,	,	PUNCT
admet-2956	461	56	s.	s.	PROPN
admet-2956	461	57	ren	ren	PROPN
admet-2956	461	58	,	,	PUNCT
admet-2956	461	59	c.	c.	PROPN
admet-2956	461	60	zhou	zhou	PROPN
admet-2956	461	61	.	.	PUNCT
admet-2956	462	1	combination	combination	NOUN
admet-2956	462	2	strategies	strategy	NOUN
admet-2956	462	3	on	on	ADP
admet-2956	462	4	the	the	DET
admet-2956	462	5	basis	basis	NOUN
admet-2956	462	6	of	of	ADP
admet-2956	462	7	immune	immune	ADJ
admet-2956	462	8	checkpoint	checkpoint	NOUN
admet-2956	462	9	inhibitors	inhibitor	NOUN
admet-2956	462	10	in	in	ADP
admet-2956	462	11	non	non	ADJ
admet-2956	462	12	-	-	ADJ
admet-2956	462	13	small	small	ADJ
admet-2956	462	14	-	-	PUNCT
admet-2956	462	15	cell	cell	NOUN
admet-2956	462	16	lung	lung	NOUN
admet-2956	462	17	cancer	cancer	NOUN
admet-2956	462	18	:	:	PUNCT
admet-2956	462	19	where	where	SCONJ
admet-2956	462	20	do	do	AUX
admet-2956	462	21	we	we	PRON
admet-2956	462	22	stand	stand	VERB
admet-2956	462	23	?	?	PUNCT
admet-2956	462	24	.	.	PUNCT
admet-2956	463	1	clinical	clinical	ADJ
admet-2956	463	2	lung	lung	NOUN
admet-2956	463	3	cancer	cancer	NOUN
admet-2956	463	4	19	19	NUM
admet-2956	463	5	(	(	PUNCT
admet-2956	463	6	2018	2018	NUM
admet-2956	463	7	)	)	PUNCT
admet-2956	463	8	1	1	NUM
admet-2956	463	9	-	-	SYM
admet-2956	463	10	11	11	NUM
admet-2956	463	11	.	.	PUNCT
admet-2956	464	1	http://doi.org/10.1016/j.cllc.2017.06.005	http://doi.org/10.1016/j.cllc.2017.06.005	PROPN
admet-2956	465	1	[	[	X
admet-2956	465	2	67	67	NUM
admet-2956	465	3	]	]	X
admet-2956	465	4	f.	f.	PROPN
admet-2956	465	5	conforti	conforti	PROPN
admet-2956	465	6	.	.	PUNCT
admet-2956	466	1	sex	sex	NOUN
admet-2956	466	2	-	-	PUNCT
admet-2956	466	3	based	base	VERB
admet-2956	466	4	heterogeneity	heterogeneity	NOUN
admet-2956	466	5	in	in	ADP
admet-2956	466	6	response	response	NOUN
admet-2956	466	7	to	to	ADP
admet-2956	466	8	lung	lung	NOUN
admet-2956	466	9	cancer	cancer	NOUN
admet-2956	466	10	immunotherapy	immunotherapy	NOUN
admet-2956	466	11	:	:	PUNCT
admet-2956	466	12	a	a	DET
admet-2956	466	13	systematic	systematic	ADJ
admet-2956	466	14	review	review	NOUN
admet-2956	466	15	and	and	CCONJ
admet-2956	466	16	meta	meta	ADJ
admet-2956	466	17	-	-	PUNCT
admet-2956	466	18	analysis	analysis	NOUN
admet-2956	466	19	.	.	PUNCT
admet-2956	467	1	journal	journal	NOUN
admet-2956	467	2	of	of	ADP
admet-2956	467	3	the	the	DET
admet-2956	467	4	national	national	PROPN
admet-2956	467	5	cancer	cancer	PROPN
admet-2956	467	6	institute	institute	PROPN
admet-2956	467	7	111	111	NUM
admet-2956	467	8	(	(	PUNCT
admet-2956	467	9	2019	2019	NUM
admet-2956	467	10	)	)	PUNCT
admet-2956	467	11	772	772	NUM
admet-2956	467	12	-	-	SYM
admet-2956	467	13	781	781	NUM
admet-2956	467	14	.	.	PUNCT
admet-2956	468	1	http://doi.org/10.1093/jnci/djz094	http://doi.org/10.1093/jnci/djz094	VERB
admet-2956	469	1	[	[	X
admet-2956	469	2	68	68	NUM
admet-2956	469	3	]	]	X
admet-2956	469	4	v.	v.	CCONJ
admet-2956	469	5	velcheti	velcheti	PROPN
admet-2956	469	6	,	,	PUNCT
admet-2956	469	7	s.	s.	PROPN
admet-2956	469	8	chandwani	chandwani	PROPN
admet-2956	469	9	,	,	PUNCT
admet-2956	469	10	x.	x.	PROPN
admet-2956	469	11	chen	chen	PROPN
admet-2956	469	12	,	,	PUNCT
admet-2956	469	13	m.	m.	PROPN
admet-2956	469	14	catherine	catherine	PROPN
admet-2956	469	15	pietanza	pietanza	PROPN
admet-2956	469	16	,	,	PUNCT
admet-2956	469	17	t.	t.	PROPN
admet-2956	469	18	burke	burke	PROPN
admet-2956	469	19	.	.	PUNCT
admet-2956	470	1	first	first	ADJ
admet-2956	470	2	-	-	PUNCT
admet-2956	470	3	line	line	NOUN
admet-2956	470	4	pembrolizumab	pembrolizumab	NOUN
admet-2956	470	5	monotherapy	monotherapy	NOUN
admet-2956	470	6	for	for	ADP
admet-2956	470	7	metastatic	metastatic	ADJ
admet-2956	470	8	pd	pd	PROPN
admet-2956	470	9	-	-	PUNCT
admet-2956	470	10	l1	l1	ADJ
admet-2956	470	11	-	-	PUNCT
admet-2956	470	12	positive	positive	ADJ
admet-2956	470	13	nsclc	nsclc	NOUN
admet-2956	470	14	:	:	PUNCT
admet-2956	470	15	real	real	ADJ
admet-2956	470	16	-	-	PUNCT
admet-2956	470	17	world	world	NOUN
admet-2956	470	18	analysis	analysis	NOUN
admet-2956	470	19	of	of	ADP
admet-2956	470	20	time	time	NOUN
admet-2956	470	21	on	on	ADP
admet-2956	470	22	treatment	treatment	NOUN
admet-2956	470	23	.	.	PUNCT
admet-2956	471	1	immunotherapy	immunotherapy	NOUN
admet-2956	471	2	11	11	NUM
admet-2956	471	3	(	(	PUNCT
admet-2956	471	4	2019	2019	NUM
admet-2956	471	5	)	)	PUNCT
admet-2956	471	6	889	889	NUM
admet-2956	471	7	-	-	SYM
admet-2956	471	8	901	901	NUM
admet-2956	471	9	.	.	PUNCT
admet-2956	471	10	http://doi.org/10.2217/imt-2019-0061	http://doi.org/10.2217/imt-2019-0061	NOUN
admet-2956	472	1	[	[	X
admet-2956	472	2	69	69	NUM
admet-2956	472	3	]	]	PUNCT
admet-2956	472	4	s.	s.	PROPN
admet-2956	472	5	liang	liang	PROPN
admet-2956	472	6	,	,	PUNCT
admet-2956	472	7	h.	h.	PROPN
admet-2956	472	8	wang	wang	PROPN
admet-2956	472	9	,	,	PUNCT
admet-2956	472	10	h.	h.	PROPN
admet-2956	472	11	tian	tian	PROPN
admet-2956	472	12	,	,	PUNCT
admet-2956	472	13	z.	z.	PROPN
admet-2956	472	14	xu	xu	PROPN
admet-2956	472	15	,	,	PUNCT
admet-2956	472	16	m.	m.	PROPN
admet-2956	472	17	wu	wu	PROPN
admet-2956	472	18	,	,	PUNCT
admet-2956	472	19	d.	d.	PROPN
admet-2956	472	20	hua	hua	PROPN
admet-2956	472	21	,	,	PUNCT
admet-2956	472	22	c.	c.	PROPN
admet-2956	472	23	li	li	PROPN
admet-2956	472	24	.	.	PUNCT
admet-2956	473	1	the	the	DET
admet-2956	473	2	prognostic	prognostic	ADJ
admet-2956	473	3	biological	biological	ADJ
admet-2956	473	4	markers	marker	NOUN
admet-2956	473	5	of	of	ADP
admet-2956	473	6	immunotherapy	immunotherapy	NOUN
admet-2956	473	7	for	for	ADP
admet-2956	473	8	non	non	ADJ
admet-2956	473	9	-	-	ADJ
admet-2956	473	10	small	small	ADJ
admet-2956	473	11	cell	cell	NOUN
admet-2956	473	12	lung	lung	NOUN
admet-2956	473	13	cancer	cancer	NOUN
admet-2956	473	14	:	:	PUNCT
admet-2956	473	15	current	current	ADJ
admet-2956	473	16	landscape	landscape	NOUN
admet-2956	473	17	and	and	CCONJ
admet-2956	473	18	future	future	ADJ
admet-2956	473	19	perspective	perspective	NOUN
admet-2956	473	20	.	.	PUNCT
admet-2956	474	1	frontiers	frontier	NOUN
admet-2956	474	2	in	in	ADP
admet-2956	474	3	immunology	immunology	NOUN
admet-2956	474	4	14	14	NUM
admet-2956	474	5	(	(	PUNCT
admet-2956	474	6	2023	2023	NUM
admet-2956	474	7	)	)	PUNCT
admet-2956	474	8	1249980	1249980	NUM
admet-2956	474	9	.	.	PUNCT
admet-2956	475	1	http://doi.org/10.3389/fimmu.2023.1249980	http://doi.org/10.3389/fimmu.2023.1249980	PROPN
admet-2956	476	1	[	[	X
admet-2956	476	2	70	70	NUM
admet-2956	476	3	]	]	PUNCT
admet-2956	476	4	a.	a.	NOUN
admet-2956	476	5	prelaj	prelaj	PROPN
admet-2956	476	6	,	,	PUNCT
admet-2956	476	7	e.	e.	PROPN
admet-2956	476	8	galli	galli	PROPN
admet-2956	476	9	,	,	PUNCT
admet-2956	476	10	v.	v.	CCONJ
admet-2956	476	11	miskovic	miskovic	ADJ
admet-2956	476	12	,	,	PUNCT
admet-2956	476	13	m.	m.	NOUN
admet-2956	476	14	pesenti	pesenti	PROPN
admet-2956	476	15	,	,	PUNCT
admet-2956	476	16	g.	g.	PROPN
admet-2956	476	17	viscardi	viscardi	PROPN
admet-2956	476	18	,	,	PUNCT
admet-2956	476	19	b.	b.	PROPN
admet-2956	476	20	pedica	pedica	PROPN
admet-2956	476	21	,	,	PUNCT
admet-2956	476	22	a.	a.	PROPN
admet-2956	476	23	pedrocchi	pedrocchi	PROPN
admet-2956	476	24	.	.	PUNCT
admet-2956	477	1	real	real	ADJ
admet-2956	477	2	-	-	PUNCT
admet-2956	477	3	world	world	NOUN
admet-2956	477	4	data	datum	NOUN
admet-2956	477	5	to	to	PART
admet-2956	477	6	build	build	VERB
admet-2956	477	7	explainable	explainable	ADJ
admet-2956	477	8	trustworthy	trustworthy	ADJ
admet-2956	477	9	artificial	artificial	ADJ
admet-2956	477	10	intelligence	intelligence	NOUN
admet-2956	477	11	models	model	NOUN
admet-2956	477	12	for	for	ADP
admet-2956	477	13	prediction	prediction	NOUN
admet-2956	477	14	of	of	ADP
admet-2956	477	15	immunotherapy	immunotherapy	NOUN
admet-2956	477	16	efficacy	efficacy	NOUN
admet-2956	477	17	in	in	ADP
admet-2956	477	18	nsclc	nsclc	NOUN
admet-2956	477	19	patients	patient	NOUN
admet-2956	477	20	.	.	PUNCT
admet-2956	478	1	frontiers	frontier	NOUN
admet-2956	478	2	in	in	ADP
admet-2956	478	3	oncology	oncology	NOUN
admet-2956	478	4	12	12	NUM
admet-2956	478	5	(	(	PUNCT
admet-2956	478	6	2023	2023	NUM
admet-2956	478	7	)	)	PUNCT
admet-2956	478	8	1078822	1078822	NUM
admet-2956	478	9	.	.	PUNCT
admet-2956	479	1	http://doi.org/10.3389/fonc.2022.1078822	http://doi.org/10.3389/fonc.2022.1078822	PROPN
admet-2956	479	2	©	©	PROPN
admet-2956	479	3	2025	2025	NUM
admet-2956	479	4	by	by	ADP
admet-2956	479	5	the	the	DET
admet-2956	479	6	authors	author	NOUN
admet-2956	479	7	;	;	PUNCT
admet-2956	479	8	licensee	licensee	PROPN
admet-2956	479	9	iapc	iapc	PROPN
admet-2956	479	10	,	,	PUNCT
admet-2956	479	11	zagreb	zagreb	PROPN
admet-2956	479	12	,	,	PUNCT
admet-2956	479	13	croatia	croatia	PROPN
admet-2956	479	14	.	.	PUNCT
admet-2956	480	1	this	this	DET
admet-2956	480	2	article	article	NOUN
admet-2956	480	3	is	be	AUX
admet-2956	480	4	an	an	DET
admet-2956	480	5	open	open	ADJ
admet-2956	480	6	-	-	PUNCT
admet-2956	480	7	access	access	NOUN
admet-2956	480	8	article	article	NOUN
admet-2956	480	9	distributed	distribute	VERB
admet-2956	480	10	under	under	ADP
admet-2956	480	11	the	the	DET
admet-2956	480	12	terms	term	NOUN
admet-2956	480	13	and	and	CCONJ
admet-2956	480	14	conditions	condition	NOUN
admet-2956	480	15	of	of	ADP
admet-2956	480	16	the	the	DET
admet-2956	480	17	creative	creative	ADJ
admet-2956	480	18	commons	common	NOUN
admet-2956	480	19	attribution	attribution	NOUN
admet-2956	480	20	license	license	NOUN
admet-2956	480	21	(	(	PUNCT
admet-2956	480	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-2956	480	23	)	)	PUNCT
admet-2956	480	24	https://doi.org/10.5599/admet.2956	https://doi.org/10.5599/admet.2956	NOUN
admet-2956	481	1	http://doi.org/10.1016/j.cllc.2017.06.005	http://doi.org/10.1016/j.cllc.2017.06.005	PROPN
admet-2956	481	2	http://doi.org/10.1093/jnci/djz094	http://doi.org/10.1093/jnci/djz094	PROPN
admet-2956	481	3	http://doi.org/10.2217/imt-2019-0061	http://doi.org/10.2217/imt-2019-0061	NOUN
admet-2956	481	4	http://doi.org/10.3389/fimmu.2023.1249980	http://doi.org/10.3389/fimmu.2023.1249980	PROPN
admet-2956	481	5	http://doi.org/10.3389/fonc.2022.1078822	http://doi.org/10.3389/fonc.2022.1078822	PROPN
admet-2956	481	6	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN